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Preface 
Reflexivity- How I came to this research topic 
In qualitative research, the term reflexivity describes the importance of ‘self- awareness, 
political/ cultural consciousness, and ownership of ones’ perspective.’ This is important as it 
is a hallmark of quality in qualitative research and provides credibility to the findings. This 
thesis compiles the findings of my work within multi-cultural collaborations on projects in 
Australia and in India. Thus, I preface this thesis to share with the reader my background and 
its relevance to this body of work.    
 “I have been interested in socio-determinants of health since high school due to several key 
experiences. These included volunteering at centres for abused children, medical student 
attachments at Aboriginal Community Controlled Health Services in Australia, attachments to 
different types of hospitals in China, and a HIV clinic in Uganda. From these experiences, I 
observed health inequity and inequalities in both low to middle income countries, and within 
developed countries. I have a passion in taking a holistic approach to health and addressing 
social as well as biomedical determinants to health.  
I completed a MBBS in Sydney, and worked in the public hospital system before completing a 
Masters in International public health. My work at the George Institute for Global Health  with 
the Kanyini Vascular Collaboration and partnering Aboriginal Community Controlled health 
services have further consolidated my belief that primary health care which is universal, 
community-led, efficient, affordable and of high quality plays a crucial role in improving health 
for all.  
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During this journey, however, I have been frustrated with the process of research and its 
impact on public health.  There is so much time, money and effort that is poured into this area 
but from my observations, the impact is minimal or at least is seemingly slow to effect change. 
However, I still believe public health research is needed to provide much needed evidence-
based interventions to improve health systems. Thus, I humbly embarked on this journey of 
study, with the aim in understanding how to develop and evaluate ‘holistic’ interventions 
which can be translated into meaningful patient-centred outcomes, and in doing so, help close 
the gap in health equity.”  
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THESIS ABSTRACT 
Background 
Strengthening health systems to provide affordable, effective and accessible care in a life-
course approach is necessary to address the growing global burden from non-communicable 
diseases (NCD). To address deficiencies in the health system, researchers have designed and 
trialled ‘complex interventions’ which are defined as interventions with multiple interacting 
components, and complexity in its implementation. Process evaluations alongside 
randomised controlled trials (RCT) of complex interventions are highly valuable. They 
explore implementation and different stakeholders’ perspectives as to for whom, how and 
why a complex intervention has an impact.  
Research aim and Methods 
My research aim is to demonstrate that PEs are necessary to enable a deeper understanding 
of how interventions are implemented in a given setting through the analysis of local health 
system context and stakeholders’ perspectives; and in doing so, help refine the intervention 
to address local needs, and inform future research priorities.  
This was done through:  
1) A systematic review which provides a synthesis and appraisal of the methods used in 
process evaluations of primary care interventions, and their main findings on 
implementation barriers and facilitators. (Chapter 2) 
2) Two process evaluations of complex interventions that aim to improve access to 
affordable evidence-based care. First, is the process evaluation of a RCT of a 
secondary cardiovascular prevention strategy. The trial examines the efficacy of the 
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combined cardiovascular polypill in Australian primary health care to improve 
prescribing and patients' use of indicated therapy. (Chapter 3) Second, is the process 
evaluation of a RCT of a tertiary intervention, which is the training of family carers to 
provide basic rehabilitation for post-stroke patients in India. (Chapter 4) In these 
chapters, I highlight the relevance of the process evaluation findings for health 
system strengthening, and examine the facilitators and barriers to collaborative 
research.  
3) A qualitative study where we explored Australian decision makers’ perspectives of 
how evidence generated by researchers can be more relevant in informing their 
investment in NCD prevention. (Chapter 5)  
Overall findings and implications from the thesis 
Synthesising the findings and implications of individual studies (Chapters 2 to 5), there were 
three key crosscutting findings in the thesis.  
First, we found that individual, organisation and policy level factors were critical to the 
sustainability and scale-up of complex interventions. For example, factors affecting patient 
adherence (such as patient-provider relationship), providers’ perspective of the inflexibility 
of dosages, and policy changes (such as pharmaceutical benefits scheme) should be 
considered in the future implementation of the cardiovascular polypill. This implies that a 
‘top-down’ (i.e. engaging policy makers) and ‘ground-up’ (i.e. engaging patients and their 
providers) approach is concurrently required to address NCDs across the breadth of relevant 
stakeholders (as depicted in Figure 1, reproduced from Chapter 5). Therefore, relevant 
stakeholders should be engaged early in the design of complex interventions so that: the 
intervention is clearly aligned with the needs of local stakeholders; that the roles and 
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responsibilities of key actors are better understood; and unanticipated consequences arising 
from context-specific barriers to implementation can be minimised.  
Second, we identified the facilitators and barriers to the effective co-production of evidence 
such that the evidence generated fits the needs of the end-users (practitioners, patients and 
policy-makers). Facilitators to effective ongoing co-production include relationship building, 
values (such as equality and reciprocity), and locally driven research. For example, because 
of the successful completion of the ATTEND trial, a local stroke network in India was 
successfully funded to capitalise on their existing research network and infrastructure (e.g. 
staff, data collection). 
However, key barriers to co-production include challenges in reconciling stakeholders’ 
diverse perspectives to align with the common research objective in a timely manner, and 
balancing competing service delivery and research activities. These findings imply that 
significant time for consultation and communication is required to build these critical 
relationships; and investment into capacity building and research infrastructure is essential.  
Third, collectively this body of work demonstrates that process evaluations can be a useful 
tool for the effective co-production of evidence through two mechanisms. Process 
evaluations emphasises the importance of articulating the needs of end-users (patients, 
providers, practitioners, and policy-makers) within their local context; and doing so, further 
inform intervention design and implementation strategies needed for the sustainability and 
scaling up of locally relevant interventions. Moreover, a careful examination of contextual 
factors can help identify gaps in care and inform future research priorities.  An example of a 
future research priority identified from the process evaluation of the ATTEND RCT is the 
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need to raise the public’s awareness of stroke and the benefits of early presentation and 
rehabilitation.  
Therefore, process evaluations can facilitate the effective co-production of evidence. This is 
possible through an iterative approach of understanding end users’ ongoing needs, 
developing locally relevant interventions, implementation strategies, and identifying future 
gaps in care. This will provide critical evidence to stakeholders’ question of ‘is this 
intervention acceptable, effective, affordable and feasible (for me or) for this population?’ 
Making small but steady advances in strengthening health systems such that health care can 
be affordable, accessible and of high quality for all.  
 
 Consumer:  Determing the 
acceptability of prevention 
strategies to modify behaviour
e.g. Coaching on lifestyle 
interventions, preventative 
medications, tax on tobacco, 
healthy living spaces, early 
childhood interventions 
Funders: Financing of the health 
system
e.g.Tax payer for overall  government 
budget (Federal for primary health 
care and pharmaceutical benefits and 
State for public hospitals), with 
allocation dependent on treasury, 
Insurance industries and 
pharmaceautical industries 
dependent on market forces and  
consumer out of pocket costs
Health providers: Providing 
service delivery of chronic 
disease care. 
e.g. Government and private 
hospitals, primary health care 
practitioners, allied health, health 
promotion and other services 
provided by public health units 
within local health districts
Researchers: Generating 
evidence- outcome, process 
and economic evaluations
e.g. Government evaluations of 
prevention programs, health 
organisations monitoring and 
evaluation of health service 
delivery, insurance companies 
evaluation of chronic care 
management services, academic 
institutions' clinical trials
Other stakeholders: Federal 
and cross sectoral investments 
related to prevention  
e.g  Legislation, education, 
environment planning, transport, 
general workforce, food industry
Policy Makers: Health system 
Structuring 
e.g. Population health strategies, 
Primary health care training and 
staffing, subsidized medications 
through the pharmaceutical benefits 
scheme, medicare items promoting 
preventative health, integrated 
health between hospitals and 
primary health care in providing 
chronic disease care
Figure 1: Contextual Map of Stakeholders in NCD prevention. The complexities of the provision of prevention strategies by various stakeholders, highlighting their 
roles and interlocking relationships which impact upon the consumer’s behaviour change. (Reproduced here from Chapter 5) 
CHAPTER 1: INTRODUCTION 
Chapter Overview 
Strengthening health systems to address the burden of non-communicable disease is 
challenging because the prevention of NCDs is inherently complex due to its distal and 
proximal determinants, and requires a life-course approach involving multiple sectors and 
stakeholders.  Complex interventions as defined by their multiple interacting components 
(although additional dimensions of complexity include the difficulty in their implementation 
and the number of organisational levels they target), are used to target health system 
deficiencies. Process evaluations of complex interventions have been recommended to 
examine implementation and explore for whom, how and why an intervention has an 
impact. 
This chapter presents an overview of the role of process evaluations in the field of health 
systems research.  This chapter then sets out the research aim of the thesis with a 
description of the thesis structure and specific objectives related to each chapter. My 
research aim is to demonstrate that process evaluations can help us understand how 
interventions are implemented in given settings, through the analysis of local health 
systems and stakeholders’ perspectives; and in doing so, help refine the intervention to 
address local needs, and inform future research priorities. The following chapters explore 
the methods and role of process evaluations of primary care interventions; contain case 
studies of process evaluations of secondary and tertiary interventions; and explore the use 
of evidence in informing investment in NCD prevention. 
1
The Role of PEs in Health Systems Strengthening   
Non-communicable diseases (NCDs) is rapidly rising in rank as a priority in lower and middle 
income countries (LMIC) undergoing epidemiological transition and already exert a huge 
burden in high income countries. (1) In 2016, it was estimated that 71% of deaths worldwide 
were due to NCDs. In 2018, there was a high level United Nations Meeting urging 
governments to reinforce their commitments to have a one-third reduction in the probability 
of dying from NCDs (between 30-70 years of age) by 2030. However, addressing the burden 
of NCDS is extremely challenging because the causes of NCDs are inherently complex, often 
involving an array of interacting social, environmental and individual life-style related risk 
factors. (2, 3) It involves taking a life-course approach requiring the effective integration of 
population health, primary and tertiary care, and other sectors (e.g. transport, food industry, 
and education), which adds another level of complexity.  
The significant health and social impact of NCDs and the resultant inequity makes NCDs a 
priority for health systems research. The unpredictability and interconnectedness of human 
and ecological factors have been posited as a reason for the lack of global progress in 
addressing NCDs. (4) Some researchers have described that a way forward would be to 
embrace the ‘complexity’ through systems thinking and accept the complex and emergent 
changes inherent in the health system. (5) This would require the use of innovative 
interventions and evaluations to find sustainable solutions in the local dynamic context. (6) 
Increasingly, collaborative research using partnerships between health services and 
researchers to co-produce locally relevant evidence is desirable. This co-production approach 
presents a shift from the unidirectional traditional research pipeline of researchers generating 
evidence to be consumed by the end-users (patients, health practitioners, policy- makers). (7) 
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In order to strengthen the health system and address NCDs in an affordable, accessible and 
effective way, practitioners and researchers have designed and trialled complex 
interventions. These complex interventions are defined by their “multiple interacting 
components (although additional dimensions of complexity include the difficulty in their 
implementation and the number of organisational levels they target).” Evaluations of complex 
interventions include outcome/impact, process and economic evaluations. Impact 
evaluations determine effectiveness using comparison groups (i.e. in the absence of the 
intervention) and include study designs such as step-wedged and randomised controlled trials 
(RCTs). RCTs have been recommended as the gold standard in research designs to provide 
robust outcome evidence. (8) Therefore, in this thesis we decided to examine process 
evaluations of RCTs to determine whether and how evidence from RCTs can effectively and 
sustainably address NCDs.  
Process evaluations alongside trials of complex interventions are important because they 
examine whether a complex intervention was implemented as intended, and address 
questions of for whom, how and why the intervention had an impact. (9) Process evaluation 
(PE) is defined by the UK Medical Research Council as a study which aims to ‘understand the 
function of an intervention, by examining implementation, mechanisms of impact, and 
contextual factors’. (9) Therefore, PEs can shed light on important contextual individual to 
policy level barriers that impact on the real-world implementation of an intervention. (10) For 
instance, the affordability of an intervention has an obvious influence on uptake of an 
intervention, but is also highly dependent on the level of subsidy available and the specific 
socio-economic circumstances of individuals.  (11, 12) The quality of the interventions is 
dependent on the distribution and underlying training of the workforce, and on physical and 
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referral infrastructures. Access to services is impacted by factors such as patient awareness 
of need, long waiting times, and the availability of financial risk protection. (11) Therefore, 
PEs can improve our understanding of intervention mechanisms within local health system 
context through stakeholders’ lived experiences. For example, in a PE, it may be useful to 
explore the impact of costs of care on end-users (patients, providers, policy makers). This is 
especially relevant for trials in low to middle-income countries (LMIC) and in populations who 
have complex needs. (13) This is because of the recognised decreased economic productivity 
resulting from NCDs and the burden on low-income households. (14) This forms a vicious cycle 
of financial catastrophe and family hardship, making future care (e.g. acute rehospitalisation 
or rehabilitation) less accessible and affordable. (13, 15, 16)  
PE methodology is evolving. (9) Previously, they were used to examine the extent of 
implementation through the documentation and analysis of quantitative process indicators 
in a trial. Subsequently, PEs developed into qualitative research alongside trials to provide a 
deeper understanding of the disease condition, acceptability of an intervention and 
implementation issues. (8) These PEs were largely used to determine, in the wake of a 
negative trial result, whether the result was due to either implementation or intervention 
failure. However, there is growing recognition that using qualitative and quantitative data, 
and theoretical frameworks within PEs will help facilitate evidence to practice. (17, 18) 
Findings from such PEs can help inform stakeholders’ question of ‘Is this intervention 
acceptable, effective, affordable and feasible (for me or) for this population?’ (19)   
A recognised barrier in the translation of evidence into practice is the lack of stakeholder 
engagement with the results of the research.(20) As highlighted earlier, collaboration with 
and between stakeholders from the onset of the research through to dissemination may be a 
4
solution. (21) However, collaborative research can be fraught with difficulties and exploring 
what enables or hinders effective stakeholder partnerships can be a useful component of a 
PE.  Economic evaluations (such as cost-effectiveness studies, cost-benefit analysis) provide 
evidence of the cost effectiveness of a program versus the comparison.  The underlying 
assumption by the research community is that the evidence from the impact, process and 
economic evaluations of complex interventions would inform decision makers in the 
investment for NCD prevention. To check this assumption and make progress towards NCD 
2030, it would be useful to explore the use of economic evidence by stakeholders in informing 
investment in NCD prevention. 
Research Aim and Structure of this Thesis  
My research aim is to demonstrate that PEs are necessary to enable a deeper understanding 
of how interventions are implemented in a given setting through the analysis of local health 
system context and stakeholders’ perspectives; and in doing so, help refine the intervention 
to address local needs, and inform future research priorities.  
To achieve my research aim, the answers to the following questions are addressed in the 
subsequent chapters: What are the methods and key findings of PEs of primary care 
interventions? Can I effectively conduct PEs of secondary and tertiary NCD intervention, and 
identify for whom, how and why these interventions have an impact on? And finally, how is 
evidence (outcome, process and economic) actually used by stakeholders in informing the 
investment for the prevention of NCDs? 
Chapter 2: The MRC PE framework is used to help synthesize the available evidence of 
published PEs of RCTs of complex primary care interventions. This is to identify key 
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implementation factors, the design features of PEs; and to highlight areas for improvement 
and development.   
Chapters 3 and 4: In these chapters, PEs of complex interventions that aim to improve access 
to affordable, evidence-based care are presented. Chapter 3 contains the results of a PE of a 
randomised controlled trial (RCT) of a secondary cardiovascular prevention strategy, using the 
combined cardiovascular polypill, in Australian primary health care to improve prescribing 
and patient use of indicated therapy.  Chapter 4 contains the protocol and results of a PE of a 
randomised controlled trial of a tertiary intervention, involving the training of family carers 
to provide basic rehabilitation for post stroke patients in India. The relevance of PE findings 
for health system strengthening are highlighted, and the facilitators and barriers to 
collaborative research are examined. 
Chapter 5: Through a qualitative study, we explored the use of evidence in informing 
investment in NCD prevention by Australian decision makers, and provide recommendations 
on ways to bridge the research translation gap in the prevention of NCDs.  
Chapter 6: The key findings from each chapter are consolidated providing a succinct summary 
of the thesis as a whole. Overall implications from the thesis for future research in this field 
are discussed.  
This body of work was created as a useful resource for researchers, practitioners and policy 
makers regarding the use of PEs in informing the generalisability and sustainability of patient-
centred complex interventions that are needed in health systems strengthening.  While this 
thesis has a focus on addressing NCDs, there may be transferable insights to the evaluation 
of complex interventions in other fields.   
6
References 
1. NCD collaborators. NCD Countdown 2030: worldwide trends in non-communicable disease 
mortality and progress towards Sustainable Development Goal target 3.4. Lancet. 
2018;392(10152):1072-88. 
2. Gibson O, Lisy K, Davy C, Aromataris E, Kite E, Lockwood C, et al. Enablers and barriers to the 
implementation of primary health care interventions for Indigenous people with chronic diseases: a 
systematic review. Implement Sci. 2015;10:71. 
3. Davy C, Bleasel J, Liu H, Tchan M, Ponniah S, Brown A. Effectiveness of chronic care models: 
opportunities for improving healthcare practice and health outcomes: a systematic review. BMC 
Health Serv Res. 2015;15:194. 
4. Horton R. Offline: NCDs-why are we failing? Lancet. 2017;390(10092):346. 
5. Braithwaite J, Churruca K, Long JC, Ellis LA, Herkes J. When complexity science meets 
implementation science: a theoretical and empirical analysis of systems change. BMC Med. 
2018;16(1):63. 
6. Greenhalgh T, Papoutsi C. Studying complexity in health services research: desperately 
seeking an overdue paradigm shift. BMC Med. 2018;16(1):95. 
7. Vindrola-Padros C, Eyre L, Baxter H, Cramer H, George B, Wye L, et al. Addressing the 
challenges of knowledge co-production in quality improvement: learning from the implementation of 
the researcher-in-residence model. BMJ Qual Saf. 2018. 
8. Lewin S, Glenton C, Oxman AD. Use of qualitative methods alongside randomised controlled 
trials of complex healthcare interventions: methodological study. BMJ. 2009;339:b3496. 
9. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of 
complex interventions: Medical Research Council guidance. BMJ. 2015;350:h1258. 
10. Lau R, Stevenson F, Ong BN, Dziedzic K, Treweek S, Eldridge S, et al. Achieving change in 
primary care--causes of the evidence to practice gap: systematic reviews of reviews. Implement Sci. 
2016;11:40. 
11. Ekawati FM, Claramita M, Hort K, Furler J, Licqurish S, Gunn J. Patients' experience of using 
primary care services in the context of Indonesian universal health coverage reforms. Asia Pacific 
family medicine. 2017;16:4. 
12. Khan JA, Ahmed S, MacLennan M, Sarker AR, Sultana M, Rahman H. Benefit incidence analysis 
of healthcare in Bangladesh - equity matters for universal health coverage. Health policy and planning. 
2017;32(3):359-65. 
13. Cordero C, Delino R, Jeyaseelan L, Lansang MA, Lozano JM, Kumar S, et al. Funding agencies 
in low- and middle-income countries: support for knowledge translation. Bulletin of the World Health 
Organization. 2008;86(7):524-34. 
14. Kieny MP, Bekedam H, Dovlo D, Fitzgerald J, Habicht J, Harrison G, et al. Strengthening health 
systems for universal health coverage and sustainable development. Bulletin of the World Health 
Organization. 2017;95(7):537-9. 
15. Tetroe JM, Graham ID, Foy R, Robinson N, Eccles MP, Wensing M, et al. Health research 
funding agencies' support and promotion of knowledge translation: an international study. The 
Milbank quarterly. 2008;86(1):125-55. 
16. Evans DB, Edejer TT, Adam T, Lim SS. Methods to assess the costs and health effects of 
interventions for improving health in developing countries. Bmj. 2005;331(7525):1137-40. 
17. Curry LA, Nembhard IM, Bradley EH. Qualitative and mixed methods provide unique 
contributions to outcomes research. Circulation. 2009;119(10):1442-52. 
18. Lamont T, Barber N, de Pury J, Fulop N, Garfield-Birkbeck S, Lilford R, et al. New approaches 
to evaluating complex health and care systems. BMJ. 2016;352:i154. 
19. Bonell C, Oakley A, Hargreaves J, Strange V, Rees R. Assessment of generalisability in trials of 
health interventions: suggested framework and systematic review. BMJ. 2006;333(7563):346-9. 
7
20. Orton L, Lloyd-Williams F, Taylor-Robinson D, O'Flaherty M, Capewell S. The use of research 
evidence in public health decision making processes: systematic review. PLoS One. 2011;6(7):e21704. 
21. Harvey G, Marshall RJ, Jordan Z, Kitson AL. Exploring the Hidden Barriers in Knowledge 
Translation: A Case Study Within an Academic Community. Qualitative health research. 2015. 
 
8
CHAPTER 2: SYSTEMATIC REVIEW EXAMINING THE USE OF PROCESS 
EVALUATIONS OF COMPLEX INTERVENTIONS ADDRESSING 
CHRONIC DISEASES IN PRIMARY HEALTH CARE 
 
Chapter Overview 
This chapter reports the protocol and the findings of a systematic review of process 
evaluations of complex interventions addressing chronic diseases in primary health care.  
The chapter consists of a published protocol and a submitted manuscript of its findings.   
Process evaluations (PE) alongside randomized controlled trials of complex interventions are 
valuable because they examine implementation fidelity, and address questions of for whom, 
how and why the interventions had an impact. Recognising the rising global burden of 
chronic disease, and the pivotal role primary health care has in addressing it; we sought to 
identify key implementation factors, and methodology that could inform future research in 
this field. We used the UK Medical Research Council guidance for process evaluations as a 
guide, to provide a synthesis and appraisal of the methods used in PEs of primary care 
interventions, and their main findings on implementation barriers and facilitators.  
Author Contributions: HL and SJ conceived the idea for the systematic review of process 
evaluations.  DP, SJ and MH provided guidance to HL in the development of the protocol. 
AM, JM, and MN assisted HL in the selection of papers and data extraction. TL assisted with 
the adjudication of the papers.  HL drafted the manuscripts and all authors contributed to 
the revisions of the manuscript and approved the final manuscripts.   
Manuscript details:  
9
(1) Liu H, Muhunthan J, Hayek A, Hackett M, Laba TL, Peiris D, Jan S. Examining the use of 
process evaluations of randomised controlled trials of complex interventions addressing 
chronic disease in primary health care-a systematic review protocol. Syst Rev. 2016 Aug 
15;5(1):138.  
(2) Liu H, Mohammed A, Muhunthan J, News M, Hayek A, Hackett M, Laba TL, Peiris D,  Jan 
S. A systematic review of process evaluations of primary care interventions addressing 
chronic disease. Submitted to BMJ open in 2018, under review.  
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Background
Why is this field of research important?
With a rapidly rising global burden of disease attributed
to non-communicable diseases, access to high quality
primary health care (PHC) is essential. Complex interven-
tions, defined as ‘interventions that comprise multiple
interacting components, although additional dimensions of
complexity include the difficulty of their implementation
and the number of organisational levels they target’, are
frequently deployed in an attempt to address health
system deficiencies experienced by patients and providers
[1]. Choosing a study design to assess effectiveness of
complex interventions is not straightforward, and it is rec-
ommended to consider randomisation to prevent selec-
tion bias and provide robust evidence [2, 3]. Process
evaluations, which are typically carried out in conjunction
with randomised controlled trials of such interventions,
can help explain for whom, how and why a complex inter-
vention had a particular impact [4].
Such evaluations address the question ‘Is this interven-
tion acceptable, effective, affordable and feasible (for me
or) for this population?’ [5]. Process evaluations can enable
patient-centred care by providing the opportunity for often
over-looked patients’ perspectives to be considered. As an
example, while a pragmatic trial of a cardiovascular polypill
in Australian PHC indicated the polypill was an effective,
cost-effective strategy for improving patient adherence and
the prescribing of indicated medications, our process
evaluation interviews found that clinicians need to consider
the polypill strategy alongside other evidence-based
strategies. These strategies should cater to specific pa-
tient factors such as health literacy, sense of well-being,
financial considerations, establishing ongoing respectful
clinician and patient relationships and improving acces-
sibility to health care [6].
Despite the generation of good quality evidence, this
often does not translate into improved health outcomes
[7]. A key barrier in the literature to research translation
is cost at different levels, e.g. high outpatient costs for
screening to the patient or cost of medications for the
programme [8–10]. While health economic evaluations
are increasingly being conducted as separate studies to
provide evidence of cost-effectiveness to decision makers,
there may be cost information that is relevant to the
objectives of a process which needs to be investigated. For
example, minimising indirect costs to patients is some-
thing that is important in understanding why an interven-
tion may be more acceptable to patients compared to
standard care. Conversely, for some, indirect costs associ-
ated with the intervention may discourage patients from
seeking care. These are economic issues which we propose
would be important to capture as part of process evalua-
tions but are not strictly captured in health economic
evaluations assessing the incremental cost-effectiveness of
interventions. It would be pertinent as part of a process
evaluation to incorporate relevant cost data from the on-
set, especially within PHC trials in low- and middle-
income countries (LMIC) and in populations which have
complex needs and limited funding to be allocated [9].
This would be important as part of a process evaluation,
to unpack whether for whom and how an intervention
can be implemented into routine practice after the trial is
completed. These findings from process evaluations can
then inform adoption of interventions into practice and
thus the scalability and sustainability of interventions [11].
What is known about this field currently?
Process evaluation methodology is evolving [4]. Process
evaluations were previously synonymous with qualitative
research alongside trials and were conducted to provide a
deeper understanding of the disease condition, implemen-
tation issues and mechanisms of the intervention [12].
However, there is a growing recognition that using quali-
tative and quantitative data (mixed methods) can help fa-
cilitate trial implementation and research translation
[13–15]. For instance, stratifying quantitative outcome
data by socio-economic status and triangulating it with
qualitative interviews, multi-level modelling and embed-
ded cost-analysis in a process evaluation may be useful in
determining the relevance and feasibility of a proven
effective complex intervention. Using mixed methods, a
clearer picture of the intervention may emerge that could
aid various stakeholders in their decision-making.
Although ‘one size fits all’ methods or methodologies
are not available, various theories or frameworks to
enhance implementation research have been used by
researchers to assist in their process evaluations. In early
2015, guidance was published by the Medical Research
Council (MRC) UK about the planning, conduct and
reporting of process evaluations to aid researchers, policy
makers and funders [11]. The article described the
proposed functions of process evaluations of looking
at feasibility and piloting, evaluation of effectiveness
and implementation post-evaluation during the different
stages of the development, evaluation and implementation
of a complex intervention. These functions expanded
upon the conventional definition of process evaluations
being limited to during trial implementation and defined
‘implementation’ as ‘the process through which interven-
tions are delivered, and what is delivered in practice’. For
example, during the post-evaluation implementation stage,
the authors recommend that the process evaluation serves
to explore how there is ‘routinisation of the intervention
into new contexts, and long term implementation/main-
tenance’. The authors suggest that this function of the
process evaluation is needed as reviews have showed
that post-trial, complex interventions are only partially
maintained. Key recommendations regarding the planning,
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design and conduct, analysis and reporting of process eval-
uations were also discussed in the MRC recommendations
[4, 11]. For example, arguments for whether there should
be a separation or integration of the process evaluation
and outcome evaluation teams were presented. The need
to integrate process and outcome data in the analysis and
the timing of when process data should be analysed in rela-
tion to outcome data were discussed.
The appraisal of the quality of process evaluations has
not been straightforward partly because of the variability
in methods [11, 16, 17]. Grant et al. in a literature review
found that the process evaluations were of poor and in-
consistent quality and proposed seven criteria for the
reporting of process evaluations including clearly label-
ling that it is a process evaluation [17]. Other sugges-
tions include appraising the quality of the process
evaluation based on the methods used. Given that most
process evaluations will have a qualitative component, a
set of criteria to examine the quality in the reporting of
qualitative research will be relevant to most process
evaluations [18, 19].
Dissemination and reporting of findings from process
evaluations especially in academic publications can also
be difficult due to a variety of reasons including feasibil-
ity due to limited resources for research projects, lag
time till dissemination of result or publication bias as
usually positive outcome trials will be reported but not
necessary negative trials [11, 20]. This in turn could limit
the likelihood of such relevant findings affecting policy
and practice.
Why do this review?
The George Institute for Global Health has a current
programme of research which focuses on addressing
NCDs through cost-effective and equitable strategies in
primary health care settings including LMIC, and with
indigenous populations [21]. Our studies trial complex
interventions such as capacity-building initiatives with
local providers [22], use of innovative mobile technology
[23], and cost-effective generic medications (e.g. polypill)
within primary health care settings [24]. We have found
that at times, despite acceptability and effectiveness of
these strategies, there are significant challenges that im-
pact upon their scale up. These barriers could be cul-
tural, political or institutional factors [25], but an
important reason for limited translation seems to lie in
the lack of understanding of implementation issues
within contextual factors for the different stakeholders
(e.g. patient, provider, policy makers). For example, while
a trial in India of a clinical decision support system on a
mobile tablet improved initial diagnosis and antihyper-
tensive management of trial patients, and was deemed
acceptable by end-users, only 35% of patients attended
the scheduled 1-month follow-up [23]. Interviews with
stakeholders found that limited patient accessibility to
medicines and doctors (for a variety of reasons including
inadequate staffing, limited primary health care infrastruc-
ture) as the key barrier which needs to be overcome. This
contrasts with other trials of electronic health tools (e.g.
decision support, text messages) in Australia which tend
towards generally more positive and sustained results as
such presumably because system issues were less of a sig-
nificant barrier given the universal and subsidised health
care available [26–28]. Given the greater burden of early
mortality from NCD in LMIC and disadvantaged popula-
tions [29], consolidating our findings in this proposed sys-
tematic review with an equity-focused lens to better
understand how to strengthen PHC within relevant con-
textual policy and system issues would be useful. Indeed,
systematic reviews of interventions in primary health care
have concluded that in addition to clinical outcomes, rigor-
ous evaluations of implementation outcomes (e.g. through
process evaluations) are needed to ensure changes in prac-
tice [30, 31]. We hope that this systematic review will add
to the process evaluation methodology and understanding
of effective implementation strategies in different PHC
settings [32, 33].
Objectives and key questions
To our knowledge, this is the first systematic review of
process evaluations of randomised controlled trial
(RCTs) in complex interventions in PHC. For complex
interventions, the pre-specification of a theory for how
an intervention is expected to work can be highly in-
formative in identifying the mechanisms by which an
intervention was hypothesised to have an impact and
why it was found to be successful (or not). It provides a
framework for assessing the behaviour of individual ac-
tors in the implementation of an intervention, potential
breakdowns in the interactions between parties and puts
into context these actions. Thus, findings from process
evaluations from both positive and negative trials can shed
light upon implementation facilitators and barriers, which
would add to the collective lessons for researchers. More-
over, given that there are numerous theories and frame-
works in this area, we thought it would be informative to
describe the breadth of methods used and to make some
recommendations on evaluation methods that should be
incorporated into PEs of complex interventions. Thus,
we aim to consolidate the methodology and methods
from process evaluations of complex interventions in
PHC and their findings of facilitators and barriers to
intervention implementation in this important area of
health service delivery.
These objectives will be achieved through addressing
these questions: (a) Is there and what is the explicit theory
behind the conducted process evaluations? (e.g. normal-
isation process theory, realist framework); (b) What are
Liu et al. Systematic Reviews  (2016) 5:138 Page 3 of 7
13
the methods used in these process evaluations? (e.g. quali-
tative research through semi-structured interviews, sur-
veys); (c) At what stage is the process evaluation done?
(i.e. feasibility and piloting, evaluation of effectiveness, or
post-evaluation implementation.); (d) If an aim is stated
(i.e. in the evaluation of effectiveness stage), how are the
results of the RCT integrated with the findings from the
process evaluations?; (e) What are the strengths, limita-
tions and potential solutions identified by the authors in
conducting the process evaluations?; and (f) What are the
barriers and facilitators to the implementation of complex
interventions identified by the authors?
Methods/design
This systematic review will focus on process evaluations
of RCTs of complex interventions addressing chronic
disease in PHC. We have described our methods as per
Preferred Reporting Items for Systematic Review and
Meta-Analysis for protocol (PRISMA-P) recommendations,
and this checklist is included as an Additional file 1 [34].
Eligibility criteria
Definitions as per PICO-D have been adapted for the
purpose of this review [20, 35]:
Participants—participants include patients and health
providers in the PHC setting addressing the prevalent
chronic diseases as defined by the World Health Organi-
sation—cardiovascular disease, chronic kidney disease,
chronic respiratory disease, type 2 diabetes mellitus and
depression. PHC as defined by the Alma-Ata declaration
[36] as health services provided within the community
setting by doctors, nurses and allied health with the goal to
achieve better health for all through reforms in universal
coverage, public policy, service delivery and leadership [37].
‘Intervention’—complex interventions defined as those
‘interventions that comprise multiple interacting compo-
nents, although additional dimensions of complexity in-
clude the difficulty of their implementation and the
number of organisational levels they target’ within PHC
[4]. This includes a single-faceted intervention that re-
quires multiple actors or pathways and thus makes the
implementation complex. It is envisaged that the com-
plex interventions for chronic diseases (if not explicitly
defined as a complex intervention) will have elements of
the Wagner chronic care model such as community sup-
port, case management, self-management, facilitated
family support, organisational change, delivery system
design, decision support for health care providers and
clinical information systems [38].
Comparator—not applicable
‘Outcomes’—(1) findings from the process evaluations
of stated implementation barriers and facilitators to the
complex intervention. (2) The stated strengths and limi-
tations of the process evaluation methodology from the
perspectives of the authors. Both findings will be useful
for future conduct of complex interventions in PHC in
the planning, conduct of process evaluations and in the
consideration of intervention implementation and what
barriers need to be overcome in different PHC settings.
Timing—years of search from 1998. This was chosen
because a systematic review by Davies et al. shows that
there was poor use of theory in implementation research
until at least 1998 [39].
Design—process evaluations of randomised controlled
trials of complex interventions in PHC. Process evaluation
as defined by ‘a study which aims to understand the func-
tioning of an intervention, by examining implementation,
mechanisms of impact, and contextual factors’ [11]. As
discussed by Grant et al., because process evaluations are
not clearly labelled as such, qualitative research conducted
alongside RCTs with similar aims will be included [17, 40].
Exclusion criteria—articles were excluded if they were
not a journal article, not a report based on empirical
research (e.g. protocol, editorial), not reported in English
and reviews and not human research.
Search strategy
Information sources
Databases reporting academic publications (MEDLINE,
SCOPUS, PsychInfo, CINAHL, EMBASE, Global Health.)
In order to locate any process evaluations whose findings
were not published or missed in the database searches, we
will search major clinical trial registries for completed
process evaluations (e.g. Cochrane Central Registry of
Controlled Trials, EU registry, ANZTRN and clinical trial
registry (USA)). Authors will be contacted in regard to the
outcomes of the RCT and findings of their completed
process evaluations.
A search strategy was developed and adapted for each
database with the initial support of a medical research
librarian. Search terms were based on the review objec-
tives and early scoping searches (see Additional file 2:
search strategy), key words: process evaluations (including
programme evaluation, qualitative research), complex
intervention (including chronic care model and its com-
ponents of community support, case management, self-
management, facilitated family support, organisational
change, delivery system design, decision support for health
care providers and clinical information systems), rando-
mised controlled trials, PHC (including family practice,
general practitioners) and chronic disease (including car-
diovascular disease, chronic kidney disease, chronic re-
spiratory disease, type 2 diabetes mellitus and depression).
Study records
Data management
After the searches, the shortlisted articles will be exported
to Endnote. Data will be stored in a common file that is
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password protected on the Institute’s server that is access-
ible by the two reviewers. At each stage of the data selec-
tion process during the review (e.g. after consolidation of
all articles prior to assessing eligibility based on title and
abstract), back up files of the endnote database will be
made in order to retrace any steps as needed in the review
process, and for any third party adjudication.
Selection process
Two reviewers will screen all titles and abstracts identify-
ing potential eligible studies based on inclusion and exclu-
sion criteria, and duplicates are to be removed. This will
be done independently to reduce the risk of bias. All
eligible studies will be retrieved in full text and reviewed
by the two reviewers using predesigned eligibility forms
(see Additional file 3). Disagreements will be resolved by
consensus of a third party in the review team.
Data collection process
Data from all included studies will be extracted by two
reviewers using the eligibility and data extraction forms.
The data extraction forms (see Additional file 4) were
partly guided by the MRC recommendation for process
evaluations and Grant et al.’s suggested minimal factors
for reporting on process evaluations [4, 17]. The forms
will be pilot tested by the two reviewers on the same
three articles, iterative changes will be made when
appropriate and the two reviewers will independently ex-
tract data from the rest of the included list of articles.
Data items
Variables to be extracted include data on the RCT and its
process evaluation: (1) RCT—study design, setting (rural,
urban, country), results (positive, negative or equivalent);
(2) process evaluation—any published process evaluation
protocol or evidence of pre-specified process evaluation in
the main trial protocol, or stated aims of the process
evaluation (e.g. examining recruitment, or explaining
results), the process evaluation theory, justified methods
of integrating trial and process outcomes, stage during
which the process evaluation is done (feasibility and
piloting, evaluation of effectiveness and post-evaluation
implementation), methods of analysis and inclusion of
costs incurred.
Outcomes and prioritisation
The outcomes of interest for our aims are (1) the stated
strengths and limitations of the process evaluation meth-
odology from the perspectives of the authors and (2)
findings from the process evaluation of stated imple-
mentation barriers and facilitators of the complex inter-
vention. Both findings will be useful for future conduct
of complex interventions in PHC—in the planning, con-
duct of process evaluations and when considering the
scaling up of an interventions and what barriers need to
be overcome in a PHC setting depending on context [1].
For example, the community’s need, the type of model
or availability of PHC services will be different in
developed settings as compared to LMIC.
Risk of bias in individual studies
For this review, we drew on the use of Tong et al.’s cri-
teria for reporting of qualitative studies [19], on Grant
et al.’s proposed framework of minimal requirements for
the reporting of process evaluations of cluster rando-
mised controlled trials [17] and on MRC recommenda-
tions for process evaluations of complex interventions
[4]. Combining insights from these papers, a form of ap-
praisal for risk of bias was derived (see Additional file 5).
For the purposes of this review in examining the use of
process evaluations alongside RCTs in PHC, studies
were not excluded based on quality [20]. Instead, the
quality of the studies is presented as a risk of bias graph
(low, unclear and high risk) [41].
Data synthesis
This will involve the aggregation or synthesis of qualitative
findings to generate a set of statements that represent that
aggregation and categorisation of these findings on the
basis of similarity in meaning and contexts. These categor-
ies will then be subjected to thematic synthesis in order to
produce a single comprehensive set of synthesised find-
ings that can be used as a basis for evidence-based prac-
tice. The synthesis of these qualitative data aims to satisfy
the criteria established for the reporting of the synthesis of
qualitative health research [18]. Abstracted quantitative
data (e.g. number of positive trials) will be presented to-
gether with a descriptive narrative form including tables
and figures to aid in data presentation where appropriate.
We will examine how authors address potential bias
through a narrative synthesis how well these are reported
in the papers and strategies that may have been employed
to mitigate this (e.g. triangulation of key findings). De-
pending on papers included, there may be subgroup ana-
lysis of further exploration of any differences of the
barriers and facilitators to intervention implementation by
context such as indigenous versus non-indigenous and of
developed settings as compared to LMIC.
Discussion
There is a global call for PHC reform in the areas of
service delivery, public policy and leadership to enable
greater equity and improved health to different popula-
tions. To effect this change will require complex interven-
tions involving multiple players (clinicians, community,
allied health professionals, policy makers), disciplines
(e.g. education, health) and what is successful in one con-
text may not be suitable in another. Process evaluations
Liu et al. Systematic Reviews  (2016) 5:138 Page 5 of 7
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conducted alongside RCTs of complex health interven-
tions are valuable in determining whether a complex
intervention should be scaled up or modified for other
contexts.
The conduct of process evaluations is still a dynamic
area with no clear defined method, partly due to the
spectrum of methods (e.g. observation, interviews and
routine monitoring data). De Silva et al. in 2014 outlined
the integration of the Theory of Change into the MRC
framework for complex interventions, and one of its
aims was to combine ‘process and effectiveness indicators
into a single analysis which can help untangle whether,
how and why an intervention has an impact in a par-
ticular context, and whether it may be suitable for scale
up or adaptation for new settings’ [42]. Moreover, in re-
gard to future scale up of complex interventions, eco-
nomic issues pertinent to stakeholders (e.g. patients and
providers) would be crucial to policy makers and fun-
ders—while this has not been traditionally incorporated
together with process evaluations, it would be helpful to
see if it has been done [35, 43].
Process evaluations of complex interventions have
been increasing in recent years and seem to be variable
in objectives, methodology and quality. The MRC guidance
in the conduct of process evaluations and in the interpret-
ation of the RCT outcomes may be helpful for researchers
to aid in the implementation of effective interventions be-
yond the research setting. This protocol outlines our
methods and design in our efforts to systematically con-
solidate the collective experience of researchers in this field
in conducting, analysing and reporting process evaluations
by assembling the findings within the MRC’s process
evaluation recommendations and to understand previous
challenges and potential solutions in the implementation
of evidence-based complex interventions in PHC accord-
ing to context.
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ABSTRACT  
Objective: Process evaluations (PE) alongside randomized controlled trials of complex 
interventions are valuable because they examine implementation fidelity, and address 
questions of for whom, how and why the interventions had an impact. We used the UK 
Medical Research Council guidance for PE as a guide to provide a synthesis and appraisal of 
the methods used in PEs of primary care interventions, and their main findings on 
implementation barriers and facilitators. 
Design: Systematic review  
Setting: Primary health care  
Participants: Patients with non-communicable diseases, and their health providers  
Findings: 69 studies were included. There was an overall lack of consistency in how PEs were 
conducted and reported. The main weakness is that only 30 studies were underpinned by a 
clear intervention theory often facilitated by the use of existing theoretical frameworks. The 
main strengths were robust sampling strategies, and the triangulation of qualitative and 
quantitative data to understand intervention’s mechanisms. Findings were synthesized into 
3 key themes: 1) a fundamental mismatch between what the intervention was designed to 
achieve and local needs, 2) the required roles and responsibilities of key actors were often 
not clearly understood and; 3) the health system context – factors such as governance, 
financing structures and workforce- if unanticipated could adversely impact 
implementation.   
Conclusion: Greater consistency is needed in the reporting, and the methods of PEs. In 
particular, greater use of theoretical frameworks to inform intervention theory. More 
emphasis on formative research in designing interventions is needed to align the 
intervention with the needs of local stakeholders; and to minimise unanticipated 
consequences due to context-specific barriers.  
 
Registration with PROSPERO Registry: registration number is CRD42016035572 
Keywords: process evaluations, primary health care, complex interventions, systematic 
review, chronic disease, non-communicable disease, qualitative   
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Strengths and Limitations of the study 
- A study limitation is appraising the studies using a tool which we developed based on 
the UK Medical Research Council’s guidance on process evaluations, which has not 
been tested elsewhere. 
 
- A strength of this review is having a multidisciplinary team of authors with vast 
experience in clinical trials and process evaluations to enable a reflexive thematic 
synthesis and interpretation of the papers.   
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INTRODUCTION 
 An accessible, effective and affordable primary health care (PHC) system is needed to 
equitably reduce the rising non-communicable disease burden. (1-3) Complex interventions 
comprising of “multiple interacting components (although additional dimensions of 
complexity include the difficulty in their implementation and the number of organisational 
levels they target)” are often used to reduce this burden. (4) Such interventions addressing 
chronic disease often require individual and organisational behaviour change within 
dynamic policy, local environment and health system contexts. (5) (6) Randomised 
controlled trials (RCTs) of complex primary care interventions have been conducted but 
there is often ambiguity as to what was  actually implemented. (7-9) Process evaluations 
(PE) are conducted alongside trials examine if a complex intervention was implemented as 
intended, and to explore if, for whom, how and why the intervention had an impact. (4)  
A process evaluation is defined by the United Kingdom Medical Research Council (MRC) as a 
study to ‘understand the functioning of an intervention, by examining implementation, 
mechanisms of impact, and contextual factors’. (4) The MRC process evaluation framework 
and guidance published in 2015 is based on the synthesis of influential frameworks and 
theories in public health research and informed by the authors’ process evaluations. (4) 
Implementation concepts of reach, fidelity, and adoption were made explicit, as was the 
need for the intervention theory i.e. the hypothesis relating to how the complex 
intervention may interact with contextual factors to produce variation in outcomes (10, 11) 
Ideally the intervention theory would determine the process (qualitative and quantitative) 
data to be collected and analysed before the RCT outcomes are known. PE findings could 
potentially help explain variation in RCT outcome, refine the intervention theory and inform 
future research priorities. Recognising the need to facilitate implementation of evidence 
into practice and policy- the MRC guidance also expands on the importance for process 
evaluations to be conducted across all stages of research i.e. feasibility/piloting, evaluation 
of effectiveness, and post-evaluation stages. While the guidance was well-received, 
outstanding questions remain in this developing field. For example, what is the role of other 
theories and frameworks for process evaluations? What methods can be used and how?(12-
14) Synthesising the collective ‘experience’ described in published process evaluations may 
answer some of these questions.  
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This review has two primary objectives. First, to review the methods used in published 
process evaluations and their alignment with the MRC guidance, and second to identify the 
key implementation barriers and facilitators reported in these process evaluations.  
METHODS 
The systematic review protocol has been prespecified, and described in detail elsewhere. 
(15) A summary is presented here according the PRISMA guidelines.(16) 
Eligibility Criteria for the randomised controlled trials with the included process 
evaluation 
Population: Patients with non-communicable diseases(Diabetes, Depression, Cardiovascular 
Disease, Chronic Obstructive Pulmonary Disease, Chronic Kidney Disease, Type 2 Diabetes 
Mellitus), and their primary care providers.  (5)  
Intervention: complex interventions which comprise “multiple interacting components 
although additional dimensions of complexity include the difficulty of their implementation 
and the number of organisational levels they target” within PHC.(4) 
Comparator: the control condition may include treatment as usual, active control or placebo 
control.  
Outcomes for this systematic review:  (1) Strengths and limitations of each process 
evaluation using the MRC guidance as a reference point. (2) Identification of 
implementation barriers and facilitators for the complex interventions. 
Timing: published data from 1998.  
Design: process evaluation of the included randomised controlled trials (RCTs) as defined by 
the MRC as ‘a study which aims to understand the functioning of an intervention, by 
examining implementation, mechanisms of impact, and contextual factors’.  (4) Given that 
process evaluations are often not explicitly labelled as such (11), we included studies with 
comparable aims.  
Exclusion criteria: not a journal article, not a report based on empirical research, not 
reported in English, reviews and not human research.  
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Search strategy and data extraction: Standard systematic review methods were followed for 
searching (1998 till June 2018), screening and extracting data from eligible studies. (15) Two 
reviewers (HL, AM) conducted most of the data extraction, with a third reviewer (MN) 
assisting in data extraction with some papers and as part of quality assurance, checked on 
the data extraction for a 10% sample of the identified papers. Given that a key aim of this 
study was about process evaluation methodology- we deviated from the published 
systematic review protocol, by including our interpretation in addition to the study’s 
strengths and limitations posited by the authors of those papers.  
Data analysis and synthesis 
Descriptive items (e.g. number of positive RCTs) were tallied and synthesised into 3 tables.  
(1) Overall characteristics: presenting the studies grouped into different diseases and 
ordered by year of publication. (Appendix 1); (2) Methods table: grouping studies by the 
stages of the process evaluation (i.e. feasibility/ piloting, effectiveness, post-evaluation) 
(Appendix 2); (3) Quality assessment. (Appendix 3).  
Extracted qualitative data were coded by HL, and grouped into categories of context, 
mechanisms and implementation. Inductive derivation of the key themes was done through 
constant comparison between the findings from the papers within each category and 
examining the relationships between them. Appendix 4 provides illustrative quotations. The 
methodological and implementation findings were triangulated using a modified MRC PE 
framework to examine how the process evaluations elicited the implementation findings.    
FINDINGS 
(1) Characteristics of included studies 
We identified 69 studies. The PRISMA flowchart is presented in Figure 1. In summary, 66 
studies were conducted in high income countries, 1 study in Zambia, 1 in Malaysia and 1 in 
India. Cardiovascular disease, diabetes mellitus, and depression were the conditions most 
often investigated, with only six studies on chronic obstructive pulmonary disease and one 
study on chronic kidney disease.  Overall, the complex primary care interventions fit within 
the general categories of facilitating patient self-management (13 studies), organisational 
change to include collaborative care (15 studies), facilitating better case management using 
23
clinical information systems (e.g. tele-health) (15  studies), and the use of decision support 
and guideline implementation (e.g. referral systems) (22 studies). In addition, 5 studies 
explored the challenges when conducting trials in primary care e.g. the recruitment of 
patients.   
Only 22 studies were labelled clearly as process evaluations, though this was more common 
in recent years. Twenty studies were conducted at the feasibility stage with five labelled as 
PEs, 43 studies at the effectiveness stage with 17 labelled as PEs, and six studies at the post-
evaluation stage with none labelled as process evaluations. In thirty-five studies the degree 
of separation between the process and outcome evaluation researchers was explicit. The 
cost considerations for the system and stakeholders was mentioned in 10 papers (see Table 
1 for more detail). In Figure 2 the context of the studies and an overview of the main 
methodological and implementation findings are diagrammatically presented in a PE 
framework. 
 (2) Process evaluations’ strengths and limitations  
Description of Intervention theory- clear intervention description and clarification of 
causal assumptions 
Thirty papers were assessed as having clear intervention descriptions and clarification of 
causal assumptions, and in sixteen it was unclear because despite clear intervention 
descriptions, the causal assumptions were not described explicitly. An example of a paper 
that explicitly describes intervention theory is Grant et al who uses the Template for 
Intervention Description and Replication (TIDieR) checklist to clearly describe the 
researchers’ assumptions of the intervention’s mechanism as compared to the stakeholders’ 
perspectives. (17) 
Use of existing theories and frameworks:  A strength of 22 studies was the use of existing 
theoretical frameworks to inform their intervention development and/or evaluation.  (See 
Table 2) Theories and frameworks used are grouped according to Nilsen’s proposed 
categories.(18) This is depicted in Box 2, with illustrative examples from the identified 
studies. In essence, eleven studies used classic theory to inform the development of the 
intervention theory. In eight studies determinant, implementation theories and evaluation 
frameworks were used to assist in the synthesis and analysis of qualitative data.  The 
24
authors of two studies also used their findings and implementation theories to iteratively 
inform their implementation strategies. The evaluation frameworks were used by study 
authors to comprehensively evaluate and synthesise their process evaluation data. The MRC 
framework for complex interventions was used to inform the approach to intervention 
development in three studies.  
The use of theoretical frameworks seems to enable an in-depth investigation of 
stakeholders’ perspectives of the perceived mechanisms of the intervention; by in a sense, 
providing a checklist of actions and behaviours to be examined.(19-29) An illustrative 
example is the PE of a trial in improving primary care referrals of patients with diabetic 
retinopathy to specialists through the use of educational printed materials. (29) A 
behavioural theory was used to inform the design and use of a questionnaire to explore the 
mechanism of the intervention. It was found that the primary care providers’ intention to 
refer patients was the same before and after the trial, and this may have explained their 
negative trial results. The authors highlighted that the use of existing behavioural theory 
enhanced the ‘generalisability and replicability’ of their methods.  
Interaction with contextual factors: In fourteen papers the interaction of the intervention 
and contextual factors were explicitly explored. As mentioned above, theoretical 
frameworks often facilitated a closer and systematic way to consider context. For example, 
authors examined if there was ‘contextual integration’ i.e. organisational changes necessary 
to integrate a collaborative model of care for depression into routine practice. (30) 
Otherwise, contextual factors (e.g. impact of the introduction of a new policy (31)) were 
reported retrospectively in some papers in a more ad hoc manner- as reported 
implementation facilitators and barriers, or discussed as possible influences on the 
outcomes.    
Methods used 
Most authors clearly justified the choice of their methods and clearly stated the studies’ 
purpose. The methods could be categorised as: qualitative studies (e.g. interviews, focus 
group discussions, documentary analysis), quantitative (e.g. processes of care, baseline 
demographics, secondary outcomes) and studies which presented the synthesis of 
qualitative and quantitative data sources to indicate implementation, acceptability, fidelity 
25
and reach. Most of the qualitative studies were of reasonable quality as assessed by the 
consolidated criteria of reporting of qualitative research (COREQ). (See Table 2 and 
Appendix 3 for more detail.)  
A strength of some studies was the triangulation of quantitative indicators with the 
qualitative findings of the acceptability and implementation of the intervention to 
determine intervention fidelity (i.e. whether the intervention was delivered per protocol).  
(See Appendix 2 for more detail.) (32, 33) The data sources indicating intervention fidelity 
included routine administrative data, trial/study management logs (22) and trial secondary 
outcomes. (34-36) Innovative indicators of e-health interventions included recording 
process measures such as time logged on by participants. (37) Other methods to determine 
intervention fidelity across multiple sites was having independent expert assessors 
reviewing intervention delivery using standardised forms. Three studies investigated ‘for 
whom’ an intervention had an impact on with the use of logistical regression of baseline 
demographics to identify relationships of the participants’ characteristics with the primary 
or secondary outcomes. (38) 
Sampling limitations in the qualitative studies were described as potentially introducing bias 
in the findings about intervention acceptability/mechanisms. (19, 20, 24-26, 29, 39-42) For 
example, authors highlighted that respondents who having agreed to be interviewed may 
have a more favourable opinion of the intervention. (19, 39, 43-45) Maximum variation 
sampling (types of participants, socio-demographics, by ‘negative’ baseline of outcome 
characteristics’), comparing the characteristics of participants who did not partake in the 
interviews/surveys with the participants who did and triangulation with other data sources 
may increase the robustness of such findings.  (20, 21, 23, 29, 39, 40, 46)  
 (3) Process evaluation findings under mechanisms, implementation and context 
Does the intervention fit local needs? 
Stakeholders were generally motivated to adopt/implement the complex intervention if it 
addressed the contextual gap in care i.e. intervention fit. For example, a nurse-led 
secondary prevention clinic was implemented effectively when the health providers 
perceived it as improving team work, care continuity and providing a ‘safety net’ for the 
patients. In contrast, at other sites, this intervention was poorly implemented by the health 
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care providers who viewed it as duplicating the existing model of care.  (47) As another 
example, general practitioners reported that training them to manage acute and discrete 
episodes of depression, did not improve their management of depression. This was because 
this training did not upskill them for the chronic and relapsing nature of depression 
associated with personality and social problems increasingly seen in primary care. (42, 48) 
Similarly, patients’ health literacy about their chronic disease (e.g. effectiveness of lifestyle 
modification for diabetes) was crucial as it affected engagement with the primary health 
care services, and their uptake of the intervention.  (23, 26, 49-51)  
Do key actors believe in and adopt their ‘assigned’ roles and responsibilities? 
The extent to which key actors believed in and adopted their ‘assigned’ roles and 
responsibilities as part of implementing the complex intervention was a key theme under 
the heading ‘Implementation.’ (22, 27, 28, 43, 48, 52) For example, in a study which used 
tele-monitoring to improve management of COPD patients in the community- there were 
differing views of the role of the patient. Some health providers described concerns that 
tele-monitoring would reinforce the ‘sick role’ of the patient, and an over-reliance on 
technology and practitioner support; and as such were less willing to implement this model 
of care. On the other hand, some patients described that tele-monitoring was empowering 
as it provided knowledge and increased access to health practitioners who could provide 
reassurance in the management of the disease- and were keen to continue this model of 
care.(23)  
Facilitators to improve key actors’ uptake of the interventions included the provision of 
intense training over a transition period prior to the start of the trial, significant research 
support, and ongoing communication with the researchers to help identify key actor’s 
concerns and tailor implementation strategies to address them. For example, 
implementation strategies to ensure adequate communication between nurse practitioners 
and general practitioners were essential in task-shifting models of care. This facilitated 
greater trust between nurse practitioners and doctors which was needed to effectively 
deliver collaborative services. (52) Such strategies were especially relevant for collaborative 
care interventions where new tasks were introduced within established hierarchical systems 
and interaction between different stakeholders was necessary for effective implementation.   
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Is the context of the intervention conducive? 
Health system structures such as governance, health financing structures and workforce, 
were often mentioned as impacting on intervention implementation. Governance structures 
was pivotal to the successful adoption of the intervention (24, 34). For example, an 
intervention to enhance referrals to mental health services was implemented well at a site 
when it was perceived as ‘service delivery’ and directly supported by the mental health 
trust. In comparison, uptake of the intervention was limited when the intervention was not 
viewed as ‘service delivery’ and was considered ‘primary research’. (34) Similarly, cultivating 
a strong partnership between researchers and clinicians through the formation of clinical 
advisory teams facilitated the intervention implementation in bureaucratic and 
geographically complex environments. (24) A limited workforce and equipment shortages, 
and inadequate funding structures were reported by several authors as barriers to the 
adoption of the intervention. For example, health providers stated that the lack of 
government reimbursement for allied health services reduced the acceptability of the tele-
health model of care for ongoing monitoring of diabetes at home. (40) General practitioners 
reported that time constraints in their busy practices prevented them from using the skills 
they learnt through an educational intervention to better manage depression. (42) Likewise, 
macro level context such as medication being out of stock in rural Zambia, was a barrier to 
the better outcomes, in spite of an evidence-based intervention to improve clinical 
assessment and management. (33)  
Importantly, an iterative collaborative approach was described as a facilitator of 
intervention fit. (19, 37, 45, 50, 51, 53, 54). For example, study authors described how early 
stakeholder involvement identified the key characteristics of the lay worker needed (i.e. 
female, with visibility in the community) for their intervention to improve mental health 
care in India. This preparatory phase in the development of their model of care led to a 
definitive RCT with positive outcomes. In their process evaluation of the RCT- they found 
that the provision of a lay worker was not relevant for the private primary care practitioners 
with established therapeutic relationships with their patients, but more so for the public 
health providers who were time poor.  These findings would then inform future scale up of 
the intervention within the right context (i.e. public health system) for the intervention. (53, 
55)  
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Discussion  
Statement of principal findings 
To our knowledge this is the first systematic appraisal using MRC guidance on process 
evaluations of primary care interventions. 66 of 69 studies were conducted in high-income 
countries; whilst cardiovascular disease, diabetes and depression were the most frequently 
studied conditions. There was an overall lack of consistency in the way PEs were conducted 
and reported. Indeed there was a lack of consistency in nomenclature with only 47 of the 69 
studies identifying as ‘process evaluations’ although their purpose were essentially as such. 
Few studies (n=30) were underpinned by an intervention theory- description of 
hypothesised intervention mechanisms of action within local contextual factors. Most 
studies used robust sampling strategies and frequently triangulated qualitative and 
quantitative data to better understand the mechanisms of implementation.  The MRC PE 
guidance with its focus on the interaction/configuration between context, implementation 
and mechanisms of intervention, provided a useful framework for the synthesis of the 
findings. The  findings of these studies can be synthesised into a number of key messages: 1) 
that often there was a fundamental mismatch between what the intervention was designed 
to achieve and local needs, 2) that the roles and responsibilities of key actors required to 
implement the intervention were often not clearly understood and; 3) that health system 
context – factors such as governance, financing structures and workforce – were often 
critical to implementation and as a consequence there were a number of studies where the 
unanticipated influence of these adversely impacted on implementation.   
Comparison to other literature and implications 
A key finding is identifying the breadth of literature which fits the MRC definition of process 
evaluation. This highlights the growing scope in this field to potentially address the evidence 
to practice gap through greater understanding of the interactions between intervention 
mechanisms, context and implementation. (13, 56, 57) However, greater consistency is 
needed in the reporting of PEs – as this would facilitate evidence synthesis, prevent 
research duplication and enhance transferability of interventions to other settings. (58) We 
note that the consistency in reporting seems to have increased since the publication of the 
MRC guidance.  
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An important finding is that theoretical frameworks helped guide a more in-depth 
development of intervention theory, design and implementation. (13, 59) The MRC PE 
guidance suggests that PE can help to explain the outcomes variations, and by doing so help 
refine the intervention theory. (18) We note that given the growing focus on self–
management for chronic diseases, that the theories around behavioural change (e.g. 
empowerment) were most commonly used. Secondly, the focus on organisational change 
and the adoption of guidelines in NCDs, meant that implementation theories such as 
Normalisation Process Theory (NPT) were particularly relevant. Thus, there should be more 
consistent use of theoretical frameworks, recognising that different frameworks will be 
applicable to different settings. In addition, the use of checklists such as the Template for 
Intervention Description and Replication (TIDieR), or the Standardised for Reporting 
Implementation (StaRI) will ensure consistency in the reporting of intervention theory and 
implementation, thus reducing research waste. (56, 60, 61) 
We found that the intervention interaction with dynamic contextual factors was often 
inconsistently reported or reported retrospectively in an ad hoc manner. This gap has been 
similarly reported in the literature. (62)These findings emphasis MRC PE guidance’s value in 
explicitly appraising context through “examining factors that shape theories, and affect 
implementation, and act to ‘sustain the status quo, or potentiate effects.” (4) However, this 
guidance is relatively broad and non-specific, and the question remains as to what should be 
explored a priori, and how best to report such findings. For example, the Context and 
Implementation of Complex Interventions (CICI) framework highlights seven domains of 
context (“geographical, epidemiological, socio-cultural, socio-economic, ethical, legal and 
political context”) that could be examined.(56) Similarly, STaRI checklist has context as an 
item in the methods (i.e. “consider social, economic, policy, healthcare, organisational 
barriers and facilitators that might influence implementation elsewhere”) and in the results 
(“contextual changes (if any) which may have affected outcomes”.)(60) These domains are 
comprehensive, and as a consequence if a study is to examine only a subset of these factors, 
it is better that it this is pre-specified in full acknowledgment of the evaluation as a whole. 
This should be consistently reported, and linked through a full report or reference to a 
protocol. (4) As a baseline, a standardised PHC template informed by the questions of “Does 
the intervention fit local needs? Do the key actors believe in and adopt their ‘assigned’ roles 
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and responsibilities? Is the health system context (looking specifically at health workforce, 
governance, health financing structures and availability of medications) conducive?” and 
relevant implementation theories (e.g. NPT) could be presented for testing in a systematic 
way. This could be done by primary health care researchers engaging with stakeholders at 
various time points, and iteratively added to. (63-65) Such an approach could potentially 
facilitate a greater shared understanding between stakeholders and greater consistently in 
the reporting of context.  (62, 64, 66-68)  
Most of these studies were conducted in high income countries with established PHC 
systems and universal health coverage (e.g. National Health Service in the UK). Therefore, 
some primary care interventions (e.g. improving referrals in collaborative care) may be of 
limited relevance to LMIC PHC systems given the different context especially with regards to 
health system structures. (69, 70)  This reinforces the need for more formative research 
with local stakeholders when developing evidence-based interventions which addresses 
local needs, and minimises the unanticipated consequences of health system factors. (71, 
72)  
Strengths and limitations of this study  
We were unable to conduct a subgroup analysis of implementation findings by country 
context (i.e. of high income countries as compared to lower middle income countries)as we 
identified studies conducted mainly in high income countries. Some studies conducted in 
LMIC initially identified in the search were excluded because they did not meet our criteria 
(not RCTs, not on NCDs) and as such, a review with different inclusion criteria may be better 
suited for this secondary objective.  Another limitation, is that we appraised the studies 
using a tool which we developed based on the MRC guidance (4), which has not been tested 
elsewhere. This was challenging given the heterogeneous studies that were included. For 
example, we only assessed qualitative methods with COREQ, and did not appraise the 
quality of statistical methods such as modelling.  A strength of this review is having a 
multidisciplinary team of authors with vast experience in clinical trials and process 
evaluations to enable a reflexive thematic synthesis and interpretation of the papers. (73)  
Conclusion 
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Greater consistency is needed in the reporting of, and the methods used, in PEs. In 
particular there should be more consistent use of theoretical frameworks to inform 
intervention theory; and the triangulation of qualitative and quantitative data. Greater 
emphasis on formative research in designing primary care interventions is needed so that 
they are clearly aligned with the needs of local stakeholders, that the roles and 
responsibilities of key actors are better understood and that unanticipated consequences 
arising from context-specific barriers to implementation are minimised. We hope this review 
will inform future process evaluations and facilitate the sustainability of evidence-based 
interventions. 
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Figures and Tables  
Figure 1: PRISMA figure 
Figure 2: MRC PE framework which provides an overview of the findings (legend: MRC PE 
framework that provides an overview of the findings across context, mechanisms, and 
outcomes (key areas of the process evaluation, in blue), and the intervention description 
and outcomes. This is done by showing the number of studies across these headings, and to 
triangulate the synthesised qualitative findings about the studies' strengths and limitations, 
and barriers and facilitators).  
Table 1: Summary of the characteristics of the included studies 
Table 2: Summary of the methodology used and quality assessment of the studies 
Box 1: Illustrative examples of the use of Theories and Frameworks 
 
APPENDIXES 
1) Table 1- PICO table (organised into sections based on the types of NCDs, and within 
each section, studies are ordered by years) 
2) Table 2- Methods table, organised into sections based on stage of process 
evaluation, and within each section, ordered by years)  
3) Table 3- Quality of studies table as informed by the MRC recommendations and the 
COREQ 
4) Table 4- Illustrative examples for the synthesised findings 
5) PRISMA Statement 
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From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
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Additional records identified 
through other sources 
(n = 9 ) 
Records after duplicates removed 
(n =1944) 
Records screened 
(n =1944) 
Records excluded 
(n = 1851) 
Full-text articles assessed 
for eligibility 
(n = 101) 
Full-text articles excluded, 
with reasons. (n=32)  
1) Did not fit target 
population= 7 
2) Not linked to a RCT= 
5 
3) Not a results paper= 
13 
4) Not a process 
evaluation  = 7 
 
 
 
 
 
Studies included in 
synthesis 
(n = 69) 
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DESCRIPTION OF THE 
INTERVENTION AND ITS CAUSAL 
ASSUMPTIONS 
(1)Complex intervention as per the 
chronic care model elements 
(N=number of studies) 
Self- management (N=13)  
Organisational change/collaborative 
care (N=15)  
Case management with the use of 
clinical information systems (N=15) 
Decision support and guideline 
implementation (N=22)  
(2)Limited intervention description 
and hypothesised causal 
mechanisms described  
(N=26)  
Theories and frameworks used in 
the development and evaluation of 
the intervention was a strength 
(N=22) (see Box 1 for illustrative 
examples) 
  
 
 
 
OUTCOMES 
 
RCT outcomes: 33 Positive, 21 Negative  
14 N/A  
-aimed to explain the RCT outcomes. 
(N=51) 
 
Maintenance/ Long term impact – (i.e. Is 
the complex intervention generalizable, 
scalable and sustainable through exploring 
stakeholders’ experiences of the complex 
intervention and its potential impact?) 
(N=6)  
IMPLEMENTATION 
Implementation (i.e. Reach and 
recruitment, Fidelity and Dose, 
adoption) (N=59) 
Costs considerations- 10 papers  
2) Methods- Quantitative 
indicators of implementation could 
be triangulated with the qualitative 
findings. Heterogeneity in how 
authors evaluated sustainability 
post-trial. 
3) Barriers and Facilitators- 
 Do key actors believe in and adopt 
their ‘assigned’ roles and 
responsibilities? 
 
CONTEXT 1) Setting and disease:  22 UK, 9 USA, 10 Australia, , 5 Ireland, 5 Netherlands 3 Canada , 3 New Zealand, 1 India,  1 Norway, 1 Malaysia, , 1 Sweden, 1 
Germany, 1 Zambia. Types of chronic diseases addressed: 25 cardiovascular disease, 20 Depression, 17 diabetes, 6 Chronic Obstructive Pulmonary Disease, 1 chronic 
kidney disease. 2) Methods- Interaction with contextual factors were often not explicitly explored. 3) Barriers and Facilitators – Is the context of the intervention 
conducive? – i.e. dependent on workforce issues, financing structures, and governance structures. 
 
MECHANISMS OF IMPACT 
Effectiveness and 
acceptability- (i.e. What are 
the stakeholders 
perspectives as to how, why 
and for whom does the 
complex intervention work 
for?) (N=34) 
2) Methods- Qualitative 
interviews with maximum 
purposive sampling (from 
different stakeholders, and 
characteristics) a strength. 
Triangulation of quantitative 
indicators and qualitative 
findings a strength. 
3) Barriers and Facilitators -
Does the intervention fit 
local needs? 
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Table 1: Summary of the characteristics of the included studies 
Disease 
Condition 
interventions Setting RCT Outcomes 
Cost 
Considerations 
(Y/N/NA) 
20 studies on 
depression. 
Interventions mostly around 
collaborative care through increasing 
expertise of different roles (e.g. lay 
worker, nurse for pro-active care, GP for 
PHC) (16 studies), times to implement 
practice guidelines (4 studies), and 
trialling specific interventions such as 
physical exercise and cognitive 
behaviour therapy. (2 studies). 
 
9 UK, 
7 USA,  
1 Sweden,  
1 Germany,  
1 Australia  
1 India. 
11 positive RCTs,  
5 Negative,  
4 N/A 
4/19 Y,  
14 N, 
2 N/A 
17 studies on 
diabetes  
The interventions included improving 
guideline-based referral and treatment (7 
studies), patient self-management, 
community support (7 studies) and tele-
health (3 studies).  
3 Ireland,  
3 UK,  
1 Norway,  
2 USA,  
2 Canada (1 of the 
First Nations),  
2 Australia,  
1 New Zealand,  
1 Malaysia 
 
6 Positive,  
10 Negative, 1 N/A 
3/16 Y,  
13/16 N,  
1/16 N/A 
25 studies on 
CVD.  
10 studies were about improving the 
screening and management of CVD 
using best-practice guidelines. (e.g. 
educational materials to improve referral, 
or decision analysis). 10 studies were 
about organisational change with models 
of care that incorporated new roles such 
as a nurse-led clinic, or the use of a lay 
worker for angina management, and 
technology (e.g. tele-monitoring, point of 
care testing). 5 studies explored trial 
implementation such as recruitment of 
patients and providers, and were less 
about the intervention. 
 
9 UK,  
6 Australia,  
3 Canada,  
2 New Zealand,  
2 Netherlands,  
1 Ireland,  
1 USA,  
1 Zambia  
15 Positive,  
5 Negative,  
5 N/A 
3 Y,  
15 N,  
6 N/A 
6 studies on 
COPD (2 
including other 
chronic 
disease), and 1 
addressing 
CKD. 
4 studies were about improving self- 
management of patients through 
educational materials, or use of 
monitoring, with support from health 
providers. 2 studies were about 
stimulating physical activity through the 
use of technology. 1 study was about 
implementing management guidelines in 
CKD in primary health care. 
 
3 Netherlands,  
1 Ireland,  
1 UK (Scotland),  
1 USA,  
1 Australia 
2 Positive,  
1 Negative,  
4 N/A 
0 Y,  
5 N,  
2 N/A. 
Overall 
Synthesis of 69 
studies in total. 
20 Depression, 
17 Diabetes, 25 
CVD, 6 COPD 
and 1 CKD. 
Overall, the complex primary care 
interventions fit within the general 
categories of facilitating patient self-
management (13 studies), 
organisational change to include 
collaborative care (16 studies), 
facilitating better case management 
using clinical information systems 
(e.g. tele-health) (15 studies), and the 
use of decision support and guideline 
implementation (e.g. referral systems) 
(22 studies). In addition, 5 studies 
were exploring the conduct of trials in 
primary health care e.g. the 
recruitment of patients.  
22 UK,  
10 Australia,  
9 USA,  
5 Ireland,  
5 Netherlands,  
3 Canada,  
3 New Zealand, 
1 Sweden,  
1 Germany,  
1 India,  
1 Norway,  
1 Malaysia,  
1 Zambia  
In addition, 2 
studies focused 
on First Nations 
peoples in 
Australia and in 
Canada. 3 
studies were 
focused on the 
populations 
living in 
disadvantage. 
33 Positive,  
21 Negative  
14 N/A  
10 Y*,  
47 N,  
11 N/A 
41
 Abbreviations: COPD: Chronic Obstructive Pulmonary Disease; CKD: Chronic Kidney Disease; CVD: 
Cardiovascular Disease; GP: General Practices; N: No; N/A: Not Applicable; RCT: Randomised Controlled Trial; 
UK: United Kingdom; USA: United States of America; Y: Yes.  
* Of note two were full evaluation reports (outcome, process and economic evaluations) in the UK journal of 
Health Technological Assessments in addressing the question of whether an innovation with limited evidence 
base in a pragmatic setting (e.g. introducing cognitive behaviour therapy in schools) should be scaled up. Eight 
papers included descriptions of the how costs considerations such as financing incentives/ government 
subsidies impacted on intervention implementation. 
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Table 2: Summary of the methodology used and quality assessment of the studies 
Stage of 
process 
evaluation 
Methodology & Methods Analysis 
 
 
Quality criteria 
 
 
Feasibility/ 
Piloting 
 
20 Studies 
 
9 studies used theories or 
frameworks.  
18 used interviews. 3 used focus 
group discussions, 4 used 
questionnaires or surveys, 2 
studies used routine monitoring 
data, field notes, minutes of 
meetings and observations.  
Thematic analysis, 
constant comparative 
approach most 
commonly used, with 
some using framework 
analysis.  
 
Planning: Team description: 11Y, 6N, 3 N/A 
Design and Conduct:  
Purpose: 20 Y 
Intervention description and causal 
assumptions clarified: 
5 Y , 6 unclear, 9 N/A, 0 N 
Justify choice of timing and methods: 19Y, 1 N  
COREQ covered out of the 3 domains (17 
applicable studies): 
3 domains: 11  
2 domains: 4 
1 domain: 3  
Reporting  
Clearly labelled as process evaluations: 5 
Protocol/full report: 8 
 
Evaluation of 
effectiveness 
 
43 studies 
 
12 studies used existing theories 
and frameworks. (6 Classic 
theories,  
3 evaluation frameworks, 3 
implementation theories) 
2000-2004: 3 studies 
documented specific processes 
of care as part of the process 
evaluation, which were reported 
as part of the main trial. 4 
studies investigated acceptability 
of an intervention using 
surveys/questionnaires. 
2005 onwards- 12 studies used 
interviews alone to explore 
implementation and 
acceptability; 20 studies used 
interviews triangulated with 
other sources of data (e.g. chart 
audit). 2 studies used routine 
administrative data to indicate 
fidelity. 3 studies used 
questionnaires or surveys.   
Descriptive statistics were 
used for the quantitative 
data. Thematic, constant 
comparison and 
framework analysis for 
the qualitative data.  
The studies that used 
mixed methods, used the 
quantitative data to 
indicate level of 
implementation, reach 
and the dose. This was 
used to triangulate the 
qualitative findings on 
implementation and 
intervention 
acceptability. The studies 
which used evaluation 
frameworks (e.g. REAIM) 
and implementation 
theories (e.g. NPT) used 
them for the analysis and 
presentation.  
Planning: Team description: 21 Y, 21 N, 1 NA 
Design and Conduct:  
Purpose: 43 
Intervention description and causal 
assumptions clarified: 25 Y, 8 Unclear, 5N/A, 
5N  
Justify choice of timing and methods:40Y, 1 N, 
2NA 
Report whether the process data are analysed 
blind to trial outcomes/ or post hoc: 29Y, 7N, 
7N/A 
COREQ covered out of the 3 domains (30 
applicable studies): 
3 domains: 12 
2 domains: 13 
1 domain: 5 
Reporting  
Clearly labelled as process evaluations: 17 
(of note- 2 before 2008, 6 till 2015, and 9 after 
2015) 
Protocol/full report: 21 
 
Post 
evaluation  
 
6 studies  
 
1 study used existing theory.  
2 studies used interviews, 2 used 
documentary analysis, and 1 
used the administrative data and 
registry data 
Descriptive statistics, 
subgroup analysis and 
thematic analysis. 
Planning:  Team description: 3 Y,  2 N, 1 NA 
Design and Conduct:  
Purpose: 6 
Intervention description and causal 
assumptions clarified:0Y, 2 unclear, 2 N/A, 2 N 
Justify choice of timing and methods: 5Y, 1 N 
COREQ covered out of the 3 domains (3 
applicable studies): 
3 domains: 1 
2 domains: 1 
1 domain: 1 
 
Reporting  
Clearly labelled: 0 
Protocol/full report: 1 
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Classic Theories 
 
Theory of Planned behaviour-. “Using the theory of planned behaviour (TPB), we hypothesised that changes in thiazide prescribing 
would be reflected in changes in intention, consistent with changes in attitude and subjective norm, with no change to their perceived 
behavioural control (PBC), and tested this alongside the RCT…A strength of this study is its use of a well-tested theory of behaviour 
operationalized according to best recommended practice to investigate the underlying mechanisms of an implementation intervention.” 
(Presseau) This theory informed their process evaluation to explore if their intervention of printed educational materials increased 
practitioners’ intention to prescribe according to recommendations in the guidelines. 
 
Self Determination theory - “self-determination theory which proposes that real shifts in behaviour arise through heightened autonomy 
or personal ownership of behavioural success.” (Chalder) This theory informed their theoretical model underpinning their intervention 
to improve physical activity for the management of depression.  
 
Grounded theory- “ This qualitative study was conducted with the objective of better understanding the PP intervention in the BETTER 
Trial described above, including the development of the PP role, perceived barriers, facilitators, benefits and disadvantages, and of 
exploring the feasibility and sustainability of this approach for CDPS.” (Manca) This study used grounded theory to better understand 
their intervention as implemented and to retrospectively describe their intervention theory.  
 
Diffusions of Innovation-“Key principles, which derive from diffusion of innovations theory, include working initially with practices and 
clinicians that not only have an interest in the innovation and view it as compatible with their needs, values, and resources, but also 
have the ability to try it with minimal investment and observe its impact.” (Dietrich) The theory was used to inform their practice 
change strategy for the sustainability of a chronic care model for depression proven effective in an RCT.  
 
Determinant Frameworks 
PARIHS as an implementation model-“We used the Promoting Action on Research in Health Services (PARIHS) framework as an 
‘Implementation model’ to assist clinical partners in adopting the health-coaching intervention. The PARIHS framework posits three 
interrelated elements that influence successful implementation of evidence-based practices: the (I) perceived strength of the ‘evidence’, 
(ii) ‘context’ of the environment and (iii) ‘facilitation’ support created for implementation of the intervention….Using a codebook 
developed a priori from sub elements of the PARIHS framework ” (Naik) This study used PARIHS to inform their participatory approach 
between research team and primary health care teams, and also used it in evaluation of the qualitative data in assessing the building of 
the partnership to test and implement a health-coaching intervention.  
 
Implementation theories 
NPT- Normalisation Process Theory -“as part of mixed-methods process evaluation, semi-structured interviews were conducted by 
phone with 27 providers participating in the study. Interviews were audio-taped and transcribed. Thematic content analysis was used to 
identify themes. Themes were categorized according to the four domains of Normalization Process Theory (NPT)”. (Vest) The authors 
discuss how the findings are informing their ongoing implementation strategies e.g. clinical mentors for the general practitioners who 
described a discomfort in their lack of expertise in screening and managing early chronic kidney disease. (other papers include: Burridge 
,Coupe, Gask, Hanley, Vest) 
 
Evaluation frameworks 
MRC- Medical Research Council’s framework for complex interventions,-“The MRC framework provided a useful structure through 
which to examine our theoretical hypothesis and analyse the feasibility evidence.” (Sturt) 
“Guided self-help intervention was developed following a modelling phase which involved a systematic review, meta synthesis and a 
consensus process…” (Lovell) The authors used the MRC framework for intervention development. Similarly Byrne et al also used the 
MRC framework for intervention development of literature review, focus group discussion and modelling and then interviews to refine 
the intervention.  
 
REAIM- “The process evaluation followed the RE-AIM (Reach, Efficacy/effectiveness, Adoption, Implementation and Maintenance) 
framework. Data were collected on attendance and attrition for classroom-based CBT and attention control PSHE by programme 
facilitators. An independent observer attended 5% of classroom based CBT sessions to assess treatment fidelity. Feedback was gathered 
from teachers, young people and facilitators using questionnaires and qualitative interviews.” (Stallard)  (other papers include: Stallard, 
Wozniak, Lakeverld) 
 
Realist Evaluation-   
“All data assigned to codes relating to the polypill strategy in CVD management were analysed …and the Realist framework of context–
mechanism–outcomes utilized to develop the themes” (Liu) The framework was used to guide the analysis of the qualitative data.  
 
44
CHAPTER 3: A PROCESS EVALUATION OF THE KANYINI GUIDELINES 
ADHERENCE WITH THE POLYPILL (GAP) TRIAL 
 
Chapter Overview 
This chapter reports the findings of a process evaluation of the Kanyini GAP randomised 
controlled trial in Australian primary health care testing the combined cardiovascular 
polypill in mainstream general practices and Aboriginal health services.  The chapter consists 
of three manuscripts titled: 1) Patients’ and Providers’ Perspectives of a Polypill Strategy to 
Improve Cardiovascular Prevention in Australian Primary Health Care. 2) Facilitators and 
barriers to implementation of a pragmatic clinical trial in Aboriginal health services. 3) 
Implementing Kanyini GAP, a pragmatic randomised controlled trial in Australia: findings 
from a qualitative study.  
In Chapter 2, greater use of theoretical frameworks and mixed methods was highlighted as 
important for PEs. This chapter presents the PE of a RCT using the combined cardiovascular 
polypill to improve provider prescribing and patient taking of indicated therapy. I chose to 
use Realist principles for this PE.  During the analysis of the qualitative data, an inductive 
conceptual framework was developed. This framework highlighted the relationships and 
links between the main codes identified through line by line coding and in-depth discussion.   
The conceptual framework highlighted the patient journey and acceptability of the polypill, 
and provided possible explanations for the outcomes. These findings resonated with the key 
questions of ‘for whom, how and why’ in Realist evaluation. Therefore, the Context-
Mechanisms-Outcomes configuration used in Realist Evaluation seemed to be a natural fit 
for the synthesis of the thematic findings. 
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The first manuscript provides an example of how such contextual factors can be analysed 
and reported, and the relevance in the use of mixed methods to help explain variation in 
trial outcomes. For example, using Realist principles to inform the thematic synthesis helped 
identify the relevance of the polypill strategy in the midst of the contextual patient level 
factors that affected adherence to medications.  In addition, using the secondary trial 
outcomes (such as prescribing data) to triangulate the qualitative findings highlighted that 
the polypill strategy in its existing formulations was more suited for high risk primary 
prevention patients as less tailoring of medication was required.   
The next two manuscripts describes the facilitators and barriers in the conduct of 
collaborative research with practitioners in real world settings through pragmatic trials. 
Given the importance of locally driven Indigenous research, there was one manuscript 
focusing on the collaboration with Aboriginal community controlled health sector, and 
another manuscript exploring pragmatic trial implementation with the primary health sector 
in general.  
 
Authors’ contributions: HL was one of two lead analysts of the qualitative data of the 
process evaluation of Kanyini Guidelines Adherence with the Polypill (GAP) trial. HL helped 
manage the study, led the data analysis, drafted and revised all the manuscripts and is 
responsible for the integrity of the work. LM managed the study, led the data collection, 
conducted the analysis, and helped revise the manuscripts. SJ designed the study, helped 
with the data collection, analysis, and writing and revising of the papers. TL assisted with the 
set-up of the study, data collection, and helped write and revise the papers. AE assisted with 
data collection, and helped write and revise the paper. AC, AP, DP, JR, KH and TU helped 
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design the process evaluation, refine the theoretical and methodological approach, and 
helped write and revise the papers. All authors read and approved the final manuscripts. 
In addition, The Kanyini Guidelines Adherence with the Polypill (GAP) trial was a project of 
the Kanyini Vascular Collaboration (KVC). HL was the program manager of KVC, prior to the 
start of the PhD, and was responsible for community engagement, trial set up, including 
ethics application, and the site recruitment and training of principal investigators at the sites 
and trial staff (e.g. project managers, monitors, research nurses).  
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1Cardiovascular disease is a major cause of mortality and morbidity worldwide and is projected to be the lead-
ing cause of death in 2030.1,2 A major part of the problem is 
large treatment gaps globally—for instance, audits of primary 
healthcare in Australia indicated that prescription of guide-
lines-recommended therapy is as low as 50%.3,4 Nonadherence 
to the treatment is likely to further extend this treatment 
gap because it is estimated that ≤50% of patients in high-
income countries do not adhere to prescribed cardiovascular 
disease (CVD) medications, with similar suboptimal adher-
ence in low- and middle-income countries.5,6 The reasons for 
nonadherence fit into well-recognized categories—health 
Background—This study explores health provider and patient attitudes toward the use of a cardiovascular polypill as a 
health service strategy to improve cardiovascular prevention.
Methods and Results—In-depth, semistructured interviews (n=94) were conducted with health providers and patients from 
Australian general practice, Aboriginal community-controlled and government-run Indigenous Health Services participating 
in a pragmatic randomized controlled trial evaluating a polypill-based strategy for high-risk primary and secondary 
cardiovascular disease prevention. Interview topics included polypill strategy acceptability, factors affecting adherence, and 
trial implementation. Transcribed interview data were analyzed thematically and interpretively. Polypill patients commented 
frequently on cost-savings, ease, and convenience of a daily-dosing pill. Most providers considered a polypill strategy 
to facilitate improved patient medication use. Indigenous Health Services providers and indigenous patients thought the 
strategy acceptable and beneficial for indigenous patients given the high disease burden. Providers noted the inflexibility 
of the fixed dose regimen, with dosages sometimes inappropriate for patients with complex management considerations. 
Future polypill formulations with varied strengths and classes of medications may overcome this barrier. Many providers 
suggested the polypill strategy, in its current formulations, might be more suited to high-risk primary prevention patients.
Conclusions—The polypill strategy was generally acceptable to patients and providers in cardiovascular prevention. 
Limitations to provider acceptability of this particular polypill were revealed and a perception it might be more suitable 
for high-risk primary prevention patients, though future combinations could facilitate its use in secondary prevention. 
Participants suggested a polypill-based strategy as particularly appropriate for lowering the high cardiovascular burden 
in indigenous populations.
Clinical Trial Registration—URL: https://www.anzctr.org.au. ANZCTRN 12608000583347.  (Circ Cardiovasc Qual 
Outcomes. 2015;8:00-00. DOI: 10.1161/CIRCOUTCOMES.115.001483.)
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system, condition, patient, therapy, and socioeconomic.7,8 A 
review of strategies targeting CVD medication nonadher-
ence in disadvantaged populations found that interventions 
directed at patients and providers simultaneously showed 
statistically significant improvements in relative adherence.6 
Cardiovascular polypills which are fixed-dose combinations 
of frequently indicated cardiovascular medications for high-
risk primary prevention and secondary prevention have been 
trialled internationally to improve provider prescribing and 
patient medication use. Encouragingly, recent results from 
randomized controlled trials have shown effectiveness in 
improving adherence.9–11
However, whether this promising result is generalizable and 
can be successfully implemented in health services outside of 
trial settings depends partly on whether the polypill strategy 
will be well received by health providers and importantly to 
patients. This can be addressed by qualitative research con-
ducted alongside trials exploring relevant stakeholders’ per-
spectives.12–14 The Realist framework has been successfully 
used in process evaluations as a theoretical basis for iden-
tifying potential causal mechanisms of how an intervention 
works for whom, under what contexts, and thus fosters uptake 
of research-based knowledge into practice.15–19
In this article, we present the qualitative findings of a 
process evaluation set within a multicenter pragmatic ran-
domized, controlled trial (PRCT) of a cardiovascular-based 
polypill strategy in Australian primary care known as the 
Kanyini Guidelines Adherence with the Polypill (KGAP) 
trial.1,9 Patients received a fixed-dose combination containing 
aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, and either 
atenolol 50 mg or hydrochlorothiazide 12.5 mg in the polypill 
group. The usual care group continued cardiovascular preven-
tive treatment, with separate medications and doses prescribed 
at their treating doctor’s discretion.
This pragmatic trial was conducted in a variety of primary 
healthcare services across Australia in urban, rural, and remote 
settings, thereby maximizing potential generalizability20 and 
sought to improve patient medication use and the prescrib-
ing of indicated therapy for high-risk primary and secondary 
CVD prevention patients. Significantly, in Australia where 
indigenous patients have a higher burden of CVD,21 the trial 
was conducted in accessible and culturally safe indigenous 
health services (IHS).22,23
Primary outcomes were measured by self-reported medi-
cation use and changes in biological markers of changes in 
systolic blood pressure and total cholesterol. Results showed 
that “After a median of 18 months, the polypill-based strat-
egy was associated with greater use of combination treatment 
(70% versus 47%; relative risk 1.49; 95% confidence inter-
val [CI] 1.30–1.72; P<0.0001; number needed to treat=4.4 
[3.3–6.6]) without differences in systolic blood pressure (−1.5 
mm Hg [95% CI −4.0 to 1.0]; P=0.24) or total cholesterol 
(0.08 mmol/L [95% CI −0.06 to 0.22]; P=0.26). At study 
end, 17% and 67% of participants in polypill and usual care 
groups, respectively, were taking atorvastatin or rosuvastatin.” 
(ANZCTRN 12608000583347)10
We aim to explore the relevance of the polypill strategy for 
health providers and patients as a health service strategy to 
improve prescribing of indicated therapy and improve patient 
medication use.24 Understanding the mechanism of the polyp-
ill strategy from patients and providers perspectives will assist 
in translation of the polypill intervention to other contexts and 
so inform policy and practice in the area.
Methods
A predefined protocol for the overall process evaluation was used and 
had been published.24 Our methods are presented across key areas for 
reporting in qualitative research.25
Research Team and Reflexivity
Study investigators involved in the design and implementation of 
KGAP developed the process evaluation protocol and interview 
guides. The interviews were conducted by a team of 7 researchers 
who varied in qualitative research experience and had diverse back-
grounds (nursing, health economics, pharmacy, Indigenous health). 
Three were indigenous and 4 were nonindigenous researchers. Two 
of the interviewers were research coordinators and had existing 
relationships with several of the participants interviewed, but the 
other interviewers were not known to the participants before the 
interviews.
Study Design
Participants were recruited purposively based on maximum variation 
of specified variables, which could potentially affect participants’ 
views of a polypill-based strategy and with trial implementation. A 
sampling matrix was used with the following characteristics: for pa-
tients, these were location, age, sex, ethnicity, primary versus second-
ary CVD, and self-reported adherence at baseline; and for providers, 
location and profession.26 All health providers and patients were ap-
proached by a letter of invite detailing the study and purpose and a 
follow-up phone call by the project coordinator. All health providers 
approached agreed to participate, though 5 patients declined to be in-
terviewed and 2 patients were unavailable. Written informed consent 
was obtained.
The interview guides covered the key domains about the polyp-
ill strategy in CVD management, patient satisfaction or prob-
lems with the polypill, issues regarding trial implementation, and 
WHAT IS KNOWN
•	 Although effectiveness trials have shown a signifi-
cant improvement in patient medication use with 
a specific polypill formulation (a combination of a 
statin, 2 blood pressure lowering agents, and anti-
platelet agent) when compared with usual care for 
high-risk primary and secondary CVD prevention, 
patients’ and providers’ perspectives of this approach 
are unknown.
WHAT THE STUDY ADDS
•	 After conducting qualitative interviews with both 
providers and patients involved in a pragmatic clini-
cal trial in Australia, we found general acceptability 
of the polypill-based strategy with patients report-
ing greater convenience and cost savings with the 
polypill.
•	 However, some prescribers highlighted limitations 
of this particular formulation in regards to dosage 
inflexibility and recommended that more doage 
combinations be made available.
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translation of the polypill into clinical practice. Interview guides 
were iteratively revised to explore themes and issues emerging 
from earlier interviews. Interview guides are available as Data 
Supplements.
Ninety-four semistructured interviews were conducted at the end 
of KGAP with 47 providers (25 general practitioners [GPs], 13 phar-
macists, 6 Aboriginal Health Workers, and 3 Chronic Care Nurses) 
and 47 patients in New South Wales, Queensland, and Victoria. 
Twenty-two and 25 patients were in the polypill arm and usual care 
arm, respectively. Twenty-one and 26 patients were in the primary 
and secondary prevention arm, respectively. There were 28 nonindig-
enous patients and 19 indigenous patients. Participant characteristics 
are included in Table in the Data Supplement.
Most interviews (ranging from 30 minutes to an hour) were con-
ducted face to face either at home or at the health service and audio-
recorded. Two interstate participants were unavailable at a time that 
coincided with travel to their health services. It was not feasible to 
schedule an additional visit because of time, interviewer availability, 
and cost. Instead, these 2 interviews were conducted by phone and 
audio-recorded. To ensure consistency, one researcher (L. Massi) was 
involved in most of the interviews. She conducted 42 alone and an-
other 40 with another researcher.26 L. Massi was trained in qualitative 
research methods and coordinated the study. Preliminary thematic 
data analysis was conducted by L. Massi alongside the interviews and 
discussed with the research team. Thematic saturation was reached, 
and further interviews were conducted to ensure that we had gleaned 
perspectives from the different regions.
Analysis
Interviews were professionally transcribed and coded by 2 researchers 
(H. Liu and L. Massi) using NVivo 9 (QSR International, Melbourne, 
VIC) at the completion of the interviews. Using the constant com-
parative method,14 these researchers coded the same 12 transcripts in-
dependently through 3 iterative stages and developed an initial coding 
framework encompassing both patients’ and providers’ perspectives, 
allowing triangulation of findings within each code. Insights gained 
by the KGAP research team about the local setting and empirical 
results of the PRCTs were used to aid interpretation.27,28 The cod-
ing framework was refined with input from study investigators and 
interview team. This included 2 IHSs clinicians who were site princi-
pal investigators and provided respondent validation.27 H. Liu and L. 
Massi coded the remaining interviews equally, drawing up memos for 
each interview to provide additional context for others analyzing the 
data and recoded the original 12 interviews. Minor, iterative changes 
to code definitions were made. An audit trail was kept. For this article, 
all data assigned to codes relating to the polypill strategy in CVD 
management were analyzed by H. Liu and the Realist framework of 
context–mechanism–outcomes utilized to develop the themes15,16 (see 
Figure). Further description of the major codes and the coding frame-
work are available as Data Supplements. The study was approved by 
7 regional ethics committees.
Results
Three principle themes relating to the polypill as a health 
service strategy to improve CVD prevention in Australian 
primary care were derived ( Table in the Data Supplement is 
available with additional quotes).
Overall Acceptability of the Polypill Strategy
Ease and Convenience
A key strength described by many patients and providers 
was that overall the polypill was liked and perceived as a 
beneficial strategy because of the ease and convenience of a 
single daily-dosing capsule. It was physically easier to take 
and to remember to take, which was highlighted by some 
providers and patients as especially important for the elderly 
and for those with stressful and competing life priorities. 
A few providers assumed that the polypill would increase 
adherence because long-term adherence to preventative 
medication was challenging for their patients. An indig-
enous patient described how the polypill reduced her psy-
chological pill burden:
… taking so many individual tablets became stressful, 
it’s like you knew what was happening like this organ 
and that organ is not working but with the polypill, 
because it’s all in one and you’re not having these 
different things laid out before your eyes. It was easy. 
(Patient 31, remote IHS)
Figure. Codes and themes within the 
realist framework (context–mechanism–
outcome). CVD indicates cardiovascular 
disease.
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Cost Savings
The polypill strategy was a pragmatic trial, which aimed to 
mimic real-world cost impacts on participants. In the Austra-
lian context, where medications could be subsidized through 
the Pharmaceutical Benefits Scheme (PBS), nonconcession 
card holders would pay full copayments for prescriptions 
(≈$AUD30), whereas concession card holders would pay sub-
sidized copayments of $AUD5.60 for each prescription. For 
these groups, there was a potential 4-fold cost advantage of 
the polypill. For indigenous participants who were eligible 
for complete medication subsidization through a government 
scheme newly introduced during the PRCT, there was no cost 
advantage of the polypill because treatment in both arms was 
subsequently free. Thus, depending on individual circum-
stance, the savings varied for the patients.
When I was working [all] my medications … used 
to cost me almost $320 a month at the full price. 
Individually some of them are very expensive; you 
might be paying $20 or $25 for each one. Now [on 
pension rates], it is $5.80 for the combined [polypill]. 
(Patient 17, rural GP clinic)
[The cost of medications does not impact me be-
cause], I’m working, and I’ve got a good job. (Patient 
38, regional GP clinic)
Before I went on the polypill it was so hard. It’s the af-
fordability, and taking all these different tablets at dif-
ferent times, whereas now it’s one tablet, and it’s free, 
so you can’t get it any better than that. (Indigenous 
patient 13, IHS)
Most of the providers recognized that the polypill would 
help improve their patients’ adherence to CVD medications 
because of ease, convenience, and cost-savings of the polypill. 
A GP described the advantages of the polypill for his patients 
and in starting medications:
Taking one pill instead of four is excellent and im-
proves compliance with patients; there is a cost factor 
that is an advantage. There is a simplicity factor – it’s 
easier to start someone early on, on a four-medication 
thing if they need it. If someone sort of never comes 
in and is poorly compliant and for months or years 
they’ve sort of had little warning signs that they re-
ally need something done but they don’t really do it, 
the polypill does make it possible to fairly easily say, 
‘let’s take this pill instead of this pill, it’s just that this 
pill contains four medications.’ (GP 27, urban IHS)
The perceived advantages of the strategy as described by 
many of the providers may explain the difference in the pre-
scription of antiplatelet, statin, and at least 2 blood pressure 
lowering agents which at baseline percentage was 50% and 
increased to 79% in the polypill arm and only 52% in the usual 
care arm.
Adherence Depends on Other Factors
However, despite many patients describing how and why the 
polypill could improve medication use, other factors were 
also described by the patients as being key to their adher-
ence. Patients indicated that their adherence behavior was 
determined by intrinsic factors, such as establishing routine 
medication regimens, their sense of well-being, and their 
understanding of medications, aided by external factors, such 
as the perceived quality and accessibility of their healthcare, 
family, and community support, respectful patient–provider 
relationships, and financial assistance from the government. 
Examples of quotes illustrating these factors include:
Because the one [reason] that keeps my heart going, 
well, because I’ve got my little fellow now. I want to 
try and stay here long as I can for him. (Patient 22,re-
gional GP clinic)
I mean when you see the people that are dying around 
you … the same age as you and even younger, it’s all 
to do with health that they died not taking medication. 
(Patient 4, urban IHS)
Keep the medication affordable; cost of living is high 
enough now…especially for black people because 
for black people, diabetes, sugar and all those type 
of things, is something that has impacted on us since 
colonisation of this country and the introduction of 
processed foods. So we need to have medication avail-
able to us to keep us living a longer life than what 
we’re currently living and if medication is the only 
way to keep us going then we need to be able to afford 
to have it. (Patient 10, urban IHS)
Patients also described initiatives, such as having dose 
administration pack, removed the hassle of carrying many 
medications, and served as a reminder to take their medications.
Similarly, many providers perceived intrinsic and extrinsic 
factors affected their patients’ medication use.
It’s very hard, we’ve done motivational training [in 
regards to adherence] and the Division [of GP’s] 
has tried all sorts of things to help these people and 
they’re just not interested. They have lives often with 
so many complexities which they can’t manage. (GP 
36, regional GP clinic)
Clearly the evidence around the world is that the 
primary care practitioner/patient relationship is the 
magic ingredient in the health system. There’s con-
tinuity and there’s trust. You get better outcomes and 
part of that is that people are more willing to commit 
to treatment plans. I think the General Practitioner’s 
role is key in promoting adherence. (GP 1, rural GP 
clinic)
Many providers indicated that the perceived potential 
impact of the polypill strategy in improving their patients’ 
medication use depended on existing adherence behavior. For 
example, though pharmacist 42 (remote IHS-related phar-
macy) talked about how if pill burden was a key barrier then 
the polypill would be ideal, another pharmacist described a 
limited impact of the polypill strategy if patients were already 
adherent and used dose administration devices:
People’s compliance is pretty high. So whether they 
have good result or not, because they are using a 
[dose administration pack], they pop it anyway. So if 
they have four pills, all separate, or one pill in polyp-
ills, it’s no difference. (Pharmacist 21, urban IHS-
related pharmacy)
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Polypill Strategy in Patient Management
Limitations of a Fixed Dose Combination
Some providers described certain limitations of the polyp-
ill strategy in patient management. They commented on the 
inflexibility of a fixed dose combination and on the complex-
ity in identifying which component of the polypill caused any 
reported side effect.
I think the Polypill is a good idea in principle but it 
also showed me how complicated it is to give some-
body a pill with four components. One of the biggest 
parts of my work is dealing with adverse drug reac-
tions and if you give a person one medication there’s 
a pretty good chance they’re going to get an adverse 
reaction. Now it may be a minor one, may not be, if 
you give them four, that’s a lot more chances. And 
then teasing out which one is difficult. (GP 10, urban 
GP clinic)
At some sites, providers described patients on the trial with 
complex medical problems that in hindsight were not suffi-
ciently stable for the polypill.
I was surprised with some of the patients whom others 
had been happy to put on it because when we looked 
at the problems that some [patients] had, I thought, 
well I wouldn’t have put that person in the trial, in the 
first place [because]) they were quite complicated and 
there will be potential risks of having some problems 
on the polypill. (GP 36, regional GP clinic)
Some providers found that the polypill formulations used 
in the trial contained inadequate dosages for their patients, 
expressing an inclination to discontinue its use if additional 
medications were needed because the advantage of a one 
daily-dosing pill was lost.
Adequacy of the Polypill Components
The therapeutic efficacy of the generic components within the 
polypill was discussed by many of the providers. There were 
2 perspectives: some GPs questioned whether these particular 
polypill formulations would represent best practice, given the 
perceived superiority of some of the newer on-patent medica-
tions available. Conversely, some providers preferred the use 
of off-patent medications contained in the polypill because of 
the cost-savings and the greater evidence-base of these older 
medications. A GP gave the following opinion of the on-pat-
ent medications compared with the older generics:
So much of the PBS is bound up with cardiovascular 
management. I have a personal belief that we spend 
far too much on the PBS. There are far too many medi-
cations that are not generic and we seem to want to 
have the most expensive and I personally don’t believe 
in that. I think people are prepared to live their lives 
as they wish and [some] smoke and drink. We do our 
best and we assume that the medication is, a hundred 
per cent, is all the treatment, which it’s not. So I don’t 
believe they have to have Rolls Royce medications 
when they lead a beat up Hyundai Lifestyle. What they 
need is to actually take the medications regularly, un-
derstand what they’re for... I’d much rather go with 
a lot more evidence-based cheaper medications and 
getting people to take them. (GP 39, remote IHS)
Some GPs also expressed an uncertainty about the indi-
vidual components. Several providers were uncertain about 
the use of aspirin for nondiabetic patients without established 
CVD. Some of the GPs and the patients’ cardiologists pre-
ferred to prescribe the newer statins if possible. This was also 
reflected in the PRCT’s data, which showed that at the end 
of the study, 17% and 67% of participants in polypill and 
usual care groups, respectively, were taking atorvastatin or 
rosuvastatin.
I think that there was one local cardiologist who wasn’t 
at all supportive of the polypill …. And this particu-
lar cardiologist also tended to use the top end dose of 
statins when he’d seen a patient, so that had the poten-
tial to raise an issue for a patient who we would then 
have to prescribe polypill plus an additional statin to 
keep them on the same dose as the cardiologist… I’m 
not actually convinced that the patients all needed to 
be on that dose. (GP 25, urban IHS)
These providers’ perspectives about limitations of a fixed 
dose combination and questions regarding the adequacy of 
the polypill components offer possible explanations of why 
28% of patients who were randomized to the polypill stopped 
it at some stage with around half of these discontinuations 
being because of prescribing and, thus apparently, were 
provider-initiated.
Future Combinations Would be Beneficial
Many providers and patients believed the above mentioned 
limitations could be overcome by having other polypills with 
different drug combinations. Some providers also stated a 
combination pill could be formulated for other diseases like 
diabetes mellitus, as in the following quote:
Once the general principle of a cardiac medication 
that’s polyvalent is established then there ought to 
be some flexibility as to what components might be 
added, with the advantage of future research. (GP 23, 
urban IHS)
Who Could it be Suitable for?
High-Risk Primary Prevention Patients
Many providers were of the belief that the polypill formula-
tions used in the study were inappropriate for some secondary 
prevention patients because of the low and inflexible dosing. 
Rather, its niche was in high-risk primary prevention patients 
who were stable medically.
Using a generalised polypill with lower doses where 
you have a person who hasn’t got the cardiovascular 
disease but has cardiovascular risk would be good 
just to help them from developing full-on cardiovas-
cular disease. I think there’s a role there - where there 
might be the one blood pressure tablet … because 
they might have had minor hypertension and putting 
a statin in there with aspirin just keeps everything 
functioning well and stops them getting established 
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cardiovascular disease. Whether it’s got a role in the 
patient who already has cardiovascular disease, I’m 
not sure because you can’t alternate the doses the way 
you want. (Pharmacist 7, urban IHS)
This theme supports the trial finding of the polypill-based 
strategy, resulting in a proportionately greater improvement in 
combination treatment use among high-risk primary preven-
tion patients, though this improvement was also significant in 
patients with established disease.
Strategy to Address CVD Burden in Indigenous Patients
Although the acceptability of the polypill strategy on improv-
ing adherence was reported by both patients and providers 
in IHSs and private clinics, a strong finding was that there 
could be particular advantages for indigenous patients. A GP 
thought the polypill could be an effective strategy to reduce 
the CVD burden in his community:
Being an Aboriginal doctor I see the burden of disease 
especially in cardiovascular health…. The youngest 
fellow we’ve had coming in here is 28 having a heart 
attack. So we see heart disease early and it’s not un-
common for some of our patients to have heart attacks 
in their 30s, 40s and 50s. So I think we need some 
other strategy to help decrease that risk and that’s 
where I’ve seen the place for the polypill and it’d be 
interesting to see what results come out of it. (GP 28, 
urban IHS)
A GP (Provider 43, remote IHS) described the usually 
lengthy process of starting medications in indigenous patients 
and how the polypill could be used to expedite this process. 
Moreover, by not having a pharmacist provide medications 
in a medication dose aid might mean increased ownership of 
health for his patients on the polypill. An indigenous patient 
thought the polypill would be a way to bridge the health lit-
eracy gap:
It would be a good thing … for a lot of our people … 
if they’ve got to take about half a dozen tablets or four 
tablets you know they might get confused. Some of our 
people you can’t read much to know what tablets to 
take. They just take them... [They] don’t know what 
they’re taking it for. I reckon it’s a good idea if they’ve 
got the polypill [which] is all in the one. (Indigenous 
patient 43, remote IHS)
Several GPs at some IHSs thought the polypill strategy 
complemented their services’ chronic disease model of care, 
updated them on their CVD guidelines, and encouraged them 
to use the CVD absolute risk calculation in their patient man-
agement. Provider 20 (pharmacist, urban IHS) thought the 
polypill strategy worked synergistically with the GP’s edu-
cation of patients and the pharmacists’ provision of the dose 
administration aid to improve patients’ adherence.
It seemed that the polypill strategy could potentially be 
beneficial for the indigenous population, given the high dis-
ease burden and the complexities associated with taking mul-
tiple medications. It was viewed as an acceptable strategy by 
patients and providers for high-risk, medically stable patients. 
Many IHS providers thought the polypill strategy could be 
an effective component of CVD care that could be integrated 
into strategies that address other factors, such as accessible 
care, health promotion, and social determinants. Indeed, the 
PRCT subgroup analysis showed that there was a signifi-
cant improvement in medication use among the indigenous 
patients randomized to the polypill strategy.
Discussion
The polypill strategy is relevant to patients’ and providers’ 
needs as an acceptable health service strategy to improve 
CVD prevention in Australian primary healthcare. Using the 
Realist framework, the effectiveness of the polypill strat-
egy was dependent on whether the health provider felt that 
the polypill components were adequate for the management 
of individual patients’ CVD, and would encourage patient’s 
adherence because of its ease and convenience, and cost sav-
ings for the patient. However, the sustainability and impact 
of the polypill strategy in improving adherence depended on 
other patient factors, such as affordability of medications, 
level of health literacy, compatibility with existing adherence 
strategies, sense of well-being, patient–provider relationship, 
access to quality care, and disease stability and severity. The 
main limitation of the strategy was the inflexibility in dosing, 
but this was viewed as a shortcoming that could be addressed 
with introduction of a wider range of combinations. In its cur-
rent formulations, many of the providers in this study deemed 
it to be particularly suited to high-risk primary prevention 
patients and some indigenous populations in Australia.
Our study confirms some findings of other qualitative stud-
ies which showed a growing acceptance of prescribing the 
polypill for primary and secondary prevention, provided there 
is evidence of effectiveness and cost benefits.29–31 However, 
our study also highlighted overall patient acceptability of the 
polypill strategy and a key recommendation by providers to 
improve the flexibility of the polypill strategy in meeting the 
varied needs of patients by introducing more formulations. 
Using qualitative research alongside a PRCT enabled us to 
better appreciate the role of the polypill strategy in address-
ing inequity within contextual factors of Australian primary 
healthcare, such as high CVD burden within indigenous com-
munities, existing costs of medications, and concurrent gov-
ernment policies for medication subsidies.
This study was limited in that it was an in-depth explora-
tion of issues from a sample that was not necessarily repre-
sentative of all participants and providers in the trial. Fewer 
interviews were done in remote sites, and staff who had left 
the service or participants who had withdrawn by the end of 
the study would not have been interviewed. Other limitations 
of our study include having 2 interviews done over the phone 
in comparison to face to face, varying level of experience of 
qualitative research among the study team and achieving only 
partial member checking during a presentation of preliminary 
findings to a subset of providers.
Though the KGAP trial showed that there was improved 
adherence in the polypill arm, patients’ adherence in both 
arms of the study progressively declined over time, which is 
consistent with the literature.32–34 Thus, the question remains 
as to how to best use the polypill strategy to improve sustained 
medication adherence. A method to characterize behavior 
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change interventions was proposed by Michie et al through 
the use of a behavior change wheel, which comprises a behav-
ior system at the hub, encircled by 9 intervention functions 
aimed at addressing the deficits in capability, motivation, and 
opportunity and then by 7 policy categories to enable the inter-
ventions to occur.35 Applying Michie’s behavior change wheel 
to our results, it seems that the polypill strategy has the inter-
vention functions of enablement and incentivization; to effect 
behavior change, but perhaps other intervention strategies 
and policies are needed for sustained change. Multifaceted 
approaches to improve adherence have been trialled inter-
nationally.8,36,37 In Australian primary health care, a quality 
improvement intervention with pharmacists-led education to 
improve health literacy and electronic decision support for the 
prescribing of preventative medications has been shown to be 
effective.36 Our study findings suggest that the polypill strat-
egy could potentially be used successfully and synergistically 
with similar health service strategies to improve medication 
persistence in this setting.
The polypill strategy is increasingly being recognized as a 
part of a solution for improving global CVD prevention, with a 
growing body of evidence showing effectiveness in improving 
provider prescribing and patient adherence to indicated CVD 
medications.10,11,38,39 The economic evaluation conducted with 
the KGAP trial40 and a cost-effectiveness study of a multidrug 
regimen (similar to the polypill components) in a lower middle 
income setting41 provide promising evidence that the polyp-
ill strategy could reduce the high global economic burden of 
CVD, given the availability of the inexpensive yet effective 
drugs. As more CVD medications come off patent, our find-
ings imply a key challenge would be to have different polypill 
versions made available as an affordable and attractive health 
service strategy for both high-income and lower middle–
income countries. However, barriers to the implementation of 
the polypill strategy include the manufacture of the polypill 
as a viable business for pharmaceutical companies, despite its 
huge public health potential and having supportive legislation 
and policy changes. As such, the amalgamation of evidence 
from international trials combined with further research in cost 
effectiveness and acceptability of the strategy in different con-
texts will determine the feasibility and policy significance of 
the polypill strategy in improving CVD prevention worldwide.
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Facilitators and barriers to implementation 
of a pragmatic clinical trial in Aboriginal 
health services
Trials that 
address a 
priority health 
issue, have 
had strong 
health service 
engagement 
and adequate 
local support 
seem more 
likely to 
succeed
 The principles of conducting ethically sound health re-search involving Aboriginal 
and Torres Strait Islander peoples 
have been well documented.1-3 There 
are, however, many challenges to 
implementation of these princi-
ples and negative experiences have 
been reported.4-11 A key element to 
the National Health and Medical 
Research Council (NHMRC) guide-
lines for ethical conduct in Aboriginal 
and Torres Strait Islander health re-
search is the notion of reciprocity — 
that the benefits of the research be 
clearly articulated, negotiated and 
implemented in such a way that it 
will build community capacity.1 In 
the context of clinical trials, this in-
cludes ensuring that studies test in-
terventions in the settings in which 
they will eventually be delivered, 
rather than contrived environments 
that are conducive to easier trial im-
plementation. Such trials are often 
referred to as pragmatic randomised 
controlled trials (PRCTs).12
The Kanyini Guidelines with the 
Adherence Polypill (KGAP) study 
was a PRCT that tested whether 
a polypill-based strategy would 
improve prescriber and patient 
adherence to recommended treat-
ments for cardiovascular disease 
(CVD).13-15 The trial was conducted 
between 2008 and 2012 across five 
Australian states in 20 general prac-
tices, 11 urban, rural and remote 
Aboriginal community-controlled 
health services (ACCHSs) and one 
government-run Indigenous health 
service. Participating services were 
each supported by one to three 
nominated community pharmacies. 
Design features that mimicked real-
life practice included the prescrib-
ing of medicines by treating general 
practitioners, patient copayment 
charges for all study and other med-
icines at standard Pharmaceutical 
Benefits Scheme rates and the 
dispensing through community 
pharmacies. A major challenge to 
trial implementation was attaining 
target recruitment rates; only 623 
of the target 1000 participants were 
randomised.16 This led to a longer 
study duration than anticipated, 
with concomitant budget pressures . 
In this qualitative study, we aimed 
to identify facilitators and barriers to 
trial implementation in the ACCHSs 
and government health service from 
the perspective of providers and trial 
participants. The study forms part of 
a broader trial process evaluation.15
Methods
Fifty-three interviews were con-
ducted with 32 health care providers 
and 21 Aboriginal and Torres Strait 
Islander patients at six ACCHSs and 
the government health service from 
April to December 2012. (Appendix 
1 and Appendix 2). Five ACCHSs 
that were involved in the trial were 
unable to participate due to limited 
capacity at the time when interviews 
were being conducted. Participants 
were recruited purposively to yield 
a maximum variation sample based 
on location, age, sex, ethnicity, pres-
ence of CVD, and medication for pa-
tients, and location and profession 
for providers. 
Interviews were conducted at the 
conclusion of the trial as part of 
the overall process evaluation and 
included exploration of experiences 
regarding trial implementation. 
Interview guides were developed 
and iteratively revised to explore 
themes and issues emerging from 
earlier interviews. A team of 
Abstract
Objective: To identify facilitators and barriers to clinical trial 
implementation in Aboriginal health services.
Design: Indepth interview study with thematic analysis.
Setting: Six Aboriginal community-controlled health services and one 
government-run service involved in the Kanyini Guidelines Adherence with 
the Polypill (KGAP) study, a pragmatic randomised controlled trial that 
aimed to improve adherence to indicated drug treatments for people at high 
risk of cardiovascular disease.
Participants: 32 health care providers and 21 Aboriginal and Torres Strait 
Islander patients.
Results: A fundamental enabler was that participants considered the 
research to be governed and endorsed by the local health service. That 
the research was perceived to address a health priority for communities 
was also highly motivating for both providers and patients. Enlisting the 
support of Aboriginal and Torres Strait Islander staff champions who were 
visible to the community as the main source of information about the trial 
was particularly important. The major implementation barrier for staff 
was balancing their service delivery roles with adherence to often highly 
demanding trial-related procedures. This was partially alleviated by the 
research team’s provision of onsite support and attempts to make trial 
processes more streamlined. Although more intensive support was highly 
desired, there were usually insufficient resources to provide this. 
Conclusion: Despite strong community and health service support, major 
investments in time and resources are needed to ensure successful 
implementation and minimal disruption to already overstretched, routine 
services. Trial budgets will necessarily be inflated as a result. Funding 
agencies need to consider these additional resource demands when 
supporting trials of a similar nature.
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seven researchers, including three 
Aboriginal researchers, from a range 
of disciplinary backgrounds (health 
economics, pharmacy, nursing and 
public health) who were not involved 
in the implementation of the trial 
conducted the interviews. Most 
interviews were conducted face-to-
face, with a small number conducted 
by telephone for logistic reasons. 
Interviews were professionally tran-
scribed and coded by two research-
ers (H L and L M) using NVivo 9 (QSR 
International). Twelve transcripts 
were selected (six patients and six 
health care providers — pharma-
cists, GPs, nurses and Aboriginal 
health workers [AHWs]) and were 
coded independently by the two 
researchers. These researchers iden-
tified the major themes arising from 
these 12 interviews and developed 
an initial coding framework. Insights 
gained by the research team about 
the context of the interviews and the 
local setting were documented and 
used to aid interpretation. The cod-
ing framework was then discussed 
and refined by a multidisciplinary 
group comprising the study investi-
gators and the interview team. This 
included two ACCHS clinicians who 
were site principal investigators on 
the trial. The two researchers then 
coded the remaining interviews 
and made minor, iterative changes 
to code definitions. 
For this study, we analysed codes 
specifically relating to issues relat-
ing to trial implementation. The ran-
domised controlled trial, including 
its process evaluation, was approved 
by seven regional human research 
ethics committees, including one 
Aboriginal-specific committee. All 
participants who contributed data 
were provided a description of the 
study by the interviewer and given 
the opportunity to discuss any 
concerns before obtaining written 
consent.
Results
Four principal themes relating to bar-
riers and facilitators for trial imple-
mentation were derived. Appendix 3 
contains additional quotes that fur-
ther illustrate the findings. 
Health service governance of 
research
Ensuring community representation 
in governance of the research was a 
dominant issue. ACCHSs were in-
vited to participate through initial 
discussions with senior management 
and governing boards. Formal mem-
oranda of understanding (MOUs) 
with the coordinating research insti-
tutes were established. Amendments 
were made to the standard Medicines 
Australia clinical trial agreement to 
include intellectual property rights of 
ACCHSs and the roles and responsi-
bilities associated with data custodi-
anship. The discussions associated 
with setting up these agreements 
were critical in establishing mutual 
roles and responsibilities, data gov-
ernance, capacity building plans and 
establishment of funding arrange-
ments. One participant referred to 
the MOU as being a “landmark docu-
ment” (GP 23, urban service).
In some instances, these agreements 
were facilitated by local governance 
processes. An AHW at an urban 
ACCHS described how previous 
negative experiences with external 
researchers prompted the establish-
ment of a local research committee 
that would scrutinise external organ-
isations’ research proposals:
In the past, the research that’s 
been conducted has left some 
scars … what has helped has 
been being more organised 
about having our own research 
agenda … so if you want to do 
research [with us then] this is 
what’s important to us. (AHW 
47, urban service)
Motivation to participate
An expectation that the intervention 
could tangibly address an important 
health issue was extremely important 
for both patients and providers:
When you see people that are 
dying around you that are 
the same age as you and even 
younger, it’s all to do with 
health that they died not taking 
medication. Maybe if they were 
given the one pill instead of tak-
ing half a dozen they might be 
still here today. (Patient 4, urban 
service)
Several participating services 
had been involved in the Kanyini 
Vascular Collaboration before the 
trial and many staff were aware of 
the treatment gaps documented in 
the collaboration’s audit of patient 
records.14 Consequently, there was 
strong support from health care pro-
viders for strategies to address these 
gaps.
Effectively communicating the need 
to address these gaps to the commun-
ity was particularly important. At one 
urban ACCHS this was done through 
a community forum and launch of 
the trial. 
A related facilitator of participation 
was the role played by Aboriginal 
staff champions. These staff were 
often the initial point of contact for 
participants seeking information and 
were also referred to by other staff. 
One AHW discussed her role: 
At first it was hard to commu-
nicate with them. But once it got 
mentioned once, twice, maybe 
three times what was in the 
tablet, what the benefits would 
be it started sinking into their 
brains then. (AHW 32, urban 
service)
Balancing service delivery and 
research requirements
An important aspect of the research 
was to incorporate the intervention 
into usual service delivery. Efforts to 
streamline the intervention included 
the prescribing and dispensing of the 
polypill within existing software 
platforms, timing pathology tests to 
coincide with scheduled visits and re-
cruiting community pharmacies that 
were accessible to the participating 
sites. Despite these efforts to integrate 
the intervention into routine care 
processes, some GPs felt it created 
“confusion in their management” and 
“confusion about what they were on 
when they went into hospital”.
Some providers indicated challenges 
balancing trial operations with exist-
ing workloads. This manifested 
differently in urban and remote set-
tings. For example, in urban settings, 
transport services were enlisted to 
facilitate study visits and access to 
medicines, potentially leading to 
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limited transport availability for non-
trial patients. In remote settings, fly-
in fly-out doctors provided services 
to highly mobile populations. This 
created substantial challenges for 
clinic staff to coordinate follow-up 
study visits. One GP felt that the trial 
was more suited to urban ACCHSs: 
You cannot compare it to an 
AMS [Aboriginal Medical 
Service] in Sydney … because 
we are serving about 200 000 
square kilometres at this AMS. 
… our patients might come into 
town but they could be based 
500 kilometres away … and it’s 
a very transient place for many 
of our patients. (GP 40, remote 
service)
Such logistic challenges inevitably 
resulted in delays in recruitment and 
follow-up. To alleviate these chal-
lenges the study team committed 
additional unbudgeted resources to 
support trial sites. 
Research capacity-building 
challenges
A core study objective was to build 
health service research capacity 
through involvement of staff in the 
clinical trial. Most of those inter-
viewed considered trial participa-
tion to be a positive experience, with 
many staff members describing en-
hancement of clinical skills, increased 
awareness of clinical trial processes, 
and deeper collaborations between 
the health service and pharmacies.
A key capacity-building initiative 
was the creation of local Indigenous 
research fellow (IRF) positions to per-
form trial coordinator duties. In prac-
tice, however, recruitment of suitably 
trained individuals was challenging 
and only four positions were filled. 
The idea was that we were 
going to have an [IRF] is a great 
idea, but it just turned that we 
didn’t really have anyone that 
took it on with a passion … [The 
role] is quite complicated … (GP 
3, urban service)
Moreover, like all clinical staff, IRFs 
frequently had competing responsi-
bilities, and found it difficult to bal-
ance their research role with service 
delivery. This led to staff turnover 
in the early part of the study, which 
affected the trial conduct. Overall, 
most trial sites commented that 
additional on-site support from 
research institute staff would have 
been beneficial. This was easier to 
provide at those sites located closer to 
the coordinating research institutes, 
and those sites tended to manage the 
trial with fewer challenges.
Discussion
This study examined the often-
overlooked views and experiences 
of patients and health care provid-
ers from Aboriginal health services 
participating in a clinical trial. The 
key facilitators of participation were 
the interrelated factors of research 
governance, patient and provider per-
ception of the need for this research, 
deployment of effective strategies for 
communication to the community at 
large, and enlisting the support of 
Aboriginal staff champions. These 
facilitators were tempered by several 
challenges related to adequate inte-
gration of the intervention strategy 
into routine care processes, large 
competing demands with routine 
service delivery, and only partially 
successful attempts at building local 
research capacity. These challenges 
manifested differently due to the 
highly diverse settings in which the 
participating services operated.
In Australia, several Indigenous 
health RCTs have been successfully 
conducted through established health 
service–researcher partnerships, par-
ticularly in the area of child health.17-19 
Many have experienced challenges 
in meeting recruitment targets and 
implementing the trials as originally 
conceived. Occasionally, trials have 
had to be abandoned altogether due 
to insurmountable constraints.20 Our 
findings help determine the factors 
that both hinder and promote suc-
cessful conduct of such trials. The 
integration of complex trial proto-
cols that are not supported by senior 
management into underresourced 
health service settings is a recipe for 
implementation failure. Conversely, 
trials that address a priority health 
issue, have had strong health service 
engagement and adequate local sup-
port seem more likely to succeed.
The study was an indepth explora-
tion of issues from a sample that was 
not necessarily representative of all 
participants and providers in the 
trial. Fewer interviews were done in 
remote sites, and staff who had left 
the service or participants who had 
withdrawn by the end of the study 
were not interviewed.
Although this study was based on a 
PRCT, such a design will not always 
be feasible nor acceptable. Alternative 
designs, such as stepped wedge trials 
and cluster RCTs of health service 
interventions, have been successfully 
implemented in collaboration with 
ACCHSs.21,22 Other designs, such as 
crossover studies, interrupted time 
series analyses and propensity score 
matching, are also practical and often 
cheaper to implement. Use of auto-
mated de-identified data extraction 
and opt-out consent processes can 
considerably reduce data collection 
burden and reduce demands on 
Aboriginal health services.22 There 
is also much to be gained from obser-
vational studies, in which routinely 
collected clinical audits can inform 
the evidence base about effective 
health service strategies.14,22-27
Although community participation 
in prioritising the research ques-
tion is of fundamental importance, 
substantial research infrastructure 
investment in health services is 
of equal importance. Aboriginal 
governance and leadership of the 
research agenda must be in place, and 
there are now good examples of how 
large-scale research can incorporate 
this from the outset.28,29 Associated 
with this is clear articulation of the 
resource implications associated with 
participation and ensuring there is 
adequate recognition of this within 
study budgets. The model for capa-
city building had mixed success, 
mainly due to the excessive and com-
peting demands on individuals and 
limited existing research capacity; 
novel models to increase research 
capacity are needed.
There is clearly a need for more 
interventional studies to build the 
evidence base of what works in 
Aboriginal health service settings.23,30 
It is important that research fund-
ing bodies recognise the factors 
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highlighted in this study in their 
grant schemes. The overall $5 mil-
lion (around $8000 per randomised 
patient) spent on the Kanyini GAP 
trial was several times higher than 
the amount originally granted and 
multiple additional funding appli-
cations were required. Although 
guiding statements on appropriate 
ethical conduct of research involving 
Aboriginal and Torres Strait Islander 
peoples acknowledge these issues, 
project-specific funding schemes 
tend not to recognise the impor-
tance of long-term investments in 
research capacity building, beyond 
what is immediately required to 
complete the project.1,2 In addition to 
non-project specific schemes, such as 
the NHMRC Centres for Research 
Excellence, project-specific load-
ings for research conducted in col-
laboration with already overstretched 
Aboriginal and Torres Strait Islander 
health services ought to be consid-
ered to support local research capa-
city building and establishing the 
governance arrangements needed 
to ensure community support. Such 
investments would build the evi-
dence base on models associated with 
success and strengthen the applica-
tion of reciprocity in the conduct of 
Aboriginal and Torres Strait Islander 
research.
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Abstract
Background: Pragmatic randomised controlled trials (PRCTs) aim to assess intervention effectiveness by accounting
for ‘real life’ implementation challenges in routine practice. The methodological challenges of PRCT implementation,
particularly in primary care, are not well understood. The Kanyini Guidelines Adherence to Polypill study (Kanyini
GAP) was a recent primary care PRCT involving multiple private general practices, Indigenous community controlled
health services and private community pharmacies. Through the experiences of Kanyini GAP participants, and using
data from study materials, this paper identifies the critical enablers and barriers to implementing a PRCT across
diverse practice settings and makes recommendations for future PRCT implementation.
Methods: Qualitative data from 94 semi-structured interviews (47 healthcare providers (pharmacists, general
practitioners, Aboriginal health workers; 47 patients) conducted for the process evaluation of Kanyini GAP was used.
Data coded to ‘trial impact’, ‘research motivation’ and ‘real world’ were explored and triangulated with data
extracted from study materials (e.g. Emails, memoranda of understanding and financial statements).
Results: PRCT implementation was facilitated by an extensive process of relationship building at the trial outset
including building on existing relationships between core investigators and service providers. Health providers’ and
participants’ altruism, increased professional satisfaction, collaboration, research capacity and opportunities for improved
patient care enabled implementation. Inadequate research infrastructure, excessive administrative demands, insufficient
numbers of adequately trained staff and the potential financial impact on private practice were considered
implementation barriers. These were largely related to this being the first experience of trial involvement for
many sites. The significant costs of addressing these barriers drew study resources from the task of achieving
recruitment targets.
Conclusions: Conducting PRCTs is crucial to generating credible evidence of intervention effectiveness in
routine practice. PRCT implementation needs to account for the particular challenges of implementing collaborative
research across diverse stakeholder organisations. Reliance on goodwill to participate is crucial at the outset. However,
participation costs, particularly for organisations with little or no research experience, can be substantial and should be
factored into PRCT funding models. Investment in a pool to fund infrastructure in the form of primary health research
networks will offset some of these costs, enabling future studies to be implemented more cost-effectively.
Trial registration: ACTRN126080005833347
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Background
Randomised controlled trials are generally seen as the ‘gold
standard’ for assessing the efficacy of health sector interven-
tions. Challenges in applying the evidence based on ex-
planatory trials of interventions tested in optimal conditions
have led to a growing emphasis for pragmatic randomised
controlled trials (PRCTs). PRCTs involve a comparison of
interventions and using health outcome measures that are
relevant to ‘real-world’ healthcare delivery. This allows for
generalisability of the PRCTs’ findings which may be more
accessible to decision-makers and thus be translated into
practice and policy [1–6]. PRCT interventions are often
multifaceted with multipurposed analyses and the provider
and the recipient of an intervention may not only be the
health professionals and patients respectively but can be
other members in the health system [2].
Designing PRCTs is not straightforward. For instance,
in primary care settings, given the broad spectrum of
disease presentation and diverse practice settings, maxi-
mising generalisability in a PRCT without overly com-
promising reliability or accuracy has proven difficult [8].
In this regard, strategies to deal with design issues such
as unblinded treatment allocation and recruiting repre-
sentative participants have been suggested [9]. More
recently, a tool of ten domains known as the Pragmatic-
Explanatory Continuum Indicator Summary (PRECIS)
was developed by Thorpe et al. as a guide for researchers
in designing PRCTs [10, 11]. The ten domains include
participant eligibility criteria, intervention and comparison
flexibility and expertise, follow-up intensity, participant
compliance and participant adherence to study protocol,
selecting and analysing primary outcomes which are rele-
vant to clinical practice [7]. It is thought that by capturing
‘real-life’ practice variation the evidence generated will be
more relevant to policy-makers [7].
The Kanyini Guidelines Adherence with the Polypill
study (Kanyini GAP) provides a recent example of a PRCT
that was implemented within Australian primary care.
Kanyini GAP sought to explore whether a strategy based
on the use of a fixed-dose combination pill (polypill),
comprising low-dose aspirin, a statin and two blood pres-
sure lowering agents, would improve patient adherence to
and provider prescribing of evidence-based cardiovascular
disease (CVD) preventive medications [12, 13]. This trial
was conducted in primary care rather than in hospitals
reflecting the setting where, in practice, prevention and
early management of cardiovascular disease is most likely
to take place [14].
Kanyini GAP included a range of diverse practice sizes
and settings across Australia: 12 Indigenous Health Services
(IHS) (which were 11 Aboriginal Community Controlled
Health Services and 1 government-run health service) and
21 private mainstream general practices. Medications were
dispensed through community pharmacies with patients in
both treatment groups required to pay for their medicines
at the prevailing co-payment rate. By incorporating these
design features, the study sought to mimic the systems
through which the comparative treatments would be deliv-
ered in practice; therefore, potentially yielding more gener-
alisable assessments of ‘real-life’ effectiveness. Figure 1
shows the organisation of the trial management between
the research coordinating centres and primary care services.
A Consolidated Standards of Reporting Trials (CONSORT)
flow diagram and checklist of this completed randomised
controlled trial (RCT) are included as additional documents
(see Additional files 1 and 2). Despite Kanyini GAP being
designed according to recommendations in the PRCT-
related literature, a number of problems were encountered
in implementation: recruitment fell considerably short of
expected targets (n = 623 c.f. 1000), challenges related to
stakeholders not having prior research experience yet re-
quired to comply with Good Clinical Practice [15], study
duration was considerably longer than expected and the
costs exceeded the projected budget.
At present, there is very little published evidence that de-
scribes the experience of implementing a PRCT in primary
care from the perspectives of the participants. To address
this gap in evidence, this paper aims to identify the critical
enablers and barriers to implementing Kanyini GAP.
Drawing on the experiences of patients and providers par-
ticipating in Kanyini GAP and key trial documentation, we
sought to make recommendations for the future imple-
mentation of PRCTs in primary healthcare settings.
Methods
This study uses qualitative data from the overall process
evaluation of Kanyini GAP [16]. A predefined protocol
for the process evaluation was used [16]. The methods
are described across the three domains as specified in
the consolidated criteria for reporting of qualitative
studies developed by Tong et al. from a review of estab-
lished guidelines and qualitative studies [17].
Research team and reflexivity
Study investigators (TU, SJ, JR, TL, DP, and AC) who
were involved in the design and implementation of
Kanyini GAP developed the interview guides which
were iteratively revised to explore themes and issues
emerging from earlier interviews. Views about the poly-
pill strategy in CVD management, patient satisfaction
or problems with the polypill, issues regarding trial im-
plementation, and perspectives of translation of the
polypill into clinical practice were key domains of the
interview guides. The interviews were conducted by a
team of seven interviewers. Two of the interviewers
had existing relationships with some of the participants
interviewed as they were research coordinators in the
trial but the other interviewers were not known to the
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participants prior to the interviews. The team had diverse
backgrounds (health economics, nursing, pharmacy, Indi-
genous health), varied experience in qualitative research
and three were Indigenous and four non-Indigenous
researchers.
Study design
Site recruitment for the Kanyini GAP trial was initiated
with the general practitioners (GPs) of private practices
and IHSs, as well as the board members of IHSs. A
critical enabler to the recruitment of GPs was the
extensive process of undertaking relationship building
and leveraging existing networks amongst Kanyini
GAP chief investigators. In particular, prior to Kanyini
GAP, a relationship between the research-team and
several of the IHSs existed as part of the Kanyini
Vascular Collaboration – a chronic disease-based re-
search collaboration between the two research insti-
tutes and participating IHSs around Australia.
Participants were purposively recruited for the qualita-
tive study from these participating Kanyini GAP sites
based on maximum variation of specified variables
which were based on adherence literature which may
affect participants’ experience with a polypill-based strat-
egy and also variables which may impact trial implemen-
tation. We used the sampling matrix to select patients
based on these characteristics; for patients these were
location, age, gender, ethnicity, primary versus secondary
CVD, and self-reported adherence at baseline; and for
providers variables included location and profession
[18]. All health providers and patients were sent an invi-
tation letter outlining the study and its objectives, and
followed-up by a phone call by the project coordinator
(LM). Five patients declined to be interviewed and two
patients were not available, and all health providers
agreed to be interviewed. Written informed consent was
obtained from all participants.
Most face-to-face interviews, which ranged from
30 min to an hour, were conducted either at home or at
the health service, and audio-recorded. Two participants
from interstate were not available for a face-to-face
interview. Phone interviews were conducted with these
two participants and audio-recorded. One researcher
LM was involved in almost all the interviews to ensure
consistency [18]. She conducted 40 with another inter-
viewer and 42 alone. LM coordinated the study and was
trained in qualitative methods. She conducted prelimin-
ary thematic data analysis alongside the interviews. The-
matic saturation was achieved and interviews stopped.
Analysis
Interviews were professionally transcribed. At the com-
pletion of all the interviews, two researchers (HL and
LM) used NVivo 9 (QSR International, Melbourne, VIC,
Australia) to code and manage the qualitative data.
Using the constant comparative method [19], these re-
searchers coded line by line the same twelve transcripts
independently (six patients and six health providers
across the variables) through three iterative stages and
an initial coding framework was developed. Insights
about the local setting, context of the interviews and
empirical results of the PRCT were documented and
used to aid interpretation and triangulation [20, 21]. The
overarching coding framework (which is included as an
Additional file 3) was developed for provider and patient
interviews and refined with the study investigators and
the interview team. This included two IHSs clinicians
(TU and DP) who were site principal investigators on
Fig. 1 Organisational structure of the Kanyini GAP study. Kanyini GAP was conducted in 33 sites across urban, rural and remote Australia and
recruited 623 patients through 12 Indigenous health services and 21 private general practices. There was one central coordinating centre based
in Sydney and two regional coordinating centres based in Alice Springs and Victoria, which recruited and coordinated the sites in NSW,
Queensland, Victoria and the Northern Territory. Each ‘site’ included either a general practice clinic or an Indigenous health service and 1–3
community pharmacies
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the trial and provided respondent validation [20]. The
two researchers (HL and LM) coded the remaining
interviews equally, drawing up memos for each interview
to provide additional context for other researchers ana-
lysing the data, and recoded the original twelve inter-
views. Minor, iterative changes to code definitions were
made. An audit trail was kept.
To address the aims of this study, provider and patient
experiences that were related to trial implementation
which were coded to: ‘trial impact’ and ‘research motiv-
ation’ and ‘real world’, were explored.
Additionally, some triangulation of findings was obtained
through a review of existing Kanyini GAP documents (e.g.
Email communications, Memoranda of Understanding, and
financial statements) [17].
The study was approved by 7 regional committees
including 1 Aboriginal-specific committee jurisdiction
(Sydney South West Area Health Service (HREC Ref.
08/RPAH/126); Aboriginal Health and Medical Research
Council of NSW (642/08); Cairns Base Hospital (HREC/
08/QCH/10-546); Princess Alexandra Hospital Centres
for Health Research (HREC/08/QPAH/160); Central
Australian Human Research Ethics Committee (2008.09.
04); Northern Territory Department of Health and Menzies
School of Health Research (HREC 2010–1466; Monash
University Human Research Ethics Committee (CF09/
2353 – 2009001370)).
Results
At the end of Kanyini GAP, 94 semi-structured inter-
views were conducted by the interview team with 47
providers (25 GPs, 13 pharmacists, 6 Aboriginal health
workers (AHW) and 3 chronic care nurses) and 47
patients in NSW, Queensland and Victoria. There were
22 and 25 patients who were in the polypill arm and
usual care arm, respectively. There were 26 non-
Indigenous patients and 21 Indigenous patients.
The critical enablers and barriers to implementing this
PRCT in Australian primary healthcare settings were
broadly grouped within three key themes: recruitment
and participation; research and primary practice settings;
and participant costs. Tables 1 and 2 summarise the
identified barriers and enablers to conducting a primary
care PRCT within these three key categories and pre-
sents suggested strategies to overcome barriers and
maximise enablers when implementing future PRCTs in
primary practice settings.
Recruitment and participation
Site recruitment
The recruitment process for enlisting sites included a num-
ber of initial meetings, workshops and dinners to introduce
the trial and elicit expressions of interest. This approach
proved an effective way to develop and strengthen existing
relationships with primary care services. Kanyini GAP also
built upon previous research done with the IHSs, which
found a gap in the prescribing of indicated CVD medi-
cations; thus site recruitment to Kanyini GAP was seen
as a ‘natural progression’ (Provider 47, AHW). This is
evident from the following comment from a GP based
at an urban IHS:
‘The other thing that was really helpful was the way
the service was engaged by The George Institute so
that the community all knew about polypill. They’d
engaged with the Board very well, the Board and the
service had agreement so the CEO and the manager
in the service knew about it. They’d held a launch
day at the service and people were asking questions,
so there was a lot of engagement, a lot of patients
knew about it, so there was general awareness.’
(Provider 8, GP)
Some participating GPs envisaged tangible benefits to
their practice through involvement in primary health-
care research, in terms of quality improvement and staff
morale. As a GP at an urban private practice site
describes:
‘Philosophically I like the idea as a practice being
opened up to researchers …… I’ve done a lot of quality
improvement with practices and one of the things that
builds the team is opening it to the outside world.
And, participating in research is a way of opening it to
the outside world, so it’s actually a plus for team
building. Practices feel proud that they’re actually
working at this level.’ (Provider 1, GP)
In addition to staff morale, a collective increase in
research capacity at the health service level was thought
to be a positive impact of participating in primary care
research, as one GP from an urban IHS noted:
‘It was good for our research capacity, it was a project
we all believed in and got behind. … our name came
up just on the weekend at the conference that I was
at … people mentioned that we were part of the
Kanyini GAP trial. So I think from that point of view
it was good for our health service, good for our
reputation. … participating in research I think was a
good experience for those workers some of whom were
Aboriginal, so that’s increasing the research capacity,
Indigenous research capacity for (the) clinic which is
a good thing.’ (Provider 33, GP)
Providers’ research motivation
Motivation to take part in the research study was fre-
quently mentioned, with many providers stating that
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being part of a trial is for the ‘greater good’. The follow-
ing GP from an urban IHS outlined her motivation to
take part in investigator-led research:
‘I really liked and felt comfortable and trusted the
Kanyini polypill … that it was put together on the
basis of what was going to be best for people with
Table 1 Strategies to overcome barriers to implementing primary care pragmatic randomised controlled trials
Barriers Strategies to help overcome
Recruitment and participation
Prescriber disagreement about recruitment across sites:
clinical eligibility compared to trial suitability
• Prior to implementation, identify potential sources for disagreement, provide examples
and workshop solutions with providers
• Throughout recruitment, facilitate a forum for providers to discuss with research team
actual difficulties encountered
Potential negative impact of evaluated intervention on
provider’s business revenue
• Identify and discuss potential impacts (immediate and long-term) with providers;
• If possible, ensure lost revenue adequately compensated
• Educate potential providers about the value of the intervention to public good
Highly mobile patients • Consider provision of mobile recruitment services
Research and primary practice settings
Inadequate research infrastructure • Ensure adequate physical space available for trial processes
• Understand information technology (IT) capacity at sites and use study systems that
can integrate with pre-existing IT, thus minimising training requirements
• Consider using data extraction tools to minimise access time to information
technology systems
• Ensure adequate remuneration to participants for time and service provided
• Consider provision of dedicated research coordinator at sites, particularly those already
understaffed
Pre-existing workforce strains • Adequately understand workforce-related issues at participating sites
• Ensure adequate personnel support is available and can respond to high staff turnover
• Ensure adequate training at practice level, and refresher training available and
budgeted for
Potential miscommunication across multidisciplinary health
services beyond primary care
• Provision of simple communication tools at the patient and practice levels that
highlight patient involvement within the trial.
• Adequately educating patients and carers regarding about trial and need for
communicating to all healthcare providers
• Identify participant multidisciplinary providers at enrolment and target trial
communication strategies accordingly
Increased administrative burden relative to health service
delivery and patient care demands
• Provide adequate research support to sites that can minimise administrative burden
• Consider automated procedures that ensure Good Clinical Practice compliance and
can integrate with current health service processes
• Ensure site service delivery requirements are fully understood prior to implementatin
• Provide clear education about Good Clinical Practice
• Practice requirements and administrative needs prior to recruitment
Costs
High trial running costs • Ensure adequate budget for provision of research support personnel at sites to
maintain recruitment timelines, ease administrative burden to sites and reduce
opportunity cost to sites
• Additional funding load to accommodate inadequate primary care research
infrastructure
• In medium to long term establish a funding pool to invest in primary healthcare
research infrastructure
Opportunity cost to participants • Understand potential costs to participants prior to implementation
• Provide adequate remuneration to participants in light of actual time required for
administration, including time spent with research nurses
• Ensure simple processes for sites to apply for and receive remuneration
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cardiovascular disease rather than the profit motive
which pharmaceutical companies have to go by
because they’re private companies and have
shareholders.’ (Provider 33, GP)
Many of the pharmacists participated because they
were interested in the intervention under evaluation.
Several were candid about the potential negative effect a
polypill strategy could have on their revenue. As
described by a pharmacist in an urban site based close
to an IHS:
‘Now I’m aware of different critical remarks among
community pharmacists … instead of three or four
dispensing fees we see one … not being a pharmacy
owner … I’m less sensitive to that issue … By and large
it’s good for customers, it’s good for compliance, it’s
good for the government I suppose.’ (Provider 15,
Pharmacist)
For some, participating in a trial was also thought to
create an opportunity for health professionals and ser-
vices to improve the care given to patients while pro-
moting collaborations with other organisations, as this
next Aboriginal health worker from a remote IHS
described:,
‘I’d say well it gives them (the health service) the
opportunity to give their patients the best possible care
that they can … offer this one more thing (that) can
actually influence a lot of the patients that we have.
So that offers better care for our patients. But then,
you know, helping out studies also yields partnerships
with people, other organisations.’ (Provider 41, AHW)
Recruitment of patients
Patient recruitment in the pragmatic trial required sub-
stantial effort due to the diversity of the health services
and broad characteristics of patients expected to partici-
pate. For instance, recruitment in remote services was
particularly challenging given patient populations were
highly mobile and health considerations complex. A GP
in a remote IHS described it as such:
‘I think there's a difference between being eligible and
suitable, so I think that was something that wasn't
really teased out properly. We got, I think, nearly close
to our target, because we recruited a lot of eligible
Table 2 Strategies to maximise enablers to implementing primary care pragmatic randomised controlled trials
Enablers Strategies to help maximise
Recruitment and participation
Leveraging pre-existing networks and relationships with key
stakeholders
• Provide adequate pre-recruitment engagement with stakeholders and elicit
expressions of interest
• Engage with stakeholders at trial-design stage to build a sense of ownership and
address research objectives of participants
Increased research capacity • Understand research needs of sites and fulfil gaps in research capacity as requested
• Incorporate capacity building as a key outcome for participation
• Provide opportunity for training at health service level to build research capacity
within primary healthcare.
Research as a quality service indicator and team building
exercise
• Provide structured training for sites as a means for team building between and
across sites
• Research participation as a quality assurance indicator for primary practices: policy
development consideration
Professional support for the intervention under evaluation
and tangible benefits to the service or participant
• Understand and address professional concerns about the intervention under
evaluation
• Promote the potential benefits of trial participation to health service and
participants
Personal and community benefits research participation • Understand and promote benefits (and risks) of research to individuals and
community
• Educate participants about research goals and needs
• Ensure participants feel sufficiently empowered to make decisions about ongoing
participation
Research and primary practice settings
Provision of research coordinator • Prior to implementation, proactively identify site resource needs in terms of trial-
related administration, communication, data management and patient management
• Ensure adequate research and logistical support is provided
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patients. In terms of suitability, I don't know whether
we really picked patients that were appropriate for a
trial.’ (Provider 40, GP)
Moreover, for this next GP, describing the recruitment
of patients with complex comorbidities from private
practice, the broad patient eligibility criteria proved a
source for disagreement between prescribers about
recruitment:
‘I was surprised that some of the patients, who others
had been happy to put on it because when we looked
at the problems that some had, I thought, well I
wouldn’t have put that person in, in the first place…
Because they hadquite a complicated history and
potential risks of having some problems … I wanted
them to either fit in clearly or not … So I suppose I
was looking for people who didn’t really have lots of
other comorbidities … I would have said, “They’re not
suitable”.’ (Provider 36, GP)
Patients’ research motivation
For patients, an overwhelmingly positive response to be-
ing involved in the trial was expressed with many claim-
ing they were happy to be involved as ‘guinea pigs’ and
to play a part in contributing to ‘finding a cure’. Taking
part in the trial was thought to not only offer potential
benefit to them as individuals, but to others as well, and
Aboriginal and Torres Strait Islander people in particu-
lar expressed their interest in the trial for this reason:
‘You know there’s something you’re contributing to,
and it’s not just about you; it’s about how it might help
the rank and file right across the nation … if I can
help my people live longer, live better lifestyles,
healthier lifestyles, then I want to be a part of that. I
just want to be part of that group that does that.’
(Patient 10, urban IHS)
This ‘big picture’ thinking translated to a willingness
to be involved, to trust in the health system and a sense
of doing something meaningful for others even if there
were no evident or immediate benefits for themselves:
‘I don’t have a problem with studies. I think if it’s
going to ultimately benefit mankind, I'm happy to sort
of be a bit of a guinea pig. It’s an interest. It’s also a
possibility that I will suffer better health because of it,
so I don’t have a problem with those types of things
generally.’ (Patient 16, of private GP)
‘Well I did feel an obligation not to withdraw and I
don’t know how many people in your control group
stuck it out to the end but you need a certain number
to you know, validate the statistics … But I never felt
any pressure, I was always assured that I could pull
out at any time if I’d had enough. But the pressure
came from within, you know… I’ve started I should
finish.’ (Patient 25, of private GP)
Research and primary practice settings
Research infrastructure
Overwhelmingly, providers cited inadequate infrastruc-
ture as a substantial barrier to trial implementation. In-
frastructure considerations included: physical space to
conduct patient visits, access to information technology
systems, and storage space for additional supplies of
polypill (for post-trial provision of polypill to partici-
pants). Time, money and human capacity were other ne-
cessary resources which were reported as being limited.
A pharmacist in a remote area described such
challenges:
‘… I guess from our perspective, and it came down to
not necessarily The George Institute, but it was more
our settings and our dispensing program and also staff
education as well …’ (Provider 42, Pharmacist)
Research and logistical support
The provision of a research coordinator at the study
sites was described by many providers to be a key facili-
tator to trial implementation. In IHSs, the research
nurse provided logistical support for the trial through
trial-related communication with health service staff
members, administration, obtaining informed consent,
and data collection. This is evident in the following com-
ment from a GP at an urban IHS:
‘I think it has been a good thing. It's not an added, the
admin, the workload doesn’t add on because we have
the team for support here. So in that way it wasn’t
even, didn't even notice. And it's just like any other pill
really, just prescribe it. It was easy enough; it was
already on our system so we just prescribe it just like
any other.’ (Provider 5, GP)
A GP and medical director in an urban private prac-
tice also thought that the research nurse facilitated the
conduct of the study and, therefore, alleviated the effort
required from the GPs in her service:
‘… she (research nurse) facilitated everything
brilliantly. … we cringe sometimes when people ask us
to do studies in a busy general practice … without the
nurse it would have been a nightmare really, … Well, I
think the whole study would not have worked without
her, and I think it’s a real lesson for any GP research is
having a research nurse is key.’ (Provider 12, GP and
Medical Director)
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Workforce-related issues
Some sites with particularly large patient loads, long
clinic waiting times and many rotating GPs faced chal-
lenges due to potential for miscommunication between
providers, and a lack of general understanding of the
study across the service. Integrating the intervention
within the realities of a dynamic workforce and chronic
staff shortages was particularly difficult. For instance, at
some IHSs, the research coordinator position proved to
be difficult to replace as required, due to a complicated
trial coordination handover and the need for staff
re-training. A medical director of an IHS describes the
effect of high staff turnover on trial conduct:
‘I think it was more good fortune than anything else
that we actually made it to the finishing line to tell
you the truth … staffing’s been a problem the whole
way through really. I think we’ve actually had about
three or four sort of individuals that have been
identified as actually the local supports or go-to people
for the trial … within a period of 18 months, 2 years.’
(Provider 46, Medical Director)
It was also acknowledged that this problem was likely
compounded by the ongoing problem of workforce re-
tention in remote settings.
Administrative demands of clinical trials
The paperwork requiring compliance with Good Clinical
Practice guidelines, including the reporting of adverse
events, was highlighted by some GPs as being an un-
acceptable additional workload. As one GP in private
practice stated:
‘“It’s the paperwork (that) has driven me crazy … I
don’t see any future for research if that’s the amount of
paperwork you’ve got to see, … I can understand why
you’ve got to do it but it’s just insane and I think
people who design these things and make the rules
ought to go and have a good hard look at themselves
and say you know, this is stupid … Now you know,
adverse reactions are important but you know, most of
them are rubbish, most of them have got absolutely
nothing to do with the study.’ (Provider 10, GP)
When asked about future involvement in a PRCT, this
GP in an urban setting was negative about his experi-
ence, questioning the feasibility of doing ‘research on
people in the “real world” … properly’, (Provider 10, GP).
This scepticism was based on the trial’s administrative
demands competing with his fundamental priority of
adequate service delivery and patient care.
In contrast, some providers did not find the additional
paperwork overly burdensome, acknowledging time was
required to be spent on training and administrative
paperwork as a condition of committing to trial
participation.
Multidisciplinary care beyond primary care
Another area of difficulty identified with implementing a
trial in primary care settings was that it involves patients
who require multidisciplinary care that may be received
outside of the primary care sites involved in the trial. In
particular, difficulties with communicating information
about the trial between primary and secondary healthcare
was described to potentially impact patient retention, as
this next GP stated:
‘… a person that goes in and out of hospital. In which
case I think it just caused a stress. Because they’d go in
and then they’d have all of the interns and then the
residents and registrars and everybody … What is this
thing and what are you on, … And how do we, and
what do we do and how we got to change this? So I
had a couple of times when patients would actually
come and just felt that it was too difficult because of
their multidisciplinary care.’ (Provider 3, GP)
Although extensive efforts were made to inform stake-
holders about Kanyini GAP at the outset (e.g. informing
specialists about the study prior to commencement,
explaining the polypill within referral letters and providing
information cards to patients), and these were described by
providers as an essential ‘safeguard’ against miscommunica-
tion, the above finding suggests that such measures may
not have been sufficient.
Participant costs
Participants did not indicate that the incentive payments
provided for participating in the Kanyini GAP trial influ-
enced their involvement in the study, suggesting that the
altruistic motivations outlined earlier were primarily
considered. Furthermore, not all pharmacies claimed
their entitlement offered to support the dispensing and
handling of the polypill. Some pharmacists reported the
‘small’ payments were not worth the time and effort
involved in preparing the necessary paperwork.
Despite our measures to minimise the financial impact
through a remuneration of AUD$100 per patient rando-
mised into the trial, a number of GPs from private
clinics did highlight that the time involved in taking part
in the trial carried a significant opportunity cost. The
following comment from a GP, who was a private prac-
tice proprietor located outside an urban area, indicates
that even with the provision of a research nurse, partici-
pation resulted in an opportunity cost:
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‘You run a business, you really can’t, (take that much
time out), and even so we still spent quite a bit of time
with (the research nurse)… I don’t know how many
appointments we missed because of time with her even
though it wasn’t huge, it adds up.’ (Provider 37, GP
and private practice owner)
Discussion
Summary
By exploring provider and patient experiences from
Kanyini GAP, and relevant trial materials, our analysis
has revealed considerable barriers to implementing a
PRCT in primary care. Specifically, a substantive lack of
research infrastructure, limited numbers of primary care
personnel adequately trained in the conduct of clinical
trials, administrative burden from regulatory require-
ments that exceeded the demands of adequate patient
care provision and the lack of coordination across all
providers involved in the treatment of patients, including
non-primary healthcare providers, substantially impeded
implementation. Additionally, the ongoing problem of
an under-resourced primary care workforce meant that
centrally employed research nurses were needed to sup-
port the sites. As a consequence of these barriers, fund-
ing for this study – around AUD$5 million and sourced
from multiple sponsors – ultimately proved insufficient.
As a result, recruitment timelines were longer than
anticipated and ultimately targets were not met.
Despite these shortcomings, participating in Kanyini
GAP was generally considered a positive experience
with mutual benefits stated for patients and providers
involved. Benefits included professional satisfaction,
increased collaboration between the different health ser-
vices involved, improved research capacity and the oppor-
tunity for health services to improve patient care. In
addition, patients and providers participated for altruistic
reasons, being particularly motivated by the chance to
contribute to the ‘greater good’. The success of completing
Kanyini GAP appears largely attributable to an upfront in-
vestment to build and maintain collaborations across the
diverse range of Australian primary healthcare settings
and, notwithstanding the additional financial cost in-
curred, from an intensive level of research support
provided to participating sites.
Recruitment challenges in PRCT
The challenges of meeting recruitment targets particularly
within PRCTs have been well-documented [9, 22–24]. A
meta-analysis of interventions to promote patient recruit-
ment to primary care concluded that organisational char-
acteristics, especially trial infrastructure, were important
[23]. Similarly, our findings indicate that a lack of such
research infrastructure in Australian primary practice con-
tributed substantially to recruitment delays. However, the
high level of research motivation reported from both pro-
viders and patients that was underpinned by a sense of
altruism facilitated recruitment.
Some design features of Kanyini GAP, classified with
the PRECIS tool as more pragmatic than explanatory,
presented further challenges to recruitment and imple-
mentation. Specifically, the ‘participant eligibility criteria’
domain was highly flexible in Kanyini GAP such that all
patients with the condition of interest were considered
eligible [10, 11]. Using these criteria to assess site feasi-
bility on the basis of predicted recruitment targets led to
an overestimation of participant numbers compared to
what could be achieved in practice. Furthermore, the do-
main ‘experimental intervention practitioner expertise’
allowed for a full range of practitioners to apply the
intervention within the clinics [10, 11]. In larger sites
that had multiple staff on rotation, more training and
logistical support for practitioners was required through-
out the time frame of the study than might have
occurred if selected personnel were responsible for
applying the intervention. Collectively, these pragmatic
design features of Kanyini GAP meant there was a need
to engage more sites, extend study timelines and
increase expenditure to try and meet recruitment tar-
gets. However, the use of these pragmatic criteria is
necessary as they allow for real practice variation and an
assessment of the acceptability and generalisability of
the intervention.
Challenges unique to trial implementation in a primary
care setting
Our study has identified some additional challenges
which may be unique to the conduct of a clinical trial in
the primary care setting. First, in contrast to research
traditionally conducted in public healthcare facilities, a
number of primary healthcare providers in Kanyini GAP
were operating in the private sector. Although altruistic-
ally motivated to participate, the impact of the trial on
revenue and time was an important consideration. Fur-
thermore, despite establishing PRCT research partner-
ships that would now be classified as ‘best practice’, (e.g.
site feasibility pre-assessment, stakeholder involvement
and integration into usual practice workflow) [25], these
efforts were insufficient to mitigate the burden that was
experienced by some Kanyini GAP providers. In this
regard, identifying and discussing the immediate and
long-term financial impact of the trial with the health-
care providers is important at the outset. Compensation
for such costs needs to be built into existing funding
models for pragmatic trial research.
Second, as most primary care sites in Kanyini GAP
were independently owned, there was substantial vari-
ation in the day-to-day operation between sites. Chronic
staff shortages and high staff turnover were problematic,
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particularly at rural and remote sites where some of the
most disadvantaged and difficult-to-reach patients res-
ide. To enable the streamlined integration of the trial
with usual primary care processes, the provision of in-
tensive research support is needed via trained research
nurses. Research conducted in greenfield sites, involves
significant investment to increase their research capacity
for future studies.
Strengths and limitations
This study has identified enablers and barriers to the
conduct of a PRCT in Australian primary healthcare set-
tings by directly considering the experiences of partici-
pants. This information is vital for clinical researchers
who seek to generate ‘real-world’ evidence to bridge the
significant gaps known to exist between the controlled
trial environment and practice. However, this study did
not include the remote Central Australian sites involved
in Kanyini GAP. Thus, the generalisability of the study’s
findings to such sites, and to other healthcare systems
cannot be certain. So as not to influence the adherence
behaviours of participants, interviews could not be con-
ducted until the end of study. Invariably, the opinions of
participants who had dropped out of the trial prior to
the end-of-study visit, or sites that were approached but
declined to participate, could not be ascertained. How-
ever, the rigorous methods used in this study, particu-
larly triangulation of data sources, using more than one
interviewer and coder, and the breadth of clinical and re-
search experience of the research team favour robust
results.
Conclusions
A number of key recommendations for the implemen-
tation of future PRCTs in primary care have emerged.
First, significant investment in primary care research
infrastructure is needed to facilitate recruitment and
successful trial completion. Information technology sys-
tems that streamline data capture relating to key out-
comes (e.g. hospitalisation and mortality) and that can
promote communication across the various health sys-
tem levels (e.g. primary and secondary care) is one
suggestion.
Second, building research capacity within primary care
is essential. Including research as a key performance or
quality assurance indicator may increase research cap-
acity, albeit indirectly. The increased exposure of pa-
tients and practitioners to research may ultimately lead
to PRCTs being viewed as a standard feature of high-
quality primary healthcare services. This is congruent
with experiences of other PRCT trialists which found
that conducting PRCTs has the potential to achieve
greater partnerships between researchers and healthcare
systems to produce high-quality studies to improve
health-care [25].
A final strategic recommendation would be sustained
funding for adequately resourced primary care research
networks, incorporating private practices, ACCHSs
and pharmacists. Based on international evidence [26],
practice-based research networks (PBRN) are now
starting to emerge in Australia but are currently poorly
funded [27].
Notwithstanding the development of such networks,
sufficient resourcing must be set aside for individual
projects to cover the full costs of involving large num-
bers of disparate stakeholders in research. It is important
to recognise that the high unbudgeted costs in the
Kanyini GAP trial were to accommodate the lack of
research experience and training in primary care. Sub-
stantial costs associated with running trials in primary
care settings are incurred upfront, particularly when
partnering with numerous centres which have had lim-
ited or no research experience. Such upfront costs
should include not only costs to the study but the bur-
den to the individual centres for which, as uncovered in
our interviews, was often uncompensated for.
By initiating research across a numerous set of diverse
sites, Kanyini GAP has cleared paths for easier and less
costly implementation of future Australian primary care
PRCTs. A key recommendation from this project, there-
fore, is that recognition of such path-clearing investments
is required and that provision either be made (in the short
term) for loadings on research funding for new projects
that specifically set out to perform similar roles or (in the
medium to long term) the creation of a general invest-
ment pool to fund primary care research infrastructure.
Such initiatives will encourage investment in capacity that
will contribute to a broader research environment more
conducive in the long run to the running of much-needed
PRCTs.
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CHAPTER 4: A PROCESS EVALUATION OF A FAMILY-LED 
REHABILITATION TRIAL IN INDIA (ATTEND) 
 
Chapter Overview 
This chapter contains the process evaluation of the fAmily-led rehabiliTaTion randomisEd 
controlled trial in InDia (ATTEND). The chapter consists of two published and one accepted 
manuscript titled: 1) A protocol for a process evaluation of a randomised controlled trial of 
family-led rehabilitation post stroke (ATTEND) in India. 2) Family-led rehabilitation in India 
(ATTEND) - findings from the process evaluation of a randomised controlled trial. 3) Clinical 
stroke research in resource limited settings: Tips and hints. 
Whilst in Chapter 3 the use of a Realist lens of ‘Context, Mechanisms, and Outcomes’ 
allowed for greater interpretation of the micro to macro -level contextual factors in the 
process evaluation of Kanyini GAP (conducted in 2013), this chapter is informed further by 
the UK MRC process evaluation guidance published in 2015. The first manuscript provides 
the process evaluation protocol which incorporates concepts from the RE-AIM (Reach, 
Effectiveness, Adoption, Implementation and Maintenance) framework into the UK MRC 
process evaluation framework. The overarching framework and relevant data sources are 
described.  
The second manuscript provides the findings from the process evaluation, and helps explain 
why the trial, which was published in the Lancet (see appendix), was neutral and the 
implications of the findings. As a background, the ATTEND trial was a large scale randomised 
controlled trial in India which involved the training of a family care-giver to provide basic 
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evidence-based rehabilitation to a patient post stroke. The trial was initiated by local 
neurologists in India and co-Investigators in Australia and the UK, and funded by the 
Australian National Health and Medical Research Council to address a recognised deficiency 
in access to stroke rehabilitation in India - a setting where there are major economic and 
health system barriers to formal rehabilitation services. This model of care was not found to 
be effective in reducing death and dependency at 6 months after stroke.  
This process evaluation answers important questions raised in the wake of the trial: Was the 
lack of effect due to a failure of the intervention or of trial implementation, or both? What 
actually happened at the hospital and in peoples’ homes? Given that family-led 
rehabilitation is a complex behaviour-change intervention with multiple interacting 
components and actors- examining the process of trial implementation, contextual factors 
and exploring health providers’, patients’ and carers’ perspectives of the intervention could 
shed light on this ‘black box.’  Therefore, providing greater insight into the mechanisms of 
the intervention, and inform future research priorities.  
The third manuscript aims (as stated in the process evaluation protocol) to identify the 
facilitators and barriers of the ATTEND collaborative group. This publication was an invited 
review and perspectives paper. Chief investigators of the ATTEND trial, Dr Jeyaraj Pandian 
and Dr Richard Lindley, were invited by the International Journal of Stroke to provide their 
insights and hints for conducting research in limited resource settings.  The barriers and 
facilitators identified in the ATTEND process evaluation was incorporated in this invited 
narrative.  
 
 
73
Author’s contributions:  
JDP suggested the original ATTEND trial idea and the steering committee (RL, GVSM, PKM, 
PL, LAH, MLH, MW, AF, BRS, CSA and SJ) designed the trial with a process evaluation in 
mind. HL developed the process evaluation protocol with extensive and significant 
contribution from the trial management team which includes MA, CF, DBCG, SJV, DKT, AS 
and RKR.  HL led the process evaluation, trained the process evaluation team members in 
qualitative methods, contributed to the data collection and led the analysis. HL drafted the 
manuscripts and revised them. All authors read and approved the manuscript of the 
protocol and the manuscript of the findings. HL is the first author of the first two 
manuscripts, and the second author of the third manuscript. All authors contributed to the 
revisions of the manuscripts.  
Manuscript details:  
Liu H, Lindley R, Mohammed A, Felix C, Gandhi D, Verma S, Tugnawat DP, Syrigapu A, 
Krishnappa R, Pandian JR, Walker M, Forster A, Anderson C, Langhorne P,  Murthy GVS, 
Shamanna BR, Hackett ML, Maulik PB, Harvey LA,  Jan S. A protocol for a process evaluation 
of a randomised controlled trial of family-led rehabilitation post stroke (ATTEND) in India. 
BMJ open, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27633636  
Liu H, Lindley R, Mohammed A et al. Family-led rehabilitation in India (ATTEND)- findings 
from the Process Evaluation of a Randomised Controlled Trial. 2018, International Journal of 
Stroke. (accepted for publication 31st May 2018) 
Pandian JD, Liu H, Gandhi DB, Lindley RI. Clinical stroke research in resource limited settings: 
Tips and hints. International journal of stroke : official journal of the International Stroke 
Society. 2017 Jan 1:1747493017743798. PubMed PMID: 29148963. 
 
74
Protocol for process evaluation of
a randomised controlled trial of
family-led rehabilitation post stroke
(ATTEND) in India
Hueiming Liu,1,2 Richard Lindley,1,2 Mohammed Alim,3 Cynthia Felix,4
Dorcas B C Gandhi,4 Shweta J Verma,4 Deepak Kumar Tugnawat,5
Anuradha Syrigapu,5 Ramaprabhu Krishnappa Ramamurthy,6 Jeyaraj D Pandian,4
Marion Walker,7 Anne Forster,8 Craig S Anderson,1,2,9 Peter Langhorne,10
Gudlavalleti Venkata Satyanarayana Murthy,5 Bindiganavale Ramaswamy Shamanna,11
Maree L Hackett,1 Pallab K Maulik,3,12 Lisa A Harvey,2 Stephen Jan1,2
To cite: Liu H, Lindley R,
Alim M, et al. Protocol for
process evaluation of
a randomised controlled trial
of family-led rehabilitation
post stroke (ATTEND) in
India. BMJ Open 2016;6:
e012027. doi:10.1136/
bmjopen-2016-012027
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2016-
012027).
Received 23 March 2016
Revised 23 June 2016
Accepted 24 August 2016
For numbered affiliations see
end of article.
Correspondence to
Dr Hueiming Liu;
hliu@georgeinstitute.org.au
ABSTRACT
Introduction: We are undertaking a randomised
controlled trial (fAmily led rehabiliTaTion aftEr stroke in
INDia, ATTEND) evaluating training a family carer to
enable maximal rehabilitation of patients with stroke-
related disability; as a potentially affordable, culturally
acceptable and effective intervention for use in India.
A process evaluation is needed to understand how and
why this complex intervention may be effective, and to
capture important barriers and facilitators to its
implementation. We describe the protocol for our
process evaluation to encourage the development of
in-process evaluation methodology and transparency in
reporting.
Methods and analysis: The realist and RE-AIM
(Reach, Effectiveness, Adoption, Implementation and
Maintenance) frameworks informed the design. Mixed
methods include semistructured interviews with health
providers, patients and their carers, analysis of
quantitative process data describing fidelity and dose
of intervention, observations of trial set up and
implementation, and the analysis of the cost data from
the patients and their families perspective and
programme budgets. These qualitative and quantitative
data will be analysed iteratively prior to knowing the
quantitative outcomes of the trial, and then triangulated
with the results from the primary outcome evaluation.
Ethics and dissemination: The process evaluation
has received ethical approval for all sites in India. In
low-income and middle-income countries, the available
human capital can form an approach to reducing the
evidence practice gap, compared with the high cost
alternatives available in established market economies.
This process evaluation will provide insights into how
such a programme can be implemented in practice and
brought to scale. Through local stakeholder
engagement and dissemination of findings globally we
hope to build on patient-centred, cost-effective and
sustainable models of stroke rehabilitation.
Trial registration number: CTRI/2013/04/003557.
INTRODUCTION
With a rapidly rising global burden of
disease attributed to non-communicable dis-
eases, access to high-quality evidence-based
Strengths and limitations of this study
▪ A strength of our study protocol includes the use
of implementation theories, quantitative and
qualitative research methods and our iterative
approach to analysis.
▪ Consideration of costs to the patient is vital to
assess whether a programme would be afford-
able outside a trial setting, which is often inad-
equately reported in trials. The design of this
process evaluation allowing the triangulation of
within-trial cost data and qualitative data will add
to the limited current evidence regarding the
socioeconomic burden of stroke to patients and
their families in India.
▪ Limitations to our current approach include the
overlap between the trial coordinating team and
the process evaluation team. While a strength of
this approach is that the team members have an
in-depth knowledge of the trial and its imple-
mentation, a challenge for the process evaluation
is for team members to be aware of their own
biases in the conduct of the interviews for posi-
tive findings towards the trial.
▪ Our sampling approach for the interviews has
been designed to maximise variation which
should increase our understanding of the differ-
ing contextual factors. Pragmatically this is only
a small sample (about 100 participants) of a
1200 patient trial. However, this is a large
sample for qualitative research, and other data
sources such as observations, administratively
collected data and relevant policies would be
reviewed to provide additional context.
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healthcare is essential. Complex interventions, deﬁned
as interventions with multiple interacting components,
are frequently deployed in an attempt to address health
system deﬁciencies experienced by patients and provi-
ders.1 Process evaluations, which are typically carried out
for trials of complex interventions, can help explain for
whom, how and why the intervention had a particular
impact.2 Such evaluations address the question ‘Is this
intervention acceptable, effective and feasible (for me
or) for this population?’3 Gaining a clear understanding
of the causal mechanisms of complex interventions is
vital in being able to scale up or deliver an effective
intervention in other settings.
This is especially relevant for the randomised con-
trolled trial known as the fAmily led rehabiliTaTion
aftEr stroke in INDia (ATTEND), which is being con-
ducted at 14 hospitals in India—across populations with
differing languages, cultures and health systems.4–6 The
annual incidence of stroke in India is estimated to be
152–262 cases per 100 000 population, with prevalence
of 0.47–0.54%.7 This means that there is a signiﬁcant
burden on society due to stroke disability with limited
stroke units isolated to urban areas and limited rehabili-
tation services.8 Table 1 highlights some socioeconomic
health indicators and available stroke incidence data in
different states where our sites are based.
The ATTEND intervention has multiple interacting
components. We developed an evidence-based rehabili-
tation intervention package consisting of providing infor-
mation on stroke, identiﬁcation and management of low
mood, importance of repeated practice of speciﬁc activ-
ities, task-oriented training, early supported discharge
planning and joint goal setting with the patient and
nominated family. Physiotherapists employed for the
trial are trained in this evidence-based rehabilitation
intervention package.6 These physiotherapists (known as
stroke coordinators in the trial) provide support to the
patient and family within the hospital and in subsequent
home visits, with the aim of training a nominated carer
and in enabling optimal rehabilitation of the patient. As
such, a careful consideration of the contextual patient
factors, such as health literacy, access to care and ﬁnan-
cial considerations, is needed.9–11 The context of each
patient can have an impact on the behaviour of the
carer and the patient, which will affect patient improve-
ment in disability and dependence outcomes as mea-
sured by the modiﬁed Rankin scale (mRS) and other
outcome measures (see ﬁgure 1).6 Thus, the process
evaluation could help explore reasons for any variations
in trial effectiveness, and address questions about the
generalisability of this intervention across different set-
tings. A deeper appreciation of the needs of patients
poststroke and their families will be valuable for health
system and policy reform in India.4
A key role of our process evaluation would be to
inform how the intervention can be implemented into
practice and policy, if proven effective. It is well recog-
nised that the generation of good quality evidence does
not always translate into improved patient health out-
comes.12 Financial barriers, such as high out of pocket
costs for diagnostic imaging or provision of treatment,
are possible reasons for an intervention not being deliv-
ered once shown to be efﬁcacious in a trial.13–16 Such
costs are likely to frame the ﬁnancial incentives of differ-
ent players within the system and explain behaviour that
is potentially at odds with the idealised operation of an
Table 1 Sociodemographic health indicators across the participating ATTEND sites
City/state of
participating sites
Life expectancy at
birth (2002–2006)*
(years)
Poverty level
(2004–2005)*
(%)
Per capita health
expenditure (in Rs)*
Age-standardised incidence rate for
stroke† (from population stroke
epidemiology studies)
Ludhiana, Punjab 69.4 8.4 1359 Not available
New Delhi, Delhi Not available Not available Not available Not available
Kochi and
Trivandrum, Kerala
74 15 2950 135/100 000 person-years
Guntur, Andhra
Pradesh
64.4 15.8 1061 Not available
Chennai and Vellore,
Tamil Nadu
66.2 22.5 1256 Not available
Kolkata, West
Bengal
64.9 24.7 1259 145/100 000 person-years
Tezpur, Assam Not available 19.7 774 Not available
Hyderabad, Andhra
Pradesh
64.4 15.8 1061 Not available
Bangalore,
Karnataka
65.3 25 830 Not available
INDIA 63.5 27.5 1201 119–145 per 100 000 person-years
*Ministry of Health and Family Welfare, Government of India. Annual report to the People on Health. December 2011.
†Pandian J, Suhan P. Stroke Epidemiology and stroke care services in India. J Stroke 2013;15(3):128–134.
ATTEND, fAmily led rehabiliTaTion aftEr stroke in INDia.
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intervention. Understanding these cost barriers can
inform how remuneration and payment systems may be
shaped to facilitate implementation beyond a trial
setting.14 Incorporating an assessment of stakeholders’
perceptions of how an intervention can be practically
funded, delivered and scaled up is crucial.
Process evaluations can also add to the literature of
how collaborations between stakeholders (ie, health
providers, academics, policymakers, patients, carers)
may facilitate research translation.17 Understanding
how and why an international collaboration of stroke
experts came together to design and implement a feas-
ible, locally adapted large-scale trial in India would also
be helpful for future research. Lessons learnt from this
trial, which is funded by the National Health and
Medical Research Council (NHMRC) of Australia, with
capacity building objectives in India, would be valuable
in informing future international collaborative
research.
The UK Medical Research Council (MRC) recom-
mends publishing a protocol for a process evaluation so
as to promote development of methodology and trans-
parency in the reporting of the ﬁndings. In this proto-
col, we outline our aims, methods and study design. The
core aims of this process evaluation are: (1) to explore if
the ATTEND trial was delivered as intended (eg, ﬁdelity and
dose); (2) to understand whether, how and why the intervention
had an impact, through exploring providers’, patients’ and
carers’ perspectives of their usual care and of the intervention;
(3) and to explore if the results are likely to be generalisable,
scalable and sustainable through exploring stakeholders’ (hos-
pital stroke unit staff, providers, patients and carers) experiences
of the intervention and its perceived impact. This would
include an evaluation of costs from the societal perspective,
including the health system and also for the patients and fam-
ilies. Finally, (4) we aim to explore implementation barriers and
facilitators of a complex intervention by an international
collaboration.
Figure 1 The ATTEND RCT
flow chart. This highlights the
outcome measures used and the
study visits. ADL, activities of
daily living; ATTEND, fAmily led
rehabiliTaTion aftEr stroke in
INDia; EQ-5D-3L, EuroQol
5-Dimensional, 3 Levels; NIHSS,
National Institutes of Health
Stroke Scale; RCT, randomised
controlled trial; WHOQOL-BREF,
WHO Quality of Life (Brief ).
Liu H, et al. BMJ Open 2016;6:e012027. doi:10.1136/bmjopen-2016-012027 3
Open Access
group.bmj.com on October 4, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
77
METHODS AND ANALYSIS
Theoretical frameworks informing this process evaluation
Two theoretical frameworks with emphasis on translating
evidence in the real-world setting were used to inform
our methods.
The ﬁrst was the RE-AIM (Reach, Effectiveness,
Adoption, Implementation and Maintenance) frame-
work. It has been used by researchers in the develop-
ment, evaluation and dissemination of research, using
qualitative and quantitative methods.18 The framework’s
ﬁve domains highlight the need to look into the propor-
tion and representativeness of the participants involved
in the intervention, the impact of the intervention, the
ﬁdelity of trial implementation and at how a programme
may be institutionalised into organisational practice after
the conclusion of the trial. Thus, pending ATTEND’s
results, and resources permitting, there may be scope
for a post-trial evaluation to explore how and why there
were changes in practice and policy.19
The second framework that informed our methods
was the Realist framework (Context, Mechanism,
Outcomes).20 It has been successfully used in process
evaluations as a theoretical basis for identifying potential
causal mechanisms for how an intervention works for
whom, under what contexts and therefore fosters uptake
of research-based knowledge into practice.21 22 Given
the complexity of the ATTEND trial from contextual
macrolevel factors, such as different socioeconomic
demographics, cultural differences, health system
funding structures at each state, to microlevel factors
such as literacy of patients and carers; the realist frame-
work would be valuable in framing our analysis in under-
standing the mechanism within the ‘black box’ of the
intervention.23
Our process evaluation framework and the hypothesised
causal mechanisms of ATTEND
The framework (ﬁgure 2) highlights the key questions
for the process evaluation, incorporating the above the-
ories and our work plan. We have brieﬂy outlined our
hypothesised causal mechanisms of ATTEND’s complex
intervention within the framework as per the MRC’s
guidance on process evaluations.19 The framework is
divided into sections of context, implementation of the
trial, mechanisms of the trial and outcomes of the trial
with the ﬁnal objective of reducing the burden of stroke
through a sustainable model of care.
Mixed methods used to address the aims of the process
evaluation
1. To explore if the trial was delivered as intended (eg,
ﬁdelity and dose)
Figure 2 The ATTEND process evaluation framework. The process evaluation components are highlighted in blue boxes—
exploring contextual factors, the implementation of the ATTEND trial, mechanisms of impact from the intervention. Questions
informed by the RE-AIM and Realist framework fit within these components. These components are informed by the causal
assumptions of ATTEND intervention and will inform the interpretation of the primary and secondary outcomes. ATTEND, fAmily
led rehabiliTaTion aftEr stroke in INDia; RE-AIM, Reach, Effectiveness, Adoption, Implementation and Maintenance.
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This will be achieved through an analysis of the adminis-
tratively collected process data (eg, competency mea-
sures, frequency of training), electronic case record ﬁle,
quantitative data and activity logs (eg, the measurement
of the total time spent per patient in both arms of the
trial with the usual care physiotherapist, the number of
meetings and time spent with each family caregiver by
the stroke coordinator during their inpatient stay and
after discharge). If the analysis provides any evidence of
variation between the active and control groups in terms
of amount of time spent on different tasks, we will inves-
tigate and provide further training if required.
2. To understand whether, how and why the interven-
tion had an impact through exploring the providers’,
patients’ and carers’ perspectives of usual care and of
the intervention
▸ Non-participant observations of all the sites to
understand the contextual factors at each site,
which may help explain variations in outcomes.
Our observation template has been adapted from
a process evaluation of a similar intervention24
and includes issues on trial set up, trial implemen-
tation and impact. See online supplementary add-
itional ﬁle 1 for a copy of the template.
▸ Semistructured in-depth interviews will be con-
ducted with patients, carers, stroke coordinators
and the stroke unit staff of hospitals to understand
their perspectives of the causal mechanisms of the
intervention and to seek their suggestions on how
the intervention could be scaled up or rolled out.
Methods for our qualitative interviews have been
described as per the consolidated criteria for
qualitative research:25
A. Research team and reﬂexivity: The research team is
multidisciplinary and comprises of the trial’s chief
investigators, the clinical trial coordinating staff and
research fellows from India, UK and Australia. The
team has background in medicine, physiotherapy,
health economics, pharmaceutical trials and public
health; with varied experience in qualitative research.
In particular, three of the team members (HL, MA
and SJ) have training in qualitative methods. HL who
coordinated the team, organised face-to-face qualita-
tive workshops to train the rest of the team prior to
the conduct of interviews and will take a leading role
in analyses. A team of six people will conduct the
interviews. The team members, who are part of the
clinical trial management team, have a good under-
standing of the trial and are known to the principal
investigators, stroke coordinators and blinded asses-
sors but will not have established relationships with
the patients and their carers.
Semistructured interview guidelines based on our study
objectives have been developed and pilot tested. The key
areas covered include overall views of the health and
socioeconomic impact of stroke on patients and families,
stroke management in India, acceptability of the
family-led rehabilitation intervention, the general
healthcare experience of patients and their families and
translation of the intervention into practice and policy.
Early ﬁndings will be discussed with the study team, and
minor changes made to the interview guidelines if
needed. (See online supplementary additional ﬁles 2–4
for the interview guidelines for the health provider,
carer and patient, respectively.)
B. Study design: Sampling: Participants for the interviews
will be recruited using maximum variation purposive
sampling. Variables to be considered for patients and
carers are: usual care versus intervention arm,
primary outcome (as measured by the mRS at 6
months), gender and the region of India they are
from. Variables to be considered for stroke unit
providers: healthcare roles (ie, neurologists, phy-
siotherapists, nurses and the stroke coordinators),
private versus public government hospitals and the
region of India the hospitals are located.
A list of patients and caregivers who match our sam-
pling criteria will be generated. They will be contacted
by the local site staff (either the stroke coordinator or
the ‘blinded assessor’) and where relevant, reasons for
not participating will be elicited. They will be formally
consented by the interviewer face-to-face. Interviews with
carers and patients will be conducted either individually
or with both together either at the participant’s home
or at the hospital. These interviews will be conducted in
local languages and the services of an interpreter may
be required. The beneﬁts of interviewing the patient
and carer separately would be to gather perspectives
which otherwise may not be shared should the other be
present. Healthcare providers will be invited to partici-
pate in interviews either by a letter or in person by the
clinical coordinating team during their site visits, and
conducted in English. Written informed consent (see
online supplementary additional ﬁle 5 for a copy of the
form) will be obtained from all interviewed participants.
As per qualitative research methods,26 analysis is iterative
and thus the interviewer will carry out preliminary the-
matic data analysis at the end of each interview and
discuss any highlights with the rest of the interview
team. For example, the ﬁndings from the pilot inter-
views were discussed during the qualitative workshop, in
order for the team of interviewers to explore emerging
themes in subsequent interviews. It is estimated that at
least ﬁve sites would be sampled, with 3–4 health provi-
ders and about 4–6 patient/carer dyads interviewed from
each site. According to the sampling matrix, we will inter-
view equal numbers from both usual care versus interven-
tion arm, and also include sampling for gender. For
example, at each site, two usual care dyads and two inter-
vention group dyads will be invited to participate.
In addition, some of the stroke coordinators and the
independent assessors at the other sites will be inter-
viewed. That is, an estimated 80–100 interviews will be
conducted though the ﬁnal numbers will be determined
by saturation of themes and resources permitting.
Interviews will be conducted face-to-face, audio recorded
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and professionally translated and transcribed verbatim.
These will be uploaded into a software program NVivo
V.9 (QSR International, Melbourne, Victoria, Australia)
to assist with data management.
3. To explore if the results are generalisable, scalable
and sustainable through exploring health providers’,
patients’ and carers’ experiences of the intervention
and its perceived impact. This will include an evalu-
ation of costs from the societal perspective including
the health system, and for patients and their families.
(note this is separate to the formal cost-effectiveness
study which has been set out in the original trial
protocol)6
▸ One of the key domains in the semistructured
interviews will be exploring participants’ perspec-
tives of what they expect post-trial in relation to this
intervention. The ﬁndings related to these ques-
tions will address this aim.
▸ Cost components of the intervention which will be
relevant to implementation outside a trial setting
will be considered. This will be extracted from the
programme budget and trial contracts and
includes, for example, costs of employment of a
physiotherapist to implement the intervention,
travel costs of the home visits and costs of any edu-
cational material required as part of the interven-
tion. Relevant questions asked by the blinded
assessor at the 3-month and 6-month follow-up
visits include loss of family income (eg, number of
hours of work taken off) due to carer’s additional
responsibility and medical costs. (Participants are
encouraged to keep receipts of related medical
costs.)
4 To explore implementation barriers and facilitators
of a complex intervention by an international
collaboration.
A research fellow not involved in the implementation
of the trial will conduct focus group interviews and
semistructured interviews with members of the clinical
trial coordinating team and also with the trial investiga-
tors in regards to perceived barriers and facilitators
to trial implementation. Findings from these interviews
in addition to relevant ﬁndings from the interviews
with the health providers, patients and carers will
inform lessons learnt from this trial for future research
collaborations.
Analysis plan for the process evaluation
Thematic analysis will be used for the qualitative analysis
to code closely to the data and establish themes within
the subheadings of the process evaluation framework
(ﬁgure 2).26 Constant iterative comparison between
sources, for example, patient, carer and health provider
will be carried out in order to identify common, as well
as distinctive, themes.26 Contextual information from
observations, other process data and costs to patients
and families will be used to triangulate the emerging
themes.27 The quantitative process data will help inform
ﬁdelity and the time logs of the stroke coordinator will
provide descriptive data on dose. Fidelity data will be
reviewed at six monthly intervals.
The process evaluation framework (ﬁgure 2) will aid
in the analysis by triangulating the process’s quantitative
data with the relevant qualitative data addressing the
questions within its subheadings.27 For example, under
the heading ‘implementation—ﬁdelity and dose’, a spe-
ciﬁc question would be whether usual care is provided
equally in both arms of the intervention, and thus the
quantitative process data would be the time spent by the
usual care physiotherapist and should be almost equiva-
lent in both arms documented in the logs (or not), and
the qualitative data would include, for example, the
usual care physiotherapists’ responses as to whether they
did treat all the patients equally, or the neurologist’s
description of what happens to the study participants.
Other forms of triangulation to increase the reliability
of our results include the sampling of different perspec-
tives, that is, patient, carer, neurologists and stroke coor-
dinators and also through the triangulation of different
analysts in the team who bring their own cultural back-
grounds, academic experience (eg, rehabilitation medi-
cine, pharmacy, physiotherapy) and knowledge about
different aspects of the trial into the analysis.26
In line with the MRC guidelines, the process evalu-
ation data should be analysed prior to knowing the trial
outcomes, ﬁrst to remove bias, though there is a role for
post hoc exploration of reasons for trial outcomes.2
First, we will analyse our process evaluation data itera-
tively on an ongoing basis. If there are any process issues
which would impact on trial integrity that need to be
addressed, these will be fed back through the usual man-
agement communication channels.28
The framework serves as a template to consolidate the
ﬁndings, and will be a dynamic structure with changes to
be made if required. This means that our understanding
of the causal mechanisms of the intervention may change
with the iterative analysis of the process evaluation data.
There will also be a post hoc examination of the
process evaluation ﬁndings, in light of the main results
of the trial.29 For example, in our experience, our
assumption is that early supported discharge, as part of
the intervention, will decrease costs to the system and
family, enable early patient rehabilitation which may
improve patient recovery (primary outcome) and result
in shorter hospital stays in the intervention arm.
However, in piloting our observation template at one
site, we discovered that there was shortage of beds such
that at that government hospital patients were dis-
charged at the earliest possibility, for example, when
they were medically stable. This may perhaps be different
to developed country settings, such as UK, and ultimately
may explain potential divergences in the ﬁndings of this
study to that of a recent meta-analyses of rehabilitation
trials (which showed positive results of early supported dis-
charge).30 31 A major consideration in the process evalua-
tion therefore may be regarding the length of stay in
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hospital. The examination of such secondary outcomes
and contextual ﬁndings from the process evaluation is an
example of how we could gain a deeper understanding of
the assumed causal mechanisms of the ATTEND interven-
tion (as depicted in the logic model in the overall process
evaluation framework). Such insights will help inform the
ﬁnal logic model of how the intervention truly impacted
the trial effectiveness outcomes, and inform the generalis-
ability of the intervention.
ETHICS AND DISSEMINATION
Ethics
Ethical approval for the trial and process evaluation has
been obtained from Research Integrity, the Human
Research Ethics Committee at the University of Sydney
and at each local site. See online supplementary add-
itional ﬁle 6 for the details of ethic committees at the
local sites.
The ethical implications of this scope of research
include the considerations of NHMRC ethical guidelines
such as research merit and integrity, beneﬁcence and
respect in relation to qualitative methods.32
Dissemination
Our process evaluation aims to complement a robust
blinded outcome evaluation of the trial end points and
inform our stakeholders how, for whom and why this
model of family led rehabilitation could have an impact.
This is especially relevant for India which is in ‘epi-
demiological transition’ with a diverse sociodemographic
proﬁle, and an increasing burden from non-
communicable diseases which could result in greater
health inequity.4 16 A stated aim in India’s key national
strategy for non-communicable diseases is to increase
access to healthcare to 80% with costs not being a key
barrier. Strategies such as the family-led rehabilitation
programme, which marshal family and community
resources in the care of patients with chronic conditions
will, by ﬁnancial necessity, play a greater role in the
future. In low-income and middle-income countries, the
available human capital can form one approach to redu-
cing the evidence practice gap, compared with the high
cost alternatives available in established market econ-
omies. This process evaluation will provide insights into
how such a programme can be implemented in practice
and brought to scale.
The Indian Institute of Public Health has been allo-
cated resources for the dissemination of results through
the engagement of local policymakers and health practi-
tioners. Apart from stakeholder engagement, dissemin-
ation of our ﬁndings globally will be accomplished
through publishing our results in relevant journals and
conferences to build on the literature in providing
affordable, holistic and accessible stroke rehabilitation
models of care.
We describe our protocol to encourage development
in process evaluation methodology, transparency in
reporting and to build on this emerging area of health
services research which is much needed in addressing
the complicated global health needs through sustain-
able, patient-centred and evidence-based complex
interventions.
Trial status
In regards to the ATTEND trial, the ﬁrst patient was
randomised on 13 January 2014 and the recruitment
surpassed the sample size of 1200 in January 2016. The
ATTEND process evaluation, started in March 2015
with the observational visits of the sites and the ﬁdelity
and dose quantitative data have been reviewed in six
monthly intervals since March 2015, pilot interviews
were conducted with health providers in July 2015 and
completion of the patient, carer and health provider
interviews is expected by May 2016, with ongoing prelim-
inary and iterative analysis.
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ABSTRACT 
Background: Training family carers to provide evidence-based rehabilitation to stroke 
patients could address the recognised deficiency of access to stroke rehabilitation in low- 
resource settings. However, our randomised controlled trial in India (ATTEND), found that 
this model of care was not superior to usual care alone.  
Aims: This process evaluation aimed to better understand trial outcomes through assessing 
trial implementation and exploring patients’, carers’ and providers’ perspectives.  
Methods: Our mixed methods study included process, healthcare use data and patient 
demographics from all sites; observations and semi-structured interviews with participants 
(22 patients, 22 carers and 28 health providers) from 6 sampled sites. 
Results: Intervention fidelity and adherence to the trial protocol was high across the 14 sites, 
however, early supported discharge (an intervention component) was not implemented. 
Within both randomised groups some form of rehabilitation was widely accessed. ATTEND 
stroke coordinators provided counselling and perceived that sustaining patients’ motivation to 
continue with rehabilitation in the face of significant emotional and financial stress as a key 
challenge. The intervention was perceived as an acceptable community-based package with 
education as an important component in raising the poor awareness of stroke. Many 
participants viewed family-led rehabilitation as a necessary model of care for poor and rural 
populations who could not access rehabilitation.  
Conclusion: Difficulty in sustaining patient and carer motivation for rehabilitation without 
ongoing support, and greater than anticipated access to routine rehabilitation may explain the 
lack of benefit in the trial. Nonetheless family-led rehabilitation was seen as a concept worthy 
of further development.  
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INTRODUCTION 
The global burden of stroke is increasing, and in low and middle income countries (LMICs) 
tends to affect individuals at an earlier age than in high income countries, resulting in a 
significant societal burden. (1) India is in the midst of a major epidemiological transition, 
with an increasing stroke prevalence but limited accessibility to affordable and high quality 
rehabilitation services. (2-4) Task shifting through family-led rehabilitation may offer a 
potential sustainable solution in India and other LMICs. (5-7)   
The ATTEND Trial (fAmily led rehabiliTaTion trial aftEr stroke trial in INDia) was a 
randomised controlled trial (RCT), which recruited 1250 patients across 14 hospitals. (8) The 
intervention involved a physiotherapist (known in the trial as a ‘stroke coordinator’) training 
a family carer to deliver a basic evidence-based rehabilitation intervention tailored to the 
Indian context. (9) The intervention had five main components including education, 
positioning/early mobilisation, early supported discharge planning, joint goal setting with 
each patient and carer, and task-orientated training. Stroke coordinators trained family carers 
to provide rehabilitation during hospital admission and at subsequent home visits (maximum 
of six) in the first two months. A culturally appropriate intervention manual documenting 
intervention components was provided to the patient during the first home visit. Patients and 
carers were followed up at three and six months by an assessor blinded to intervention 
allocation and its content. The recently published results indicated that this model of ‘task 
shifting’ rehabilitation to family carers compared to usual care alone did not achieve a 
benefit, as measured by a decrease in death or dependency. (8)  
In the wake of ATTEND’s neutral results, important questions remain about the future of 
family-led rehabilitation and uncertainty as to what transpired on the ground: was the trial 
result due to failure of the intervention or of trial implementation, or of both? (10)  
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AIMS 
Our process evaluation was conducted alongside the ATTEND RCT to explore how, for 
whom and why this complex intervention had (or did not have) an impact. Our a priori aims 
were: (1) To explore if the ATTEND trial was conducted rigorously; (2) To understand 
providers’, patients’ and carers’ perspectives of the perceived effect of the care they received 
or delivered; (3) To explore if the results are likely to be generalisable, scalable and 
sustainable through exploring stakeholders’ experiences of the intervention and its perceived 
impact. (11)  
METHODS 
The process evaluation methods were pre-specified in detail in a published protocol. (11) We 
present a summary here.  
Process evaluation framework 
The design of our mixed methods process evaluation (Figure 1) was informed by two 
theoretical frameworks covering different aspects of the evidence generation-to-practice 
translation continuum. The RE-AIM framework incorporates concepts of Reach, 
Effectiveness, Adoption, Implementation and Maintenance to address questions of 
generalisability and translation into practice. (12) The Realist framework highlights potential 
mechanisms of action within contextual factors and is pertinent for complex interventions 
such as ATTEND. (13, 14)  Our hypothesised causal mechanisms are stated explicitly in 
Figure 1 of how this intervention may impact upon proposed trial outcomes.   
Data sources 
We collected quantitative process data on intervention delivery, patient demographics and 
healthcare use data across all 14 sites. Qualitative data included semi-structured interviews 
with 28 health providers (seven neurologists, eight stroke coordinators, eight blinded 
assessors, four physiotherapists responsible for usual care and one clinical nurse), 22 patients 
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and 22 carers (11 usual care and 11 intervention arm dyads), observations (using a 
standardised template), and documentary analysis from six purposively sampled sites to 
enable a cross-section of geographical locations and types of institutions. (15) Patient and 
carer dyads were purposively sampled by patient gender and study arm, and interviews at the 
hospital were conducted shortly after their six months follow-up visit by interviewers who 
had no interactions with the dyads before the interviews. Questions covered patients’ health 
care journey, components of the intervention and contextual factors. Healthcare providers 
were interviewed (by AM, HL, RL, AF, MW) in English and all patients and carers were 
interviewed (by AM, DG, CF, SV) in their local Indian languages where possible. There were 
two sites in which interpreters were used to communicate in local languages. All interviews 
were audio recorded. The interviews lasted on average 30 minutes and all were transcribed 
verbatim by professional transcribers and translators. We received ethical approval for the 
conduct of the health provider interviews from each study site, with one site not granting 
approval for patient and carer interviews and as such patient and carer interviews were only 
conducted at five sites. (Supplementary file 1 provides key participant characteristics and 
additional illustrative quotes.) 
Analysis 
Iterative thematic analysis of the qualitative data was conducted by the team blinded to the 
RCT outcomes. (14) NVivo software was used to manage the data. A coding tree based on 
the main headings of our process evaluation framework and line by line coding was created 
by HL. (Supplementary file 2) As pre-specified in the process evaluation protocol, 
triangulation of the qualitative findings was then conducted with baseline demographics, 
healthcare use and primary and secondary outcomes, and then systematically analysed against 
our hypothesised causal mechanisms according to the Realist configuration of Context-
Mechanisms-Outcomes. (14)  
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RESULTS 
Our results are summarised and depicted in Figure 2.  
 (1) Trial fidelity: trial implementation and intervention fidelity 
Reach and Recruitment: 
We assessed ATTEND baseline data to determine whether recruited patients were 
representative of the broader Indian stroke population and found that ATTEND patients had a 
higher level of education and monthly household income than the national population 
average. (8, 16) The limited feasibility for the ATTEND stroke coordinators to follow up 
patients living more than 50 km from the 14 participating mainly urban RCT sites (4 
governmental central institutes, 4 Christian Mission and Academic Institutions, and 6 private 
corporate hospitals) may have contributed to this difference. 
We explored healthcare use to determine the level of access to healthcare and rehabilitation 
by the patients recruited and found that at 6 months, most of the patients in the intervention 
and usual care arm continued non-trial conventional therapy i.e. either rehabilitation or 
medications. In both groups, about 45% reported incurring charges for outpatient 
rehabilitation therapy at 3 months, and about 30% at 6 months.  
We synthesised our findings to better understand routine care. We found that the different 
types of hospitals had differing costs of treatment and available routine care in terms of 
stroke unit guidelines, specialist staffing, and presence of multidisciplinary outpatient clinics. 
In particular, we noted at 3 hospitals routine care comprised of outpatient clinics with 
rehabilitation provided by physiotherapists who described training family carers as part of 
routine care. Three hospitals had multidisciplinary outpatient clinics -including one corporate 
hospital which had established links (e.g. conducting capacity building workshops) with free-
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lance private physiotherapists in the community who could provide rehabilitation in patients’ 
homes.   
Unblinding:  
Assessors reported any unblinding to the project manager. The reports showed that 
unblinding occurred in 5.3% in the intervention group, and 3.3 % in the usual care group 
(p=0.09).  An example of ‘unblinding’ included inadvertent incidents such as the intervention 
manual being seen on the table at home.  
Contamination:  
The potential for ‘contamination’ of usual care patients due to lack of space, or curtains 
around beds to conduct the intervention in privacy at smaller hospitals was noted during 
observation visits.  
Intervention Fidelity: 
The activity logs highlighted that the ATTEND components of goal setting, gait training and 
functional mobility training were implemented as per protocol. (8) Intervention dose, as 
indicated by duration of therapy provided, showed an average hospital training time of 2.96 
hours, (SD 1.56, median 2.92), mean home training time of 3.07 hours (SD 1.69, median 
2.75). Patients and carers self-reported 17.8 hours (SD 21.56) of activities in the first 30 days 
following hospital discharge. Activity logs of the usual care physiotherapists show that 
similar non-trial rehabilitation care was provided both randomised groups. Early supported 
discharge as a component of the ATTEND intervention was not achieved, with both groups 
having a similar length of hospital stay. (8) 
(2) For whom, how and why? To understand providers’, patients’ and carers’ perspectives of 
the perceived effect of the care they received / delivered. 
Early supported discharge welcomed in concept 
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Health providers stated that the early supported discharge component of ATTEND was 
welcomed in concept due to potential cost savings for patients and earlier release of bedspace 
for the hospital. However, several neurologists described early supported discharge was not 
implemented due to an inadequate number of hospital beds, which resulted in patients being 
discharged as early as possible, or even not admitted for care, irrespective of enrolment in 
ATTEND. At one hospital it was estimated that 40% of patients discharged themselves from 
the hospital against medical advice reportedly due to the unaffordable costs of hospitalisation. 
With the exception of one stroke coordinator, most health providers indicated that the 
ATTEND intervention was not factored into the discharge planning (i.e. time of discharge) 
for patients in the intervention group.     
Stroke education is needed 
Education about stroke, stroke risk factors and the value of rehabilitation was provided to 
patients and carers in the intervention arm. A carer of an intervention patient described how 
community members had initially expected his father to die but they have since seen that 
“(his father) can walk on his own…and said because of exercises only he has improved that 
much.”  Indeed, carers and patients in the intervention arm described a deeper understanding 
of the pathophysiology of stroke and a greater confidence in recovery.  Most of the health 
providers stressed that addressing the low level of community health literacy was a priority as 
there was often poor management of risk factors in the community (as seen by the relatively 
young age of participants compared to high income countries) and delayed presentation to 
hospital.  
ATTEND is an acceptable model of care  
Many stroke coordinators and intervention carers indicated that joint goal setting with patient 
and carer was a key component of ATTEND and that this process was crucial in the patients’ 
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recovery. For example, an intervention patient described how “half of my body had become 
useless. But I am thankful to my children, within fifteen days they helped me...I just stood like 
that, with the support of their shoulders…then they instructed me to do things.”  Some stroke 
coordinators commented favourably on the multi-disciplinary aspect of ATTEND (e.g. 
components of occupational and speech therapy) and the active rehabilitation (e.g. task-
specific training), as compared to the passive physiotherapy they previously provided. This 
was evident in the activity forms, which showed a greater emphasis (as indicated by 
percentage of time spent) on goal setting and functional task training provided by the stroke 
coordinators as compared to usual care physiotherapists. (8)  
Stroke coordinators liked the training of a nominated caregiver in ATTEND which 
encouraged continuity of the care provided to the patient. The ATTEND trial intervention 
manual and videos were key resources for the patients and carers. The stroke coordinators 
and a few neurologists highlighted that home visits added valuable contextual information for 
functional training. Moreover, home visits were preferred by the patients and carers as this 
removed the cost and travel barriers faced when attending hospital follow-up visits.  
Sustaining patient and carer motivation was a key challenge 
Several of the stroke coordinators reported that counselling was critical in the early stages 
post stroke to maintain patient motivation and overcome their initial despair. A few of the 
stroke coordinators suggested that more visits than the trial goal of three to six visits would 
be necessary to sustain patients’ and carers’ motivation to persist with rehabilitation. A stroke 
coordinator observed that individual patients’ will to recover was affected by their gender 
roles, he described that “males don't have much patience as they have to go earn for his 
family… They don’t want to spend much time on bed… Usually more females are housewives, 
and some (lose) their hopes from getting up from bed.” The importance of this observation is 
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highlighted when triangulated with the finding that men appeared to benefit more than 
women in the trial. (8) A doctor described that carers’ motivation depended on individual 
family circumstances regardless of education and literacy status, and that “it just depends on 
how stressed the family is…there are other patients who are totally illiterate but they are so 
willing to learn this, so willing to do it for their relatives…I mean every patient…their 
situation is different.” Additionally, managing bowel incontinence, and patients’ pain were 
also described as particularly trying for carers.  
Financial stress due to loss of income and cost of treatment was iterated by many of the 
participants as impacting on the complexities of the patients’ and carers’ relationship, mental 
health, and motivation. For example, a female carer described selling her jewellery to tide 
their family through financial difficulties and saw little hope for the future. A stroke 
coordinator observed that “if the stroke affects a middle-aged man, the family is [in] a 
disaster” due to the decrease in household income which could lead to poverty and reduce 
children’s educational opportunities.   
(3) To explore if the results are likely to be generalisable, scalable and sustainable through 
exploring stakeholders’ experiences of the intervention and its perceived impact. 
ATTEND is a sustainable model of care especially for those with limited access to 
rehabilitation  
Many participants perceived that ATTEND would be ideal for the poor and those in rural 
settings who could not access acute treatment and rehabilitation due to distance to services 
and high cost. A physician cited ATTEND as a proof of concept of a model of care for her 
region where there were “no physiotherapists out there who will go to the (villagers’) homes 
or whom patients can go to and get help.” She described that “even before this study started, 
94
13 
 
we were giving the relatives the education that they needed and trying to teach them to help 
their patients…”  
When affordability was an issue, carers would seek advice from the community on managing 
rehabilitation at home. The source of such information included local physiotherapists, other 
community members who had recovered from stroke or paralysis, and traditional masseurs. 
For example, a control arm carer described how they could not afford the INR300 per 
physiotherapist visit and had pleaded with him to “please teach us. As our condition is such 
we will do it ourselves. After that we do on our own. We are still doing it.” 
While ATTEND was delivered free in the trial, many of the intervention patients and carers 
indicated they would be willing to pay a fee and would recommend this treatment to others 
indicating an assumption that the intervention was effective. Indeed, two ATTEND carers 
described providing rehabilitation for other stroke patients in their community. Some health 
providers suggested incorporating the ATTEND intervention into their routine practice at the 
stroke unit. A neurologist suggested conducting ATTEND training workshops for the free-
lance physiotherapists practicing in the community. For areas with limited access to service 
providers, two neurologists suggested community-based models of care as potentially 
feasible. One described the potential to have Accredited Social Health Activists (ASHAs) 
trained and certified to provide the ATTEND intervention. However, other neurologists and 
physiotherapists stressed that such community-based models would require significant 
upskilling, supervision and monitoring so as to prevent exploitation by other non-
licensed/untrained providers.  
DISCUSSION 
Our data confirm that ATTEND was a rigorously conducted trial of an intervention designed 
to balance existing best practice rehabilitation with local norms and economic constraints. (8, 
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9) Furthermore, the process evaluation was conducted with a pre-specified protocol and 
conceptual framework. (11) We found that intervention fidelity and adherence to the protocol 
was consistently high across sites with the exception that early supported discharge was 
welcomed in concept but not widely implemented. Using the Realist framework of Context-
Mechanisms-Outcomes, we have identified two reasons for why we did not achieve the 
expected trial result (as depicted in Figure 2). (13) First, whilst we had hypothesised that a 
family carer providing rehabilitation would represent a step-up in access to care (4), our 
contextual findings suggest that many patients from both randomised groups already had 
access to rehabilitation which included rehabilitation that family members had been trained to 
deliver. Second, whilst we confirmed our hypothesis that a key mechanism of ATTEND was 
joint goal setting, we found that sustaining behaviour change for patients and carers in the 
face of significant emotional and financial pressures was a challenge. We also noted that 
stroke coordinators spent time counselling the patients and carers (which was not outlined in 
the protocol), and this may have decreased the time available for teaching physical training 
and task specific activities. Thus, the failure to reduce death and dependency over usual care 
is likely to be due to difficulties in initiating rehabilitation training because of the counselling 
needs of the patient, ongoing challenges in sustaining patient and carer motivation; and the 
higher than expected levels of rehabilitation may have diluted any potential benefits of death 
and dependency (as measured by the modified Rankin scale) and the other secondary 
outcome measures (such as patient mood, quality of life and carer strain).    
 
Our findings also imply that in regions where rehabilitation is not accessible, the concept of 
task-shifting to community members (e.g. ASHA) and family carers has a lot of support. (2, 
4, 5) The challenge lies in how the intervention could be adapted in the future for such 
settings, whilst ensuring that the training is standardised and certified. (17) Given the high 
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penetration of mobile telephones in India, mobile technology-enabled training and 
rehabilitation could be tried in rural settings with remote monitoring provided by specialists 
through video-links i.e. telemedicine. (18, 19) In addition, community-based prevention 
strategies including e-health may be beneficial in addressing the poor awareness of stroke, its 
risk factors and treatment as highlighted in this and other studies. (20-22) Critically, future 
versions of the family-led rehabilitation model will require increases in training intensity, 
duration and dose to encourage sustained behaviour. The timing of these functions should be 
informed by the patients’ and carers’ capacity to assimilate information. As such, training to 
provide rehabilitation may be more effective when patients and family carers are past the 
acute stroke crisis stage of intense shock and grief. (5, 23) Moreover, given the impact of 
financial stress upon patient and carers, we will further examine the economic data from 
ATTEND to identify critical variables contributing to out of pocket costs and household 
financial catastrophe.    
A limitation of this process evaluation is the generalisability of our qualitative findings based 
on six sampled sites. Moreover, participants who agreed to be interviewed may have been 
biased positively to ATTEND, and we may have missed contradictory insights. However, our 
purposive sampling by hospital characteristics, inclusion of usual care dyads and 
triangulation with other data sources increases the validity of the findings. (24) The use of the 
theoretical frameworks especially around the topics of Reach and Maintenance, and the 
Context-Mechanisms-Outcomes configuration was valuable in synthesising our findings. In 
addition, describing the initial hypothesised causal mechanisms of the intervention provided a 
systematic way of analysing the data and exploring reasons for the trial outcomes. (14) In 
retrospect, more formative work by conducting qualitative interviews (with patients, carers 
and implementers) alongside the single centre pilot feasibility trial may have identified some 
finer details of implementation  (e.g. timing for patients and carers to assimilate information) 
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and dosing (e.g. number of optimal visits) that may have  promoted efficacy of the ATTEND 
intervention. (9) Such in-depth exploratory work alongside pilot trials could inform key 
modifications needed to improve complex interventions such as ATTEND.(25, 26)  
CONCLUSIONS 
Our findings indicate that family-led rehabilitation is worthy of further development 
especially for the poor and rural populations in India. Future family-led rehabilitation should 
include behavioural change and sustainability components, with an increase in the intensity 
and duration of effective training modules; whilst maintaining cost and logistic feasibility for 
populations with limited access to rehabilitation. The ATTEND trial and process evaluation 
is the first step for the ATTEND collaboration in further developing patient-centred 
rehabilitation models of care needed to address the rising burden from stroke in India and 
other LMICs. (27)  
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Figures 
Figure 1: The ATTEND process evaluation framework.  Process evaluation components are 
highlighted in blue.   *Reproduced with permission. (11)  
Figure 2: Summary of the process evaluation findings (in blue italics) as compared against our 
hypothesised contextual assumptions and causal mechanisms (in non-italics) in impacting upon 
the outcomes of the RCT.  
 
Supplementary files 
Supplementary file 1: Participant characteristics and Illustrative quotes.  
Supplementary file 2: Coding Tree 
Supplementary file 3: CONSORT statement (main trial paper) 
Supplementary file 4: COREQ checklist 
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Description of ATTEND intervention 
components which address the 
assumed causal mechanisms 
contributing to the stroke burden in 
India 
Poor awareness of stroke and 
effectiveness of stroke rehabilitation 
ATTEND: Education is provided to patient 
and carers on stroke 
Limited resources and staffing to provide 
repetitious and active practice for the 
patients especially upon discharge. 
Limited accessibility to multi-disciplinary 
stroke rehabilitation team.  
ATTEND: Focus on gait training, 
functional activities, home based care, 
with inclusion of communication 
strategies.  Need for goal setting to 
foster independence. 
Post stroke care is provided mainly by 
family members with limited knowledge 
and training  
ATTEND: Joint goal setting with caregiver 
and patient; and training of the carer of 
suitable exercises.  
Cost to outpatient care is a barrier for 
stroke rehabilitation 
ATTEND: Early supported discharge to 
decrease costs to the system and family 
and also to enable early patient 
rehabilitation at home and foster 
independence.  
Outcomes-Trial Impact 
Effectiveness/Outcomes- What is the primary 
outcome measured at 3 months and at 6 
months?  Is there a difference? What are the 
secondary outcomes e.g hospital length of stay, 
caregiver burden? (b) 
 
Economic evaluation- What is the cost 
effectiveness of this intervention from a societal 
and health systems perspective? (b) 
 
Maintenance/ Long term impact - Is the family 
led rehabilitation model of care sustainable and 
can it lead to a reduction in the burden for 
stroke patients and to the health system? (g) 
Implementation 
Reach- How are the sites recruited? 
What is the burden of stroke in the 
area? What is the representativeness 
of the sites in providing care to stroke 
patients? How are the patients 
recruited? Are they representative of 
our target patient population? How 
many agreed or did not and why?  (a, 
c, d) 
Fidelity and Dose - Is the intervention 
delivered according to protocol at all 
the sites? Is there any contamination 
of the intervention to the control arm?  
(a, b, c, d, e, f)  
Adoption- How is intervention 
incorporated into care provided?  Are 
there any barriers and facilitators to 
this process? (d, e, f)  
Costs considerations- What is the cost 
of training and site visits? (a) What are 
the costs of usual care and the 
intervention to patients?  (b) 
Implementation- What are some 
barriers & facilitators to trial 
implementation? (a, d, e, f) 
 
Context- What are the contextual factors that are different across sites? (i.e socio- economic factors, pre-stroke/stroke/post stroke factors e.g accessibility of outpatient rehabilitation 
services, availability of below the poverty line insurance policies, availability and affordability of medications) What is part of usual care post stroke at each site?  (c,d) 
Mechanisms of Impact 
Effectiveness- How, why and 
for whom does the 
intervention work? What are 
the health providers, patients 
and carers' experiences and 
attitudes towards the 
intervention and what they 
think the causal mechanisms 
are? (e,d) 
Maintenance - Is this program 
generalizable, scalable and 
sustainable through exploring 
stakeholders’ (hospital stroke 
unit staff, providers, patients 
and carers) experiences of the 
intervention and its perceived 
impact. Is there a plan in place 
to continue this intervention 
post-trial? (e, f) 
Data sources 
(a)Administratively collected process data 
(b)Electronic case record quantitative data  
(c)Documentary analysis 
(d)Non-participant observations 
(e)Semi-structured in depth interviews 
(f)Focus group interviews 
(g)Post-trial process evaluation- *dependent on results.  
Figure 1: The ATTEND process evaluation framework.   
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Context 
1)Poor awareness of stroke and effectiveness 
of stroke rehabilitation  
Need to address this was highlighted by 
participants 
 
 
2) Limited resources and staffing to provide 
repetitious and active practice for the patients 
especially upon discharge. Limited accessibility 
to multi-disciplinary stroke rehabilitation 
team.  
Availability of a range of rehabilitation 
services available at the hospitals recruited 
though participants highlighted limited 
accessibility and affordability to multi-
disciplinary rehabilitation in rural areas. 
3) Post stroke care is provided mainly by 
family members with limited knowledge and 
training  
Training is provided to the usual care family 
members at outpatient clinics post discharge 
and private physiotherapists were available in 
the community.   
 
 
 
4) Cost to outpatient care is a barrier for 
stroke rehabilitation.  
 Barrier to patient engagement for 
rehabilitation was due to travel and treatment 
costs, and loss of family income. 
Mechanisms of impact 
1)Education is provided to patient and carers on 
stroke  
ATTEND trial has raised the awareness in the 
community about stroke risk factors and the value of 
rehabilitation. 
 
2)Focus on gait training, functional activities, home 
based care, with inclusion of communication 
strategies.  Need for goal setting to foster 
independence.  
ATTEND is an acceptable model of care especially for 
regions of limited accessibility. 
 
 
 
3)Joint goal setting with caregiver and patient; and 
training of the carer of suitable exercises 
In addition to the joint goal setting, the relationship 
between trial staff and patient and family seemed 
protective against poor mental status but 
maintaining motivation post intervention could be 
challenging. 
 
 
4) Early supported discharge to decrease costs to the 
system and family and also to enable early patient 
rehabilitation at home and foster independence.  
 While early supported discharge is welcomed in 
concept, implementation depended on hospitals bed 
pressure, and patient factors (such as affordability of 
hospitalisation). 
Outcomes from the ATTEND RCT (8) 
Our baseline demographics which was 857 male, 
and 413 female with a mean age of 57.7 years old, 
and a majority of 89.7% married; had a high risk 
factor profile of 73.9% hypertension, 43.9% 
diabetes mellitus, 24.3% smoking, and 26.8% 
alcohol use, with a 18% of recurrent stroke/ TIA.  
Patients of higher socio-economic status were 
recruited from urban sites with stroke unit 
guidelines/protocols and availability of 
multidisciplinary outpatient teams and private 
physiotherapy; with 459/533 (86.1%) 
(intervention) and 446/512 (87.1%)(control) 
accessing conventional therapy 
(medications/rehabilitation) at 6 months.  
Primary outcome: 
a) 285/607 (47%) were dead or disabled in 
the intervention group, 287/605 (47.4%) 
in the control (odds ratio 0.98, 95% CI 
0.78 to 1.23, P=0.87) 
b) Lack of benefit confirmed with adjusted 
analysis.  
c) One significant interaction by sex of 
reduced odds of death or dependency in 
men at 6 months (odds ratio 0.83, 95% CI 
0.63 to 1.10 versus odds ratio 1.39, 95% 
CI 0.93 to 2.05 for women, P=0.04 for 
interaction) 
 
Secondary outcomes: 
No difference in length of hospital stay (9.3 versus 
9.5 days, P=0.58)  
No difference in measures of basic and extended 
activities of daily living, health-related quality of 
life, mood and carer strain.  
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Clinical stroke research in resource
limited settings: Tips and hints
Jeyaraj D Pandian1, Hueiming Liu2, Dorcas BC Gandhi1 and
Richard I Lindley2
Abstract
Background: Most stroke research is conducted in high income countries, yet most stroke occurs in low- and middle-
income countries. There is an urgent need to build stroke research capacity in low- and middle-income countries.
Aims: To review the global health literature on how to improve research capacity in low- and middle-income countries,
provide additional data from the recently completed ATTEND Trial and provide examples from our own experience.
Summary of review: The main themes from our literature review were: manpower and workload, research training,
research question and methodology and research funding. The literature and our own experience emphasized the import-
ance of local stakeholders to ensure that the research was appropriate, that there were robust local ethics and regulatory
processes, and research was conducted by trained personnel. Research training opportunities can be developed locally, or
internationally, with many international schemes available to help support new researchers from low- and middle-income
country settings. International collaboration can successfully leverage funding from high income countries that not only
generate data for the local country, but also provide new data appropriate to high income countries.
Conclusions: Building stroke research capacity in low- and middle-income countries will be vital in improving global
health given the huge burden of stroke in these countries.
Keywords
Low-income countries, ethics, funding, training, India, Asia, stroke, research
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Introduction
In this second paper of a ﬁve-paper series on how to do
good quality clinical research, we will discuss research
in limited resource settings. The Global Burden of
Disease investigators estimated that 70% of incident
stroke and stroke deaths, half of all prevalent strokes
and nearly 80% of DALYs lost were in low- and
middle-income countries (LMICs), yet most research
is done in high-income countries.1 However, LMICs
have only about 3% equivalent purchasing power to
fund this demand.2 Furthermore, it has been estimated
that 90% of medical research is targeted on the health
needs of the richest 10% of the world.3 1As stroke is
occurring at an earlier age in LMICs, there is a dispro-
portionate loss of DALYs in these countries. This has
major implications for families, as those with stroke are
often the breadwinners of the family, and thus stroke
commonly leads to catastrophic ﬁnancial hardship.4
The resulting mismatch between burden and research
has led to large evidence practice gaps in global health.5
In addition, there is the inevitable tension in LMICs
between cost eﬀective public health strategies to
reduce the burden of stroke (such as the identiﬁcation
and treatment of hypertension and stroke unit care),
and the attraction of implementing the current ‘‘state
of the art’’ stroke interventions, such as thrombec-
tomy. There is a risk that piecemeal implementation
of aspects of western medicine could consume all the
available stroke resources, for very little public health
beneﬁt.
High-quality research is needed in LMICs to deter-
mine which local solutions work, and what is their cost-
eﬀectiveness. In this review article, we will discuss the
barriers and facilitators of conducting clinical research,
provide examples from our own experience, review the
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literature in this area and provide some new data from
our recently completed stroke rehabilitation trial in
India.
Methods
We utilized a mixed methods approach of a focused
literature search, reﬂections from our own research car-
eers and insights from a recent Process Evaluation from
the ATTEND Trial.6 Our literature search was per-
formed using the search terms ‘‘stroke’’ ‘‘clinical
research,’’ ‘‘resource poor settings,’’ ‘‘developing coun-
tries,’’ ‘‘low and middle income countries’’ to identify
relevant articles. This had to be broadened to cover all
aspects of health as our initial search failed to reveal
stroke speciﬁc examples, and experience from other dis-
ciplines was likely to be informative.
We supplemented this literature search with some of
our ﬁndings from our process evaluation of the
ATTEND trial which had an aim to identify critical
facilitators and barriers in the implementation of a ran-
domized controlled trial (RCT) in India by inter-
national research collaboration.6 The methods of this
research have been published in detail previously,6 but
in brief, this involved focus groups and in-depth inter-
views with thematic analysis of 8 clinical trial coordi-
nating staﬀ, 4 chief investigators, 26 health providers,
22 patients and 22 carers involved in the RCT.
We synthesized the main themes arising from our
literature search, our own personal experience, and
some of the relevant ﬁndings from the ATTEND trial
process evaluation (see Box 1).
Results
The main themes identiﬁed were manpower and work-
load, research training, research question and method-
ology, and research funding.
Manpower and workload
From a survey of the 1312 members of the Indian
Academy of Neurology (recorded in January 2015), it
was calculated that approximately 935 million people in
India had no neurologists working in their geographical
area, with only 3% of members recorded to be working
in rural areas (covering a further 85 million).7 India is
not unusual in this respect as the World Health
Organization reported 0.03 neurologists per 100,000
population in Africa, 0.07 in South-East Asia, against
4.84 in Europe.8 Neurologists in India (data from 2007)
typically cater to 30 to 50 patients a day and approxi-
mately 15% of neurologists see more than 50 patients a
day.9 These numbers translate to a private academic
institute seeing around 200 neurological patients per
day, private clinics seeing 100–150 patients per day,
and government institutes seeing 800 patients per day.
Demand on neurosurgery is also large with an approxi-
mate seven month waiting period for elective neurosur-
gery at one government hospital in India.7 These
enormous clinical workloads contrast with more man-
ageable numbers seen in high income countries, and
thus leave little time for research in LMIC urban
areas, and lead to virtually no healthcare provision in
many rural areas of the world.
The limited number of trained professionals, and the
need to cater to a large number of patients, results in a
lack of ‘‘protected time’’ for research for neurologists in
LMICs, thus limiting their ability to perform good
quality research in stroke. In the process evaluation
of ATTEND, we found that establishing a supernumer-
ary research team with various roles and responsibilities
(e.g. project management, data collection) with on-site
training and monitoring according to Good Clinical
Practice, was key to facilitating the ‘‘time poor’’ neur-
ologists in conducting research, while balancing service
delivery.
The lack of research training and relative lack of
research funding adds to the challenges.
English et al.10 have discussed the concept of a
Learning Health System that provides an opportunity
to conduct pragmatic RCTs, integrated into routine
clinical care.10 However, busy clinicians are only
likely to devote a proportion of their time to research
if they see the value of such research improving the
health of their patients, and presumably providing an
interesting and stimulating environment in which to
work.
Our experience in trials conducted at Christian
Medical College and Hospital Ludhiana might help
beginners in establishing a good research environment.
The stroke unit at our institute is functional as a multi-
disciplinary team and was initiated in 2008. A basic
observation (by a neuro-physiotherapist of the team)
of the common shoulder issues post stroke, led to the
formulation of a study on the eﬀects of shoulder taping
for shoulder pain and injury post stroke.11 The team
reviewed the literature and designed a low cost, 4-centre
RCT to prevent shoulder pain. Another study used an
indigenously designed low cost (approx. USD7.7)
mirror therapy box to be used for rehabilitation in
patients with hemi neglect post stroke. This single
center study provided class I evidence that mirror ther-
apy improved hemi neglect in thalamic and parietal
lobe strokes.12 Finally, through an intramural research
fund, a 7-center observational study was designed to
assess the impact of pre-morbid undernutrition status
on short-term stroke outcome.13 All these studies
required an appropriate mentor (see next section,
Research Training) and beneﬁted from industry
International Journal of Stroke, 0(0)
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Box 1. Illustrative quotes from the ATTEND process evaluation
Manpower and workload
Team work relieving the high work load
‘‘You have a structured research program in the trial, each aspect of the trial is taken care of by different people, there is no burden on one
person. Previously all the research work that I’ve done, it was all upon me. I am the coordinator, do everything is done, but here it is all
structured. So I spend only one hour a week, and so I ask how many patients (the stroke coordinator) has recruited and now I identify
patient and tell her, and so it’s been really smooth for me, and with all other work that I have to do in the hospital and other research and
that has been a great thing from my perspective.’’(Neurologist)
Research training
Lack of research training
‘‘There is only a few universities which speak about evidence-based practice, and it is a subject which is not taught at all. . .Many physios
don’t know how – what evidence means, what evidence-based practice means? They are not aware of it of how evidence works or our trials
work or how systematic reviews work? What is the importance of guidelines? What is the importance of clinical pathways, protocols?’’
(Physiotherapist)
Building of capacity
‘‘ I didn’t have much idea (about research) at the beginning because after I finished my bachelor’s, I just came here. It was a very new
experience because I had done my project work in my final year, but that was entirely different than this. My experience with the research
was very little so this gave me an opportunity to have better experience and better exposure to research and how to go about things, so it
was very good for me to learn. . .and it helped me to boost up my confidence with the patient interaction and how to communicate with
them and how to deliver the interventions.’’ (ATTEND Stroke coordinator, a physiotherapist)
Role of regular communication
‘‘The workshops regularly updating our skills, having a teleconference bi-monthly. It’s all great to have such a thing in the trial, as sometimes
we may be lost continuing to doing our work. Having such kind of thing is very good and I appreciate the administrative team and the role
of people who are involved in this.’’ (ATTEND Stroke Coordinator, a physiotherapist)
Respect and teamwork
‘‘We want this number of patients to be recruited. Look at the bigger picture. . . So (the principal investigators) have been very inspiring and
you know, good messages coming across from all of us in the management team (to the sites) that this is the thing, and we will be
presenting your data here. . . They are getting the constant training. . . So it helps. They know that they are being looked into. It isn’t that
they are on their own. They know that they are being monitored. The monitor is doing the job correctly, monitoring the site. The other
people are looking into the monitor’s work as well. So it’s a coordinated team effort, which has gone into the trial, so it’s everybody’s efforts.’’
(Clinical trial team member 1)
Challenges in maintaining the trained workforce
‘‘Actually when ATTEND finishes, we have to see whether there is any other trial we are able to get. Currently at present there is nothing in.
Most of the time (for the) really good staff I will find out some study which I will try to continue. (Name withheld) has been for more than
four years now, because being somebody who has been with us for sometime, it is very useful because she maintains all our data, all that
prospective database, everything she keeps in, and we put in all the forms. . .That made a big difference in our quality of care.’’
(Neurologist)
Research question and methodology
Research motivation
‘‘. . .in research we learn new things because the practical knowledge we get in the research, clinical research, we deal with the patients.
The main thing is we are serving the patients. We are doing something for the betterment of the patients either directly or indirectly. . .the
present patients may not get the benefit of the research but the upcoming patients they will surely get the benefits of the research. . .so they
may get that proper treatment in stroke in future.’’ (Trial assessor)
Improvement in care
‘‘I think this trial was very important, one of the biggest trial I have taken part, and I think I learnt so many things already from conducting
this trial here like, for example, like when we teach something for the patient we think that they will follow it strictly, they’ll go back and do
it, but in many cases it’s not so. One, it may be because of the lack of applicability of what we are telling them. Like suppose, for example
like we had one patient who was told to do transfer, how to transfer from the bed onto the chair but later we found out the patient doesn’t
have even a bed at home. . ..So lot of things we found out about our patients which was totally new to us. This was a learning experience.’’
(Neurologist)
Ethical dilemma
‘‘It is just, that I felt that certain patients, those patients who are in the control have to get certain other things. . . Because after all they are
patients also; so we cannot leave that person- that you are on his own if you want to do any physiotherapy or something. ’’ (Stroke
Coordinator)
(continued)
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support of other commercially sponsored trials run in
parallel. This early track record was noticed by local
philanthropists, who, in turn provided additional
resources to improve the existing stroke care services
at the institution, thus further supporting stroke
research capacity.
Research training
Research training is essential to achieve high-quality
research and reduce research waste.14 Training can
occur locally or internationally and there are estab-
lished models for both. Local training has the advan-
tage of usually being low cost but will remain
challenging due to the competing requirements for clin-
ical service. In cardiovascular medicine, Yusuf15 has
described the local research training by participation
in a large-scale international trial during the
establishment of the EMERAS (Estudio Multicentrico
Estreptoquinisa Republicasde Americ de Sur) collab-
orative group in South America, that helped build
research capacity and led to subsequent projects. The
Road traﬃc Injuries Research Network have reported
that seed grants, short-term scholarships, sabbaticals to
enable staﬀ from LMICs to work in established high-
income country (HIC) units and support to present at
international conferences, were successful in building
research skills and capacity.16 In our recent stroke
rehabilitation trial in India, international funding
allowed 35 full time staﬀ to be employed, and their
participation in the trial collaborative meetings, site
training visits and participation in national and inter-
national stroke conferences provided important oppor-
tunities to learn and practice research methods (such as
Good Clinical Practice guidelines).17,18 Our process
evaluation found that respect between members of the
Box 1. Continued
Research Funding
‘‘You need to have that ground level experience knowing people from different backgrounds across Indian state lines and to be able to put
together something of this magnitude- hundred patients across twelve to fourteen centers is a large number for a country like India where the
barriers between states and cultures are so huge. Each state is a country in itself, so to bring them all together is a big challenge and a busy
clinician just wouldn’t have the time and you know wouldn’t be that motivated. . .So, I was glad that someone actually made it happen to have
the time invested into it, to have the financial resources come into it, and to have the dedication to find the right staff and to empower them,
inspire them through a long period, I mean its three year study. So, that’s not easy to do.’’ (clinical trial team member 2)
Box 2. Case study of funding: The ATTEND trial of family-led rehabilitation for stroke in India.18
 2000: Family-led stroke care developed in India.
 2010: International collaboration initiated (European Stroke Conference, Barcelona) and developed (World Stroke Congress in
South Korea).
 2010: Medical Research Council (UK)-Indian Council of Medical Research Grant unsuccessful.
 2010: Australia India Council Disability Workshop, Hyderabad. Strengthened and enlarged Indian collaboration, e.g. Indian
Institute of Public Health involvement.
 2011: First application to Australian National Health and Medical Research Council (NHMRC) – just missed out on funding.
 2012: Pilot study funded (AUD$10,000) by George Institute for Global Health and re-application to NHMRC.
 2012: Australian NHMRC funding (AUD$1.5million) obtained on second attempt.
 2013: Indian staff appointed, regulatory approval obtained, first Investigators’ Meeting (Hyderabad).
 2014: recruitment commenced, second Investigators’ Meeting (Trivandrum).
 2015: Third Investigators’ meeting (Shimla).
 2016: February, completion of recruitment.
 2016: 25th October final investigators’ meeting Hyderabad.
 2016: 29th October, public announcement of results (World Stroke Congress).
 2016/7: New international collaboration formed, with leadership from University of Central Lancashire, England.
 2017: ATTEND Trial published in the Lancet 5 August 2017.
 2017: Follow-up stroke research utilizing the ATTEND collaborative group. Unsuccessful application to the Research Councils
of the United Kingdom Global Challenges Research Fund.
 2017: Successful application (£1.9 million) to National Institute of Health Research, Global Health Research (UK), led by Dame
Caroline Watkins, University of Central Lancashire, UK.
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team and the international collaborators was funda-
mental for the mutual learning and success of the trial
implementation – a ﬁnding which has been reported by
other research collaborations.19 Regular communica-
tion between the site staﬀ and the clinical coordinating
members was highly valued by the clinical research staﬀ
on the ground. The cultivated team work approach was
a facilitator to trial implementation (e.g. successful
patient recruitment and follow-up) which was con-
ducted according to study timelines and within bud-
geted resources. An illustration of the themes
identiﬁed is given in Box 1.
While research skills can be learnt during a busy
clinical post with appropriate local mentoring and
training, a period of research training through scholar-
ships and international training has also proven to
increase research capacity. The advantages of an inter-
national training scholarship include the opportunity to
escape the brutal local clinical workload, with time to
concentrate on acquiring research skills. A disadvan-
tage of such a program is that this can lead to a
‘‘brain drain’’ if the scholar chooses to stay in the
host country! Heimburger et al.20 have described the
success of the Fogarty International Clinical Research
Scholars and Fellows Program, demonstrating increas-
ing focus on non-communicable diseases, and a good
publication record and excellent subsequent grant suc-
cess (two-thirds of subsequent grant applications being
funded). A more organized and planned research train-
ing curriculum is needed in the three year Neurology
training and allied health courses in academic institu-
tions across all LMICs. Within LMICs, those with
international stroke reputations have an important
role in providing local mentorship and being a role
model for their institution, and driving change to sup-
port a stroke clinician scientist career path in their
country.
Research question and methodology
Many of the papers stressed the importance of locally
driven research priorities from practitioners and
researchers in limited resourced settings in order to
truly address the contextual factors and disease
burden.21–25 Cross-sectional studies of clinical trials
compared to global burden of diseases have highlighted
the mismatch between disease burden and the number
of trials.24,25 For example, Condo et al.23 highlighted
that in Rwanda, clinical trials were mainly focused on
HIV transmission but that testing of interventions that
address the epidemiological transition from infectious
diseases to non-communicable diseases, including the
signiﬁcant mental health trauma post genocide were
needed. In a paper regarding clinical nephrology
research in low resource settings, Anand et al.22
recommended that high quality epidemiological studies
and data registries be a priority in order to highlight
local areas of need and channel international funding
through research collaborations.
Senior researchers in a panel discussion about neph-
rology research in resource limited settings advised that
broad areas of research questions that align with global
interests and still address local needs would be strategic
in securing funding.22 For example, addressing chronic
kidney disease as part of the non-communicable disease
global burden. Incorporating health systems research
within the research question/design to ensure sustain-
ability and exploring issues of ‘‘equal access’’ and
‘‘equitable ﬁnancing,’’ e.g. registries to inform gaps,
and the collection of relevant data (e.g. health utiliza-
tion data) would be ideal.26 Such research evidence
addressing broad global interests would also facilitate
the ‘‘reverse innovation phenomena’’ whereby the
research ﬁndings from LMIC would be applicable to
high income countries.27 The INTERSTROKE study is
a good example of this ‘‘reverse innovation
phenomena’’.28
This process of gap analysis and priority setting was
reﬂected in our journey in India – with stroke registries
set up at partner sites which helped identify the gap in
service delivery and the signiﬁcance of the research
question for an aﬀordable community-based rehabilita-
tion model which was then tested in a RCT.29 Our pro-
cess evaluation found that because the research
addressed an issue of local priority (the lack of access
to multidisciplinary rehabilitation), it was highly moti-
vating for Indian health providers, principal investiga-
tors, research staﬀ, patients and carers to participate in
the trial. Health providers also described improvements
to clinical care, while the trial was conducted, due to
the robust data collection and follow-up and greater
understanding of the patients’ contextual factors.
Moreover, an example from the process evaluation of
how evidence from high income countries may lack
relevance to the local health system context was evident
in how a component of our intervention (early sup-
ported discharge) was welcomed in concept but not
implemented due to the health system issues like bed
pressure and aﬀordability of hospitalization.18 As an
example of the ‘‘reverse innovation phenomena’’ – in
our last investigators’ meeting and at the World Stroke
Congress, researchers from LMIC (e.g. Uganda,
Indonesia) and high income countries (Australia and
USA) expressed interest in the task shifting model of
rehabilitation, as they thought it would be applicable
for their remote populations who also have limited
access to stroke rehabilitation.
In LMICs, appropriately trained research staﬀ are a
pre-requisite to ensure that research methodology is
robust, and not prone to bias.27 There is increasing
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awareness of research waste, and in a resource-limited
environment, it will be essential that research is not
wasting precious resources (in both opportunity costs
of wasted time and also money). Dandona et al.30 have
summarized a probable strategic framework which
would help in improving the quality and number of
public health related research in India. Formal training
institutes for public health research, exposure, and
encouragement towards hands on research experience
for medical and paramedical undergraduates and devel-
opment of performance-based opportunities to public
health research scholars for career enhancement can
improve the quality of manpower available for research
purposes.
In LMICs, collaborative research work has opened
many channels for budding professionals to be trained
and put their skills to use. Collaborative research work
like the ATTEND trial in India18; the Headpost trial in
India, Brazil, Chile, Columbia, Taiwan and Sri
Lanka31; the RECOVER trial in China32; and the
ENCHANTED trial in Brazil, China, Columbia,
Thailand and Vietnam33; have all used resources from
high income countries to recruit patients globally
and have established stroke research networks, with
resulting high impact studies. Such collaborative
research work has enabled resources from rich coun-
tries to be used in LMICs in the employment of
research staﬀ.
Our own experience in the ATTEND trial18 has
shown the successful employment of 14 professional
physiotherapists and 14 blinded assessors and clinical
coordinators of varied health science background.
Although not all of these employees had a previous
formal training in research, the structured trial training
and experience have empowered and motivated many
of them to pursue a career in research, and contribute
to research capacity development in India. Several of
the principal investigators described securing additional
funding through other research projects to maintain
their trained clinical research staﬀ after the completion
of the ATTEND trial, and thus these staﬀ could con-
tinue to drive local research and improve quality of
care.
The current status of the ethics and regulatory sys-
tems also need to be considered, and some countries
may need to establish an ethics framework before
research should begin. Ensuring appropriate ethical
conduct, as discussed in depth by Solbakk and Vidal,
is essential and they point out the importance of a
robust local ethics review.3 Condo et al.23 noted a key
challenge for setting locally relevant clinical trial prio-
rities for Rwanda was that local ethics and regulatory
institutions lacked the local capacity and expertise to
follow through the ethics, design, and integrity of clin-
ical trials.23 In our experience, during the
implementation of the ATTEND trial,18 the ethics
and regulatory environment in India were suited to
behavioral intervention trials but not for pharmaceut-
ical trials, due to onerous requirements to compensate
healthcare costs in drug trials (regulations that have
now been changed to facilitate more drug trials in
India). During the conduct of trial, additional ethical
dilemmas may occur. For example, during the follow-
up of patients and carers in the ATTEND trial, clinical
trial staﬀ described their ethical dilemma following up
families who could not aﬀord rehabilitation and were in
ﬁnancial strife.
For those wishing to begin clinical stroke research,
one pathway is to understand the local stroke epidemi-
ology by obtaining local ethics approval to collect and
record patient details in a systematic manner in the
form of case report forms. This can be accomplished
by training nurses or other ward staﬀ who will be in
contact with the patient for a longer time than the neur-
ologist. In this manner, the local context can be
described and research priorities will emerge
(Figure 1). These data are also required for site surveys
before commencing any industry-sponsored trials that
can also help a local site begin and gain experience in
research methods. Those in private practice can also
collaborate with bigger institutes for large scale multi-
center studies.
Research funding
High quality research requires suﬃcient funding which
is a key challenge in resource limited settings. One solu-
tion is obtaining funding from international resources,
but this potentially comes with its own challenges of
‘‘whose priorities’’ are the research actually address-
ing.15,21 For example, Condo et al.23 described the
risk of ‘‘unequal partnerships’’ and the risk of research
not addressing local population needs when clinical
trial priorities were set by in Rwanda by local represen-
tatives (e.g. Rwandan government, academics) and
international agencies (e.g. pharmaceutical companies,
non-governmental organizations) with greater funding.
Ali et al.21 described a challenge of conducting cancer
research in India, with potential ethical concerns with
multinationals conducting pharmaceutical trials in India
in regards to the lack of informed consent and the exploit-
ation of the poor and illiterate. Such challenges related to
the leverage of international funding strongly reinforce
the importance of locally driven research.
International funding bodies need to team with the
local researchers to ensure that their research builds
local research capacity and strengthens the local
health systems.19,21,23,27 For example, Ali et al.21
described their strategies in overcoming their challenges
in 2005 due to the lack of clinical trial and regulatory
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infrastructure (e.g. inexperience staﬀ, no established
standard operating procedures) as experienced by
their INDOX (India and Oxford) cancer research net-
work. Their strategies included the joint design and
conduct of research by the principal investigators
from Institute for Cancer Medicine in Oxford and lead-
ing cancer centers in India, tailoring of standard oper-
ating procedures, extensive monitoring of quality and
good clinical practice at sites, dedication of site staﬀ to
help the ‘‘time poor’’ principal investigators in trial
management and working closely with the Drug
Controller General of India to obtain regulatory
approval for their trial.
In the ATTEND trial,6 the initial negative percep-
tion by the regulatory authorities of the agenda by
international collaborators and Australian funding
agency (and thus the relevance of the research question)
was a key barrier that had to be overcome. This was
achieved through extensive discussions that outlined
that the research was led, initiated and piloted by a
local academic neurologist and the Indian Institute of
Public Health, in collaboration with academics from
UK and Australia. Moreover, the research addressed
an issue of local priority, which was the lack of access
to multidisciplinary rehabilitation, and was highly
motivating for Indian health providers, principal
investigators, patients, and carers. Improvement to
clinical care due to the robust data collection and
follow up and greater understanding of patient context-
ual factors was described by health providers. Thus,
our ﬁndings highlight the need for transparency, early
consultation and engagement of local health, ethics and
research authorities, and value of international collab-
orative research in strengthening health systems in lim-
ited resource settings.
Our case study of the ATTEND collaboration also
highlights the importance of discussion at international
stroke conferences, and we would recommend that con-
ference organizers provide future sessions with a
‘‘research in low and middle-income countries’’ session
theme, including plenty of opportunity for panel and
audience discussion (Box 2). ATTEND also provides a
good example of international funding providing initial
feasibility funding, followed by more substantive fund-
ing, that built local research capacity, and then led to
further international funding, thus providing more
long-term research sustainability. The ATTEND trial
collaborated with 14 hospitals and academic centers
across India with a mix of state and central govern-
ment, private, and corporate institutions. The Indian
government has now funded a large Indian Stroke
Clinical Trial (INSTRUcT network) constituting 27
Figure 1. Creating the basic infrastructure to start research.
Hospital/clinic based 
collecon of all paent 
related data for 
documentaon and 
Analysis of the collected 
data periodically (aer 
approximately 1000 
paent records) 
Idenfying research 
quesons that can be 
answered from the 
collected data 
Designing and implemenng 
simple intervenon, open 
label trials based on the 
quesons raised 
Escalaon to populaon 
based trials with experience 
from previously conducted 
trials 
Academic mulcenter 
studies 
Industry sponsored 
mulcenter clinical trials 
International Journal of Stroke, 0(0)
Pandian et al. 7
111
institutes across India which are empowered to imple-
ment and run trials while employing and training
research staﬀ. With the formation of the INSTRUcT,
further research capacity growth, supported by success-
ful global grant applications, promises a bright future,
with new data likely to drive local health improvement,
and contribute to global health. This illustrates the
importance of engaging with policy makers in creating
a research culture.
Conclusions
The solutions to the challenges of research in limited
resource settings are interlinked and include research
training, research design and leveraging access to
global research funding. Many of our own examples
were driven, in part, by informal discussions at inter-
national conferences, and taking opportunities as they
arose. Collegiality, and collaboration ensures we dis-
cuss the great challenges that many face in limited
resource settings, and between us, we have the resources
to build further research capacity for the beneﬁt of our
global citizens.
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CHAPTER 5: EXPLORING THE USE OF EVIDENCE TO INFORM 
INVESTMENT IN DISEASE PREVENTION 
 
Chapter Overview 
In this chapter, a qualitative study initiated by NHMRC-funded Australian Prevention 
Partnership Centre (TAPPC), is used to explore whether evidence is relevant to high level 
decision makers with responsibilities for investing in NCD prevention in Australia (from 
Treasury, state health departments and the insurance industry).  The findings of a 
qualitative study examining the evidence to practice and policy gap, specifically relating to 
the prevention of NCDs in Australia, are presented.  The chapter consists of a published 
manuscript titled: “Exploring the use of economic evidence to inform investment in disease 
prevention- a qualitative study.”   
In Chapters 3 and 4, examples were given of how process evaluations of RCTs provide 
evidence of micro to macro contextual factors explaining for whom, how and why these 
interventions had an impact on; and provide insights to barriers and facilitators for future 
collaborative research. However, a missing part of the thesis’ narrative is whether the 
evidence generated by impact, process and economic evaluations of complex interventions, 
do indeed guide decision makers to invest in programs addressing NCD. This chapter 
provides some important insights and implications for future partnership research in 
tackling NCDs in Australia.  
 Authors’ contributions: SJ, PH and AS initiated the study on behalf of the health economics 
group of the Australian Prevention Partnership Centre.  SJ led the study and was the lead 
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interviewer. JM managed the study, co-interviewer and contributed to data collection, and 
the analysis. HL was the lead analyst of the qualitative data and a co-interviewer with SJ. HL 
mentored JM in qualitative methods, drafted and revised the manuscript, and all co-authors 
provided input in the revisions and approved of the final manuscript.  
Publications details:  
Liu, HM. Muhunthan, J. Ananthapavan, J. Hawe, P. Shiell, A. Jan, S on behalf of the TAPPC 
Economics group. Exploring the use of economic evidence to inform investment in disease 
prevention- a qualitative study ANZJPH (accepted on 2nd October 2017).  
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Evidence-based investment in prevention is crucial in addressing Australia’s rising health, economic and 
social burden from lifestyle-related non-
communicable diseases (NCD).1 Prevention 
strategies are prominent in the World Health 
Organization’s ‘best buys’ in addressing this 
burden.2 Despite such evidence, investment 
in prevention of NCDs in Australia is low 
compared to other countries with similar 
epidemiological profiles.3,4 Such disparity 
in expenditure potentially reflects a low 
value attached to the evidence around its 
effectiveness and cost-effectiveness by policy 
makers in this country. However, we note that 
a recent report argues that the proportional 
amount of spending on prevention by a 
country, compared to others, may be an 
overly simplistic means to assess its value or 
worth.5
In the past 20 years, the use of economic 
evidence in Australia has been growing 
through the pioneering initiatives in the 
1990s to introduce cost-effectiveness criterion 
in the listing of new drugs for government 
subsidy through the Pharmaceutical Benefits 
Advisory Committee (PBAC).6 In spite of 
the recognised leadership role Australia 
has played in institutionalising the use of 
economic evidence in informing investment 
in healthcare (such as PBAC, as well as 
the Medical Services Advisory Committee 
[MSAC]), little has been done to promote 
greater use of cost-effectiveness evidence in 
NCD prevention. 
A reason for this may be that in the 
prevention space, unlike that of healthcare, 
policy makers may be less willing to cede 
discretion over investment decisions to an 
evidence-based approach that is driven by 
cost-effectiveness. In principle, the role of 
economic evidence is to guide the allocation 
of resources efficiently across population 
groups and individuals by identifying 
programs that optimise social outcomes for 
given resources.7 However, economic analysis 
tends to be underpinned by a reductionist 
perspective on investment decision making. 
In this world view, decisions are characterised 
by a choice to either accept or reject an 
investment proposal by benchmarking 
the observed incremental cost per unit of 
health outcome of the intervention against 
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Abstract
Objective: In the context of growing financial pressures on health budgets, cost-effective 
prevention strategies are needed to address the burden from non-communicable disease in 
Australia. We explored how decision makers use economic evidence to inform such investment 
and how such evidence generated can more effectively meet the needs of end users.
Methods: Thematic analysis of in-depth interviews with 15 high level stakeholders (Treasury, 
state health departments and the insurance industry), supplemented by documentary analysis.
Results: Types of prevention approaches and economic evidence relevant to decision 
makers differed by organisational perspective. Capacity building in understanding economic 
evaluations and research evidence that addresses the differing criteria for investment used 
by different organisations is needed. The task of determining investment priorities in disease 
prevention comes with significant challenges including ideological barriers, delayed outcome 
measures, and implementation uncertainties.
Conclusions and Implications for public health: Promoting the greater use of economic 
evidence in prevention requires more work on two fronts: tailoring the methods used by 
economists to better match the organisational imperatives of end users; and promoting 
greater consideration of broader societal and health sector perspectives among end users. 
This will require significant infrastructure development, monitoring and evaluation, stronger 
national leadership and a greater emphasis on evidence coproduction. 
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an accepted cost-effectiveness threshold 
(in Australia this has been posited as being 
between $50,000–70,000 per quality adjusted 
life year gained). The logic underlying this is 
that with successive decisions made on the 
basis of this balancing of costs and outcomes, 
as a community, we are led incrementally 
toward a hypothetical efficiency ideal (or 
‘frontier’).8 One possible reason for the 
exception of prevention to this logic is that 
the outcomes of interventions are often 
multi-dimensional, long-term and diffuse – 
affecting sectors outside of health.9 As such, 
while this has a high degree of acceptance as 
a framework for allocating resources in many 
parts of the health sector, it may be at odds 
with prevailing norms that govern the way 
investments are made in prevention.10-14 
Therefore, gaining a better understanding of 
key actors’ perspectives (as depicted in Figure 
1) is vital in identifying the factors that drive 
investment decisions and in overcoming any 
perceived barriers to the implementation of 
evidence-based prevention strategies into 
practice and policy.10,15-17 For this study, we 
explored how decision makers (policy makers, 
insurers and funders) use economic evidence 
to inform investment in the prevention of 
lifestyle related NCDs, and identified how 
economic evidence can better match their 
needs. 
Methods 
Our methods are outlined here according to 
criteria for qualitative research.18,19
Approach
The study was carried out and supported by 
a research collaboration that promotes multi-
disciplinary research into chronic disease 
prevention, with a focus on developing 
system solutions. The interview guide 
(Supplementary file 1) was developed by 
health economists and covered the following 
key questions: What type of evidence is 
used when making investment decisions in 
disease prevention? What role does economic 
evidence play? What types of analyses are 
used? Is there scope for generating economic 
evidence that better matches decision 
makers’ needs? 
Setting and sampling strategy
Recruitment of the participants was 
purposive. We sought to elicit views from 
individuals within three distinct types of 
organisations: state health and Treasury 
departments and private health insurance 
companies. The research collaborators helped 
identify key individuals who were responsible 
for investment decisions. An ethics-approved 
information sheet and invitation letter were 
sent to potential participants. Ethics approval 
was granted by University of Sydney before 
commencement of research. 
Data collection techniques
We conducted semi-structured interviews 
with these decision makers that lasted 
between 30 and 45 minutes. All participants 
provided written informed consent. A health 
economist took the lead in conducting the 
face-to-face interviews, accompanied by two 
public health researchers with backgrounds 
in medicine and law, respectively. Three 
interviews were conducted on the phone due 
to distance. All interviews were recorded with 
a digital recorder. Any supporting documents 
referred to by the interviewees were obtained 
by the team so they could be analysed. 
Analysis
Interviews were professionally transcribed 
verbatim and managed by NVivo software. 
A coding framework (Supplementary file 2) 
was developed using a ‘ground up’ approach 
by the two public health researchers using 
three transcripts and iterative changes made 
as necessary with the coding of subsequent 
transcripts. The team met regularly to discuss 
the emerging themes. Thematic saturation 
was reached at 15 participants and interviews 
were stopped. Constant comparison 
across cases was undertaken as all data 
coded to each major code was analysed. 
Documents20-31 referred to by participants 
during the interviews were analysed by a 
senior health economics researcher for the 
purpose of triangulating the findings.32 The 
findings from the documentary analysis are 
provided in Supplementary file 3. 
Results
We interviewed high-level decision makers; 
four were from the insurance industry, 
eight from state health departments and 
three from a state Treasury department. 
Three key themes were derived about how 
organisational perspectives frame types 
of economic evidence used; the need to 
increase the accessibility and acceptability 
of health economics to end users; and 
the significant barriers to the prevention 
agenda. Further illustrative quotes are 
Figure 1: Contextual map of stakeholders. The complexities of the provision of prevention strategies by various 
stakeholders, highlighting their roles and interlocking relationships which impact upon the consumer’s behaviour 
change.
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Exploring use of economic evidence for investment in prevention 
presented in Box 1. Table 1 presents a 
summary of the identified barriers to the use 
of economic analysis in prevention and our 
recommendations to address them. 
Organisational perspectives frame the 
preferred prevention approaches and 
types of economic evidence used 
Industry (insurance companies) – business 
case and return on investment 
The industry perspective focused on the use 
of economic evidence to justify their business 
case and stewardship of members’ funds. 
Industry stakeholders wanted evidence 
relating to the minimisation of hospitalisation 
for their members and consequently 
defined ‘return on investment’ in those 
terms, as this was the most tangible means 
of demonstrating value to the business. In 
comparison, primary prevention or health 
promotion activities were highlighted by 
another insurer as part of their ‘branding’ and 
marketing campaign. Industry stakeholders 
also described how cost savings generated 
by their programs were often realised in the 
public sector (e.g. reduced pharmaceutical 
costs through Medicare), but indicated that 
these were generally not factored into the 
company’s decision making. One option 
raised was the possibility of cost-sharing 
arrangements with government in which 
there were mutual benefits.
Health departments – population health 
approach 
Health department stakeholders described 
using an evidence-based approach to 
demonstrate the potential benefits of a 
concerted prevention strategy with a ‘range 
of interventions’ and indicated that there was 
a need to incorporate other sectors. These 
stakeholders recognised that economic 
evidence would provide greater ‘credibility’ 
for what they do, although some described 
a reticence to use financial outcomes and a 
preference to only focus on health outcomes. 
A health policy maker indicated the advocacy 
value of cost of illness evidence such as 
“the cost of overweight and obesity being 
estimated to be 19 billion dollars a year” as a 
way of effectively framing the problem as a 
community rather than an individual issue. 
Economic evidence such as costing data 
(rather than cost- effectiveness evidence) 
was used primarily to better inform the 
implementation of programs, and less so 
to set broader priorities. Two health policy 
makers perceived that economic evidence 
Box 1: Illustrative quotes across themes.
 Organisational perspectives frame the preferred prevention approaches and types of economic evidence used 
“… we are involved in activities which I would probably classify as primary prevention, but it’s not a deliberate investment activity, it’s 
more from a brand activity … So, we like to shoot positive health messages out there to the general population in regards to good diet 
and exercise behaviours …” (Insurer perspective)
“But we don’t have those answers. You’re getting to sort of where we get frustrated. I mean return on investment, as we are able to use 
it, gives us some sense of being able to compare, say one cooking program against another cooking program. It’s useful in that sense in 
that we can get some sense of, which is the most technically efficient program if you like. And we can purchase on that basis … we can’t 
compare, one type of approach to another type of approach (for example, advertising, changing environments or in advertising versus, 
you know, a diabetes risk assessment tool) with the tools that we have available to us or any of the return on investment analysis that I’ve 
seen anywhere. And that is the holy grail process.” (Health perspective)
“We kind of take the whole of government approach ... A program might require investment through the health sectors, through the 
education sectors, family and community services and it’s about understanding holistically… You’ve got a number of service sectors, sort 
of involved in this and whilst success in one sector doesn’t necessarily mean, you know, success in say, education or family and community 
services. So, it’s about looking at the whole across government, how much is it going to cost across government, what are the benefits 
across government.” (Treasury perspective)
Increasing acceptability and accessibility of health economics to end users
“I think they (other government agencies) confuse the word economic analysis with financial analysis. There’s just no way in reality 
that the agencies are currently geared up for that kind of thing. Completely missing that capability. We want to build up capability 
and understanding of those things … So, there’s a series of opportunities there to work with government (about what) would be an 
acceptable kind of framework that we can all agree on so that we can sort of move the debate forward onto then what sort of things we 
should be funding.” (Treasury perspective)
“I think from my perspective I feel like (the use of economic evidence) is an area I hardly know anything about and so I reckon that there’s 
a role for, you know, economic evaluation 101 for senior managers … It would also be really helpful for me … in the area of overweight 
and obesity or tobacco control or alcohol ¬– preventing alcohol related harm – [to know] what’s the current landscape, what in terms of 
economic evaluation of intervention and policy in those areas, is really helpful for someone in my role.” (Health perspective)
“So, then what I’m looking at is my health economists have gone away and done some really nice modelling around the types of people 
that will be going through [a health program]. So, they’re over 60 and they look like this and therefore, on average, and depending on all 
those variables, we have different combinations, this is what they would expect to cost … I’m going to say that I’m forecasting 30 to 40% 
reduction in patients re-admitting over a 90-day time frame that go through this program, so therefore how does that stack up?” (Insurer 
perspective)
Prevention agenda for NCD faces significant challenges 
“So, in tobacco I think there’s not so much contention around tobacco as an area where government would intervene. We’ve got 30 years 
of evidence in relation to [success], so these policy changes and these programmatic and services are an appropriate mix. Whereas, in 
overweight and obesity, it’s not as well clearly understood, nor is it equally accepted as a place for government intervention.” (Treasury 
perspective)
“Because we would often get a phone call from the (funders) saying okay, you’ve now spent this huge investment in prevention. How 
many kids did you stop from becoming obese? Now that’s quite a hard question to answer. Not reducing …the number of kids who are 
(overweight) down into the healthy weight area, but how many did you stop from going up the scale into the unhealthy weight?” (Health 
perspective)
“In the health space, we know there’s a kind of cost trajectory valve, and health costs are going to rise into the future. And you know, we 
need to be doing more about keeping people out of hospital to start with … there is a recognition that we need to be investing in health. 
it’s a question of what we should be investing in … that the proposed [strategy], you know it’s worked elsewhere, is it actually going to 
work here? Do we have the right conditions, capacity and capability?” (Treasury perspective)
that tackled allocative efficiency questions 
across different types of prevention strategies 
would be the ‘holy grail’ in informing their 
decisions. 
Treasury – whole-of-government and inter-
sectoral approach
Treasury decision makers stated the use of 
a ‘whole-of-government approach’ in the 
assessment of inter-sectoral prevention 
interventions and indicated they would 
consider costs and benefits across 
government. Return on investment and the 
‘bottom line’ did come into play; however, 
they were also concerned with broader 
economic dynamics such as inter-sectoral 
(e.g. transport and education) contributions 
to investments and their roles in promoting 
healthy living and the economic impact of 
improved health status. 
Increasing acceptability and 
accessibility of health economics to 
end users
Capacity building in health economics for 
end users
Some stakeholders in health and Treasury 
indicated that the health sectors’ capacity 
to understand economic evidence was 
limited, and capacity should be built either 
through collaborations or workshops. A 
high-level policy maker in health stated, 
“there’s a role for economic evaluation 
101 for senior managers”. Interviews often 
ended with requests from the interviewees 
for documents that synthesised the cost-
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and interactive tool, which also incorporates 
the complexities of service delivery and 
health outcomes. Since many of the health 
insurance stakeholders described return on 
investment as their key driver, they were 
keen to have greater links between the 
intermediate clinical outcomes and cost 
savings. Another suggestion from a Treasury 
stakeholder was that early consultation with 
end users in the development of predictive 
economic models would be beneficial, as 
this would be “getting people to use this kind 
of data [by] helping people to understand 
how it’s done so that it’s not just a sort of 
impenetrable black box”. 
A few stakeholders in Treasury and the 
health departments suggested that lessons 
could be derived from other sectors (e.g. 
transport) in using economic analysis that 
included socioeconomic determinants. 
Indeed, several of the documents referred 
to by the interviewees (health and Treasury 
departments) were evaluation frameworks 
and government strategy documents related 
to policies both within and external to the 
health sector. The evaluation framework 
documents emphasise the importance of 
economic appraisal for efficient allocations 
of resources.20,26 The documents generally 
recommend using cost benefit analysis (CBA) 
and endorse the use of cost-effectiveness 
analyses (CEA) only in some sectors (e.g. 
health) where it may be more difficult to 
monetise the benefits.20,22,23 The strategy 
documents emphasised the importance of 
investing in research that includes economic 
evaluations and implementing cost-effective 
interventions.28,30 In addition, health equity 
and equity in general were highlighted as 
objectives or guiding principles of their 
policies,23,25,27-29 and government evaluation 
guidelines propose that equity impacts 
should be described and quantified when 
possible.20,22 
Prevention agenda for NCD faces 
significant challenges 
Political and ideological considerations
Some stakeholders indicated that promoting 
a prevention agenda is difficult when 
there is a prevailing ideology that can be 
characterised as emphasising personal 
responsibility over government action. A 
few stakeholders suggested that when there 
is a change in government, support for 
prevention programs tends to come under 
closer scrutiny. As a consequence, investment 
in individual prevention programs is tied 
Table 1: Identified barriers to the use of economic analysis in prevention and the prevention agenda and our 
suggested recommendations to overcome them.
Barriers to the use of 
economic analysis 
Recommendations
Lack of relevance of current 
economic analysis to end 
users
For analysts to have a deeper understanding the context of the stakeholders’ perspectives. 
In Australia:
•	 Treasury: managing the governmental budget, thus a whole-of-government approach. Thus, a 
need for strong evidence and economic analysis including effects across different government 
sectors.
•	 Health: a need for a holistic approach towards population health, for there to be an increasing 
appreciation for economic analysis and costs to be included to provide ‘credibility’ for their 
agenda.
•	 Insurance Companies: Financial bottom line for the insurance companies in regards to reducing 
hospitalisation for their members.
Lack of capacity to 
understand health economics 
literature
Building capacity through workshops, in-house health economists, or collaboration, or outsourcing 
through commissioning
Better communication of health economic evidence, to help stakeholders understand its 
significance, such as policy briefs, evaluation frameworks, systematic reviews.
Methodology in prevention is 
a ‘black box’.
Co-production of economic evidence by including decision makers in the development of models 
and making assumptions explicit. 
More development needed in this area to make this economic evidence more accessible to decision 
makers, e.g. Modelling and links between the behavioural risk factors, the clinical risk factors and 
life years saved.
Health economics perceived 
as prioritising costs over 
health outcomes. 
Improving capacity within organisations to understand the fundamentals of health economics (i.e. 
effectiveness, efficiency and equity).
Equity focused economic analysis (e.g. for Indigenous health programs) are needed to provide 
relevant evidence for decision makers.
Barriers to the Prevention 
agenda 
Recommendations
Difficulty maximising upon 
the different approaches of 
prevention as organisational 
perspectives frame the 
preferred prevention 
approaches. 
More collaboration across sectors and health funders to provide prevention programs as a concerted 
effort. 
Priority setting across stakeholders from different sectors will be beneficial.
Established institutional processes for the use of health economics (with standardised methods) in 
prevention.
Develop diverse investment portfolios (i.e. incorporate both high and low-cost interventions with 
variable levels of available evidence) in prevention that consider the potential need for risk to effect 
return and encourages innovation.
Prevailing ideology regarding 
prevention as to whether it 
is personal responsibility or 
government action. 
Understanding and addressing various stakeholders’ views (consumers, health providers, policy 
makers, funders) through consultation. 
Building the evidence base and increasing the public awareness of cost effective prevention 
strategies addressing lifestyle related risk factors as this will affect political will.
Timing of funding cycle is 
short but prevention delivers 
long-term benefits and short-
term benefits are less visible.
The need to use intermediate measures to show progress and modelling to show potential benefits.
This requires the development of a strong infrastructure for the monitoring and evaluation of 
prevention strategies as a prevention platform e.g. IT infrastructure, workforce acceptance of 
performance metrics as part of ongoing monitoring and evaluation, data linkage, use of process 
data.
Use of evidence is varied 
across stakeholders
Evidence generated needs to be pragmatic. There should be more evidence in implementation 
methods, with in-depth contextual understanding.
Increasing preference for co-production of evidence between academic institutions, government 
departments and insurance companies.
More synthesis of the evidence, e.g. through reviews of economic evaluations specific to a particular 
area of prevention such as obesity or tobacco control.
Ways to improve knowledge exchange, e.g. use of databases, policy briefs, knowledge brokers.
The need to incorporate other 
sectors
Including knowledge brokers and the use of economic evidence across sectors
Systems approach to prevention which could be incorporated into research (so that it is not single 
intensity and focused only). This requires a clear picture of the current political influences, health 
system (private, public, out of pocket expenses), other non-health sectoral influences, e.g. market 
forces regarding housing, pharmaceuticals.
effectiveness evidence in obesity, tobacco 
and alcohol in order to understand the 
“current landscape”; to be better equipped 
in economic methods that would suit 
their needs; and to be able to confidently 
commission others to do so. In comparison, 
the insurers did not indicate this request as 
they had in-house personnel with skills in 
economics and modelling. 
Increasing the relevance of health 
economics methodology 
Many respondents described a need for 
economic evidence that serves as a predictive 
Liu et al.
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with an inherent level of uncertainty. In 
response to this, solid evidence plays a role in 
addressing these uncertainties. A participant 
from Treasury described how a strong track 
record of 30 years of evidence was needed 
to enable smoking cessation programs to 
be more acceptable to government decision 
makers, in contrast to how “in overweight and 
obesity, it’s not as clearly understood nor is it 
equally accepted as a place for government 
intervention”.
Prevention delivers long-term benefits; 
short-term benefits are less visible 
There was a general consensus among 
many stakeholders that the delay for health 
promotion and early prevention strategies 
in demonstrating ‘hard’ health outcomes can 
be problematic, due to the constant pressure 
to justify investments in light of competing 
priorities (such as acute care) within short 
funding cycles. The stakeholders emphasised 
that infrastructure in acute care allowed for 
more robust data collection (e.g. number 
of hospitalisations) than the infrastructure 
available to monitor and evaluate preventive 
care. This lack of outcome measures to show 
progress in prevention meant less leverage 
for policy makers when trying to sustain 
funds for prevention as compared to acute 
care. For example, a stakeholder in health 
described getting calls from funders asking 
questions such as: ‘“You’ve now spent this 
huge investment in prevention. How many 
kids did you stop from becoming obese?’ Now 
that’s quite a hard question to answer”. Health 
policy advisors suggested that identifying 
valid “proxies, [such as] people’s behaviour, 
people’s participation, people’s motivation to 
change” may be needed to “predict the future 
[of that] program outcome” and to enable 
these potentially long-term effects to be 
reflected in investment decisions. 
Enabling the commitment to prevention 
requires significant infrastructure
Another key barrier to the prevention agenda 
was the generalisability and scalability of 
effective programs. A Treasury stakeholder 
recognised that “there’s a kind of cost 
trajectory valve, and health costs are going to 
rise into the future” but that the question they 
had was “what we should be investing in … 
you know it’s worked elsewhere, is it actually 
going to work here? Do we have the right 
conditions, capacity and capability?” 
Most participants emphasised that enabling 
evidence-based investment in prevention 
requires advancements in infrastructure, 
including the availability of informative 
(baseline and process) data, processes for 
ongoing data collection and workforce 
capacity building. There was also a stated 
need to leverage other available resources 
(e.g. from primary healthcare, insurance 
companies, hospitals, primary health 
networks). All this would facilitate improved 
monitoring and evaluation, which would 
allow for continued funding and expansion of 
the projects. 
Discussion
Our results highlight the significant political 
and pragmatic challenges faced by decision 
makers in investing in prevention. It is 
within this context that ‘economic’ data 
can sometimes be in a form that does not 
resemble the traditional way that cost-
effectiveness evidence is defined, even 
though it is used routinely by stakeholders. 
The types of evidence used, framed by 
prevailing organisational perspectives, 
include forward estimates of budgetary 
impacts and ‘return on investment’, i.e. range 
of benefits as specific to the organisational 
imperatives of the stakeholders (e.g. decrease 
in hospital admissions for the insurers). 
Furthermore, economic evidence tends to be 
used to support activities such as advocacy, 
financial management and communication 
between stakeholders, which fall outside the 
functions economic evaluations are typically 
designed to inform. Indeed, the finding that 
prevention is seen as part of the branding 
activity by health insurers (regardless of 
prevention’s economic benefit) fits with the 
observation that decision makers often hold 
knowledge to have more symbolic value than 
instrumental value.33
The limited capacity of conventional 
economic evaluation methodologies and 
cost-effectiveness metrics to provide all 
the information decision makers need 
is well recognised in the international 
literature.10-12,34,35 A solution may lie in an 
adoption of an evidence co-production 
approach,36 which means that research is 
characterised as a joint enterprise rather than 
as the end-product of a process in which 
it is ‘delivered’ by researchers to a group of 
decision makers.37 Conversely, more work can 
be done to encourage decision makers to 
look beyond their organisational perspectives 
and to take on board evidence of societal 
and sector-wide impacts. This may include 
promoting recent initiatives in the health 
economics literature such as the use of cost 
consequences analyses of ‘social impact 
inventories’, which represent evaluation 
techniques that take multi-dimensional social 
outcomes into account.38,39 
Another key implication is that economic 
evaluation tools could potentially address 
some of the barriers faced by prevention 
programs (e.g. short-term benefits are less 
visible). Thus, an area for further development 
is for health economic researchers to re-orient 
analyses in prevention so that evidence can 
be used to guide future action, rather than 
as a means of evaluating past decisions. This 
requires greater use of modelling techniques 
based on epidemiological evidence to 
provide decision makers with stronger 
predictive capabilities. In addition, the use 
of priority setting tools such as program 
budgeting and marginal analysis that involve 
the decision maker in the process40,41 and 
studies41,42 that synthesise existing evidence 
and incorporate a broader concept of benefit 
would be useful in prospectively informing 
investment decisions.
Given the dynamic nature of the political 
and ideological context around prevention, 
stronger national leadership and establishing 
processes for the use of health economics 
within organisations may be needed.43,44 
Advances in the use of economic evaluations 
in policy in Australia have mainly been in 
the field of health technology assessments 
for drugs and devices. We had expected 
this to filter through to prevention, but 
our evidence suggests that this has not 
happened to any major extent. A reason 
inferred from the findings was that 
implementation of prevention programs (e.g. 
taxation of soft drinks) faces political and 
ideological challenges and that consumer 
acceptability is key in this process. While a 
universal PBAC-type system for assessment 
of new prevention ‘technologies’ may be 
challenging given the diversity of funders 
and organisational imperatives that drive 
decision making in the prevention sphere, 
the evolution of the partnership between 
UK Department of Health and the National 
Institute for Health and Care Excellence (NICE) 
to provide evidence-based recommendations 
for public health practitioners and policy 
makers indicates that such challenges can 
be overcome.6,45,46 As indicated in this study, 
much of the evidence sought by those 
charged with investing in prevention falls 
outside the purview of what is conventionally 
Exploring use of economic evidence for investment in prevention 
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considered health economic evidence and is 
specific to organisation. Part of the solution 
is in encouraging the application of existing 
methods of economic analysis that are 
sympathetic to what it is that prevention 
achieves, and the other part is to create the 
incentives for decision makers to factor into 
their investment decisions outcomes that 
are broader than their narrow organisational 
perspectives.1,7
A limitation of the study may be the small 
number of participants, although it should 
be recognised that our focus was on senior-
level decision makers, and that we did 
achieve thematic saturation. Sampling from 
the different organisations also provided 
triangulation from different perspectives 
given the relevance of the public and private 
sector in the prevention agenda. It is possible 
that a level of social desirability may have 
biased the findings, given that the interviews 
were led by a health economist. However, we 
found respondents to be candid and openly 
critical of economics and often highlighted 
organisational shortcomings in addressing 
issues raised. 
Conclusion
To ensure the better use of evidence in 
investment in prevention in Australia, 
researchers need to be attuned to the varied 
organisational imperatives faced by the 
various organisations who are players in 
this space. Evidence needs to be fit for such 
purposes but, at the same time, more can be 
done to encourage potential funders to take 
into account cost-effectiveness evidence that 
highlights cross sector and societal impacts. 
This will require significant infrastructure 
development, monitoring and evaluation, 
stronger national leadership and a greater 
emphasis on evidence co-production. 
Acknowledgements
We would like to thank all participants who 
gave so generously of their time and for their 
valuable insights. This research was supported 
by The Australian Prevention Partnership 
Centre through the NHMRC partnership 
centre grant scheme (Grant ID: GNT9100001) 
with the Australian Government Department 
of Health, NSW Ministry of Health, ACT Health, 
HCF, and the HCF Research Foundation. 
HL is funded by a NHMRC postgraduate 
scholarship, SJ is funded by a NHMRC Senior 
Research Fellowship. AH was funded through 
NHMRC #571372.
The authors acknowledge the contribution of 
The Australian Prevention Partnership Centre 
(TAPPC) Health Economics Group. Stephen 
Jan co-authored the paper on behalf of 
TAPPC, and other group members comprise 
of: Andrew Milat, Beth Stickney, Alison Hayes, 
Thomas Wai-Chun Lung, Rob Carter, Louise 
Sylvan and Tracey-Lea Laba.
References
1. Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron 
V, Chisholm D. Tackling of unhealthy diets, physical 
inactivity, and obesity: Health effects and cost-
effectiveness. Lancet. 2010;376(9754):1775-84.
2. World Health Organisation. From Burden to “Best Buys”: 
Reducing the Economic Impact of Non-Communicable 
Diseases in Low- and Middle-Income Countries. Geneva 
(CHE): WHO; 2011.
3. Organisation for Economic Co-operation and 
Development. Health Expenditure Indicators [Internet]. 
Paris (FRC): OECD; 2017 [cited 2017 Aug 18]. Available 
from: http://dx.doi.org/10.1787/data-00349-en 
4. Australian Institute of Health and Welfare. Australia’s 
Health 2016 [Internet]. Australia’s Health Series No.: 
15. Canberra (AUST): AIHW; 2016 [cited 2017 Aug 25]. 
Available from: http://www.aihw.gov.au/WorkArea/
DownloadAsset.aspx?id=60129555788 
5. Jackson H, Shiell A. Preventive Health: How Much Does 
Australia Spend and is it Enough? Canberra (AUST): 
Foundation for Alcohol Research and Education; 2017. 
6. Lung TW, Muhunthan J, Laba TL, Shiell A, Milat A, Jan S. 
Making guidelines for economic evaluations relevant to 
public health in Australia. Aust N Z J Public Health. 2016.
7. Sassi F, Hurst J. The Prevention of Lifestyle- Related 
Chronic Diseases: An Economic Framework. OECD Health 
Working Papers. Paris (FRC): OECD; 2008.
8. George B, Harris A, Mitchell A. Cost-effectiveness 
analysis and the consistency of decision making: 
Evidence from pharmaceutical reimbursement 
in australia (1991 to 1996). Pharmacoeconomics. 
2001;19(11):1103-9.
9. Merkur S, Franco S, McDaid D. Promoting Health, 
Preventing Disease: Is There an Economic Case? Geneva 
(CHE): WHO; 2013.
10. Madden L, King L, Shiell A. How do government health 
departments in Australia access health economics 
advice to inform decisions for health? A survey. Aust 
New Zealand Health Policy. 2009;6:6.
11. Ross J. The use of economic evaluation in health care: 
Australian decision makers’ perceptions. Health Policy. 
1995;31(2):103-10.
12. Salkeld G, Davey P, Arnolda G. A critical review of health-
related economic evaluations in Australia: Implications 
for health policy. Health Policy. 1995;31(2):111-25.
13. Hoffmann C, Graf von der Schulenburg JM. The 
influence of economic evaluation studies on decision 
making. A European survey. The EUROMET group. 
Health Policy. 2000;52(3):179-92. 
14. Hoffmann C, Stoykova BA, Nixon J, Glanville JM, Misso 
K, Drummond MF. Do health-care decision makers find 
economic evaluations useful? The findings of focus 
group research in UK health authorities. Value Health. 
2002;5(2):71-8.
15. Salkeld G, Henry D, Hill S, Lang D, Freemantle N, 
D’Assuncao J. What drives health-care spending 
priorities? An international survey of health-care 
professionals. PLoS Med. 2007;4(2):e94.
16. Moreno-Peral P, Conejo-Ceron S, Fernandez A, 
Berenguera A, Martinez-Andres M, Pons-Vigues M, 
et al. Primary care patients’ perspectives of barriers 
and enablers of primary prevention and health 
promotion-a meta-ethnographic synthesis. PLoS One. 
2015;10(5):e0125004. 
17. Wiseman V. Comparing the preferences of health 
professionals and members of the public for setting 
health care priorities: Experiences from Australia. Appl 
Health Econ Health Policy. 2005;4(2):129-37.
18. Tong A, Sainsbury P, Craig J. Consolidated criteria for 
reporting qualitative research (COREQ): A 32-item 
checklist for interviews and focus groups. Int J Qual 
Health Care. 2007;19(6):349-57. 
19. Kitto SC, Chesters J, Grbich C. Quality in qualitative 
research. Med J Aust. 2008;188(4):243-6.
20. New South Wales Treasury. Guidelines for Economic 
Appraisal [Internet]. Sydney (AUST): State Government 
of NSW; 2007 [cited 2015 Oct 8]. Available from: 
http://www.treasury.nsw.gov.au/__data/assets/
pdf_file/0016/7414/tpp07-5.pdf
21. NSW Health. Healthy Spaces and Places [Internet]. 
Sydney (AUST): State Government of NSW; 2009. [cited 
2015 Oct 8]. Available from: http://www.healthyplaces.
org.au/userfiles/file/HS&P%20An%20overview.pdf
22. Transport for New South Wales. Principles and 
guidelines for economic appraisal of transport 
investment and initiatives. Transport economic 
appraisal guidelines 2013 [Internet]. Proceedings of 
the ITLS Leadership and Policy Seminar; 2013 Sep 10; 
Sydney, AUST. Sydney: University of Sydney Institute of 
Transport and Logistics Studies; 2013 [cited 2015 Oct 
8]. Available from: http://www.transport.nsw.gov.au/
sites/default/files/b2b/publications/tfnsw-principles-
and-guidelines-for-economic-appraisal-of-transport-
initiatives.pdf
23. New South Wales Government. Advertising Handbook 
2015 [Internet]. Version 3.4. Sydney (AUST): State 
Government of New South Wales; 2015 [cited 2015 
Oct 8]. Available from: http://www.advertising.nsw.gov.
au/sites/default/files/downloads/page/advertising_
handbook_december_2015_v4.pdf
24. Aboriginal Environmental Health Unit. Closing the Gap: 
10 Years of Housing for Health in NSW. An Evaluation of a 
Healthy Housing Intervention [Internet]. Sydney (AUST): 
New South Wales Department of Health; 2010 [cited 
2015 Oct 8]. Available from: http://www.health.nsw.
gov.au/environment/Publications/housing-health.pdf
25. O’Hara BJ, Phongsavan P, McGill B, Maxwell M, Ahmed 
N, Raheb S, et al. NSW Get Healthy Information and 
Coaching Service. The First Five Years 2009 – 2013 
[Internet]. Sydney (AUST): New South Wales Ministry 
of Health; 2014 [cited 2015 Oct 8]. Available from: 
http://www.gethealthynsw.com.au/assets/pdf/
medicalprofessionals/resources/Get_Healthy_Service_
Evaluation_Report_WEB_version.pdf
26. New South Wales Department of Premier and Cabinet. 
Evaluation Framework [Internet]. Sydney (AUST): State 
Government of New South Wales; 2013 [cited 2015 Oct 
8]. Available from: http://www.dpc.nsw.gov.au/__data/
assets/pdf_file/0009/155844/NSW_Government_
Evaluation_Framework_Aug_2013.pdf
27. NSW Health. Healthy Urban Development Checklist 
[Internet]. Sydney (AUST): State Government of 
New South Wales; 2009 [cited 2015 Oct 8]. Available 
from: http://www.health.nsw.gov.au/urbanhealth/
Publications/healthy-urban-dev-check.pdf
28. NSW Health. Promoting the Generation and Effective 
Use of Population Health Research in NSW, A Strategy for 
NSW Health 2011-2015 [Internet]. Sydney (AUST): State 
Government of New South Wales; 2010 [cited 2015 
Oct 8]. Available from: http://www.health.nsw.gov.au/
research/Publications/pop-health-res-strat.pdf
29. NSW Health. NSW Healthy Eating and Active Living 
Strategy: Preventing Overweight and Obesity in New 
South Wales 2013-2018 [Internet]. Sydney (AUST): State 
Government of New South Wales; 2013 [cited 2015 Oct 
8]. Available from: http://www.health.nsw.gov.au/heal/
Publications/nsw-healthy-eating-strategy.pdf
30. Transport for New South Wales. Sydney’s Walking Future, 
Connecting People and Places [Internet]. Sydney (AUST): 
State Government of New South Wales; 2013 [cited 
2015 Oct 8]. Available from: http://www.transport.nsw.
gov.au/sites/default/files/b2b/publications/sydneys-
walking-future-web.pdf
31. City of Sydney. Walking Strategy and Action Plan 
[Internet]. Sydney (AUST): State Government of New 
South Wales; 2015 [cited 2015 Oct 8]. Available from: 
http://sydneyyoursay.com.au/walking-strategy
32. Patton MQ. Qualitative Research & Evaluation Methods. 
3rd ed. Thousand Oaks (CA): Sage Publications; 2002.
Liu et al.
121
2017 Online Australian and New Zealand Journal of Public Health 7
© 2017 The Authors
33. Weiss CH. Research for policy’s sake: The enlightenment 
function of social research. Policy Anal. 1977;3(4):531-
45.
34. Williams I, Bryan S. Understanding the limited impact 
of economic evaluation in health care resource 
allocation:A conceptual framework. Health Policy. 
2007;(80):135-43.
35. Hutubessy RC, Baltussen RM, Torres-Edejer TT, Evans 
DB. Generalised cost-effectiveness analysis: An aid 
to decision making in health. Appl Health Econ Health 
Policy. 2002;1(2):89-95. 
36. Jackson CL, Greenhalgh T. Co-creation: A new 
approach to optimising research impact? Med J Aust. 
2015;203(7):283-4.
37. Boyle D, Slay J, Stephens L. Public Services Inside Out: 
Putting Co-production into Practice. London (UK): NESTA; 
2010.
38. Sanders GD, Neumann PJ, Basu A, Brock DW, 
Feeny D, Krahn M, et al. Recommendations for 
conduct, methodological practices, and reporting 
of cost-effectiveness analyses: Second panel on 
cost-effectiveness in health and medicine. JAMA. 
2016;316(10):1093-103. 
39. Jan S, Wiseman V. Updated recommendations for cost-
effectiveness studies. JAMA. 2017;317(1):89-90.
40. Mitton C, Dionne F, Donaldson C. Managing healthcare 
budgets in times of austerity: The role of program 
budgeting and marginal analysis. Appl Health Econ 
Health Policy. 2014;12(2):95-102. 
41. Vos T, Carter R, Barendregt J, Mihalopoulos C, Veerman 
JL, Magnus A, et al. ACE–Prevention Team. Assessing Cost-
Effectiveness in Prevention (ACE–Prevention): Final Report. 
Brisbane (AUST): University of Queensland; 2010.
42. Mauskopf J, Rutten F, Schonfeld W. Cost-effectiveness 
league tables: Valuable guidance for decision makers? 
Pharmacoeconomics. 2003;21(14):991-1000.
43. Liverani M, Hawkins B, Parkhurst JO. Political and 
institutional influences on the use of evidence in 
public health policy. A systematic review. PLoS One. 
2013;8(10):e77404. 
44. Wutzke S, Morrice E, Benton M, Wilson A. What will 
it take to improve prevention of chronic diseases in 
Australia? A case study of two national approaches. 
Aust Health Rev. 2017;41(2):176-81.
45. National Institute for Clinical Excellence. History of NICE 
[Internet]. London (UK): NICE; 2017 [cited 2017 Aug 
22]. Available from: https://www.nice.org.uk/about/
who-we-are/history-of-nice
46. National Institute for Health and Care Excellence. 
Framework Agreement between Department of Health 
and NICE [Internet]. London (UK): NICE; 2014 [cited 
2017 Aug 22]. Available from: https://www.nice.org.uk/
Media/Default/About/Who-we-are/NICE-framework-
agreement.pdf 
Supporting Information
Additional supporting information may be 
found in the online version of this article:
Supplementary Table 1: Interview Guide.
Supplementary Table 2: Coding Tree.
Supplementary Table 3: Documentary 
analysis.
Exploring use of economic evidence for investment in prevention 
122
CHAPTER 6: SUMMARY AND IMPLICATIONS 
 
Chapter Overview:  
This chapter comprises of three sections. First, the results of the thesis as a whole will be 
summarised and the common findings presented across macro, meso and micro levels.   
Second, the three main overall implications from the thesis will be discussed. Third, the 
strengths and limitations of the thesis will be discussed through an appraisal of the PE 
framework used, a researcher’s lens of reflexivity and synthesising the three key strengths 
of the thesis.  
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SUMMARY 
In this thesis I present a body of work which demonstrates that process evaluations (PE) play 
an important role in articulating the needs of end-users (patients, providers, practitioners, 
and policy-makers) within their local context, and doing so, further inform intervention design 
and implementation strategies needed for the sustainability and scaling up of locally relevant 
interventions. This was done through examining the methods and findings of published PEs 
of primary care interventions, two PEs of secondary and tertiary interventions; and exploring 
the use of evidence by end-users in investing in prevention.  
Chapter 2 
In the systematic review in Chapter 2, we used the MRC PE guidance to appraise and 
synthesise the methods and findings from published PEs of primary care interventions. We 
found that greater consistency is needed in the reporting, and the methods of PEs. In 
particular, there should be greater use of theoretical frameworks to inform intervention 
theory. The main strengths were robust sampling strategies, and the triangulation of 
qualitative and quantitative data to understand intervention’s mechanisms. Findings were 
synthesized into three key themes: 1) a fundamental mismatch between what the 
intervention was designed to achieve and local needs, 2) the required roles and 
responsibilities of key actors were often not clearly understood and; 3) the health system 
context – factors such as governance, financing structures and workforce- if unanticipated 
could adversely impact implementation.   
Chapter 3 and 4 
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Using the Realist evaluation and modified MRC PE framework alongside RCTs of secondary 
and tertiary interventions, I was able to systematically examine important individual to policy 
(i.e. micro to macro) level contextual factors impacting on the outcomes of the intervention. 
For example, at the patient level- in Kanyini GAP, we found that the other factors that affect 
patient’s adherence should be considered when prescribing the polypill. And that in hindsight, 
the polypill strategy does not seem to address a patient need for those who are on established 
medications, have a routine and are fully compliant. In ATTEND, we found that sustaining 
behaviour change for rehabilitation by patients and their carers in the face of significant 
emotional and financial pressures was a challenge. Therefore, in the development of future 
models of care, more ongoing emotional support will be required, and the timing of training 
(e.g. of mobility exercises) should align more appropriately with the stages of grief. These 
insights provided a deeper understanding of the how, for whom and why the intervention 
worked for.   
At an organisational level, in the PE of Kanyini GAP, providers described that using a model of 
the absolute CVD risk assessment and prescribing of the polypill was acceptable but found 
the prescribing inflexibility a barrier. The health providers at Indigenous health services 
recognised that the polypill suited their chronic care model. In the PE of ATTEND, through the 
analysis of the participants’ health care use, we were able to determine that patients from 
both randomised groups already had access to rehabilitation, which possibly diluted the 
effect of the intervention. However, the PE highlighted that the training of a family carer was 
an acceptable model of care and necessary for those with limited access to rehabilitation, and 
a future priority would be how to feasibly reach these populations. These micro to macro 
contextual findings resonates with the findings in Chapter 2- that greater emphasis on 
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formative research in designing primary care interventions is needed to align the intervention 
with the needs and responsibilities of local key actors, and to minimise unanticipated 
consequences due to context-specific barriers to implementation.   
However, the manuscripts on the facilitators and barriers of collaborative research (in 
Chapters 3 and 4)  also emphasised how such pragmatic trials are resource and time intensive 
for practitioners having to balance service delivery with research duties.  This was a common 
theme across the practice-based research with general practitioners in private practice and 
in Aboriginal health services, community pharmacists (for Kanyini GAP); and in the context of 
busy stroke units in across India (for ATTEND). Therefore, a key implication is that investment 
in practice-based research infrastructure, capacity building of staff knowledge and expertise, 
is absolutely needed to enable effective generation of ‘real-world’ evidence with health 
practitioners. (1-3) 
Chapter 5 
In Chapter 5, we found that the economic evidence used in decision making differed from 
conventional notions of cost-effectiveness and was determined by specific institutional 
imperatives. Participants described that investing in disease prevention came with 
significant challenges, which included ideological barriers, delayed outcome measures, and 
implementation uncertainties.  Whilst recommendations such as capacity development and 
dissemination have been well set out previously, the findings of this chapter suggest that we 
need to go further in reconciling the objectives of decision makers with the evidence that is 
generated. This requires more work on two fronts: tailoring the methods used by 
economists to better match the organisational imperatives of decision makers; and 
promoting amongst decision makers greater understanding and consideration of broader 
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societal and health sector perspectives.  This will require significant infrastructure 
development to allow for ongoing monitoring and evaluation of population health 
strategies; and a greater emphasis on evidence co-production in order to overcome 
challenges unique to the prevention agenda.   
Common findings (macro, meso, micro levels) and specific implications   
Therefore, a common finding across Chapters 2 to 5 is that co-production of evidence 
between key stakeholders is needed to generate evidence relevant to the needs of the end-
users (patients, providers and policy-makers). In Table 1, I summarise the results of Chapters 
2 to 5 into categories of patient (micro), organisational (meso) and policy (macro) level 
factors, and I outline the specific implications of each study, which informs the overall 
implications of the thesis, discussed below.  
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Summary of Chapter findings by micro, meso and macro level 
factors 
 
Specific implications 
 
 
Overall implications 
from the thesis 
 
 
Examples of micro (i.e individual) level  
 
Systematic review:  Stakeholders were generally motivated to 
adopt/implement the complex intervention if it addressed the 
contextual gap in care i.e. intervention fit. 
 
Kanyini GAP: For patients who do not have a routine for adhering 
to multiple medications and experience significant pill burden and 
costs, the polypill can facilitate regular taking of indicated therapy. 
In addition, providers found that using a model of the absolute 
CVD risk assessment and prescribing of the polypill was acceptable 
but found the prescribing inflexibility a barrier.  The health 
providers at Indigenous health services recognised that the polypill 
suited their chronic care model and Indigenous patients found the 
polypill acceptable. The dosages of the polypill trialled were more 
suited to high risk CVD prevention patients. 
 
 
ATTEND: The model of care was deemed necessary for those with 
limited access to rehabilitation. Sustaining behaviour change for 
patients and carers in the face of significant emotional and 
financial pressures was a challenge. 
 
 
 
 
More emphasis on formative research in designing interventions is needed to 
align the intervention with the needs of local stakeholders. 
 
 
The context of other factors that affect patient’s adherence should be 
considered when prescribing the polypill. In hindsight, the polypill strategy does 
not seem to address a patient need for those who are on established 
medications, have a routine and are fully compliant.   
Other forms of the polypill could allow greater flexibility in prescribing. 
Incorporating the absolute CVD risk assessment with prescribing of the polypill 
would be an acceptable model of care.  
Future research on the cardiovascular polypill should include these 
considerations in their inclusion criteria and intervention development. 
 
 
 
Majority of those recruited into the trial had access to non- trial rehabilitation 
though the intervention was hypothesised to be most relevant for the 
population with limited access to rehabilitation.  Future work is needed to 
develop a way to feasibly reach populations with limited access to rehabilitation  
 
Moreover, while the model of care was acceptable, it could be improved to 
consider timing of patients’ and carers’ stages of grief. Greater emotional and 
possibly financial support may be needed in addition to the existing model of 
joint goal setting, mobility training, communication practice, and functional task 
training. A question remains, as to whether the intervention and recruitment 
might have been modified before the phase 3 trial if interviews with patients 
and carers was conducted alongside the pilot trial. Such in-depth exploratory 
work could inform development of intervention theory and implementation. The 
 
 
 
 
Use of a process 
evaluation framework to 
facilitate iterative 
stakeholder co-
production of 
intervention theory will 
be beneficial. 
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process evaluation framework could potentially be used to facilitate the 
communication between stakeholders for the co-production of evidence in this 
iterative process.  
 
 
 
  
 
Examples at the meso (i.e organisational) level 
 
Systematic review: The extent to which key actors believed in and 
adopted their ‘assigned’ roles and responsibilities as part of 
implementing the complex intervention was a key theme. 
 
 
ATTEND: Though a key assumption was that the family-led model 
of care would address the lack of access, patients from both 
randomised groups already had access to rehabilitation.  
 
 
 
Greater emphasis on formative research in designing primary care interventions 
is needed so that they are clearly aligned with the needs of local stakeholders 
and that the roles and responsibilities of key actors are better understood, and 
implementation strategies are in place.  
 
Using individual-level patient collected data on health care use to triangulate the 
qualitative findings was informative in identifying the access to non-trial 
rehabilitation. However, on hindsight, this was resource intensive to collect and 
may not always be feasible depending on project funding. Streamlining data 
collection with existing systems may be beneficial.  
  
 
 
 
Use of a process 
evaluation framework to 
facilitate iterative 
stakeholder co-
production of 
intervention theory will 
be beneficial. 
 
Innovative and efficient 
methods of capturing 
health system context 
(such as access to care) 
are needed 
Kanyini GAP: Despite strong community and health service support, 
major investments in time and resources are required to ensure 
successful pragmatic RCT implementation in primary care and 
minimal disruption to already overstretched, routine services.   
 
 
ATTEND: Enablers such as respect, high level of intended research 
capacity building, and local leadership were essential to the 
successful completion of the large scale RCT. Challenges identified 
included the perceived ethical dilemma in conducting RCTs for 
those with limited resources; and the need for transparency, early 
Researchers and funding agencies need to consider these additional resource 
demands in collaborative research with Aboriginal health services and in primary 
health care.  Given the need to conduct pragmatic trials and the challenges in 
implementing such research across diverse stakeholder organisations-  
Investment in research infrastructure such as primary health care research 
networks will contribute to future studies being conducted more cost-
effectively.  
 
 
International collaborations can generate locally relevant evidence but need to 
be locally driven. Investment into local leadership, providing adequate research 
support and funding and capacity building is key to successful collaborative 
research 
 
 
 
 
Ongoing research 
infrastructure and 
funding, and relational 
principles (e.g. respect 
and equality) required 
for effective co-
production of research 
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consultation and engagement of local health and research 
authorities in international collaborative research. 
 
 
 
  
 
Examples at the macro i.e. policy level  
 
Systematic review: Health system structures such as governance, 
health financing structures and workforce, were often mentioned 
as impacting on intervention implementation. 
 
 
Prevention of NCDs: Barriers to the investment in prevention 
include ideological considerations, lack of evidence of long term 
outcomes within short budget cycles, and the need monitoring and 
ongoing evaluation to justify for ongoing funding into prevention 
in the face of limited health budgets.  
 
 
 
 
Greater ongoing exploration of policies, health financing structures should be 
done such that unanticipated consequences arising from context-specific 
barriers to implementation can minimised. 
 
 
 
Evidence needs to be fit for purpose through a greater emphasis on evidence co-
production. At the same time more can be done to encourage stronger national 
leadership in prevention, for significant infrastructure development for 
monitoring and evaluation and for potential funders to take into account cost 
effectiveness evidence that highlights cross sector and societal impacts. 
 
 
 
Innovative methods of 
capturing health system 
context are needed and 
the need for stakeholder 
co-production across 
sectors. 
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IMPLICATIONS FOR RESEARCHERS, POLICY MAKERS AND PRACTITIONERS 
 
(1) An iterative end-user (‘ground-up’ and top-down’) co-production of 
intervention theory would be beneficial 
 
Ground up approach for local priorities 
The PEs of both ATTEND and Kanyini GAP highlight how ground-up approaches are essential 
in the development of an intervention that addresses a local priority. Reflecting on Kanyini 
GAP and ATTEND, the underlying mechanisms for both trials was the use of evidence-based 
practice through implementation strategies (of a combined cardiovascular pill to improve 
adherence, and family-led rehabilitation to improve access to rehabilitation, respectively.) 
The question remains as to whether interviews with patients and carers earlier (e.g. during 
the pilot studies) may have led to modification of intervention theory and the target 
population (i.e. limiting recruitment to those with poor adherence to medication and with 
limited access to rehabilitation, respectively).  (4) Therefore, as reflected in our discussion in 
ATTEND PE, researchers should invest more in the earlier phases of theory building of the 
complex intervention, a recommendation which is in line with recent literature. (5-7)  
Top-down approach for sustainability 
However, both cases also exemplify how ‘top-down’ approaches, are necessary to 
sustainably address NCDs, and improve health outcomes beyond a research project. Using 
Kanyini GAP as an example, 5 years post-trial, despite the intervention’s effectiveness in 
reducing prescribing gaps and improving patient adherence to indicated therapy, and its 
potential cost savings to the health system (8, 9)- the intervention was not implemented 
into practice post-trial. Key barriers included the lack of a commercial case for polypill 
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manufacture, and hurdles related to pharmaceutical regulation in Australia. (10) Similarly, 
the systematic review in Chapter 2, provided evidence that policy and organisational level 
contexts (e.g. financing structures, workforce allocation) have to be carefully considered in 
the design and ongoing implementation of interventions.  
Iterative co-production of intervention theory by different level stakeholders across time  
In chapter 5, we spoke with Australian decision makers who highlighted how stronger 
national leadership is needed for a more concerted effort in prevention, and to inform 
investments of cost-effective interventions from a societal perspective. However, examples 
from UK have also shown the limitations of such top-down approaches (e.g. improving care 
through NICE recommended evidence-based guidelines) can also fail to improve outcomes if 
the end users (patients, health providers) do not find them useful or acceptable within their 
local contexts. (11) Therefore, as mentioned above, a ‘bottom up’ and ‘top-down’ approach 
is concurrently needed to strengthen health systems to effectively tackle NCDS. Globally, 
this is reflected in the growing recognition of the value of collaborative research, and in 
engaging communities in health systems research to enable patient-centred care, and 
effective dissemination and uptake of research evidence. (12-14) 
The co-production involving different stakeholders would ideally be conducted together and 
concurrently, so that there is a shared understanding of the ‘other’s’ perspectives and a 
common solution can be found. Future work lies in how to facilitate this co-production of 
evidence across multiple stakeholders in an effective and efficient manner, and identifying 
what suitable research tools (e.g. nominal group technique, online surveys) could be used.  
My findings are in line with the co-production literature that states that the consultation 
with the key stakeholders should take place from the start. This includes the identification 
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of the problem, and the generation of the solution including the implementation strategies. 
This proposed iterative, co-production of complex interventions with key stakeholders have 
parallels with the qualitative improvement work (e.g. Plan, Do, Study, Act cycles) initiated by 
the health providers/ managers in the public and health sectors. The slight differences lie in 
the scope of who are engaged in the co-production of the interventions. For example, 
quality improvement initiated by managers using routine data and discussed with health 
practitioners- would often result in local individual and organisation (i.e. micro and meso) 
level strategies to improve outcomes. For example through discussion and education in 
regular morbidity and mortality meetings. In comparison, co-production of complex 
interventions in research may be between external researchers, clinicians, policy makers 
and consumers to develop the intervention content and implementation strategies, which 
would be trialled, adapted to local context, and then scaled up to other settings if found 
effective. 
Therefore, for research to have an impact in the real world- more work needs to be done 
such as advocacy, active post-trial monitoring and co-production of research evidence by 
engaging with policy makers from the onset to help overcome health system barriers. (15) 
Using the PEs to explicitly examine contextual factors may be a way to generate evidence 
relevant to the breadth of stakeholders who are necessary in the co-production of 
affordable, effective and accessible models of care for the prevention of NCDs.  
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(2) Innovative and efficient methods to evaluate complex interventions is 
needed to inform end-users  
Limitations of RCTs  
In Chapter 5, we spoke to decision makers who highlighted that other approaches such as 
modelling may be particularly informative for guiding investment of population-based 
complex interventions targeting NCDs.(3) This suggestion fits into the recent discourse as to 
whether RCTs are suitable study designs for complex interventions. This is partly due to the 
dynamic change in the local context over the timing of a RCT. (16-18) For example, in 
Kanyini GAP, some health providers cited the emerging evidence (about the controversial 
use of aspirin for diabetic patients) as a barrier to the use of the combined polypill. Similarly, 
while the investigators had assumed the polypill strategy would address the cost barrier for 
the consumer who would pay for one medication instead of four- a government 
pharmaceutical reimbursement policy introduced during the trial meant that the cost 
barrier was not a contextual problem anymore.  This re-emphasises the value of explicitly 
exploring ‘contextual factors’ as per the MRC framework, and the iterative approach so as to 
be more responsive to contextual changes. (19-22) Moreover, in ATTEND, some local health 
providers questioned on hindsight, whether RCT was a suitable study design. They described 
their ethical dilemma since patients in the control arm will have significant out of pocket 
costs in order to access rehabilitation.(2) These examples from the thesis highlight how in 
some circumstances, RCTs may not be a good fit for the evaluation of complex 
interventions.   
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Innovative methods required 
While this thesis confirms that PEs of RCTs do provide relevant evidence for health systems 
strengthening- other innovative methods may provide more timely evidence for research 
translation. (13, 23, 24)  Other suggestions in the literature include complex system science 
to investigate how an intervention interacts with the system at multiple points, the use of 
modelling tools to inform policy on complex public health interventions and the conduct of 
pragmatic PEs of interventions already in practice but may have a limited evidence base.  (4, 
25) Therefore, future research as to how co-production of evidence facilitated by innovative 
methods such as modelling, may inform the iterative development of cost-effective and 
patient-centred interventions.     
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(3) Co-production of evidence requires ongoing significant funding, time 
and resources for research infrastructure and relationship building  
Facilitators to co-production 
Being part of three collaborations, provided me a unique perspective of what the barriers 
and facilitators to effective collaborative research are. In Chapter 3 and 4, through the 
individual interviews and focus groups, I found that a crucial facilitator of effective 
collaborations was the stakeholders’ shared motivation (researchers, practitioners, and local 
communities) to address a local priority. Other facilitators identified included stakeholders 
respecting each other’s unique knowledge and expertise (‘equality’ and respect), to enable 
mutual knowledge exchange and capacity building to identify solutions.  For example, in 
TAPPC, I observed that the common priority in exploring how to effectively address the 
rising NCD burden with limited resources enabled a constructive dialogue between policy 
makers in Treasury, health departments, health economists, health services researchers and 
insurance industries. This process of co-production provided the greater insights of the 
context (e.g. institutional imperatives, political considerations) which decision makers face, 
and how economic evidence generated could better suit their needs. Similar principles such 
as active end-user participation, facilitative leadership, equality amongst all stakeholders, 
and acknowledging that they can do more together (i.e. reciprocity and mutuality) have 
been reported in the literature to be the ‘active mechanisms’ of effective co-production. 
(12-14, 26, 27) (1, 2)  
Barriers to co-production 
However, I also observed that there were significant challenges in the implementation of 
such relational principles and values when the collaboration consist of stakeholders from 
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different disciplinary, cultural and social backgrounds.  For example, the Indigenous 
research fellows in the Kanyini Vascular Collaboration shared their difficulties in 
‘researching’ their own community and ‘over-promising’ the impact of their proposed 
research. They described how “We remained anxious about our ability to do justice to the 
stories with which people had entrusted us. We feared that, as Indigenous people working 
for major research institutes, we might interpret people’s experience as the white fellas 
expected us to.” (28) (1) The established relationships between all team members, and the 
leadership of a senior Aboriginal academic enabled such open communication in a ‘safe 
space’, (28) facilitated the critical discussions to address such concerns. (29) Similarly, for 
the ATTEND, the Indian neurologist had to have extensive discussions with the Indian 
research ethics committee, to be finally given permission for the conduct of the ATTEND 
trial. This was because the ATTEND RCT was mistakenly perceived initially as a ‘foreign’ 
driven research agenda due to the overseas funding and international collaborators. This led 
to a significant delay to the start of the trial. (2)  
Anticipate additional time, resources required for effective co-production 
Therefore, to enable effective co-production of evidence with end-users- funding bodies 
and researchers have to recognise and plan for the additional time, personnel and resources 
needed to build strong and respectful relationships through community consultation and 
effective communication. (1, 30, 31)  From our experience, supporting research through 
structured processes will facilitate communication and co-production. This includes for 
example strong project management, regular updates facilitated by a core group, and the 
use of staged research processes such as focus groups (facilitated by the PE objectives) with 
stakeholders where concerns can be addressed and processes altered as required.  
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In addition, funding research infrastructure (including time, and personnel) would be 
beneficial due to the competing service delivery requirements while research is being 
conducted. (1, 2) In the Kanyini GAP PE, we found that despite strong community and 
Indigenous health service support, major investments in time and resources were needed 
during Kanyini GAP to ensure successful implementation and minimal disruption to already 
overstretched, routine services. (1)  
Benefits of investment into research infrastructure for ongoing co-production  
Importantly, investment in practice-based research infrastructure encouraged future 
ongoing research. For example, an Indian stroke research network (INSTRUcT) was formed 
as a direct result of the successful conduct of the ATTEND trial. The INSTRUcT network was 
established to address local research priorities and improve service delivery through mutual 
knowledge exchange. (2)  Similarly, the Kanyini Vascular Collaboration and TAPPC have 
successfully received ongoing funding, for co-production with end users’ (with local 
Aboriginal community health services, and policy makers respectively) to generate 
contextually relevant evidence. Therefore, to sustain locally driven and relevant research, it 
will be strategic to capitalise on existing network and infrastructure formed from individual 
project research funding.  Findings from PEs of individual projects can inform future 
research priorities and facilitate an iterative stakeholder (‘ground-up’ and top-down’) co-
production of intervention theory to address NCDs. 
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 STRENGTHS AND LIMITATIONS  
1) Appraisal of PE framework 
To inform the conduct of future PEs, I reflected on the thesis and appraised the ATTEND PE 
framework’s strengths and limitations based on criteria of coherence/ completeness, 
applicability, usefulness and ease of application. (32) Box 1 provides further details, 
summarises my reflections, and implications for future PEs.    
Completeness and internal coherence? Intervention theory and context 
In ATTEND, I described the intervention theory through explicitly stating the broader 
contextual assumptions (e.g. lack of access), and the hypothesised intervention mechanisms 
to address them (e.g. training family carers can provide greater access to rehabilitation). I 
found this useful in guiding the analysis of a huge dataset, in explaining the variation of 
outcomes. However, I remain uncertain as to what is a meaningful level of detail that should 
be reported.     
Five criteria from a pilot study to assess global health interventions such that the evidence 
generated is relevant for global health policy makers, seems to provide some clarity, and 
resonates with the findings of this thesis. (33, 34) The criteria include: intervention source 
(i.e. locally vs. externally driven), intervention theory (i.e. hypothesis of how it addresses the 
problem), rationale for the components (i.e. existing evidence), and a detailed description of 
the intervention as implemented (e.g. any adjustments, similar to TIDieR), and costs 
associated with implementation. For example, reporting the ‘intervention source’ is 
important because of the need for locally driven research to ensure better intervention fit 
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and its sustainability. Therefore, for future PEs, it would be helpful to test the inclusion of 
these criteria within the PE framework.    
As noted in Chapter 2, the reporting of contextual factors in published PEs has been 
inconsistent, and guidance that is more explicit is needed on top of the MRC guidance and 
PE framework. In Kanyini GAP and ATTEND, I had categorised context as micro to macro 
level factors to aid data collection and analysis. In Chapter 2, key questions are presented 
(i.e. about intervention fit, roles and responsibilities and health system structures) that will 
be helpful to examine context in detail.  Therefore, for future PEs, it would be helpful to 
include the use of a standardised template with key questions to facilitate a systematic 
examination of micro to macro contextual factors.  
Advance theory?  Development of intervention theory with stakeholders 
In my application of the UK MRC PE guidance for health systems research, I found that this 
guidance has similarities to other implementation frameworks with the emphasis of a 
cyclical feedback loop, early and ongoing stakeholder engagement to better inform 
intervention theory and implementation. (22, 35, 36)  Being explicit about the intervention 
theory from the start enables an iterative process i.e. an ongoing modification of 
intervention theory according to documented outcomes as the study progresses. This could 
facilitate a more nuanced understanding of for whom, how and why in different contexts an 
intervention is effective, beyond the binary outcome of ‘is this effective?’  
Applicability?  Examination of Context 
A key strength of the PE framework is exploring the interaction of the complex intervention 
with contextual factors. (37) Such evidence is needed to inform decision makers for whom, 
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how and why an intervention is suited for. By examining the micro to macro context, other 
gaps in care can be identified and inform future research priorities. For example, the PE of 
the ATTEND trial highlighted how policy level factors such as the health financing structures 
significantly impacts on patients’ out of pocket costs; and is key to the impact and 
sustainability of the new model of care. These findings imply that there is need to review 
current funding policies to identify and implement funding models necessary to provide 
affordable care. Therefore, evaluating access and the policies underpinning service delivery 
and financing structures provide additional context. (38) However, such data collection (e.g. 
individual-level health care use) can be highly resource intensive, which may not always be 
feasible. (39)  Streamlining and combining PE data collection with existing systems where 
possible may be beneficial.  This would provide more timely data collection for a more 
responsive health system.(3)  
User friendliness?  Limitations of my approach, future research needed 
In my experience with the ATTEND PE and the systematic review, I have found the MRC 
guidance and the modified PE framework to be ‘user friendly’. I have learnt and built on my 
experiences in the use of Realist principles firstly as a tool to pull the thematic findings from 
the Kanyini GAP PE into a coherent narrative. This experience reinforced to me the benefits 
of using the Realist principles in the synthesis of the findings. Therefore, I was keen to use 
the MRC framework which is heavily influenced by the Realist principles for the ATTEND 
process evaluation. I found that context-mechanism-outcome configuration provided a 
useful and adaptive framework for the systematic examination of our contextual 
assumptions and hypothesised causal mechanisms to provide plausible explanations for the 
variations in the trial outcomes. 
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Assessment criteria 
 
Findings from the thesis Implications  
Completeness and coherence 
of framework 
i.e. Are definitions clear? Is the 
framework comprehensive? 
Systematic review: Ambiguity 
in the reporting of context and 
intervention theory.  
ATTEND: Initial difficulty in 
describing the intervention 
theory. A useful strategy was 
describing the contextual 
assumption that the 
intervention specifically 
addresses. Nevertheless, still 
uncertain about the level of 
detail to report on.  
 
Use of PHC template from 
Chapter 2.  
 
Incorporate contextual 
assumptions and intervention 
components in the description 
of the intervention 
 
Future research to test the 
inclusion of other criteria such 
as source, details of 
implementation and costs.  
Development and 
advancement of theory 
i.e. Is the framework 
compatible with existing 
theories, and does it advance 
theories? Does it show the 
relationship between 
components of the 
frameworks? 
Systematic review: PE 
framework encourages the use 
of existing theoretical 
frameworks and advancing the 
intervention theory for whom, 
how and when it works.  
ATTEND/KGAP: refined our 
understanding for whom the 
interventions are applicable 
for.  
 
Encourage the use of relevant 
existing theoretical 
frameworks specific to 
research question.  
 
Greater consistency in the 
reporting of hypothesised 
intervention theory is needed 
in PEs.  
Applicability 
i.e. Can the framework be 
applied to different types of 
interventions? Can the 
framework be applied to 
systematic reviews and 
different study designs? Does 
the framework portray 
complexity?  
Systematic review: 
Successfully applied to the 
synthesis of different types of 
primary care interventions. 
 
ATTEND/KGAP: applied to 
different interventions and 
portrays micro to macro level 
factors as seen in Table 1.  
Encourage the use of the PE 
framework outside the field of 
NCDs.  
 
Data collection can be 
resource intensive, 
streamlining and combining PE 
data collection with existing 
systems where possible may 
be beneficial.   
 
User-friendliness 
i.e. Can the framework be 
applied feasibly and easily? 
 
It has been applied in this 
thesis and in other projects. 
Future research documenting 
researchers’ collective 
experiences of the MRC PE 
framework needed. 
 
Future research to investigate 
if the PE framework can be a 
useful tool in the co-
production of evidence 
through an iterative approach. 
 
Abbreviations: ATTEND: Family-led rehabilitation post stroke in India randomised controlled trial ; KGAP: 
Kanyini-Guidelines Adherence with the Polypill randomised controlled trial; MRC: Medical Research Council; 
NCD: Non-communicable diseases; PE: Process Evaluations; PHC: Primary health care. 
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 I found that the PE framework seemed to provide an intuitive approach to investigate 
different types of complex interventions and study designs, as it has been easily adapted to 
other projects that I have been involved in (e.g. implementation studies, cluster RCTs). 
Future research documenting researchers’ collective experiences of the MRC PE framework 
will further ascertain its’ user-friendliness and advance its’ methodology.  
A limitation of this body of work is that while I highlighted the role of PE in formative work, 
this was not part of the case studies in Chapters 3 and 4 due to the timing of the PEs. Future 
research is needed to determine whether an iterative approach using this proposed PE 
framework to develop and intelligently adapt interventions over time would produce 
greater impact on practice and policy.  
2) Reflexivity 
As stated in the preface, through my previous experiences, I have an underlying assumption 
that primary health care which is affordable, accessible and of high quality is necessary to 
reduce health inequity and inequalities. Therefore, a limitation of this thesis is that this 
assumption may potentially bias my interpretation of the interviews. To mitigate this, there 
has been a strong emphasis on reflexivity by all PE team members in the conduct of the 
interviews and analysis. Another strategy to minimise such bias has been having another 
researcher to code and analyse the interviews together with, and critically assess each 
other’s interpretation prior to knowing the trial results.  
However, my previous clinical experiences also provide a deeper appreciation of the 
complexities of health systems research and the importance of ‘context.’ For example, when 
working at the HIV clinic in Uganda, I asked that a patient have an electrocardiogram done, 
not realising the impact of the significant out-of-pocket costs that resulted for the family. 
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This oversight was because I was used to ordering such investigations in the context of 
Australian public hospitals, where such costs are covered fully by government 
reimbursements. It was that informative experience among others, which influenced me to 
explore the impact of costs in PEs.   
I acknowledge that I am from a different cultural, socio-economic and professional 
background from the study participants, which may influence my interpretation of the 
interviews. For the PE of Kanyini GAP, I am heavily indebted to the Indigenous research 
fellows who welcomed me into their communities and guided me to conduct the research in 
a culturally safe manner, and an Indigenous researcher who provided the much-needed 
confirmation of our analysis. Similarly, for the PE of ATTEND, the local Indian staff were 
essential in checking my underlying assumptions, and in providing the critical triangulation 
of their assessment of the PE findings.  For the TAPPC qualitative study, I found that my 
‘outsider’ perspective (i.e. not being a policy maker, or health economist) was valuable. It 
enabled me to have a non-biased approach (i.e. about the value of economic evaluations) in 
aligning both the perspectives of the policy makers and health economists in the synthesis 
and write up of the manuscript.  
3) Key strengths of the thesis 
First, that the overall findings are based on primary data from all levels of stakeholders 
(consumers, practitioners and policy makers) to triangulate and inform the overall theme 
that both top-down and bottom- up initiatives are concurrently required for research to 
have impact in practice and policy. Second, is the unique benefit of hindsight over time as to 
the longer- term impact and limitations of collaborative research beyond the funding of an 
individual research project. Third, is to be able to critically appraisal the MRC framework 
144
based on the findings of the systematic review and strengths and limitations of the Kanyini 
GAP and ATTEND case studies. 
CONCLUSION 
In the thesis I demonstrate that PEs are needed to explore for whom, how and why a 
complex intervention has an impact- and in doing so, help to strengthen health systems. 
This is in the context of a rising global NCD burden due to complex proximal and distal 
determinants. I found that to effectively address NCDs, ‘ground-up’ approaches alone are 
not sufficient and concurrent ‘top-down’ approaches are needed. This requires greater co-
production of evidence with the breadth of stakeholders (in addition to patients and 
practitioners) involved in the prevention of NCDs. Policy makers and funders have to be 
engaged from the onset of research to ensure health system barriers (such as financing 
structures, health workforce, costs of medications) can be overcome. However, to 
effectively co-produce high quality evidence, significant investment is required. This includes 
investment in practice-based research infrastructure, time, capacity building and 
recognising the time and efforts needed to build critical relationships between stakeholders.   
PEs with its focus on iterative stakeholder input to develop a clear intervention theory 
within the local context can be a useful tool for the effective co-production of locally 
relevant evidence.  Reflecting on the application of the MRC PE framework through the 
systematic review and the ATTEND PE, I found that its strengths are that it advances theory, 
is applicable and is ‘user friendly’. The micro to macro contextual findings can also inform 
future research priorities, and improve the health system through capitalising on research 
networks formed. (13, 40) However, to further improve on this PE framework and make it 
more complete and internally coherent- there needs to be greater clarity in definitions and 
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reporting of context and intervention theory. Such modifications should improve the 
transferability of interventions and promote a more systematic examination of proximal and 
distal contextual factors.  
Future research should include greater emphasis on formative and developmental work, to 
ensure that the intervention meets local needs, and minimise implementation failure due to 
unanticipated health system factors. I envision that the continual use of PE will strengthen 
health systems through facilitating co-production of much needed patient-centred complex 
interventions, and using the intelligence gained from such evaluations to enable an ongoing 
process of intervention improvement. As the global community continues to tackle chronic 
health conditions with complex holistic solutions using implementation science, it is likely 
that the demand for innovative health system research using co-production and iterative 
evaluations (such as PEs alongside pragmatic trials), will increase. This will enable effective 
complex interventions to be sustainably implemented- hopefully making small but essential 
steps in strengthening the local health system such that health care is affordable, accessible 
and of high quality for all.   
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APPENDIX 2 
 
Appendix Overview 
This appendix comprises of 3 publications from the Kanyini Vascular Collaboration (KVC) 
titled: (1) Facilitating engagement through strong relationships between primary healthcare 
and Aboriginal and Torres Strait Islander peoples. (2) Effectiveness of chronic care models: 
opportunities for improving healthcare practice and health outcomes: a systematic review. 
(3) Factors influencing the implementation of chronic care models: A systematic literature 
review. 
KVC conducted a program of research which included a large qualitative study across 
Aboriginal community health services in Australia, and a systematic review of chronic care 
models of care. The qualitative study aimed to understand what an ideal health system 
would look like, through the perspectives of Indigenous community participants and health 
practitioners. The first manuscript reports on the health system factors affecting 
engagement with Aboriginal and Torres Strait Islander peoples.  The second and third 
manuscript reports on the effectiveness, and the implementation barriers and facilitators of 
chronic care models.  
Authors’ Contributions:  
Qualitative study:  AC, AB conceived the idea for the study, and obtained funding. AC, AB, 
JB, JDVries, BF, SI, RM, PS, BR, ST, HL, DP conducted the interviews, and contributed to the 
analysis. All authors provided critical input in the analysis, synthesis of the findings and 
interpretation. CD drafted the manuscript, and its revisions with input from other authors.   
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Systematic review: CD participated in the design of the study, the literature search, 
assessment of quality and bias, extraction of findings and drafting the manuscript. JB 
participated in the extraction of findings and drafting the manuscript. HL and MT 
participated in the literature search, assessment of quality and bias and extraction of 
findings. SP participated in the design of the study, the literature search, assessment of 
quality and bias, and extraction of findings. AB participated in the design of the study. All 
authors read and approved the final manuscript. 
Publications details:  
Davy C, Cass A, Brady J, DeVries J, Fewquandie B, Ingram S..Liu H et al. Facilitating engagement through 
strong relationships between primary healthcare and Aboriginal and Torres Strait Islander peoples. 
Australian and New Zealand journal of public health. 2016 
Davy C, Bleasel J, Liu H, Tchan M, Ponniah S, Brown A. Effectiveness of chronic care models: 
opportunities for improving healthcare practice and health outcomes: a systematic review. BMC 
Health Serv Res. 2015 May 10;15(1):194.  
Davy C, Bleasel J, Liu H, Tchan M, Ponniah S, Brown A. Factors influencing the implementation of 
chronic care models: A systematic literature review. BMC family practice. 2015 
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There are significant disparities in health status and life expectancy between Aboriginal and Torres Strait Islander 
peoples and non-Indigenous Australians. 
Chronic conditions account for the bulk of 
these disparities.1 Cardiovascular disease is 
the single leading cause of death,2 diabetes 
is at epidemic levels,3 and rates of chronic 
kidney disease are also disproportionately 
high compared to other Australians.4 Given 
the high prevalence of chronic disease, 
it is of concern that access to and use of 
primary healthcare services by Aboriginal 
and Torres Strait Islander Australians is 
often far lower than would be expected.5-7 
Furthermore, as chronic disease is, by 
definition, often a permanent condition in 
a person’s life,8 sustained engagement with 
primary healthcare is important for long term 
management and wellbeing in the face of 
illness. Rates of sustained engagement with 
healthcare services over time are, however, 
also far lower than would be expected 
given the high burden of chronic disease 
experienced by Aboriginal and Torres Strait 
Islander peoples.5
A number of researchers have investigated 
the reasons why engagement rates are 
suboptimal. Some of the broad reasons 
Aboriginal and Torres Strait Islander peoples 
are dissuaded from engaging with care 
include the lack of culturally appropriate 
healthcare services, racist or discriminative 
behaviour by healthcare staff, the cost 
of seeking healthcare and a lack of time 
or ability to attend appointments.9,10 
Aboriginal and Torres Strait Islander peoples 
in remote communities may be particularly 
disadvantaged due to the lack of availability 
of a broad range of healthcare services.11,12 
Where services do exist, it is often difficult to 
build lasting relationships with healthcare 
providers due to the high turnover of staff.13 
According to the 2008 National Aboriginal 
and Torres Strait Islander Social Survey, 
almost 30% of Aboriginal and Torres Strait 
Islander peoples over the age of 15 living in 
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Abstract
Objective: Given the high prevalence of chronic disease, it is of concern that access to and 
sustained engagement with primary healthcare services by Aboriginal and Torres Strait Islander 
Australians is often far lower than would be expected. This study sought to explore ways in 
which relationships can support sustained engagement with healthcare services.
Methods: Semi-structured interviews were conducted with 126 Aboriginal and Torres 
Strait Islander participants with and without chronic disease and 97 Aboriginal and Torres 
Strait Islander and non-Indigenous healthcare providers, healthcare service managers or 
administrative staff.
Results: Our findings indicate that when faced with acute health issues, Aboriginal and Torres 
Strait Islander participants did prioritise care, provided that the service was both physically and 
emotionally welcoming. Trustworthiness of healthcare providers and strong relationships with 
patients were the most important factors for encouraging sustained engagement overtime.
Conclusions: Responsibility for sustaining relationships does not rest solely with Aboriginal and 
Torres Strait Islander patients. Rather, healthcare providers need to commit to the process of 
building and maintaining relationships.
Implications: First and foremost healthcare providers should take time to establish and then 
maintain relationships. Healthcare services can also contribute by ensuring facilities are 
welcoming for Aboriginal and Torres Strait Islander peoples.
Key words: primary health care, Indigenous health, chronic disease, service delivery
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urban environments have also experienced 
problems accessing healthcare services.14
Some researchers have suggested various 
ways in which access could be better 
facilitated. For example, ensuring that 
Aboriginal and Torres Strait Islander 
peoples are employed within healthcare 
services can enhance relationships with 
patients and promote access.15 Creating a 
healthcare service that belongs to and is 
part of the community also improves access 
to healthcare services for Aboriginal and 
Torres Strait Islander peoples.16 For remote 
communities in particular, outreach services 
through which care is provided within the 
community setting have also been shown to 
improve rates of engagement with patients.17 
Few researchers, however, have specifically 
considered the question of how to support 
sustained engagement within this context.
This paper draws on findings from the Kanyini 
Qualitative Study (KQS) to identify how 
sustained engagement between Aboriginal 
and Torres Strait Islander peoples and their 
healthcare services can be better supported. 
The KQS is one of a series of discrete yet 
inter-related studies conducted by the 
Kanyini Vascular Collaboration (KVC) team 
(http://www.kvc.org.au/) with Aboriginal 
and Torres Strait Islander communities and 
primary healthcare partners in New South 
Wales, Western Australia, South Australia, 
Queensland, the Northern Territory and 
Australian Capital Territory. 
Methods
Four ethics committees approved the KQS, 
one in Central Australia, one in New South 
Wales and two in Queensland. Five healthcare 
service sites agreed to participate in the 
study. According to the Australian Standard 
Geographical Classification System,18 two 
services were in capital cities (RA1), two 
were in major regional centres (RA2-3), and 
one was in a remote area (RA4). Three of 
the participating healthcare services were 
Aboriginal Community Controlled Health 
Organisations (ACCHOs), and one was 
a government-administered Aboriginal 
healthcare service. The final site had services 
provided by a number of government 
healthcare services as well as four ACCHOs. 
Our research team comprised a group of 
geographically dispersed Aboriginal and 
Torres Strait Islander and non-Indigenous 
researchers, many of whom were also 
clinicians. The team also included five 
Aboriginal and Torres Strait Islander Research 
Fellows (ARFs), four of whom were embedded 
within KVC partner healthcare services as half-
time Aboriginal Health Workers whilst also 
working half-time on this study. The fifth ARF 
was employed within a collaborating research 
organisation but had been an Aboriginal 
Health Worker prior to participating in the 
research. Our team also included a further 
five research staff who had experience 
in undertaking qualitative research. One 
researcher identified as an Aboriginal 
Australian while the remaining four were from 
a variety of cultural backgrounds.
From July 2008 to February 2010, the ARFs 
and the qualitative researchers within our 
research team conducted semi-structured 
interviews with 223 participants (Table 1). Of 
the 126 Aboriginal and Torres Strait Islander 
community participants, 111 identified as 
Aboriginal, 10 as Torres Strait Islander and 
five as both Aboriginal and Torres Strait 
Islander. A further 97 participants who were 
Aboriginal and Torres Strait Islander or non-
Indigenous healthcare providers, healthcare 
service managers or administrative staff 
also participated in the study (Table 2). A 
purposive sampling technique19 was utilised 
in order to gain perspectives from a range of 
both community members living with chronic 
disease and their carers, as well as a variety 
of clinical, administrative and management 
staff working in the services that provided 
care. Community participants were invited 
to participate in the study by the ARF in 
their area, while healthcare providers were 
invited to participate at opportune moments 
including during staff meetings. While written 
informed consent was obtained from all 
participants, records were not kept in relation 
to the number of community members or 
staff who chose not to participate. Interview 
guides were developed and piloted prior to 
the first interview. Separate guides – one for 
community members and one for healthcare 
professionals – contained on an average of 13 
questions incorporating suggested ‘prompts’. 
Our entire research team was involved in 
data analysis which began soon after the 
initial interviews were completed. Although 
the qualitative analysis computer software 
program NVivo 8 was used to assist with 
organisation of data in subsequent stages 
of our analytic process, initially a ‘manual’ 
approach was used to inductively code 
interview data to emergent themes, in 
order to establish the underlying principles 
of qualitative data analysis for team 
members not familiar with this research 
method. After reading and re-reading 
the interview transcripts, themes were 
Table 1: Summary characteristics of all study participants.
 Aboriginal and Torres Strait 
Islander participants (n=126)
Healthcare providers 
(n= 97)
Total participants 
(n=223)
Female 71 (56%) 62 (64%) 133 (60%)
Male 55 (44%) 35 (36%) 90 (40%)
Urban 43 (34%) 30 (31%) 73 (33 %)
Regional 27 (21%) 38 (39%) 65 (29%)
Remote/Very Remote 56 (45%) 29 (30%) 85 (38%)
Table 2: Summary of healthcare provider participant characteristics.
Aboriginal Identity Type of Healthcare Service
Healthcare Provider Participants No. Aboriginal and Torres 
Strait Islander
Non-
Indigenous
ACCHOa Govb NGOc Private 
Sector
Aboriginal Health Worker 17 17 - 16 1 -
Nurse 29 4 25 13 14 2
Doctor 10 - 10 8 1 1
Allied Health 6 1 5 5 1 -
Registered Nurse manager 4 1 3 2 2 -
General Practitioner manager 6 2 4 4 2 -
Aboriginal Healthcare Worker manager 3 3 - 1 2 -
Non-clinical manager 5 3 2 3 2 -
Board member 2 2 - 2 - -
Chief Executive Officer 4 3 1 4 - -
Administrative staff (receptionist, driver, etc.) 9 7 2 6 3 -
Healthcare adviser 2 - 2 - - 2
TOTAL 97 43 54 64 28 5
a: Aboriginal Community Controlled Health Organisation
b: Government-run Service
c: Non-Government Organisation
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identified which then became the subject of 
multiple and enthusiastic team discussions. 
These discussions were integral to our 
iterative analytic approach and, critically 
given the nature of this research, allowed 
team members to compare perspectives, 
interpretations and understandings. 
Commensurate with interviewers’ skills and 
experience, themes highlighted during these 
discussions were explored during subsequent 
interviews across the sites. Although at 
the outset informed by grounded theory 
techniques,20 our analytic process became 
subject to real-world challenges, in particular 
resourcing and time constraints, which arose 
from conducting a large, complex, multi-
site study with a geographically-dispersed 
research team. Analysis and interpretation 
of data at the between-sites level was 
undertaken from May 2012 to July 2013. 
Findings from this between-site analysis are 
presented and discussed below.
Results
Our findings indicate that a number of 
factors sustained engagement between 
Aboriginal and Torres Strait Islander peoples 
and their healthcare services. We also found 
that competing demands and the stress 
associated with being diagnosed with chronic 
disease meant that care was not always a 
priority. However, when faced with acute 
health issues, Aboriginal and Torres Strait 
Islander peoples did prioritise care if the 
healthcare service was physically, relationally 
and emotionally welcoming. In particular, 
healthcare providers who were able to build 
strong and trusting relationships and who 
cared for more than just the physical needs 
of their patients encouraged care seeking. 
While strong relationships were also one of 
the keys to sustaining engagement, when 
relationships broke down as a result of 
discrimination or distrust, Aboriginal and 
Torres Strait Islander peoples were likely to 
disengage from healthcare services. This in 
turn impacted on future engagement.
Healthcare – ‘Health’ was not always 
a priority
Our study identified a number of reasons 
why Aboriginal and Torres Strait Islander 
community members did not always engage 
with primary healthcare services. In many 
cases these were related to the number of 
competing demands that Aboriginal and 
Torres Straits Islander peoples negotiate on a 
daily basis. It appeared that there was rarely 
just one problem, but a whole range of needs 
that required attention before people could 
think about seeking care for themselves.
Because sometimes people miss out on their 
appointments because they don’t have cars, 
they don’t have money because they’re all 
on welfare. And then there’s a lot of children 
in the house, you’ve got to find a babysitter, 
you’ve got to take some kids with you, and 
there’s a problem, and a lot of our people 
miss out on appointments that are very, 
very vital to their health issues, and they’ve 
got to go ...we definitely need transport for 
our customers. (Aboriginal, Community 
participant, Female, Urban)
For those living in remote areas, maintaining 
engagement with required treatments 
often involved an inability to participate in 
cultural activities, moving away from family 
and community and dislocation from their 
Country. The term Country is used in relation 
to the spiritual connections that Aboriginal 
and Torres Strait Islander feel with the land. 
Many community participants found this 
separation unsustainable, to the extent that 
some prioritised their connections with 
family and community over opportunities to 
prolong their life.
 People get homesick when they go into 
town to stay on the [dialysis] machines. They 
miss their bush food, they miss everything. 
Even their family members, they’ve got to 
like be split apart... Some people I know 
from [community names withheld] they 
just gave up hope and just came back to 
the communities and just long stay with 
the families, they just passed away...They 
miss out on a lot. (Aboriginal, Community 
participant, Male, Very Remote)
As perceived by a healthcare provider 
participant, even when treatment was 
available closer to home, it did not necessarily 
mean that healthcare providers understood 
either the client or the social and kinship 
contexts in which they lived.
It’s also just the momentum of the system to 
get the most overwhelmed person and put 
them in the most overwhelming situation by 
virtue of the fact that none of the Australian 
graduates want to work in this little Aboriginal 
community “Well we’ll just get someone from 
Nigeria and just plonk them there without 
any understanding of Medicare, Australian 
medications, the prescribing system, 
the health care system, with minimum 
orientation and no cultural orientation”. (Non-
Indigenous, Practitioner, Female, Remote) 
The possibility of being diagnosed with 
chronic disease was so stressful for some that 
they chose not to engage with services. 
I don’t know, I don’t want to know what’s 
wrong with me half the time, I’m getting 
around fine and that, you know … you 
kind of get around fine and then go to the 
doctors and get a test done … they find 
what’s wrong with you … and then you 
start stressing out about it … that’s the 
way I am, I think what you don’t know, you 
know, whereas [my husband] he’s different 
… he’s got to go and … I even said to him 
if I get taken to hospital and they tell me I 
haven’t got long to live … don’t tell me … I 
don’t want to know … I just really stress out 
… (Aboriginal, Community participant, 
Female, Urban)
Reprioritising – Opportunities to 
engage
Until the seriousness of their condition 
became undeniable, for many community 
participants leading busy lives, healthcare 
had not been a major focus.
Yeah, that was me exactly before, I was 
exactly like that [finding it hard to maintain 
motivation to stay healthy]. I’d walk every 
now and again, but it’s not until something 
drastic or dramatic happens to you and 
then it makes you reassess your life and 
then you can see the path you were going 
down. Like when you are sitting in a bed 
and you have got three or four doctors 
doing different things… that’s an eye 
opener, you know. I thought, “Oh, shit I 
was doing something wrong”. (Aboriginal, 
Community participant, Male, Regional)
In many cases, community participants 
described engaging with healthcare services 
only after acute events such as a heart 
attack. Some were also motivated to engage 
after others in their family or community 
experienced a life-threatening episode. 
[When a bloke I played touch football with] 
had the heart attack it really made me sit 
up and think … we took it for granted, our 
health. We thought we were immortal. We 
could just live forever. But when he had the 
heart attack … I went and got checked up 
… But you know, that was one story where 
what happened to them changed a lot of 
the way people thought … Now men are 
starting to see well, you know, you need to 
look after it [your health] … (Aboriginal, 
Community participant, Male, Urban)
These types of traumatic events often proved 
to be turning points in peoples’ lives. One 
community participant spoke of reassessing 
his life after a sudden heart attack and 
described engaging more regularly with 
healthcare providers, which in turn helped 
him manage his health.
155
538 Australian and New Zealand Journal of Public Health 2016 vol. 40 no. 6
© 2016 Public Health Association of Australia
No I didn’t [have a regular doctor]. You 
know what black guys are like, they don’t 
like seeing doctors … Yeah [since my heart 
attack] I see the doctor quite regularly … it 
makes me feel good every time I go around 
and see the doctor, and [he] checks all my 
weight and everything and my size around 
the waist and it’s all coming down, so that’s 
good … so I was sort of getting in tune 
with my body. (Aboriginal, Community 
participant, Male, Regional)
Some healthcare provider participants 
attributed the increasing awareness of 
the impact of chronic disease to direct 
experiences within the patient’s family and 
community, especially when “[t]hey can see 
there’re a lot of people that are dying young 
around them.”(Aboriginal, Practitioner, Female, 
Regional). These providers reaffirmed the 
community perspective that life-threatening 
events frequently proved the catalyst to long-
term engagement.
One of those guys…he’s just such a great 
success story in that…I mean it’s terrible he 
had his big scare and went into hospital and 
nearly died, but he’s quit smoking and he’s 
just taken his life into his hands as a result, 
and he’s so happy … And it’s really lovely 
to see him thriving. (Non-Indigenous, 
Practitioner, Female, Regional)
Welcoming spaces – Continued 
engagement
While acute events may motivate people 
to engage with care, both community and 
provider participants believed that having the 
right type of healthcare service in place was 
crucial to supporting continued engagement. 
Welcoming spaces where community 
members felt comfortable, accepted, and 
able to build strong and trusting relationships 
with healthcare providers encouraged 
people to remain engaged with care. This 
‘welcoming space’ did not just represent 
the physical place but also encompassed 
emotional (feeling supported and cared for), 
and relational (the quality of relationships 
between patients and providers) elements. 
One of the most important aspects of a 
welcoming space was the presence of 
Aboriginal and Torres Strait Islander staff.
Community members needed to feel the 
healthcare service was “their place” (Non-
Indigenous, Manager, Female, Regional) and 
noted the importance of feeling well treated. 
I can only answer you for myself, but you 
could ask any other Aboriginal person that 
wants to be cared for and improve their 
health and to stay healthy, they’ll tell you 
that the Doctors that work for the Aboriginal 
Medical Service, to my way of thinking and 
talking is they’re good people. They really 
care for the Aboriginal people. And [name 
withheld] I’m not only saying that because 
I’m a regular and we know one another, I’m 
saying this from my heart and I know the 
people who attend this place and come 
here for their check-ups. They’re very pleased 
with how they’re treated. (Aboriginal, 
Community participant, Male, Urban)
The use of health posters depicting 
Aboriginal and Torres Strait Islander people, 
as well as paintings and other artefacts that 
demonstrate the commitment of staff to 
providing culturally appropriate healthcare, 
were also considered to be important.
… It’s right from when you walk through 
the door, brother. It’s when you walk in, 
you see the paintings up there, you see 
the artefacts, you know. All that sort of 
stuff makes you feel welcome and makes 
you want to sit in the waiting room for an 
hour to wait … half an hour, five minutes, 
whatever. Because you feel that, you know, 
you’re okay there. Yeah. And the ladies in 
the front, they’re lovely. They’re all good. 
Really good crew. I don’t think I’ve had a 
bad experience over there … (Aboriginal, 
Community participant, Female, Urban)
Aboriginal and Torres Strait Islander staff 
– whether doctors, nurses, healthcare 
workers or administration officers – were 
key to creating the much needed feelings of 
belonging and acceptance. 
So, it’s very important to have your own 
people and you feel open to talk to, that sort 
of stuff. You go to a non-Indigenous doctor 
and they look at you sometimes indifferent, 
and you can’t be sort of more open to them, 
sort of thing. (Aboriginal, Community 
participant, Male, Urban) 
Sustained engagement wasn’t just about 
Aboriginal and Torres Strait Islander staff 
however. Strong relationships with all 
healthcare staff were fundamental to 
community members’ long-term engagement 
with a healthcare service.
You fellas in there [staff in the health centre] 
give us, the community members, a reason 
to come in. I don’t know whether youse even 
know that. But because of the way you fellas 
handle all your responsibilities, you make us 
want to come there. There are lots of places 
in our state, in our nation, where it’s because 
of the people within the organisation that 
people don’t attend … You look at those 
organisations where people aren’t going, 
why is that? (Aboriginal, Community 
participant, Female, Urban)
Relationships with healthcare staff were 
considered by many participants to be just 
as - if not more - important than the type of 
building or the quality of medical care on 
offer. When healthcare providers understood 
patients’ care needs and demonstrated 
genuine interest in the peoples’ lives, 
community participants reported feeling 
welcomed, respected and accepted.
They’re [medical staff ] caring, first of all. 
They care what’s going on. Like everything. 
Like they’ll ask, first of all health and they 
ask about home. And then with me, like I 
said, like time is the biggest thing that I don’t 
have and they just take the time out just 
to say, something nice, like you know, like 
I’m anaemic so my doctor will look up [my 
blood results] and say, “Oh you’re getting 
it up there, yeah very good woo hoo!” And 
I’ll feel better just walking in, I didn’t come 
in to see you about that, but that’s good, 
like a help for me. (Aboriginal, Community 
participant, Female, Urban) 
Closely aligned with building relationships 
were the provider’s ability to be flexible 
and their commitment to maintaining a 
connection with patients. Providers who 
focused on taking “a motivational interviewing 
approach” (Non-Indigenous, Manager, 
Male, Urban), treating each encounter as 
an opportunity to help support behavior 
change, if not on that day, then at another 
time in the future, believed that this was 
particularly successful in supporting 
sustained engagement. Community 
participants also emphasised the need 
to achieve understanding within care 
encounters. 
I think a good doctor and a good nurse is 
someone that actually talks to you and 
not talk at you … not just babble on and 
keep talking and you don’t have a clue 
and they’re not going to stop and help 
you understand. (Aboriginal, Community 
participant, Female, Remote) 
Services that were able to provide this more 
holistic approach to care were highly valued.
Yeah. It’s the holistic approach over here. 
It’s the whole bundle. You know, it’s the 
environment, it’s the people, it’s the care, 
you know, the service, right through to, 
the whole lot. From admin right through 
to your doctors and where you’re sitting. 
It’s really good. (AboriginaI, Community 
participant, Female, Urban)
Healthcare services that went beyond merely 
providing medical treatment to become part 
of the community were held in particularly 
high regard. This, in turn, encouraged 
sustained engagement.
Davy et al. Article
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They’ve got a high-quality preschool next 
door. They charge us bugger all compared to 
the rest of them. They pick them up and drop 
them off. They’ll pick me up. They’ll look after 
me. They look after my teeth. They look after 
me. If I need a lift, no worries. They’ll come 
and pick me up. They’ll actually be concerned. 
Like, I’ve got more people caring about me 
here than I’ve had in my own neighbourhood 
in the last five years, you know…And this 
year, I have been using them. And I’ve been 
a lot better off. (Aboriginal, Community 
participant, Male, Urban)
Hindering engagement – Distrust and 
discrimination
Often trust between Aboriginal and Torres 
Strait Islander communities and their 
healthcare services did not come easily, with 
both clients and providers having to “work 
hard for it” (Aboriginal, Practitioner, Female, 
Regional). Interruptions to patient-provider 
relationships occurred as a result of a breach 
of this trust, which then needed to be 
regained over time in order to re-establish the 
same level of engagement.
As workers, if we break our connection 
with people, we can go back to ‘delicate’ 
[engagement] from ‘robust’ very easily. 
That just because we think we’ve achieved a 
robust relationship, if we then disengage for 
any reason … then we actually go back to at 
least ‘delicate’. We don’t remain in the ‘robust’. 
We’ve got to re-earn our ‘robust’ credentials 
… And I think that does show how profoundly 
underlying is the basic distrust, however much 
people may know that they have to rely on 
outside service providers. (Non-Indigenous, 
Practitioner, Female, Remote)
While some people were deterred by the 
stories they heard from others, distrust also 
resulted from firsthand encounters of racism 
or inferior treatment.
… a lot of people didn’t want to go there [the 
local mainstream health service] because 
they felt the place was unfriendly, the staff 
were not friendly towards them and there 
was a lot of attitudes happening, people 
felt they were discriminated against, and 
the place was very sterile … it wasn’t like a, 
it wasn’t a comfortable environment … and 
people spoke … didn’t speak in the way we 
speak … like very abrupt, loud and abrupt, 
communication wasn’t there too, you know? 
Just that lack of understanding in how 
you talk, the tone you use for Indigenous 
people … so there was that, where there 
was no probably no cultural knowledge 
with the staff … Yeah, like discrimination, 
racism, or you know, just ignorance and 
no sensitivity and no understanding of 
Indigenous health issues … (Aboriginal, 
Community participant, Female, Urban)
Community members as well as healthcare 
staff participating in this study dwelt on the 
emotional impact of these situations. Some 
described ‘losing faith’ in healthcare services 
and people walking away from necessary care 
as a result. 
I don’t think the community have a lot of 
faith in mainstream, and I have to admit I’ve 
seen it where I’ve taken a client, or a couple of 
clients, to the hospital, and they’re just treated 
atrociously. And I don’t think it was because 
of their condition … It was because they 
identified as being Aboriginal … one of our 
clients was admitted because he had a heart 
attack, and she [one of our nurses] went in 
to visit him, and she could actually hear the 
nurses in the hallway speaking about him. 
And she walked out and she tore strips off 
them, because they were just so derogatory to 
him. And he ended up getting up and walking 
out. (Aboriginal, Manager, Female, Urban)
Yet, healthcare providers were often 
perplexed and frustrated when patients 
disengaged from care. Some were concerned 
with people’s apparent resistance to 
engaging with care, believing that it was 
about not “being dominated by white people” 
(Non-Indigenous Practitioner, Male, Remote). 
Other providers realised that there may 
be many reasons why people choose to 
disengage and importantly, recognised 
that healthcare services may need to apply 
multiple strategies to support patients to 
remain engaged. 
But when you’ve got people who are clearly 
already disempowered, and disadvantaged, 
to say that they should be taking responsibility 
… “It’s up to them to come into the clinic, and 
if they don’t present, well then that’s their own 
decision”. How can we say that they’ve made 
an informed decision? That’s, you know, 
another ethical question. … And there’s 
absolutely no one strategy … one doesn’t fit 
all sort of sizes. So you’ve got to have a range 
of strategies.(Non-Indigenous, Manager, 
Female, Remote)
Discussion
Our study found that a number of factors 
supported sustained engagement between 
Aboriginal and Torres Strait Islander peoples 
and their healthcare services. These included 
opportunities that arose after life-threatening 
events. Nevertheless, accessing healthcare 
services and remaining engaged in care 
is likely to require more than simply the 
availability of medical facilities in times of 
need. Sustained engagement was most 
likely when community members felt that 
the healthcare service was part of their 
community and where patients could have 
faith in and develop strong relationships with 
healthcare providers. These relationships 
needed time to develop and were built 
on the foundation of trust and respect. 
Importantly, sustaining these relationships 
required flexible approaches to care which 
acknowledged and accounted for competing 
interests, accepting that people may not 
always prioritise their own healthcare needs. 
While Aboriginal and Torres Strait Islander 
staff were more likely to form a strong 
connection with patients,21 participants in 
this study also acknowledged the importance 
of developing relationships with non-
Indigenous healthcare providers.22 Patients 
often found relationships more difficult 
to form with non-Indigenous healthcare 
providers, needing a willingness on the part 
of these providers to understand healthcare 
from the perspective of Aboriginal and Torres 
Strait Islander patients and their broader 
community and kinship contexts.23
Developing these types of relationships 
went well beyond the use of a patient-
centred care approach. Defined as care that 
is “respectful of and responsive to individual 
patient preferences, needs, and values and 
ensuring that patient values guide all clinical 
decisions”,24,p6 patient-centred care does 
little to acknowledge the importance of 
building relationships with the community 
in order to better understand the social and 
cultural context in which the patient lives. 
Examples of tailored services include the use 
of local language wherever possible when 
communicating with patients or providing 
appropriate healthcare facilities and services 
that accommodate cultural sensitivities and 
expectations. The notion of tailored care also 
assists with prospectively planning to meet 
the particular needs of the local population 
rather simply responding to the patients that 
walk through their door.25
Developing and sustaining these types of 
relationships will take time.26 In the context 
of colonial history and perpetual racial 
discrimination experienced by Aboriginal and 
Torres Strait Islander peoples,27,28 healthcare 
providers will need to demonstrate respect 
for their patients, their patients’ family and 
the communities they serve. Community 
members will also need to make time to 
develop trust and faith in their healthcare 
services. Time is also needed to establish 
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effective communication strategies, ensuring 
that healthcare providers understand their 
patients and that patients understand their 
healthcare providers.29,30 Finally, time is 
necessary for healthcare providers to engage 
with and understand the social and cultural 
aspects of the local community in order 
to better understand the needs of their 
patients.31 All are especially important for 
non-Indigenous healthcare providers who 
have little previous knowledge of the social or 
cultural contexts in which they practice. 
Health systems can support or inhibit 
this type of engagement. The strategies 
that systems could employ to support 
healthcare providers include ensuring that 
providers have the time to connect with 
patients, their families and the community;26 
providing cultural safety training and 
ongoing professional development to 
ensure that providers not only understand 
but take responsibility for their own cultural 
impositions to ensure they can provide 
culturally appropriate care to the community 
they serve;30 and designing employment 
contracts that facilitate the flexibility 
necessary for providers to deliver the type 
of care that communities need.32 Healthcare 
services could be better supported with the 
required resources to engage appropriately 
with communities. Employing and providing 
educational and career opportunities 
Aboriginal and Torres Strait Islander staff 
would assist with ensuring that patients feel 
welcomed and comfortable in engaging with 
services.33 
Strengths and limitations
A large number of Aboriginal and Torres Strait 
Islander community members and healthcare 
providers participated in this study. 
Participants came from a mix of remote, 
regional and urban contexts. Healthcare 
providers were drawn from the same 
healthcare centres that provided services 
to the Aboriginal and Torres Strait Islander 
community members who were involved 
in this study. Despite the large number of 
participants and the variety of contexts in 
which the study was conducted, it should not 
be assumed that the findings are necessarily 
transferrable to all primary healthcare 
services. The wide diversity of Aboriginal and 
Torres Strait Islander communities in Australia, 
each with locally specific healthcare and 
community needs, requires a contextualised 
approach to improving healthcare services.
The research team that undertook this 
study comprised a group of geographically 
dispersed Aboriginal and Torres Strait Islander 
and non-Indigenous researchers, many of 
whom were clinicians with medical, nursing 
or health worker qualifications. All of the 
team members brought a wide variety of 
perspectives and understandings to the 
research which further enriched the analysis 
and interpretation of the data collected. 
One of the most important strengths of our 
multicultural, multi-disciplinary research 
team was the ability to listen to and respect 
each other’s point of view and then discuss 
potential solutions until members were in 
agreement with the outcome. In particular, 
this provided an opportunity to discuss 
what was clear (explicit), and also what 
was not (tacit), in the stories being told by 
both community and healthcare provider 
participants.34 We also acknowledge that 
working within this research space was 
not without some costs. The process of 
negotiating the research space35 continued 
throughout analysis and interpretation. 
Considerable effort was therefore made, 
particularly in the early stages of data analysis, 
to create a safe space to jointly exchange, 
consider, discuss and debate perspectives.
Conclusions
The challenge for healthcare providers is 
clear. Improvements in Aboriginal and Torres 
Strait Islander health will not be achieved 
by simply providing ‘more’ services. Instead, 
enhancing and maintaining relationships 
between patients and providers appears to 
be at the heart of the potential for sustained 
engagement. Relationships in turn depend 
on a number of factors associated with both 
the provider and the service. Time to build 
trust and faith in the healthcare provider is 
essential. So too is the need for healthcare 
providers to demonstrate respect for and 
engage with not just patients but also the 
wider community. For healthcare services, 
ensuring that Aboriginal and Torres Strait 
Islander peoples feel welcomed and accepted 
and employing Aboriginal and Torres Strait 
Islander staff will support the development 
of these important relationships. Given that 
chronic disease is a long lasting condition that 
can be managed but rarely cured, sustained 
engagement with appropriate primary 
healthcare services will result in better health 
outcomes for Aboriginal and Torres Strait 
Islander peoples.
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Chronic diseases have a substantial impact on the lives of
people living in both developed and developing countries.
Of the 57 million deaths in 2008, 36 million (63%) were a
direct result of chronic diseases, principally cardiovascular
disease, diabetes, cancer and chronic respiratory diseases.
Nine million of these deaths occurred in people under 60
years of age and ninety per cent of these premature deaths
occurred in low- and middle-income countries [1]. It is
also the case that disadvantaged and marginalised com-
munities in developed countries suffer an increasing bur-
den of chronic disease [2].
As a way of combating this growing health crisis, re-
searchers have attempted to develop comprehensive strat-
egies to manage chronic disease and to deliver improved
chronic disease care. The primary aim of many integrated
care or chronic disease management programs is to re-
duce fragmentation while at the same time improving
health outcomes at an acceptable cost to the healthcare
system [3,4]. Many of the current chronic disease manage-
ment strategies were first identified by MacColl Institute
for Healthcare Innovation at Group Health Cooperative,
commonly referred to as the Wagner chronic care model
(Wagner CCM), which was based on six key elements
[5-7]. These elements focus on mobilising community re-
sources, promoting high quality care, enabling patient
self-management, implementing care consistent with evi-
dence and patient preferences, effectively using patient/
population data, cultural competence, care coordination,
and health promotion [8]. Yet while the broad elements
may be similar to the Wagner CCM developed by the
MacColl Institute for Healthcare Innovation, what consti-
tutes a CCM and how it is implemented and delivered
within healthcare services, has continued to evolve [9,10].
A number of systematic literature reviews have already
focused on which of the elements or combination of ele-
ments included within a CCM were effective in improving
healthcare practice and health outcomes. One of the first
systematic literature reviews to include all six elements
of the Wagner CCM focused on the provision of care
to chronic obstructive pulmonary disease (COPD) [11].
While the review found that the implementation of two or
more elements was likely to reduce healthcare usage by
COPD patients, the authors also identified significant het-
erogeneity between the ways in which each of the ele-
ments were implemented. Another systematic literature
review [12] looked at the association between improved
performance and the implementation of integrated quality
management models which included a CCM. Again, there
was some evidence that implementing interventions based
on a CCM improved performance and health outcomes.
Other systematic reviews have identified small to moder-
ate improvements in health outcomes associated with dia-
betes [13], improved adherence to inhaled corticosteroids161among asthmatics [14], and improvements to mental and
physical health outcomes for patients with mental disor-
ders such as depression [15]. Pasricha et al [16] also
conducted a systematic literature review focusing on ef-
fectiveness of two of the elements included within the
Wagner CCM - decision support and clinical information
systems. These authors found that the implementation of
either or both elements resulted in modest improvements
to care provided for people living with HIV.
These previous systematic reviews have tended to focus
on effectiveness for improving health outcomes. They
have also limited their inclusion criteria to evidence from
randomised [11,14,15] and/or non-randomised trials,
cross sectional studies and cohort studies [13,16]. This
systematic literature review broadens the work of other re-
viewers in two ways. First, it focuses on healthcare practice
as well as the health outcomes associated with implement-
ing a CCM. This is particularly important as the quality of
healthcare practice is a key determinant of health out-
comes for patients [17]. Improvements to healthcare prac-
tice not only benefit the patients in terms of improved
health outcomes but also ensure considerable savings to
the healthcare system [18].
The second feature of this systematic literature review
is that case series and case studies have also been in-
cluded. To our knowledge only one other systematic lit-
erature review has included case studies [12]. While the
main argument for excluding this type of literature is
that they are not of sufficient quality or generalizability,
case studies and case series have been included on the
basis of completeness. Rather than dismissing any study
based on methodology alone, we have instead focused
on presenting information about the quality of these and
other featured studies.
Method
Review objective and questions
The objective of this systematic literature review was to
identify and synthesise relevant international evidence
on the effectiveness of CCMs elements for improving
healthcare practices and health outcomes. The questions
asked by this review were:
1. What elements of a CCM have been implemented
into a PHC setting?
2. Do the identified elements improve healthcare practices
delivered to patients living with chronic disease?
3. Do the identified elements improve the health
outcomes of patients living with chronic disease?
Inclusion criteria
Types of participants
This review considered studies that either focused on
people with or healthcare providers that cared for people
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at least one of the following specific chronic diseases -
cardiovascular disease, chronic kidney disease, chronic
respiratory disease, type 2 diabetes mellitus, depression
and HIV/AID -) in a primary healthcare setting.
Primary healthcare is generally defined as first-contact,
accessible, continued, comprehensive and coordinated
healthcare provided by a single practitioner (e.g. GP, nurse
practitioner) or a multidisciplinary team of professionals
in a community practice. For the purposes of this review
however, primary healthcare is first-contact, accessible,
continued, comprehensive and coordinated care. First-
contact care is accessible at the time of need; on-going
care focuses on the long-term health of a person rather
than the short duration of the disease; comprehensive care
is a range of services appropriate to the common prob-
lems in the respective population and coordination is the
role by which primary care acts to coordinate other spe-
cialists that the patient may need [19]. Primary healthcare
also includes primary care settings that have only one
health professional, i.e. a general practitioner.
Elements of a chronic care model
In order to identify elements that should be included as
part of this review, a scoping exercise of published chronic
care models was undertaken. This scoping exercise identi-
fied two additional key elements - case management [20]
and family support [21] which had previously been in-
cluded as part of a chronic care model, bringing the total
number of elements included within this review to eight.
Studies which had implemented at least two of the these
eight elements were included in this review:
1. Facilitated community support (CS) to meet the
needs of patients
2. Facilitated unpaid/informal family support (FS) to
meet the needs of patients
3. Self-management support (SMS) to meet the needs
of patients
4. Health system (HS) improvement to meet the needs
of health-care providers
5. Delivery system design (DSD) to meet the needs of
health-care providers
6. Enhanced health care professional case management
(CM) support to meet the needs of patients
7. Decision support (DS) to meet the needs of
health-care providers
8. Clinical information systems (CIS) to meet the needs
of health-care providers
Types of outcome measures
In addition to describing the elements included within a
CCM, outcome measures for effectiveness included any re-
ported changes (improvements or declines) to healthcare162practice, or the health outcomes of patients as a result of
the implementation of a CCM.
Types of studies
This review focused on quantitative (e.g. randomised
and non-randomised control trials, cross-sectional and
cohort studies, case studies and case series) and qualita-
tive studies.
Search strategy
Seven electronic databases (MEDLINE, Cinahl, Embase,
Informit Online, PsycINFO, Scopus, and Web of Science)
were searched for articles published in English language
between January 1998 to April 2013 and met the above in-
clusion and exclusion criteria. The Medline search strategy
is provided in [see Additional file 1] was originally set up
in MEDLINE and then modified for the other databases.
Study selection
Four authors (CD, HL, MT, SP) were involved in study
selection. For each paper, two of these authors inde-
pendently scanned the identified studies and excluded
studies according to the criteria above, on the basis of ti-
tles and abstracts. Full text copies of the papers deemed
to meet the inclusion and exclusion criteria were these
retrieved and two of the review authors reviewed these
publications. Authors of relevant papers were contacted
if the full text article were not available. If there was un-
certainty or disagreement, consensus was reached by
discussion and consultation with the review authors.
Bias appraisal
Four authors (CD, HL, MT, SP) were also involved in
the Bias Appraisal. Two of these authors independently
assessed the risk of bias onall of the papers included in
this review. The Cochrane Handbook for Systematic Re-
views of Interventions was used to assess bias for rando-
mised and non-randomised control trials, cross-sectional
and cohort studies [22]. The Joanna Briggs critical ap-
praisal tool was used to measure the bias of case studies
and case series [23]. As the first objective of the review
was to identify elements of a CCM which have been in-
cluded in studies, and then identify the effectiveness of
these elements for improving health outcomes and the
provision of healthcare, studies were not excluded based
on this appraisal [see Additional file 1: Table S1–S5].
Data extraction
Data was extracted from primary studies and included in
pre-defined data extraction tables by the four review au-
thors (CD, JB, HL, MT). The extracted data included
specific details about the geographical context, study
methods and disease focus [see Additional file 1: Table S6],
elements included in the intervention, study participants,
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Additional files 1: Table S7–Table S11]. Data has been pre-
sented in narrative form including tables and figures to aid
in data presentation where appropriate.
Results
Literature search
The search of information sources returned 3492 articles
from the initial searches of electronic databases. The
majority of these studies were subsequently excluded
based on their title or abstract because they clearly did
not meet the inclusion criteria for this review. A total of
226 full text articles were obtained and a further 149
were excluded as they also did not meet the inclusion
criteria. This resulted in the inclusion of 77 published
peer-reviewed papers which were ultimately included in
this review (Figure 1).
Description of chronic care models
The majority of studies were conducted in the Americas,
including United States of America, Canada and Mexico
[24-76]. A number of studies were also conducted in
Europe including United Kingdom, Spain, Belgium, Italy,
Denmark, Netherlands and Germany [20,77-88]. A furtherFigure 1 PRISMA 2009 Flow Diagram.
163six studies were conducted in Australia and New Zealand
[21,89-93], one study was conducted in Taiwan [94], one
in the United Arab Emirates [95] and one in South Africa
[96] [see Additional file 1: Table S6].
The majority of studies focused on the provision of
care for diabetes [21,24,26,27,29,31,33-38,40-42,44-53,
55-60,62,65-70,72,75,76,79,80,83-87,90,91,93,94,96]. Included
studies also focused on cardiovascular disease [20,25,28,
30,32,39,43,54,61,63,64,71,73,88,89,91,95], depression [34,51,
53,74,76,90], respiratory disease [90], including chronic ob-
structive pulmonary disease [77,81,82,92,93], and renal dis-
ease [21,90]. Other studies [20,25,28,30,32,39,43,54,61,63,
64,71,73,88,89,91,95] focused on the provision of care to pa-
tients with chronic diseases more generally [see Additional
file 1: Table S6].
While a range of CCM elements were used across the
papers reviewed, the most commonly used element was
SMS, while only two papers included FS (Table 1). How-
ever, there was substantive variation between studies in
both the combination of included elements and also in
how these elements were implemented. For example, de-
scriptions of SMS implemented in primary care settings
included development of care guides and individualised
patient action plans [25,28,92], individual counselling or
Table 1 Overview of CCM Elements Reviewed
Element Number of Papers
Self-Management Support 50
Delivery System Design 39
Clinical Information Systems 37
Decision Support 36
Case Management 19
Health System 13
Community Support 13
Family Support 2
CCM - Elements Not Specified 4
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management [28,31,33,51,58,62,74,77,86,89,98,99], pro-
grams on empowerment, goal-setting and motivation
[26,42,51,58,79,92], and use of support groups [62,98,99].
Descriptions of how other CCM elements were imple-
mented also differed substantially between studies, mean-
ing that between study changes to healthcare practice and
health outcomes as a result of implementing CCM ele-
ments were not easily comparable.
Effectiveness of chronic care models
To explore the effectiveness of CCM elements, the re-
view focused on the analyses of randomised controlled
trials (RCTs), non-randomised controlled trials (non-
RCTs), retrospective cohort studies, as well as case stud-
ies and case series. Measures of effectiveness relating to
health outcomes relevant to specific chronic diseases
(e.g. improvements to HBA1c for diabetes) as well as
healthcare practice appropriate to the management of
chronic disease (e.g. concordance with clinical guide-
lines), were reported by 63 of the 77 studies included in
this review.
In a small number of studies [35,70,75] the Assess-
ment of Chronic Illness Care (ACIC) was used to assess
level of implementation of CCM elements in primary
healthcare settings. The ACIC contains 28 items across
the six elements within the Wagner CCM: CS, HS, SMS,
DS, DSD and CIS, with each assigned a numeric score
from 0 to 11. Individual providers or healthcare teams
were asked to rate level of implementation through self-
report. The equivalent patient self-reporting tool (Patient
Assessment of Care for Chronic Conditions) was also
used in three studies [47,66,87] to measure quality of
healthcare based on five sub-scales: patient activation,
DSD, DS, goal setting, problem solving/contextual coun-
selling and follow up/coordination.
Findings pertaining to the quality of the included pa-
pers and the reported effectiveness associated with spe-
cific CCM elements for improving health outcomes and
healthcare practices are presented below by study type.164Randomised controlled trials
Of the 13 RCTs that measured the efficacy of a CCM as
defined by our search criteria, the majority (n = 8) were
conducted in the USA [25,26,28,42,51,62,69,74]. Control
groups generally either received usual care or received
less intensive intervention. Six studies focused on dia-
betes [24,26,42,62,69,79], two studies on COPD [77,92],
one study on depression [51], and four studies on non-
specific chronic disease or multi-morbidity [20,25,28,74].
A significant potential risk of bias was identified in
many of the included RCT papers [see Additional file 1:
Table S1]. Of particular concern was the risk of detec-
tion bias which was assessed as either high or unclear
for all but two of the papers [69,74].
Findings of significant healthcare practice or health out-
come improvements associated with CCM interventions
were inconsistent [Additional file 1: Table S7]. While
many studies reported significant changes in health out-
comes from baseline in the intervention group, significant
between-group differences were often lacking [42,92], and
a number of studies reported no intervention effect for
any health outcome [26,28,51,69,74]. Randomised control
trials that reported significant changes in health outcomes
from baseline for the intervention groups had imple-
mented the following elements:
 SMS [62,77]
 DSD [62]
 CIS [77]
 DS [62]
 CM [24,77]
 HS [24]
Two RCTs reported on healthcare practice change.
One reported a significant improvement in monitoring
of symptoms and risk factors was associated with CM
and HS [24], while the second study identified a deteri-
oration in patient education [77].
Non-randomised control trials
Two non-RCT papers were also reviewed, one con-
ducted in the USA focusing on COPD [32] and the other
in Europe which focused on chronic disease more gener-
ally [97]. Only one of these studies looked at effective-
ness [see Additional file 1: Table S7], demonstrating
significant reductions in mortality in an intervention
group referred to a nurse care manager equipped with
specialised information and IT tools, however findings
were not significant after two year follow up [32]. The
second study evaluated implementation of CIS, SMS and
DSD elements into primary healthcare practices and re-
ported on the proportion of elements that had been im-
plemented at two year follow up [97]. While reporting
bias was low, the risk of selection, sampling, detection
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be, at best unclear, if not high [see Additional file 1:
Table S2].
Retrospective cohort studies
All six observational cohort studies were conducted retro-
spectively using chart reviews of electronic patient health
records, registries and patient databases to evaluate CCM
elements implemented at a practice or practice group
level. Four of the studies were conducted in the USA
[31,33,49,61] and two were conducted in Europe [83,85].
Five studies focused on diabetes [31,33,49,83,85] and one
focused on non-specific chronic disease risk factors [61].
The risk of selection and sampling bias was assessed as
high or unclear for all but one study [31]. Likewise, the
risk of detection bias was also considered to be high or
unclear for all but one other study [61] [see Additional
file 1: Table S3].
Three of the studies reported improvements to health-
care practice as well as health outcomes for diabetic pa-
tients [31,33,85] while one study [61] only reported on
improvements to health outcomes for diabetic patients
[see Additional file 1: Table S9]. Improvements were
found to be associated with the following CCM elements.
SMS [31,33,85]
DSD [31,33,83,85]
CIS [31,33,83]
DS [31,33,83,85]
CM [31,33]
Cross-sectional studies
Of the 11 cross-sectional studies identified in this re-
view, all but one study [91] included elements imple-
mented to support diabetic care. In addition, only two
studies [87,91] were conducted outside of the USA.
Eight of the 11 cross-sectional studies [13,35,40,
45,46,66,70,87] either did not have sufficient information
to make an assessment, or were considered to be at high
risk of selection bias. Only four of the cross-sectional
studies met the criteria for being at low risk of detection
[45-47,70] or attrition biases [35,46,60,70], while seven
were assessed as low risk for reporting bias [35,45-47,
60,75,87] [see Additional file 1: Table S4].
Three of the cross-sectional papers reported associa-
tions between implementation of CCM elements and
improvements to clinical outcomes, [35,66,91] with one
study reporting improvement in clinical outcomes and
healthcare practice [60] [see Additional file 1: Table
S10]. Improvements were found to be associated with
the following CCM elements.
 SMS [35,60,66,91]
 DSD [35,60,66,91]165 CIS [35,60,66,91]
 DS [35,60]
 CM [66]
 HS [35,91]
 CS [35]
Case studies and case series
Similar to papers presented above, the vast majority of
case studies and case series (25 of 31 papers) included dia-
betic patients when assessing the effectiveness of CCMs
for improving health outcomes of, or health care practice
[21,27,29,36-38,44,48,50,53,55-57,65,67,72,76,84,90,91,93,
94,96]. The majority of these case studies and case series
(20 of 31 papers) were conducted in USA [27,29,34,36-38,
44,48,50,53-57,63,65,67,72,76].
None of the case studies and case series papers included
in this review met all of the nine critical appraisal criteria
defined by the Joanna Briggs Institute [23]. Of particular
concern was that nine of these studies did not sufficiently
define the inclusion criteria, and only two of the 31 papers
identified confounding factors [Additional file 1: Table S5].
Twenty two of the case studies or case series papers re-
ported associations between improved health outcomes
[21,29,34,36-38,44,48,54,63,65,67,72,78,84,90,91,93-95] and
the implementation of SMS [see Additional file 1: Table
S11]. In addition, associations were also found for im-
proved health outcomes and the implementation of the
following elements.
In addition, associations were also found for improved
health outcomes and the implementation of the follow-
ing elements.
 DSD [21,29,36,37,54,65,67,72,84,95]
 CIS [21,29,37,54,65,72,76,95]
 DS [29,36,37,44,65,67,72,76,93,95]
 CM [29,34,36,44,78,90]
 HS [38]
 CS [21,29,48]
 FS [21]
Two case studies [67,95] found an association between
implementing CCM elements and a decline in a health
outcome (decreased high-density lipoprotein and in-
creased low-density lipoprotein respectively). However,
out of 77 papers included within this review, these were
the only studies to report a negative health outcome as-
sociated with the implementation of CCM elements.
Twenty five of the case studies or case series [21,27,29,
30,36-38,44,48,50,53-57,67,73,78,81,84,93-96] reported an
association between improved healthcare practices and
the implementation of the following elements.
 SMS [21,27,29,30,36-38,44,48,50,54-57,67,78,81,84,93,95]
 DSD [21,27,29,36,37,50,54,56,67,81,84,94-96]
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 DS [27,29,93,95]
 CM [29,36,44,78]
 HS [27,38,96]
 CS [21,27,29,48,50,94]
 FS [21]
Only one case study [57] out of the 77 papers included
within this review suggested an association between
implementing elements of a CCM and a decline in
healthcare practices (documentation).
Discussion
Of the papers which did include measures of effectiveness,
the majority found an association between the implementa-
tion of CCM elements and improvements with healthcare
practice or health outcomes for people living with chronic
disease. Only two papers [67,95] reported association be-
tween implementing CCM elements and a decline in any of
the health outcomes measured (decreased high-density and
increased low-density lipoproteins respectively), while one
paper [57] suggested an association between the implemen-
tation of CCM elements and a decline in healthcare prac-
tices (documentation).
One of the primary findings of this systematic litera-
ture review was considerable study variability, both in
the combination of and ways in which CCM elements
were implemented. For this reason it was impossible to
clearly identify any optimal combination of the eight
CCM elements that could lead to improvements in ei-
ther healthcare practice or health outcomes. A direct re-
lationship between any combination of CCM elements
and improvements to either healthcare practice or health
outcomes was further placed into doubt by the RCT
studies that compared outcomes from the implementa-
tion of two different combinations of CCM elements
[38,44]. Despite differences in the combination of ele-
ments included, researchers were unable to find any sig-
nificant variation in outcomes. Similarly, studies that
focused on the implementation of self-selected elements
across multiple sites found very little between site differ-
ences in either the type or strength of healthcare prac-
tice or health outcome improvements [50,57,78,95]. This
suggests that factors other than or in addition to the im-
plementation of CCM elements may play a role in im-
proving healthcare practices and health outcomes for
people living with chronic disease [100].
One of the benefits of including case studies in this
systematic review was that they tended to provide a
more detailed account of how CCM elements were im-
plemented. Of the 19 case studies that described these
processes in more detail, eight specifically utilised the
Plan-Do-Study-Act cycle [27,37,54,65,72,93,95,101], while
a further five developed various learning collaboratives166[29,50,53,57,76] as part of the development and imple-
mentation process. One of the key findings of these stud-
ies was that Plan-Do-Study-Act cycles and learning
collaboratives appeared to be associated with the develop-
ment of contextually relevant interventions. In addition,
these methods often meant that the healthcare providers
involved in the implementation process were engaged
with development, encouraging a sense of ownership and
consequently responsibility for the success of the interven-
tion. The authors of these papers also described how
healthcare providers who were involved in the develop-
ment process had an opportunity to reflect on, gaining for
example, a more nuanced understanding of how the care
they provided could address the needs and priorities of
the communities they served.
Reflective practice is a key component for developing
clinical knowledge and skills [102] and can, in and of it-
self, lead to significant improvements in healthcare by
assisting to bridge the gap between theory and practice
[103,104]. Importantly for the implementation of inter-
ventions including CCM elements, reflective practice
also encourages healthcare providers to identify anomal-
ies between the ways in which they currently practice
and organisational priorities for the future [105]. Within
a healthcare setting, this involves analysing one’s own
experiences and modifying behaviour based on these re-
flections in order to improve the way in which health-
care is provided. While not without some challenges, an
individual’s reflective practice is enhanced when there is
an opportunity to work with others in a group setting
[106]. The methods, including the Plan-Do-Study-Act
cycles and learning collaboratives described in this sys-
tematic review, can assist this process by developing col-
legial environments within which this reflective group
practice can occur.
Although not specifically addressed by papers in this
review, spending the time and resources to develop and
implement a CCM may have also underpinned both
healthcare practice and health outcome improvements
by signalling to staff that improving chronic disease care
was a priority for their healthcare service. Yet simply
communicating these messages may not be sufficient to
ensure improvement. What was evident in a number of
papers, was the key role that leaders played in guiding
the development and implementation process. Once
started, leaders within these organisations needed to be
committed to the implementation and sustainability of a
new CCM [27,31,43,52,54,71,72,93]. As was highlighted in
the Wagner CCM under HS [107], without this commit-
ment, any improvements to either health outcomes or
healthcare practices were likely to have been lost [43,52].
Providing a collegial environment which supports re-
flective practice, sending clear messages about the im-
portance of chronic disease care and ensuring that
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interventions appear to contribute to the health out-
comes and healthcare practices identified in papers in-
cluded in this review. However, this list is by no means
complete and further work is required to identify other
facilitators and barriers which could influence the imple-
mentation of similar interventions. However, the find-
ings in this systematic literature review do suggest that
other models of care, including alternatives to CCM
elements included in this review could be equally suc-
cessful in improving the health outcomes and healthcare
practices within primary healthcare services, particularly
when they address the particular needs of patients
within each context [95].
Contextual relevance is especially important given that
although the burden of chronic disease is highest within
disadvantaged populations, the majority of studies which
have implemented the eight CCM elements included in
this review have focused on interventions within advan-
taged populations living in developed countries [see
Additional file 1: Table S6]. In particular, FS which was
the least utilised CCM element (Table 1) may be particu-
larly useful within, for example, Aboriginal peoples living
with chronic disease [21]. Whether this or any other
CCM elements can help to improve healthcare practices
and health outcomes for disadvantaged populations
more generally is not as clear. Outcomes from this re-
view suggest that targeted approaches whereby leaders
provide clear direction and support [108] and also en-
courage healthcare practitioners to reflect on how their
own practices may need to change to meet the needs of
particular populations are more likely to stimulate im-
provements to health outcomes and healthcare practice.
Limitations
There are a number of limitations to this review. Of par-
ticular concern was the high risk of bias in the RCT,
non-RCT, retrospective cohort and cross sectional stud-
ies. In addition, the quality of the case studies included
in this review was considered to be poor. In addition, as
previously noted the interventions differ from one study
to another, meaning that generalizations were impossible
to make and which suggestions based on existing evi-
dence have been made for why a CCM might lead to im-
proved healthcare process and health outcomes these
are yet to be tested.
Conclusions
The key finding from this systematic literature review
was the wide variability between the elements included
within CCMs and the way in which these elements were
implemented. While the majority of papers reported im-
provements to either healthcare practice or health out-
comes as a result of implementing a CCM, it was not167possible to identify which elements or combination of el-
ements led to these improvements. Rather these results
suggested that factors other than or in addition to the
implementation of CCM elements may play a role.
While not exclusive, these may include collegial environ-
ments which support reflective practice, sending clear
messages about the importance of chronic disease care
and ensuring that leaders support the implementation
and sustainability of interventions. Given the high preva-
lence of chronic disease in disadvantaged populations in-
cluding Indigenous communities, elements including FS
could play a greater role in improving the management
of and outcomes from chronic disease for these peoples.Additional file
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Abstract
Background: The increasing prevalence of chronic disease faced by both developed and developing countries is of
considerable concern to a number of international organisations. Many of the interventions to address this concern
within primary healthcare settings are based on the chronic care model (CCM). The implementation of complex
interventions such as CCMs requires careful consideration and planning. Success depends on a number of factors at
the healthcare provider, team, organisation and system levels.
Methods: The aim of this systematic review was to systematically examine the scientific literature in order to
understand the facilitators and barriers to implementing CCMs within a primary healthcare setting. This review
focused on both quantitative and qualitative studies which included patients with chronic disease (cardiovascular
disease, chronic kidney disease, chronic respiratory disease, type 2 diabetes mellitus, depression and HIV/AIDS)
receiving care in primary healthcare settings, as well as primary healthcare providers such as doctors, nurses and
administrators. Papers were limited to those published in English between 1998 and 2013.
Results: The search returned 3492 articles. The majority of these studies were subsequently excluded based on
their title or abstract because they clearly did not meet the inclusion criteria for this review. A total of 226 full text
articles were obtained and a further 188 were excluded as they did not meet the criteria. Thirty eight published
peer-reviewed articles were ultimately included in this review. Five primary themes emerged. In addition to
ensuring appropriate resources to support implementation and sustainability, the acceptability of the intervention
for both patients and healthcare providers contributed to the success of the intervention. There was also a need
to prepare healthcare providers for the implementation of a CCM, and to support patients as the way in which
they receive care changes.
Conclusion: This systematic review demonstrated the importance of considering human factors including the
influence that different stakeholders have on the success or otherwise of the implementing a CCM.
Background
The increasing prevalence of chronic disease faced by
both developed and developing countries is of consider-
able concern to a number of international organisations
[1, 2]. Many of the interventions to address this concern
within primary healthcare settings are based on the
chronic care model (CCM) which was first developed by
MacColl Institute for Healthcare Innovation at Group
Health Cooperative in the early 1990s [3–5]. The
elements included in this original model focused on
mobilising community resources, promoting high quality
care, enabling patient self‐management, implementing
care consistent with evidence and patient preferences,
effectively using patient/population data, cultural com-
petence, care coordination, and health promotion [6].
The implementation of complex interventions such as
CCMs requires careful consideration and planning. Suc-
cess depends on a number of factors at the healthcare
provider, team, organisation and system levels [7]. Im-
plementation strategies should also take into account
contextual factors [8]. As a result, primary healthcare
services need to consider the range of interacting factors
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at many different levels and consider the possibility that
multiple often interacting factors will largely determine
whether a CCM is implemented and whether this inter-
vention succeeds in improving health outcomes for
people living with chronic disease [9].
A vast number of theories have been developed to
inform the implementation of complex healthcare inter-
ventions [10]. Process theories focus on the activities
and organisation of the change process, stage-of-change
theories consider how the steps taken to implement the
change differ according to the healthcare providers in-
volved and impact theories describe how the interven-
tion will facilitate change. There are theories that focus
on individuals within the change process including cog-
nitive, educational and motivational theories. There are
also theories that relate to social interaction encompassing
communication, social learning, social networking, team
effectiveness, professional development and leadership
theories. Finally, there are theories at an organisational
level including integrated care and quality management,
both of which underpin the development and implemen-
tation of CCMs [9].
A number of systematic literature reviews have already
considered the effectiveness of CCMs [11–17]. None,
however, have specifically focused on what impedes or
promotes the successful implementation of CCMs. This
systematic literature review goes some way to addressing
this gap by identifying the facilitators and barriers to
implementing CCMs within primary healthcare settings,
from the perspective of both patients’ and healthcare
providers’. The intention is that the outcomes from this
review will assist both policy makers and practitioners
working within a primary healthcare setting, to imple-
ment CCMs.
Objectives
The specific purpose of this review was to systematically
examine the scientific literature in order to understand
the facilitators and barriers to implementing CCMs
within a primary healthcare setting from the perspective
of healthcare providers and patients. The question asked
by this review was:
What attitudes, beliefs, expectations, understandings,
perceptions, experiences, resources and knowledge
according to healthcare providers and patients
support (facilitators) or inhibit (barriers) the
implementation of CCMs within a primary healthcare
setting?
Method of the review
A three-step search strategy was used in this review.
An initial limited search of MEDLINE and CINAHL
was undertaken followed by analysis of the text words
contained in the title and abstract, and of the index
terms used to describe article. A second keywords and
index term search was then undertaken across Embase,
Informit Online, PsycINFO, Scopus, and Web of Science.
Duplications were then identified and the most complete
record retained for subsequent review on inclusion cri-
teria. Additional file 1 provides an example of the Medline
search strategy.
Inclusion criteria
Population and context
This review considered studies that focused on patients
with one or more of the more prevlant major chronic
diseases as defined by the World Health Organisation -
cardiovascular disease, chronic kidney disease, chronic
respiratory disease, type 2 diabetes mellitus and depres-
sion [18, 19] - receiving care in primary healthcare set-
tings, as well as all primary healthcare providers such as
doctors, nurses and administrators.
Primary healthcare is generally defined as first-contact,
accessible, continued, comprehensive and coordinated
healthcare provided by a single practitioner (e.g. GP, nurse
practitioner) or a multidisciplinary team of professionals
in a community practice. For the purposes of this review
however, primary healthcare is first-contact, accessible,
continued, comprehensive and coordinated care. First-
contact care is accessible at the time of need; ongoing care
focuses on the long-term health of a person rather than
the short duration of the disease comprehensive care is a
range of services appropriate to the common problems in
the respective population and coordination is the role by
which primary care acts to coordinate other specialists
that the patient may need [20]. Primary healthcare also
includes primary care settings that have only one health
professional, i.e. a general practitioner (GP).
Phenomena of interest/intervention
The phenomena of interest were the attitudes, beliefs,
expectations, understandings, perceptions, experiences,
resources and knowledge of healthcare providers and
patients about what supports (facilitators) or inhibits
(barriers) the implementation of CCMs within a primary
healthcare setting. To be included studies must have also
referred to a CCM which included at least two of the
following elements:
1. Facilitated community support (CS) to meet the
needs of patients
2. Facilitated unpaid/informal family support (FS) to
meet the needs of patients
3. Enhanced health care professional case management
(CM) support to meet the needs of patients
4. Self-management support (SMS) to meet the needs
of patients
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5. Health organisational change (OC) to meet the
needs of health-care providers
6. Delivery system design (DSD) to meet the needs of
health-care providers
7. Decision support (DS) to meet the needs of
health-care providers
8. Clinical information systems (CIS) to meet the
needs of health-care providers
Outcome
Finally, this review only considered studies that included
attitudes, beliefs, expectations, understandings, percep-
tions, experiences, resources and knowledge according
to healthcare providers support (facilitators) or inhibit
(barriers) the implementation of CCMs.
Types of studies
This review focused on both qualitative and quantitative
studies (e.g. randomised and non-randomised control
trials, cross-sectional and cohort studies, case studies
and case series). Papers were limited to those published
in English between 1998 and 2013.
Data collection
Data was extracted from primary studies and included in
the review using a set of pre-defined tables. The ex-
tracted data included specific details about the chronic
care model, populations, study methods and outcomes
of significance to the review questions and objectives.
Extracted data included:
 Study type
 Chronic disease
 Study setting (country and region)
 Chronic care elements
These data on the included studies are presented in an
additional file [see Additional file 2].
Critical appraisal
Two reviewers independently assessed the quality of the
papers prior to inclusion in this review. The Cochrane
Handbook for Systematic Reviews of Interventions was
used to assess bias for randomised and non-randomised
control trials, cross-sectional and cohort studies [21, 22].
The Joanna Briggs critical appraisal tool was used to
measure the quality of case studies and case series [23].
As the objective of this review was to facilitators and
barriers to implementing CCMs, studies were not ex-
cluded based on these critical appraisals.
Data extraction
Data was extracted where possible by themes identified
by the authors of each study. Where themes were not
identified within the study, findings were extracted from
the narrative discussion by a reviewer (CD) in the form
of a definitive statement made by the authors and sup-
ported by the presentation of data. Qualitative findings
and the quantiative findings presented in narrative form
were pooled. Findings were first inductively grouped into
categories that were created on the basis of similarity of
meaning; categories were then subjected to a meta-
aggregation in order to produce a single comprehensive
set of synthesized findings that could be used as a basis
for evidence-based practice which would inform policy
makers and practitioners on the facilitators and barriers
associated with implementing a CCM [23].
Results
Description of studies
The search of information sources returned 3492 arti-
cles. The majority of these studies were subsequently ex-
cluded based on their title or abstract because they
clearly did not meet the inclusion criteria for this review.
A total of 226 full text articles were obtained and a fur-
ther 188 were excluded as they did not meet the criteria.
Thirty eight published peer-reviewed articles were ultim-
ately included in this review (Fig. 1).
The majority of studies were conducted in the Americas,
including United States of America, Canada and Mexico
[24–47]. Nine studies were also conducted in Europe in-
cluding United Kingdom, Spain, Belgium, Italy, Denmark,
Netherlands and Germany [48–56]. Four studies were
conducted in Australia and New Zealand [57–60] and one
study in Africa [61].
While all studies described in the included papers were
conducted within a primary healthcare setting, the major-
ity focused on the provision of care for diabetes [24, 26,
28–30, 32–34, 36, 37, 39, 40, 42, 45, 47, 49, 53–55, 60, 61].
Included studies also focused on cardiovascular disease
[28, 48, 60], depression [32] and chronic obstructive pul-
monary disease [50, 52, 60]. Other studies [25, 27, 31, 35,
38, 41, 43, 44, 46, 51, 56–59] focused on the provision of
care to patients with chronic diseases more generally.
Though a range of CCM elements were used across
the papers reviewed, the mean number of elements
across the 38 papers included in this review was four,
with only one study including seven of the elements.
None of the papers included studies utilising FS. While
the most commonly included element was SMS (Table 1),
there were substantive between study variations both in
the elements used and how these elements were imple-
mented. For example, descriptions of SMS implemented
in primary care settings included development of care
guides and individualised patient action plans [36, 48]
individual counselling or coaching [52, 54], education
programs on disease management [29, 32, 39, 50],
web-based patient portals [30] and programs on
Davy et al. BMC Family Practice  (2015) 16:102 Page 3 of 12
173
empowerment, goal-setting and motivation [35]. More
generally, a number of papers in this review reported
using plan-do-study-act or learning collaborative ap-
proaches which resulted in context specific implementa-
tion strategies for all included elements [24, 33, 35, 42, 60]
(Table 1).
Methodological quality
All 38 papers were critically appraised. The Cochrane
Collaboration’s tool was used to assess risk of bias in
randomised controlled trials, non-RCT quantitative stud-
ies, non-RCT qualitative studies and mixed-methods
evaluations [21]. Case studies and case series were
assessed in accordance with the Joanna Briggs
Reviewers’ Manual [23]. Additional files present the re-
sults of the appraisal process applied to all studies
[Additional files 3, 4, 5, 6 and 7].
Facilitators and barriers
The objective of this review was to identify the facili-
tators and barriers to implementing chronic care
models. Of the 38 papers included in this review, four
reported on randomised control trials [25, 32, 47, 51],
three on cohort studies [26, 53, 54], two on cross sectional
studies [28, 59], 11 on qualitative studies [27, 30, 31, 34,
41, 44, 45, 49, 54, 56, 57] and 17 case studies or case series
[24, 29, 33, 35–40, 42, 43, 46, 48, 50, 58, 60, 61]. All find-
ings related to identifying facilitators and barriers to
implementing chronic care models regardless of per-
spective, disease or geographical locations were pooled
to generate one cohesive set of synthesized findings
(Table 2). As such, the syntheses represent provider
and provide perspectives.
From the 38 included papers, findings pertaining to
both facilitators and barriers to the implementation of
CCMs in a primary care setting were extracted. Qualitative
as well as quantitative findings presented in a narrative
Fig. 1 Summary of literature search
Table 1 Overview of CCM Elements Reviewed
Element Number of Papers
Self-Management Support [SMS] 31
Delivery System Design [DSD] 27
Decision Support [DS] 26
Clinical Information Systems [CIS] 25
Health Organisational Change [OC] 10
Case Management [CM] 9
Community Support [CS] 9
Family Support [FS] 0
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form were grouped into ten categories and which were
then meta-aggregated into four synthesized findings.
Synthesised finding 1 – acceptability of CCM
interventions
One of the most prominently reported factors influencing
the successful implementation of CCMs was acceptability.
Generally referred to using terms such as “satisfaction”, 15
of the 38 papers included in this review reported on
acceptability from the perspective of healthcare providers
[24, 36, 43, 52], patients [25, 30, 32, 38, 49, 58] or both
providers and patients [35, 37, 41, 48, 53]. The majority of
these participants felt that the CCM implemented in their
setting was acceptable.
Category: Acceptability of the CCM intervention for
healthcare providers
The majority of papers considered acceptability from the
point of view of the healthcare providers [24, 35, 36, 48, 53].
These papers report high levels of support for CCM ele-
ments, which in turn facilitated their implementation. Not
all, however, provided reasons for why healthcare providers
felt these CCM elements were acceptable. Those that did
suggested that healthcare providers found them to be help-
ful to their work [24] and perhaps more importantly, be-
lieved that they would make a positive impact on their
patients’ health [48]. One paper also reported that healthcare
providers experienced greater work satisfaction and had
access to additional resources as a result of the model’s
implementation [35]. Finally, one paper focused on the
acceptability of the training used to prepare staff for
implementation, rather than focusing on implementation of
CCM per se [43].
Category: Acceptability of CCM interventions for patients
Of the studies which did measure patients’ perspectives,
the majority found that CCMs were acceptable [35, 37,
38, 49, 51, 53]. Nevertheless, two RCTs found no statis-
tically significant differences in levels of satisfaction be-
tween intervention and control patients [25, 32].
Another qualitative study identified a range of both
positive and negative responses in relation to a study
which aimed to provide patients with online informa-
tion as part of SMS [30]. Positive responses in this
study included patients feeling empowered as a result
of the readily available online information, as well as a
greater understanding of how lifestyle choices impacted
upon their health. On the other hand, patients in this
study also reported a number of inefficiencies which re-
duced the acceptability of the system, including missing
online results and slow response times from nurses and
doctors.
Synthesised finding 2 - preparing healthcare providers for
a CCM
Factors which influenced whether healthcare providers
embraced the implementation of a CCM also depended
on whether sufficient information was provided in an
appropriate manner and whether staff were convinced
that a change to the way healthcare was delivered would
be beneficial. This synthesised finding acknowledged
that without staff who had the necessary skills and ex-
perience to take on new roles and responsibilities, imple-
menting a new CCM would be particularly difficult. Also
noted, was the importance of ensuring that healthcare
staff are supported by strong leaders and champions
who are able to provide both management and clinical
support.
Category: Information about the change
Clearly articulated concepts and examples of how a
CCM could work once implemented, were identified as
an important facilitator to implementation [28]. Staff
who were not provided with this information may be left
wondering what the expected outcomes could or should
be [32]. Structured learning sessions involving a whole
of team approached that focused on collaborative and
supportive learning environments, providing opportun-
ities for staff to ask questions and raise concerns, were
thought to prevent any resistance to change [26, 34].
Ensuring that individual staff members have the neces-
sary knowledge and skills required to undertake their
particular roles and manage any new responsibilities
prior to implementing a new CCM was also shown to be
important [59]. If, for example, the model included
Table 2 Summary of Synthesised Findings
Synthesised Finding 1 - Acceptability of CCM interventions
• Category: Acceptability of the CCM intervention for
healthcare providers
• Category: Acceptability of CCM interventions for patients
Synthesised Finding 2 - Preparing healthcare providers for a CCM
• Category: Information about the change
• Category: A reason to change
• Category: Appropriately qualified and experienced chronic care staff
• Category: Leaders and champions for success
Synthesised Finding 3 - Supporting patients
• Category: Patients supported and encouraged to engage with care
• Category: Acknowledging patient differences
Synthesised Finding 4 - Resources for implementation and sustainability
• Category: Time needed to implement and sustain CCMs
• Category: Information and communication
• Category: Sufficient funding
• Category: Collaborations with other healthcare services
• Category: Monitoring and evaluating
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community or family support, it could be particularly
advantageous for staff to know about community re-
sources including existing disease management group
meetings, exercise facilities, mental health services, or
discounted health programs [35]. It was also considered
important for staff to feel comfortable and confident in
taking on any new responsibilities; if necessary by being
provided with opportunities for additional training and
on the job support [61]. In order to facilitate fruitful
working relationships, staff who needed to collaborate
with people external to their immediate team or an ex-
ternal organisation were believed to have benefited
from being provided with information about and even a
chance to meet with these collaborating parties prior to
implementation [54].
Category: A reason to change
One of the most important facilitators to implementing a
CCM is a well thought out and articulated argument for
change [60]. Without clearly defined benefits, healthcare
providers may become dismissive and uncooperative. A
groundswell of agreement for improvements needs to be
carefully nurtured prior to beginning the implementation
process [31]. Quality Improvement initiatives that clearly
identify gaps in care [44], where the goal can be clearly
recognised as improvements to patient care rather than
change for the change sake of change were considered to
be a useful strategy [56]. Goals and outcomes that appear
unclear or fuzzy, and a process of change that were unco-
ordinated, were believed to result in healthcare providers
disengaging from the implementation process [31]. Man-
agers, therefore, played an important role in leading staff
through the change process, which was further enhanced
by ensuring that any success was measured and appropri-
ately rewarded [41].
Category: Appropriately qualified and experienced chronic
care staff
Unsuitable or insufficient staffing undermined the im-
plementation and sustainability of a CCM [27]. While
physicians were considered to be an essential component
of the chronic care team particularly in regards to advis-
ing and supporting other healthcare providers [61], the
lack of nurses dedicated to chronic disease programs
[61], as well as management and administrative support
staff [24, 31, 55], impeded the implementation and/or
sustainability of a new CCM.
A high turnover of staff was noted as another barrier
to both implementing and sustaining a new CCM [61].
In one instance [26] a general shortage of qualified
healthcare providers meant that highly skilled staff were
being replaced by less adept medical assistants which in
turn put at risk the sustainability of the CCM. High
staff turnover, in this instance, resulted in a complete
derailing of the implementation process [33]. Irregular
rotations of both doctors and nurses in another remote
location created a lack of consistent chronic disease
care, which was vital to the success of a given model
[59]. Yet on a more positive note, the implementation
of a new CCM in one study [41] was believed to be as-
sociated with a decrease in staff turnover.
Skills and experiences of chronic care staff were also
important for the success of a new CCM. Although pro-
viding staff had a desire to learn, and sufficient time to
devote to understanding new ways of working, shortfalls
in any skills or experience could be overcome [28].
Another way of supporting staff through the change
process was to form multi-disciplinary teams [42]. Yet,
setting up a multidisciplinary team was not always easy.
Respect for the role of each discipline and enhanced
interdisciplinary communication were critical to the
success of this initiative [54]. Furthermore, if existing
staff had no prior history of working within an interdis-
ciplinary team the sustainability of the model may be
put at risk [54].
Category: Leaders and champions for success
A consistent theme within the papers reporting upon
facilitators and barriers was the need for supportive
leadership [24, 26, 31, 34, 35, 41, 42, 60]. As well as
management staff who were committed to the imple-
mentation and sustainability of the new model [24, 42],
strong clinical leaders and champions were needed to
support healthcare providers through the change process
[31]. In a primary care clinic within a teaching hospital
physician leaders were found to be essential in helping a
provider population of rotating residents and part-time
physicians implement a CCM model. Indeed the educa-
tionally rich environment fostered by these leaders was felt
to benefit temporary and permanent staff members alike
[26]. Without this type of support, the implementation
and sustainability of the model may be put at risk [31, 34].
Synthesized finding 3 - supporting patients
The third synthesised finding identified factors that were
believed to influence whether patients were able and
willing to engage with care delivered through a CCM. In
particular, patients needed to be supported to fully
engage with healthcare, particularly when a model incor-
porated aspects of self-management support. Providing
understandable information about their health, as well
as support groups that motivated them to reach their
own goals, encouraged patients to take a greater interest
in and responsibility for their health. This finding also
identified that patients may not always be able to
actively contribute to their care. Instead, it was import-
ant to acknowledge patients as unique individuals with
different levels of capacity for engagement.
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Category: Patients supported and encouraged to engage
with care
Self-management support, which relied on patients tak-
ing some responsibility for their own healthcare, was
one of the most common elements identified in this
review (see Description of Studies). Educational services
that provided clear and concise information to patients
so that they were able to respond appropriately were
generally viewed positively [45, 54]. Yet educating and
empowering patients was a challenge given the breadth
of clinical questions that may need to be covered, the
nature of patients’ concerns and anxieties, patients’ vary-
ing cultural needs, and related difficulties of concord-
ance and adherence [53]. Support groups were another
way of encouraging patients to take on a degree of
responsibility for their own care. Support groups were
found to be mutually motivating and patients participat-
ing in such groups were found to monitor their condi-
tion more closely and respond to health promoting
activities such as physical exercise, more positively [47].
Support groups were often seen as a particularly benefi-
cial adjunct to general healthcare.
However, not all patients were ready or able to take
on greater responsibility for their own healthcare [58].
In particular, poor psychological health (health beliefs,
motivation and self-efficacy), lower levels of education
(poor knowledge or awareness of education services),
and other social determinants of health (finance, trans-
port), as well as psychosocial factors (discrimination
due to having diabetes, lack of support from family,
friends or the community and inappropriate cultural
messages), can all act as major barriers to diabetes care
[40]. Other interventions including online systems that
allowed patients to monitor their own records did not
suit all patients, especially if many of the target group
did not have the necessary skills to navigate these
sometimes complex systems [56].
Category: Acknowledging patient differences
Another barrier to implementing self-management sup-
port was that advice provided in educational activities was
not personalised to the individual patient [47]. A client- or
patient-centred approach was considered to be far more
effective in supporting patients to take responsibility for
their own health [35, 57]. Individualised self-management
plans with dedicated time to speak to clients in order to
ensure they have all of the relevant information and ability
to implement the plan is required [59]. However, not all
healthcare facilities were set up to provide this level of
care. Walk-in clinics may not have the time and solo fam-
ily practices may not have the staff required to provide
extensive patient-centred self-management support [46].
In addition to patient-centred care, there was also a
need to ensure that programs were tailored to the needs
of the community or region more generally [54]. In par-
ticular, language and literacy issues were a challenge to
changing delivery system design. Strategies for address-
ing these included recruiting multilingual staff, adapt-
ing and translating materials, redesigning educational
handouts towards a pictorial focus, and using inter-
preters [50].
Synthesised finding 4 - resources for implementation and
sustainability
Features that supported implementation and sustainabil-
ity more broadly included the time and effort required
to implement a new CCM, as well as the need for suffi-
cient resources, including information and communica-
tion systems and funding. Ongoing monitoring and
evaluation to ensure continuous quality improvements
was then needed to ensure the sustainability of CCMs.
Category: Time needed to implement and sustain chronic
care models
Key to implementation was the need to maintain realis-
tic expectations regarding the time required to imple-
ment a CCM [31]. While people may have wanted or
wished that changes were quickly realised, in reality it
took time for healthcare providers and patients to come
to trust the new initiative [54]. Attempting to make too
many simultaneous changes to existing delivery of care
practices could also discourage staff from moving to-
wards a new model of care [31]. Instead, introducing the
model slowly and carefully, with sufficient time for the
necessary cultural shifts as the healthcare team take on
new roles and responsibilities, was believed to be im-
portant for success [58].
Even once implemented, new ways of delivering ser-
vices appeared to require more, rather than less, staff
time [24]. One study [57] found that the amount of time
required to conduct patient-centred care planning was a
serious barrier to implementing their CCM more widely.
Even when supposedly time saving devises such as elec-
tronic medical information systems were implemented
health providers found that such initiatives took a
significant amount of effort to integrate these into their
daily practice [45, 56]. Motivating patients to participate
in education programs [54], developing patient treat-
ment plans, encouraging self-management and meeting
preventive and psychosocial needs of chronically ill pa-
tients [41], were all found to require additional health-
care provider time, which should be recognised and
factored into daily work schedules.
Category: Information and communication
Appropriate information and communication systems
were considered to be vital tools for the implementation
and sustainability of a new CCM. These systems assisted
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by identifying and keeping track of patients with chronic
disease [42, 58], monitoring healthcare against service
standards, identifying gaps in services, and documenting
successes [29]. Information and communication systems
also aided in self-management support, for example, by
using a patient portal to connect with clients and provid-
ing up to date information on their health as well as tips
for continuing to reduce their risk of further complica-
tions from their chronic disease [26, 56].
Nevertheless, information and communication systems
that were inappropriately designed or did not function
well were a barrier to the implementation and sustain-
ability of CCMs. Healthcare providers were critical of,
for example, systems that simply replicated existing
manual systems, electronic health records that were lim-
ited in terms of not being able to provide reminders in
real time, and electronic records that required a signifi-
cant amount of time to enter or retrieve information
[56, 53]. In addition, the simultaneous demands associ-
ated with the implementation of a electronic medical
record system while at the same time changing the way
in which care is delivered were thought to be overly
onerous [31] . Intensive support was needed to ensure
that information and communication systems facilitated
rather than hindered the implementation and sustain-
ability of a new CCM [44].
Category: Sufficient funding
The implementation and ongoing sustainability of CCMs
was sometimes costly, and without sufficient funding,
the process was likely to fail [54]. Unfortunately, health-
care services often found it difficult to find the funds to
support clinical change, especially when there were other
projects competing for the same pot of money [41]. In
particular, specialised services such as support groups,
which are generally seen as a facilitator to implementa-
tion, could require significant amounts of money to fund
[47]. Funding some of the basic services such as case
management and care planning meetings, important ele-
ments to many of the CCMs discussed in this review,
were also beyond the budget of some organisations
[57]. Yet, incentivising healthcare providers to improve
healthcare practices, in combination with the imple-
menting a CCM [27], and possibly even a separate re-
imbursement for follow-up care or performance-based
pay, increased the use of CCMs in practice [32].
On the positive side one study [35] found that in-
creased visits for patients as a direct result of the imple-
mentation of a CCM provided additional income to
offset any initial loss of revenue. Likewise, another study
[39] implemented new patient scheduling arrangements
to ensure provider productivity and cost effectiveness for
Shared Medical Appointments.
Category: Collaborations with other healthcare services
Partnering with other healthcare services such as hospitals
and specialist services was considered to facilitate the im-
plementation and sustainability of CCMs. In particular,
collaboration was linked with cross institutional learning
[42] and communication [53], joint decision making [54,
60], pooling of scarce resources [34, 62]. Other important
features of collaborations was the access to healthcare ser-
vices which otherwise may not have been available [45],
and improved transitioning of patients between healthcare
services [43].
Category: Monitoring and evaluating
Finally, CCMs required systems for ongoing monitoring
and evaluation if they were to be effectively implemented
and sustained [27, 59]. One of the primary barriers to
the process of continuous quality improvements is the
lack of useful data and poor collection of existing mea-
sures [26, 31]. Yet a system for monitoring and evalu-
ation was a hindrance if providers perceived that it did
not add particular value but instead was an additional
burden [54].
Discussion
This systematic literature aimed to identify facilitators and
barriers to implementing a CCM in a primary healthcare
setting from the perspectives of healthcare providers and
patients. The four synthesised findings – Acceptability of
the CCM intervention, Preparing Healthcare Providers for
the CCM, Supporting Patients, and Resourcing Imple-
mentation and Sustainability – spoke to a need to con-
sider an holistic approach to CCM implementation and
sustainability both from patients’ and healthcare providers’
perspectives. While it is important to consider whether
the healthcare system will be able to support the imple-
mentation of a CCM, this review highlighted the import-
ance of human factors to the success or otherwise of
CCM interventions [62].
Facilitators and barriers
Whether or not the CCM was acceptable to both pa-
tients and providers was a factor for determining the
success of the interventions included in this review.
However, definitions of acceptability varied. One of the
primary difficulties in measuring acceptability is that the
term is often inclusive of a number of different con-
structs including whether the patient is willing to imple-
ment changes to their behaviour [63]. Early work in this
field suggests that from a patient’s perspective, these
constructs can include social validity, which refers to the
social desirability of an intervention [64]. In addition,
concepts such as treatment integrity and treatment use
[65] have also been used in to better understand whether
individuals like a prescribed treatment or procedure
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[66]. Adding to this complexity is the number of under-
lying issues that influence the degree to which any indi-
vidual finds an intervention acceptable. For patients this
may include the severity of their condition [67] and the
quality and amount of information that is available to
them [68]. The reputation of the service, the number of
alternative healthcare options and previous experiences
also influence patients’ perceptions [69]. Very few stud-
ies, however, considered acceptability from a healthcare
provider perspective. In addition, simply asking whether
a patient or healthcare provider liked or was satisfied
with a particular intervention may therefore not be a re-
liable method for measuring this construct.
The papers included this review also suggested that
preparing healthcare providers for change was an
important factor for success. If the information provided
is not sufficient, or alternatively if healthcare providers
do not see the benefits of implementing a CCM, it is
more likely to fail. This highlights the importance of
leaders and champions for guiding their healthcare staff
through the change process. These are the people who
not only sell the vision for the future but also legitimise
the change and “call people to action” ([70] p. 366).
Effective leaders will involve their staff from the very
beginning of the change process to help embed a sense
of ownership [71].
Patients must not be left to fend for themselves but in-
stead should receive support as part of the intervention.
Yet none of the studies described in this review utilised
FS, and only nine of the papers utilised CS. However, the
review did find that it was important to appreciate pa-
tients’ individual capacity to respond to self-management
support initiatives. Not only the degree of support, but
also the type of support needed, may vary across time and
therefore healthcare providers will need to continually
monitor patient needs. Importantly, a team approach,
whereby a range of healthcare providers are available to a
patient at any one point in time, may best support
patients’ needs [72]. Other important factors that influ-
ence the success of self-management initiatives include
ensuring that patients are able to access appropriate levels
of information in a format that they are able to under-
stand, identifying whether patients have the desire and
resources to manage their own health, being able to help
patients plan strategies that contribute to their particular
goals and ensuring there is mutual investment, with both
the healthcare provider and the patient working towards
common goals [73].
This systematic literature review also identified the im-
portance of ensuring appropriate resources are in place
to support change. Many of the CCM elements includ-
ing case management and self-management support re-
quire healthcare providers to spend more, not less, time
with patients [74]. Yet insufficient funding for employing
additional chronic care staff as well as issues pertaining
to recruiting and retaining healthcare providers particu-
larly in rural and remote areas [75] often means that
time for patients is at a premium. The time needed to
develop and use a clinical information system was also
highlighted. The perceived ease of use is also an import-
ant acceptance criteria for whether a new technology
will be accepted and used by healthcare providers [76].
A greater focus on the human factors
Three of the four synthesised findings in this systematic
literature review highlighted the significant contribution
that patients and providers can make in either facilitat-
ing or impeding the implementation of CCMs. However,
even the crucial resources identified in the fourth syn-
thesised finding such as time, underlined the importance
of human factors for implementation and sustainability.
Obstacles to implementation may therefore be as much
about the people involved, as they are about resources,
processes and systems. Yet, the two theories that are
thought to inform the development and underpin the
philosophy behind CCMs – Integrated Care and Quality
Management – have tended to take a more structural or
systems approach to the delivery of care [9].
Although not always clearly defined, the concept of
Integrated Care grew from the notion that the develop-
ment of “coherent set of methods and models on the
funding, administrative, organisational, service delivery
and clinical levels” ([77], p. 3) will lead to better con-
nectivity between healthcare services. More recently, In-
tegrated Care has evolved to become more synonymous
with individual patients’ needs [78]. Some researchers
[79, 80] going so far as to call for the development of
evaluation measures and techniques which capture
broader and more nuanced understandings of patient
perspectives. Generally, there is a move away from
regarding patients as passive recipients of healthcare to
one which acknowledges their active participation in
making choices about the way in which their health is
managed [81].
Quality management theory also started out by
emphasising the organisational level perspective [82].
This theory originated from the manufacturing sector
where quality was first assured through the inspection of
products prior to despatch. Quality control which aimed
to find defects during the production process, quality
assurance which developed processes that prevented
defects and finally total quality management which
utilised a management approach to ensuring an entire
quality system, have also been developed [10]. Within
healthcare, quality management theory has tended to
focus on the total quality management approach, seeking
to design and control systems in order to minimise harm
to patients [8]. Yet more recently there is a recognition
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that commitment to improving services from healthcare
providers is crucial to the success of quality initiatives
[83]. Rather than thinking about quality at just the sys-
tem level, “quality systems that give staff ongoing “own-
ership” and pride in a way that is akin to the era of the
craftsmen” ([84], p. 367) has been called for. As was
found in this review, commitment and support from
leaders is particularly crucial for the successful imple-
mentation of quality management programs in health-
care settings.
This systematic literature review therefore mirrors
the more recent progression in thinking behind both
Integrated Care and Quality Management theories by
re-emphasising the human factors which need to be
considered when implementing complex interventions
such as CCMs. While others have suggested that the
implementation of complex intervention primarily de-
pends on the behaviour of healthcare providers , this
review suggests that patients can also act to facilitate or
impede the implementation of CCMs.
Limitations
While no papers were excluded based on quality, of par-
ticular concern was the risk of bias, particularly in the case
of one author (CD) being responsible for the data extrac-
tion. In addition, the quality of the case studies and case
series included in this review was considered to be poor.
Yet the findings from this systematic literature review are
supported by more recent shifts in two of the primary the-
ories – Integrated Care and Quality Management – which
have informed the development of CCMs. It is important
to acknowledged that the vast majority of included studies
were conducted in the Americas. While US, Canadian and
to some extent Mexican perspectives are well represented,
the results may not thoroughly reflect facilitators and
barriers to intervention implementation in the other
countries. The authors also acknowledge that to be
included in this review the paper had to have reported
on an intervention which included at least two of the
eight specified elements (CS, FS, CM, SMS, OC, DSD,
DS, CS). It is probable that there will be other CCMs
which do not include two of these elements. Finally, the
authors also acknowledge that the key findings may be
very different had papers reporting the perspectives of
other stakeholders including, for example, policy makers
been sought.
Conclusion
The successful implementation of complex interventions
such as a CCM may depend not only on the provision of
appropriate resources and the development of effective
systems and processes, but also on a broad range of
different stakeholders who will interpret and influence
this implementation process. This systematic literature
review has re-emphasised the need to consider the human
factors, including the role of both patients and healthcare
providers, who can either facilitate or impede successful
implementation. In addition to ensuring appropriate re-
sources, this review highlights the importance of ensuring
that the intervention is acceptabile to both patients and
healthcare providers. It was also emphasises the impo-
tance of preparing healthcare providers for the change
process and ensuring that patients are supported through-
out the implementation of a CCM.
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Family-led rehabilitation after stroke in India (ATTEND): 
a randomised controlled trial
The ATTEND Collaborative Group*
Summary
Background Most people with stroke in India have no access to organised rehabilitation services. The effectiveness of 
training family members to provide stroke rehabilitation is uncertain. Our primary objective was to determine 
whether family-led stroke rehabilitation, initiated in hospital and continued at home, would be superior to usual care 
in a low-resource setting.
Methods The Family-led Rehabilitation after Stroke in India (ATTEND) trial was a prospectively randomised open 
trial with blinded endpoint done across 14 hospitals in India. Patients aged 18 years or older who had had a stroke 
within the past month, had residual disability and reasonable expectation of survival, and who had an informal family-
nominated caregiver were randomly assigned to intervention or usual care by site coordinators using a secure web-
based system with minimisation by site and stroke severity. The family members of participants in the intervention 
group received additional structured rehabilitation training—including information provision, joint goal setting, 
carer training, and task-specific training—that was started in hospital and continued at home for up to 2 months. The 
primary outcome was death or dependency at 6 months, defined by scores 3–6 on the modified Rankin scale 
(range, 0 [no symptoms] to 6 [death]) as assessed by masked observers. Analyses were by intention to treat. This trial 
is registered with Clinical Trials Registry-India (CTRI/2013/04/003557), Australian New Zealand Clinical Trials 
Registry (ACTRN12613000078752), and Universal Trial Number (U1111-1138-6707).
Findings Between Jan 13, 2014, and Feb 12, 2016, 1250 patients were randomly assigned to intervention (n=623) or 
control (n=627) groups. 32 patients were lost to follow-up (14 intervention, 19 control) and five patients withdrew 
(two intervention, three control). At 6 months, 285 (47%) of 607 patients in the intervention group and 287 (47%) of 
605 controls were dead or dependent (odds ratio 0·98, 95% CI 0·78–1·23, p=0·87). 72 (12%) patients in the intervention 
group and 86 (14%) in the control group died (p=0·27), and we observed no difference in rehospitalisation (89 [14%]
patients in the intervention group vs 82 [13%] in the control group; p=0·56). We also found no difference in total non-
fatal events (112 events in 82 [13%] intervention patients vs 110 events in 79 [13%] control patients; p=0·80).
Interpretation Although task shifting is an attractive solution for health-care sustainability, our results do not support 
investment in new stroke rehabilitation services that shift tasks to family caregivers, unless new evidence emerges. A 
future avenue of research should be to investigate the effects of task shifting to health-care assistants or team-based 
community care.
Funding The National Health and Medical Research Council of Australia.
Introduction
Stroke rates are rising in low-income and middle-income 
countries (LMICs) but services are scarce.1 Task shifting 
rehabilitation activities to unpaid caregivers might offer a 
sustainable alternative to conventional rehabilitation, and 
provide an affordable strategy to meet the health demands 
both in high-income countries and LMICs.2–5 India, with a 
sixth of the world’s population, has only around 35 stroke 
units, located mainly in urban centres.6,7 Consequently, 
most people have no access to specialised stroke care and 
little access to conventional rehabilitation programmes. 
Given that LMICs have only about 3% equivalent pur-
chasing power to spend on health care compared with 
high-income countries, any new model of stroke rehab-
ilitation should be both sustainable and effective.8,9 Our 
hypothesis was that family caregiver-delivered rehab-
ilitation would increase independence and survival after 
stroke unit admission. We report the results of the 
Family-led Rehabilitation after Stroke in India (ATTEND) 
trial, which assessed a rehabilitation training programme 
to deliver family-led rehabilitation after stroke.
Methods
Study design and participants 
ATTEND was a prospectively randomised open trial with 
blinded endpoint (PROBE) done across 14 hospitals in 
India. Approvals were obtained from the ethics committees 
of the University of Sydney, Australia, and at each part-
icipating hospital. Permission was also obtained from the 
Health Ministry Screening Committee, New Delhi, India. 
The trial methods were piloted in Ludhiana (Punjab, 
India)10 and the protocol was published before unblinding.11
Patients were eligible if they had a family-nominated 
caregiver (ie, an informal family caregiver or family-hired 
help or nurse) who was willing to deliver rehabilitation, 
were aged 18 years or older, had had a stroke within the 
Published Online 
June 27, 2017 
http://dx.doi.org/10.1016/
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past month, were able to be randomised within 7 days of 
admission to hospital, had residual disability (defined by 
needing help from another person for everyday activities), 
had a reasonable expectation of survival (ie, not for 
palliative care, with no evidence of widespread cancer or 
similar terminal condition), would be available for follow-
up for 6 months, and they and their caregiver provided 
consent. Site coordinators screened all admitted stroke 
patients and obtained written informed consent from 
patients and caregivers.
Overall management of the study was coordinated from 
The George Institute for Global Health (Sydney, 
Australia). Weekly teleconferences were undertaken 
between study personnel in Sydney and India during 
the preparation, conduct, and close-out of the trial. 
The national clinical coordination centre was based in 
Ludhiana and project management was based at The 
George Institute India (Hyderabad, Telangana, India). 
The Indian Institute of Public Health (Hyderabad, 
Telangana) provided inde pendent trial monitoring. 
Additional logic checks and central monitoring of data 
were done.
Randomisation and masking
The trial funded full-time coordinators (physiotherapists) 
and masked assessors at each site. The coordinator 
assessed patients for eligibility, obtained consent from 
them, and gathered key baseline and demographic 
data before randomisation. Coordinators were also 
responsible for training the patients and caregivers. 
Patients were randomly assigned (1:1) to intervention or 
a usual care control group via a secure web-based central 
randomisation system with minimisation by site and 
stroke severity (National Institutes of Health Stroke 
Scale [NIHSS] scores <8 vs ≥8). To address potential 
unblinding, coordinators were not permitted to treat 
other non-trial stroke patients or share an office with the 
masked assessor. Additionally, they were instructed to 
undertake patient training sessions in a private room 
or behind curtains. Assessors were kept unaware of 
the details of the trial intervention, including having 
separate training sessions at annual collaborator 
meetings. Any inadvertent unblinding at an assessment 
was recorded.
Procedures
The family rehabilitation training intervention was 
delivered in addition to routine rehabilitation at each site. 
An international steering group developed the culturally 
specific intervention, piloted an early version,10 and 
incorporated features to ensure it could be affordable 
when scaled up. The intervention was designed to be 
delivered by a rehabilitation professional (coordinator), 
started in hospital, and continued at home. It involved 
training family members to provide a simplified version 
of evidence-based rehabilitation,12–14 and included comp-
rehensive impairment and disability assessment by the 
coordinators; information provision; joint goal setting 
with the patient and caregiver for basic activities of daily 
living (ADL), extended ADL (EADL), and communication; 
caregiver training for limb positioning; encouragement 
of the practice of task-specific activities; and reminders to 
prepare the patient and carer for hospital discharge. The 
training was designed to take place for about 1 h a day in 
hospital for about 3 days, with the intention of expediting 
early supported discharge.11 After hospital discharge, the 
coordinator made up to six home visits to assess progress, 
continue caregiver training activities, and reset goals, and 
was available for further support by telephone for up to 
2 months after randomisation. No trial assessments were 
done by the coordinators during these home visits, which 
were purely for guidance and training. A written inter-
vention guide was available for the coordinators and an 
intervention manual for the patient and caregiver. To 
Research in context
Evidence before this study
In low-income and middle-income countries, community 
rehabilitation is seen as a high priority for health-care 
delivery to reduce disability. Systematic reviews of early 
supported discharge (ESD) stroke services have shown this 
model of care reduces death or dependency without adverse 
effects on family caregivers. We updated the search strategy 
(to Jan 6, 2017) for the Cochrane review of ESD services for 
people with acute stroke that categorises interventions into 
those with or without coordinated multidisciplinary team 
input. We identified two randomised controlled trials 
(n=289 in total) in the latter category that had tested a 
similar intervention: the ATTEND pilot study and an 
unpublished Chinese trial of nurse-delivered rehabilitation 
after stroke.
Added value of this study
This randomised controlled trial is the first large trial to our 
knowledge to test task shifting of stroke rehabilitation to family 
members. This approach did not improve outcome (compared 
with usual care) after stroke unit admission. The results were 
consistent with previous smaller trials of ESD services without 
multidisciplinary team coordination.
Implications of all the available evidence
Family-led rehabilitation did not improve outcomes, but did 
not increase harms such as increased burden of care for the 
family. These results do not support investment in new stroke 
rehabilitation services that shift tasks to family caregivers, 
unless new evidence emerges. Future models of low-cost 
stroke rehabilitation should investigate task shifting to 
non-family workers or team-based community care.
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reduce potential contamination, the manual was given to 
participants on the first home visit to prevent access by 
control participants in hospital.10 The coordinator ceased 
contact 1 month before the first follow-up (ie, at 2 months 
after randomisation) to reduce the risk of unblinding. 
Only the coordinators and members of the steering and 
management committees were aware of the details of the 
family rehabilitation training intervention (including the 
written guide). In our trial sites, usual care consisted of 
some therapy, in the form of assessment and treatment 
by a physiotherapist, during hospital stay, with post-
discharge care varying from no therapy to some outpatient 
therapy sessions.
To ensure intervention fidelity across sites, coordinators 
were collectively trained at study initiation and annual 
collaborator meetings, supplemented by on-site training as 
required. Intervention training was led by physio therapists 
from India and Australia. Day-to-day support was provided 
by a clinical coordination team that included a neurologist 
and physiotherapist. A log of trial interventions was kept by 
the coordinator for each participant for hospital and home 
visit activities. Intervention patients (with their caregivers) 
were encouraged by the coordinator to keep a daily log of 
rehabilitation activities for 30 days after discharge.
Baseline characteristics and events during the initial 
hospital stay were obtained by the unmasked coordinators: 
all other trial assessments were done at 3 months and 
6 months after randomisation by trained masked assessors 
who assessed the patient and caregiver at home, or at the 
hospital, or by phone if a face-to-face visit was not possible. 
Patients were assessed with the modified Rankin scale 
(mRS), which is a global seven-level measure of func-
tioning with scores of 0–2 representing good outcome and 
functional independence, 3–5 representing increasing 
levels of disability, and 6 death;15 the simple validated 
recovery and dependency questions;16 the Barthel Index of 
ADL (on a scale of 0–100 with lower scores representing 
fewer activities);17 the Nottingham EADL scale (on a scale 
of 0–66 with lower scores representing fewer activities);18 
the WHO Quality of Life (WHOQOL-BREF, with domains 
scored from 0 to 100 with lower scores representing lower 
quality of life);19 the EuroQol Group 5-Dimension Self-
Report Questionnaire, which includes an overall health 
state (on a scale of 0–100, with lower scores representing 
lower quality of life);20 and the Hospital Anxiety and 
Depression Scale subscales (HADS, with lower scores 
indicating fewer symptoms).21 Caregivers were assessed 
with the Caregiver Burden Scale (on a scale from 21 to 84, 
with lower scores representing less burden) and the 
HADS subscales.22
Outcomes
The primary outcome was the proportion of patients 
who were dead or dependent at 6 months as defined by 
scores of 3–6 on the mRS, with an ordinal shift analysis 
of the full range of categories of the mRS as a secondary 
outcome. Other secondary outcomes were the simple 
validated recovery and dependency questions, length 
of hospital stay, place of residence (whether the same 
as before stroke [yes/no]), the Barthel Index, the 
Nottingham EADL scale, quality of life (WHOQOL-
BREF and the EuroQol Group 5-Dimension Self-Report 
Figure 1: Trial profile
4832 patients screened 
1250 randomly assigned
623 assigned to the intervention group 627 assigned to the control group
10 not included in 3-month follow-up
 9 lost to follow-up
 1 withdrawn
17 not included in 3-month analysis
 15 lost to follow-up
 2 withdrawn
3582 excluded
613 included in 3-month follow-up
 600 assessed with mRS
 13 missing mRS
610 included in 3-month follow-up
 593 assessed with mRS
 17 missing mRS
607 included in 6-month follow-up and 
 analysed for primary outcome
605 included in 6-month follow-up and 
 analysed for primary outcome
6 not included in 6-month follow-up
 5 lost to follow-up
 1 withdrawn
5 not included in 6-month follow-up
 4 lost to follow-up
 1 withdrawn
Intervention (n=623)* Control (n=627) Total (N=1250)
Sex
Male 421 (68%) 416 (66%) 837 (67%)
Female 202 (32%) 211 (34%) 413 (33%)
Age (years)
n, mean (SD) 623, 57·5 (12·92) 627, 58·0 (14·21) 1250, 57·7 (13·58)
Median (IQR) 58 (50–66) 59 (49–67) 59 (50–66)
Range 18–95 19–95 18–95
18 to <40 58 (9%) 63 (10%) 121 (10%)
40 to <50 89 (14%) 97 (15%) 186 (15%)
50 to <60 189 (30%) 159 (25%) 348 (28%)
60 to <70 175 (28%) 176 (28%) 351 (28%)
70 to <80 89 (14%) 89 (14%) 178 (14%)
≥80 23 (4%) 43 (7%) 66 (5%)
Marital status
Married 563 (91%) 557 (89%) 1120 (90%)
Unmarried 16 (3%) 18 (3%) 34 (3%)
Separated 2 (<1%) 1 (<%) 3 (<1%)
Widowed 41 (7%) 51 (8%) 92 (7%)
(Table 1 continues on next page)
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Questionnaire), patient and caregiver anxiety and 
de pression according to the HADS subscales, and the 
Caregiver Burden Scale. We also assessed the following 
health economic out comes, which will be reported 
elsewhere: health-care resource use (visits to health 
professionals, hospital isation, and medication use), 
indirect costs to the family (eg, a family member giving 
up employment to act as a caregiver), direct medical 
costs (eg, private treatment, admission charges, drug 
treatments), and non-medical direct costs (eg, travelling 
costs). Adverse events, including a pre specified list 
of those most frequent after stroke, were sought. 
The prespecified list was comprised of deaths due to 
the initial stroke, myocardial infarction, pneu monia 
or other vas cular or non-vascular causes, and hospital-
isation due to recurrent stroke, myocardial infarction, 
bony fracture, infection, or other causes. Patients and 
caregivers were given a health diary to record details of 
any re-hospitalisation, with details obtained at each 
assessment.
Statistical analysis
On the basis of the Early Supported Discharge Stroke 
trials,13 in which death or dependency was 50% in controls, 
we estimated that a sample size of 1200 patients (600 per 
group) was needed to provide 90% power (α=0·05) to 
detect a 21% relative risk reduction (10·5% absolute 
reduction) in death or dependency in the intervention 
group with a 20% loss to follow-up.
All analyses were by intention to treat, and all tests were 
two-sided with a nominal level of significance of 5%. The 
primary analysis compared the proportion of patients who 
were dead or dependent (mRS 3–6) at 6 months between 
the intervention and usual care groups in an unadjusted 
logistic regression model. Sensitivity analyses were 
adjustment for study site, stroke severity (NIHSS score <8 
or ≥8), age (as a continuous variable), sex, household 
income (<5000 INR, 5000 to <15 000 INR, 15 000 to 
<30 000 INR, 30 000 INR and more, no answer or missing 
data), and patient level of education (completed college 
[diploma or certificate], university [degree], or postgraduate 
studies; completed high school [up to grade 12]; completed 
primary school or secondary school [up to grade –10]; did 
not complete primary school; no schooling or data 
missing); and a so-called leave one out analysis whereby 
the effect on the primary outcome was be calculated with 
all the participants from a single site removed one at a 
time.23 We did nine prespecified sub group analyses (age, 
sex, stroke severity, stroke pathology, stroke Oxfordshire 
Community Stroke Project Classi fication, carer type, 
education level, household income, and type of 
accommodation) by adding the subgroup variable as well 
as its interaction term, with the inter vention as fixed effects 
to the logistic regression model used for the primary 
analysis. Sex had been inadvertently omitted (due to author 
error) in the published statistical analysis plan but was 
prespecified in our internal analysis and is included for 
Intervention (n=623)* Control (n=627) Total (N=1250)
(Continued from previous page)
Main caregiver
Spouse 257 (41%) 261 (42%) 518 (41%)
Mother 14 (2%) 11 (2%) 25 (2%)
Father 3 (<1%) 6 (1%) 9 (1%)
Grandparents and others 2 (<1%) 2 (<1%) 4 (<1%)
Daughter or daughter-in-law 151 (24%) 125 (20%) 276 (22%)
Son or son-in-law 171 (27%) 192 (31%) 363 (29%)
Sister 3 (<1%) 8 (1%) 11 (1%)
Brother 17 (3%) 19 (3%) 36 (3%)
Hired help or nurse 4 (1%) 3 (<1%) 7 (1%)
Highest level of education completed (patient)
No schooling 88 (14%) 96 (15%) 184 (15%)
Less than primary school 58 (9%) 65 (10%) 123 (10%)
Primary school 113 (18%) 106 (17%) 219 (18%)
Secondary school 68 (11%) 57 (9%) 125 (10%)
High school 123 (20%) 142 (23%) 265 (21%)
College/university 142 (23%) 140 (22%) 282 (23%)
Postgraduate degree 29 (5%) 21 (3%) 50 (4%)
Unknown 1 (<1%) 0 1 (<1%)
Field of work (patient)
Management 4 (1%) 7 (1%) 11 (1%)
Professional and related 22 (4%) 19 (3%) 41 (3%)
Service 85 (14%) 75 (12%) 160 (13%)
Sales/commercial 64 (10%) 57 (9%) 121 (10%)
Construction 27 (4%) 29 (5%) 56 (4%)
Armed forces 7 (1%) 9 (1%) 16 (1%)
Farming/forestry/fishing 
and related
60 (10%) 65 (10%) 125 (10%)
Clerical/administrative support 21 (3%) 14 (2%) 35 (3%)
Installation and related 8 (1%) 4 (1%) 12 (1%)
Manufacture/production 16 (3%) 21 (3%) 37 (3%)
Transportation/driver 25 (4%) 27 (4%) 52 (4%)
Housewife 181 (29%) 186 (30%) 367 (29%)
Not applicable 102 (16%) 114 (18%) 216 (17%)
Work situation (patient)
Full-time paid work 224 (36%) 186 (30%) 410 (33%)
Part-time paid work 46 (7%) 50 (8%) 96 (8%)
Retired 96 (15%) 111 (18%) 207 (17%)
Unemployed 47 (8%) 31 (5%) 78 (6%)
Home duties 171 (27%) 203 (32%) 374 (30%)
Student 3 (<1%) 3 (<1%) 6 (<1%)
Other 35 (6%) 43 (7%) 78 (6%)
Accommodation details
Own house 501 (81%) 498 (79%) 999 (80%)
Own apartment/flat 19 (3%) 26 (4%) 45 (4%)
Rented flat 37 (6%) 36 (6%) 73 (6%)
Rented accommodation in a 
house
42 (7%) 47 (7%) 89 (7%)
Government/
company-provided house
22 (4%) 17 (3%) 39 (3%)
Jhuggi (slum) 0 1 (<1%) 1 (<1%)
Other 1 (<1%) 2 (<1%) 3 (<1%)
(Table 1 continues on next page)
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completeness.23 Other analyses included all seven 
categories of the mRS with ordinal logistic regression and 
a permutation test proposed by Howard and colleagues.24,25 
Analyses of secondary out comes at 3 and 6 months used 
t tests to compare means (eg, mean scores) and χ² tests to 
compare proportions (eg, place of residence). We analysed 
length of hospital stay using a log-rank test and serious 
adverse events using Fisher’s exact test. Further details are 
available in the Statistical Analysis Plan,23 which was 
finalised and submitted for publication before unblinding. 
All analyses were done with SAS Enterprise Guide 
version 7.1 (SAS/Stat version 9.4). An independent Data 
and Safety Management Committee monitored the 
unblinded accu mulating results and adverse events 
according to a written charter.
The trial was registered at the Clinical Trials Registry-
India (CTRI/2013/04/003557) and the Australian New 
Zealand Clinical Trials Registry (ACTRN12613000078752), 
and has a Universal Trial Number (U1111-1138-6707).
Role of the funding source
The National Health and Medical Research Council had 
no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding 
author had full access to all the data in the study and 
had final responsibility for the decision to submit for 
publication.
Results
Between Jan 13, 2014, and Feb 12, 2016, 4832 patients were 
screened, of which 1250 were randomly assigned to the 
intervention group (n=623) or the control group (n=627; 
figure 1). Baseline characteristics are shown in table 1. 
At hospital discharge, we found no between-group 
differences in mRS scores (562 [90%] of 622 patients in 
the intervention group vs 567 [90%] of 627 controls, 
p=0·96) nor in the Barthel Index scores (mean 43·0 
[SD 23·17] in the intervention group vs 43·2 [23·39] in 
controls, p=0·88; appendix).
The training programme was delivered as planned 
with a mean time of 3·0 h (SD 1·6; median 2·9 [IQR 
2·0–3·3]) in hospital. An additional 3·1 h (SD 1·7; 
median 2·8 [1·9–4·2]) of training were delivered 
during home visits. Intervention patients and caregivers 
reported 17·8 h (SD 21·6) of rehabilitation given in the 
first 30 days after hospital discharge (data available from 
574 participants). Details of the rehabilitation provided to 
both groups as part of routine care and the intervention 
are shown in the appendix. We found no evidence of a 
difference in total routine hospital rehabilitation time 
(2·0 h for intervention patients vs 2·1 h for controls, 
p=0·23), although intervention participants practised 
fewer mobility activities than did controls (521 [84%] of 
patients in the intervention group practised at least one 
activity vs 553 [88%] in the controls, p=0·023). We showed 
no statistical differences between groups in other non-
trial routine rehabilitation activities (appendix).
At 6 months, roughly the same number of participants 
were dead or dependent in the intervention group and in 
the control group (table 2). The neutral results were 
Intervention (n=623)* Control (n=627) Total (N=1250)
(Continued from previous page)
Living situation pre-stroke
Independent at home 616 (99%) 610 (97%) 1226 (98%)
Dependent at home 6 (1%) 12 (2%) 18 (1%)
Other 0 5 (1%) 5 (<1%)
Financial situation
Patient or his close family owns 
the house
507 (82%) 508 (81%) 1015 (81%)
Patient or his close family owns 
the flat
18 (3%) 20 (3%) 38 (3%)
Rented from landlord 77 (12%) 83 (13%) 160 (13%)
Government-owned or 
allocated housing
20 (3%) 16 (3%) 36 (3%)
Monthly household income (INR)†
<5000 93 (15%) 101 (16%) 194 (16%)
5000–14 999 178 (29%) 196 (31%) 374 (30%)
15 000–29 999 166 (27%) 151 (24%) 317 (25%)
30 000–59 999 99 (16%) 74 (12%) 173 (14%)
60 000–100 000 18 (3%) 20 (3%) 38 (3%)
>100 000 8 (1%) 12 (2%) 20 (2%)
Decline to answer 39 (6%) 43 (7%) 82 (7%)
Do not know 21 (3%) 30 (5%) 51 (4%)
Days from stroke onset to randomisation
n, mean (SD) 623, 4·9 (3·8) 627, 5·1 (4·1) 1250, 5·0 (4·1)
Median (IQR) 4 (3–6) 4 (2–6) 4 (3–6)
Range 0–28 0–29 0–29
Stroke type
Ischaemic 478 (77%) 478 (76%) 956 (76%)
Large artery atherosclerosis 214/478 (45%) 213/478 (45%) 427/956 (45%)
Cardioembolism 75/478 (16%) 54/478 (11%) 129/956 (13%)
Small artery occlusion 113/478 (24%) 131/478 (27%) 244/956 (26%)
Determined, other aetiology 16/478 (3%) 21/478 (4%) 37/956 (4%)
Undetermined 60/478 (13%) 58/478 (12%) 118/956 (12%)
Intracerebral haemorrhage 143 (23%) 148 (24%) 291 (23%)
Unspecified 1 (<1%) 1 (<1%) 2 (<1%)
OCSP classification‡
Total anterior circulation 
syndrome
67/478 (14%) 51/478 (11%) 118/956 (12%)
Partial anterior circulation 
syndrome
263/478 (55%) 269/478 (56%) 532/956 (56%)
Posterior circulation syndrome 72/478 (15%) 76/478 (16%) 148/956 (15%)
Lacunar syndromes 76/478 (16%) 81/478 (17%) 157/956 (16%)
NIHSS score
n, mean (SD) 622, 10·1 (4·9) 627, 9·6 (4·8) 1249, 9·9 (4·9)
Median (IQR) 9 (6–13) 9 (6–12) 9 (6–13)
Range 1–29 1–28 1–29
0 to <5 72 (11·6) 103 (16·4) 175 (14·0)
5 to <10 247 (39·7) 241 (38·4) 488 (39·1)
10 to <15 188 (30·2) 182 (29·0) 370 (29·6)
≥15 115 (18·5) 101 (16·1) 216 (17·3)
(Table 1 continues on next page)
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similar in adjusted analyses, leave-one-out sensitivity 
analyses, and across all secondary outcomes (tables 2, 3, 
figure 2, appendix). The mean number of days from 
randomisation to hospital discharge was 6·0 (SD 6·8) in 
the intervention group and 6·3 (7·5) in the controls 
(p=0·65). The intervention did not reduce total length of 
stay (mean stay of 9·3 [SD 7·4] days in the intervention 
group vs 9·5 [7·9] days in the controls, p=0·58; appendix). 
We found no significant differences in non-fatal or fatal 
adverse events: 72 (12%) deaths occurred in the 
intervention group compared with 86 (14%) in the control 
group (p=0·27); 112 non-fatal events occurred in 82 (13%) 
patients in the intervention group compared with 
110 events in 79 (13%) patients in the control group 
(p=0·80); and 89 (14%) patients in the intervention group 
were rehospitalised after discharge compared with 
82 (13%) patients in the control group (p=0·56; appendix). 
In the intervention group, deaths due to the initial stroke 
occurred in nine (1%) patients and 18 (3%) controls 
(p=0·12). We showed no between-group difference in 
caregiver strain, nor in anxiety or depression on the 
HADS. We documented unblinding in 33 (5%) 
intervention patients and 21 (3%) control patients 
(p=0·09).
Intervention (n=623)* Control (n=627) Total (N=1250)
(Continued from previous page)
Medical history
Hypertension 455/618 (74%) 460/620 (74%) 915/1238 (74%)
Diabetes mellitus 273/611 (45%) 265/614 (43%) 538/1225 (44%)
Dyslipidaemia 120/540 (22%) 132/536 (25%) 252/1076 (23%)
Atrial fibrillation 46/579 (8%) 44/589 (7%) 90/1168 (8%)
Coronary artery disease 93/595 (16%) 98/605(16%) 191/1200 (16%)
Obesity 95/621 (15%) 97/620 (16%) 192/1241 (15%)
Smoking 158/618 (26%) 143/622 (23%) 301/1240 (24%)
Alcohol use 164/619 (26%) 169/622 (27%) 333/1241 (27%)
Drug addiction 4/620 (1%) 1/621 (<1%) 5/1241 (<1%)
Carotid stenosis 112/562 (20%) 105/568 (18%) 217/1130 (19%)
Previous stroke/TIA 110/615 (18%) 112/617 (18%) 222/1232 (18%)
Rheumatic heart disease 21/611 (3%) 22/617 (4%) 43/1228 (4%)
Neoplastic disease 3/615 (<1%) 4/617 (1%) 7/1232 (1%)
Pregnancy 0/618 2/621 (<1%) 2/1239 (<1%)
Data are n (%) unless indicated otherwise. INR=Indian rupees. OCSP=Oxfordshire Community Stroke Project. 
NIHSS=National Institutes of Health Stroke Scale. TIA=transient ischaemic attack. *Data complete for sex and age. One 
patient withdrew from the intervention group after randomisation and the denominator is 622 for other baseline 
variables.†US$1=68 INR. ‡Classification for patients with ischaemic stroke.
Table 1: Baseline characteristics
Intervention (n=623) Usual care (n=627) Total (n=1250) Odds ratio (95% CI) p value*
Death or dependency (mRS score 3–6)
Month 3 (unadjusted) 336/600 (56%) 337/593 (57%) 673/1193 (56%) 0·97 (0·77–1·22) 0·77
Month 3 (adjusted)† 335/599 (56%) 337/593 (57%) 672/1192 (56%) 1·00 (0·77–1·29) 0·99
Month 6 (unadjusted; primary outcome) 285/607 (47%) 287/605 (47%) 572/1212 (47%) 0·98 (0·78–1·23) 0·87
Month 6 (adjusted)† 284/606 (47%) 287/605 (47%) 571/1211 (47%) 1·02 (0·80–1·31) 0·87
Ordinal analysis of mRS scores‡
Month 3 (unadjusted)
0 23/600 (4%) 27/593 (5%) 50/1193 (4%) 0·92 (0·75–1·12) 0·42
1 147/600 (25%) 130/593 (22%) 277/1193 (23%) ·· ··
2 94/600 (16%) 99/593 (17%) 193/1193 (16%) ·· ··
3 141/600 (24%) 133/593 (22%) 274/1193 (23%) ·· ··
4 116/600 (19%) 107/593 (18%) 223/1193 (19%) ·· ··
5 22/600 (4%) 30/593 (5%) 52/1193 (4%) ·· ··
6 57/600 (10%) 67/593 (11%) 124/1193 (10%) ·· ··
Month 3 (adjusted) 0·94 (0·76–1·15) 0·52
Month 6 (unadjusted)
0 56/607 (9%) 55/605 (9%) 111/1212 (9%) 1·00 (0·82–1·22) 1·00
1 170/607 (28%) 183/605 (30%) 353/1212 (29%) ·· ··
2 96/607 (16%) 80/605 (13%) 176/1212 (15%) ·· ··
3 120/607 (20%) 123/605 (20%) 243/1212 (20%) ·· ··
4 82/607 (14%) 65/605 (11%) 147/1212 (12%) ·· ··
5 11/607 (2%) 13/605 (2%) 24/1212 (2%) ·· ··
6 72/607 (12%) 86/605 (14%) 158/1212 (13%) ·· ··
Month 6 (adjusted) ·· ·· ·· 1·03 (0·84–1·27) 0·75
Data are n/N (%). mRS=modified Rankin scale. *p value calculated from the likelihood ratio of the logistic regression. †Adjusted analysis includes the following covariates: 
study site, stroke severity, age, sex, income, and education. ‡Ordinal analysis using proportional odds logistic regression.
Table 2: Analysis of mRS
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We found one significant interaction on the pre-
specified subgroup analysis, by sex, in which men had 
reduced odds of death or dependency at 6 months 
compared with women (figure 3).
Discussion
Our study showed that the addition of family-led 
rehabilitation training to usual stroke unit care did not 
decrease death or dependency at 6 months, nor was there 
any benefit noted at the 3-month assessment. 
Additionally, the training did not influence any of the 
other physical, emotional, or quality-of-life outcomes. 
The intervention was safe, with an observed non-
significant reduction in deaths, and no increase in 
caregiver burden. The training was delivered as planned 
with a mean of 3·0 h (median 2·9) of hospital training 
and a mean of 3·1 h (median 2·8) of community-based 
training, with components consistent with the trial 
intervention guide. In the context of these Indian stroke 
units, in which patients received a total of only 2 h of 
therapy, the intervention more than doubled the amount 
of hospital rehabilitation and provided additional 
community caregiver and patient training. In the 
intervention group, 30 min of daily rehabilitation 
activities were reported by the patient and caregivers in 
the month after discharge (17 h over 30 days).
The ATTEND intervention failed to reduce length of 
hospital stay. When our results are viewed in the context 
of the systematic review of early supported discharge after 
stroke,13 it can be seen that interventions without coord-
ination from a dedicated multidisciplinary team currently 
do not have evidence of benefit. We also note that the 
smaller RECOVER trial of nurse-delivered rehabilitation 
after stroke in China was negative (R Lindley, personal 
communication).
Our results are also consistent with the absence of 
benefit seen in a systematic review26 of trials of caregiver-
mediated exercises to improve activities of daily living. In 
this overview, the authors noted that the data were 
insufficient (only 333 patients were included in the 
six trials analysed) and that the quality of evidence was 
low to moderate. Although the ATTEND intervention 
emphasised caregiver-mediated exercises, these were not 
the only component of the intervention.
The absence of benefit of the family-rehabilitation 
intervention has important implications for stroke re-
covery research, behavioural change, and task shifting 
in general. Our training programme might not have 
Month 3 Month 6
Intervention Control p value Intervention Control p value
Recovery, dependency, and place of residence
Complete recovery from stroke* 72/546 (13%) 78/530 (15%) 0·55 133/534 (25%) 142/514 (28%) 0·28
Need help for everyday activities* 332/543 (61%) 320/528 (61%) 0·60 266/533 (50%) 245/514 (48%) 0·17
Place of residence† 0·81 0·92
Same as before stroke 516/543 (95%) 500/528 (95%) 502/533 (94%) 483/512 (94%)
Other 27/543 (5%) 28/528 (5%) 31/533 (6%) 29/512 (6%)
In another hospital since 
admission for stroke
1/27 (4%) 1/28 (4%) 1/31 (3%) 0
In family or friends’ home 17/27 (63%) 14/28 (50%) 16/31 (52%) 11/29 (38%)
In same hospital since admission 
for stroke
0 0 0 1/29 (3%)
Other dwelling place 9/27 (33%) 13/28 (46%) 14/31 (45%) 17/29 (59%)
Barthel Index
Total score‡ 0·41 0·74
n, mean (SD) 543, 76·1 (25·24) 525, 74·8 (26·05) 533, 82·1 (23·09) 512, 82·6 (23·19)
Median (IQR) 85 (60–100) 85 (60–100) 95 (70–100) 95 (70–100)
Range 0–100 0–100 0–100 0–100
Caregiver burden
Total score‡ 0·21 0·52
n, mean (SD) 543, 30·9 (10·70) 524, 31·7 (11·38) 532, 28·9 (10·01) 511, 29·3 (10·85)
Median (IQR) 27 (22–35) 29 (22–37) 25 (21–33) 25 (21–33)
Range 21–73 21–80 21–77 21–81
Nottingham Extended ADL Scale
Total score† 0·43 0·86
n, mean (SD) 537, 27·1 (17·21) 523, 26·3 (17·31) 527, 31·0 (17·67) 509, 31·2 (17·52)
Median (IQR) 27 (12–40) 25 (11–40) 31 (16–45) 32 (17–44)
Range 0–66 0–66 0–66 0–66
(Table 3 continues on next page)
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Month 3 Month 6
Intervention Control p value Intervention Control p value
(Continued from previous page)
WHO Quality of Life
Physical health‡ 0·96 0·63
n, mean (SD) 534, 51·2 (12·65) 521, 51·3 (12·28) 525, 54·3 (12·06) 509, 54·7 (12·11)
Median (IQR) 56 (44–63) 56 (44–63) 56 (44–63) 56 (44–63)
Range 13–81 6–81 13–94 19–100
Psychological‡ 0·99 0·17
n, mean (SD) 534, 49·2 (15·16) 521, 49·3 (14·99) 525, 52·1 (15·09) 509, 53·4 (14·63)
Median (IQR) 50 (38–56) 50 (38–63) 56 (44–63) 56 (44–63)
Range 6–100 6–94 0–94 6–88
Social relationship‡ 0·42 0·45
n, mean (SD) 529, 60·8 (17·21) 519, 60·0 (16·89) 523, 63·0 (17·41) 509, 62·2 (18·43)
Median (IQR) 69 (50–75) 56 (50–69) 69 (50–75) 69 (50–75)
Range 0–100 0–100 0–100 0–100
Environment‡ 0·61 0·76
n, mean (SD) 534, 65·3 (14·70) 521, 64·8 (15·78) 525, 67·8 (15·69) 509, 68·1 (15·95)
Median (IQR) 69 (56–75) 63 (56–75) 69 (56–75) 69 (56–81)
Range 19–100 13–100 19–100 19–100
Quality of life* 0·41 0·52
Very poor 21/535 (4%) 34/521 (7%) 17/526 (3%) 17/509 (3%)
Poor 97/535 (18%) 86/521 (17%) 77/526 (15%) 72/509 (14%)
Neither poor nor good 176/535 (33%) 167/521 (32%) 115/526 (22%) 105/509 (21%)
Good 225/535 (42%) 217/521 (42%) 284/526 (54%) 268/509 (53%)
Very good 16/535 (3%) 17/521 (3%) 33/526 (6%) 47/509 (9%)
Satisfaction with health* 0·31 0·65
Very dissatisfied 24/535 (4%) 17/521 (3%) 18/526 (3%) 16/509 (3%)
Dissatisfied 142/535 (27%) 123/521 (24%) 111/526 (21%) 92/509 (18%)
Neither satisfied nor dissatisfied 152/535 (28%) 156/521 (30%) 105/526 (20%) 104/509 (20%)
Satisfied 204/535 (38%) 203/521 (39%) 257/526 (49%) 254/509 (50%)
Very satisfied 13/535 (2%) 22/521 (4%) 35/526 (7%) 43/509 (8%)
EuroQol Group 5-Dimension Self-Report Questionnaire
Mobility* 0·37 0·32
I have no problems in walking 256/539 (47%) 226/523 (43%) 292/529 (55%) 282/510 (55%)
I have some problems in walking 235/539 (44%) 247/523 (47%) 201/529 (38%) 204/510 (40%)
I am confined to bed 48/539 (9%) 50/523 (10%) 36/529 (7%) 24/510 (5%)
Self-care* 0·52 0·75
I have no problems with self-care 235/539 (44%) 212/523 (41%) 278/529 (53%) 280/510 (55%)
I have some problems bathing or 
dressing myself
199/539 (37%) 197/523 (38%) 176/529 (33%) 162/510 (32%)
I am unable to bathe or dress myself 105/539 (19%) 114/523 (22%) 75/529 (14%) 68/510 (13%)
Usual activities* 0·95 0·59
I have no problems in performing my 
usual activities
185/538 (34%) 175/523 (33%) 227/529 (43%) 232/510 (45%)
I have some problems in performing 
my usual activities
210/538 (39%) 206/523 (39%) 211/529 (40%) 188/510 (37%)
I am unable to perform my usual 
activities
143/538 (27%) 142/523 (27%) 91/529 (17%) 90/510 (18%)
Pain/discomfort* 0·70 0·64
I have no pain or discomfort 228/538 (42%) 210/523 (40%) 270/529 (51%) 273/510 (54%)
I have moderate pain or discomfort 270/538 (50%) 269/523 (51%) 231/529 (44%) 208/510 (41%)
I have extreme pain or discomfort 40/538 (7%) 44/523 (8%) 28/529 (5%) 29/510 (6%)
(Table 3 continues on next page)
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been sufficient (in time and content) to deliver effective 
family rehabilitation, as we observed only about 30 min 
of daily activities in the intervention group. 
Conventional western rehabilitation is usually 
associated with greater daily therapy time (1–2 h).27 
Training of family members was designed to be 
sustainable, and if family members required more 
training to meet the needs of their family patient, then 
the aspiration of routinely providing rehab ilitation 
through task shifting to family caregivers might not be 
feasible. Family dynamics might also limit the 
effectiveness of this strategy, and task shifting to a non-
family generic health worker, such as the established 
Indian Accredited Social Health Activist (ASHA), might 
have been a more effective strategy, although probably 
more expensive. Technology-assisted rehabilitation 
might also be another option of task shifting that is the 
subject of current trials.28
Month 3 Month 6
Intervention Control p value Intervention Control p value
(Continued from previous page)
Anxiety/depression* 0·70 0·44
I am not anxious or depressed 229/538 (43%) 212/523 (41%) 265/529 (50%) 257/510 (50%)
I am moderately anxious or depressed 266/538 (49%) 272/523 (52%) 238/529 (45%) 219/510 (43%)
I am extremely anxious or depressed 43/538 (8%) 39/523 (7%) 26/529 (5%) 34/510 (7%)
Overall health state‡ 0·68 0·18
n, mean (SD) 539, 63·2 (21·21) 523, 63·8 (20·82) 529, 70·1 (20·36) 510, 71·8 (20·40)
Median (IQR) 65 (50–80) 65 (50–80) 70 (55–90) 75 (60–90)
Range 3–100 0–100 0–100 0–100
Hospital Anxiety and Depression Scale
Patient
Total score‡ 0·67 0·90
n, mean (SD) 536, 11·3 (8·35) 520, 11·5 (8·72) 527, 9·0 (7·81) 509, 9·1 (8·64)
Median (IQR) 10 (5–17) 10 (4–18) 7 (3–14) 7 (2–13)
Range 0–39 0–39 0–38 0–42
Anxiety score‡ 0·57 0·91
n, mean (SD) 536, 4·8 (4·01) 520, 4·9 (4·36) 527, 3·7 (3·74) 509, 3·7 (4·19)
Median (IQR) 4 (1–7) 4 (1–8) 3 (0–6) 2 (0–6)
Range 0–18 0–18 0–18 0–21
Score ≥8* 122/536 (23%) 138/520 (27%) 0·15 84/527 (16%) 83/509 (16%) 0·87
Depression score‡ 0·79 0·91
n, mean (SD) 536, 6·5 (4·94) 520, 6·6 (4·99) 527, 5·3 (4·64) 509, 5·3 (4·96)
Median (IQR) 6 (2–10) 6 (2–10) 4 (2–8) 4 (1–8)
Range 0–21 0–21 0–21 0–21
Score ≥8* 197/536 (37%) 198/520 (38%) 0·66 145/527 (28%) 141/509 (28%) 0·95
Caregiver
Total score‡ 0·62 0·86
n, mean (SD) 546, 7·5 (7·52) 527, 7·7 (7·88) 532, 5·5 (6·68) 511, 5·5 (6·80)
Median (IQR) 5 (2–12) 5 (1–12) 3 (0–9) 3 (0–8)
Range 0–42 0–39 0–36 0–42
Anxiety score‡ 0·67 0·91
n, mean (SD) 546, 3·7 (3·86) 527, 3·8 (4·17) 532, 2·7 (3·40) 511, 2·6 (3·51)
Median (IQR) 2 (0–6) 2 (0–6) 1 (0–4) 1 (0–4)
Range 0–21 0–20 0–16 0–21
Score ≥8* 83/546 (15%) 96/527 (18%) 0·19 55/532 (10%) 50/511 (10%) 0·77
Depression score‡ 0·61 0·82
n, mean (SD) 546, 3·8 (4·17) 527, 3·9 (4·16) 532, 2·9 (3·69) 511, 2·8 (3·60)
Median (IQR) 3 (0–6) 3 (0–6) 1 (0–5) 2 (0–5)
Range 0–21 0–21 0–21 0–21
Score ≥8* 100/546 (18%) 100/527 (19%) 0·78 68/532 (13%) 56/511 (11%) 0·36
ADL=activities of daily living. *p value by χ² test. †p value by χ² test only performed on “same as before stroke” versus “other”. ‡p value by t test.
Table 3: Analysis of secondary outcomes at months 3 and 6
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The absence of benefit might also have been due to 
individual training components being ineffective in 
changing behaviour. This possibility was raised by another 
trial, undertaken in the UK, in which caregiver training 
(part of our intervention) was ineffective in the acute 
setting.29 Because we were aware of these results before 
beginning our study, we also placed emphasis on the 
importance of continuation of caregiver training after 
hospital discharge. The comprehensive nature of our 
intervention might have diluted the effect of individual 
components, and this less specified approach—eg, too 
much time spent on information provision—might have 
been at the expense of training task-specific mobility 
exercises.
Although our primary outcome was not significant, the 
sample size might still have been insufficient to detect a 
more modest treatment effect. However, the consistency 
of results across all health dimensions provides support 
for the overall neutral effect. The main qualitative 
differences between conventional rehabilitation in high-
income countries, compared with our family rehabilitation 
intervention, are in the professional multidisciplinary 
Figure 2: Patients achieving each mRS score at 6 months
mRS=modified Rankin Scale.
Figure 3: Main subgroup analyses on the primary outcome (dead or dependent)
NIHSS=US National Institutes of Health Stroke Scale. OCSP=Oxfordshire, UK, Community Stroke Project Stroke Classification. *Household income in Indian 
rupees (INR) per month (US$1=68 INR).
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 0·78 (0·50–1·20)
 1·29 (0·84–1·97)
 1·26 (0·74–2·15)
 1·39 (0·93–2·05)  0·0374 
 0·83 (0·63–1·10) 
 1·88 (0·87–4·05) 0·1353 
 0·95 (0·65–1·38)
 0·76 (0·50–1·16)
 0·60 (0·30–1·20)
 0·81 (0·51–1·29)  0·3544 
 1·04 (0·80–1·35) 
 1·29 (0·63–2·63)  0·5097 
 1·09 (0·77–1·54) 
 0·65 (0·34–1·27) 
 1·09 (0·52–2·29) 
 1·35 (0·83–2·18)  0·4292 
 0·82 (0·54–1·25) 
 0·88 (0·62–1·26) 
 1·15 (0·47–2·80) 
 1·10 (0·70–1·73)  0·1660 
 0·60 (0·37–0·98) 
 1·11 (0·77–1·61) 
 1·23 (0·67–2·24) 
 1·31 (0·74–2·34)  0·4821 
 0·73 (0·48–1·10) 
 1·08 (0·69–1·70) 
 1·12 (0·66–1·90) 
 1·11 (0·55–2·24) 
 0·98 (0·76–1·26) 0·9774
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structure and frequent review meetings. Our results 
suggest that the lower dose of family rehabilitation 
training, delivered by one professional, although based on 
evidence-based components across multiple disciplines, is 
an ineffective model of care. Since our trial was done at 
stroke units around India, our findings have not ruled out 
the possibility that the intervention could offer benefits in 
non-specialised hospitals, especially in rural and remote 
settings.
The unexpected interaction with sex, with the observed 
improved outcome in men compared with women, 
might be due to the play of chance and requires further 
analysis. However, in Indian society, important sex 
differences might exist in the receipt and provision of a 
complex intervention such as ours. Our process 
evaluation aims to explore this, and other, aspects of the 
trial, in more detail.30
Strengths of our study include the piloting and 
development of a structured intervention supported by 
written materials and use of robust trial methods to 
address priorities set out in the WHO and World Bank 
World Report on Disability.9 Our funding provided 
sufficient resources to address the research question 
comprehensively and has contributed to building stroke 
research capacity across India. Our trial data are 
consistent with epidemiological evidence that stroke is 
affecting people in India about 15 years younger than 
those in high-income countries, highlighting the public 
health importance of improving global rehabilitation 
services, especially since many of our participants were 
still in paid work.31 However, generalisability of our 
results to other areas of the country without rehabilitation 
might be limited, given that our participants were 
generally from urban centres with higher-than-average 
education and income.
Task shifting is an attractive solution for health-care 
sustainability.4,32,33 However, none of 22 recommendations 
of the WHO Task Shifting Guidelines referenced 
evidence generation on effectiveness, despite 
acknowledgment that implementation of these 
recommendations and guidelines should be accompanied 
by rigorous evaluation.4 Our assessment of training the 
patient and family caregiver showed that this particular 
model of rehabilitation was ineffective. Our results 
illustrate that task shifting away from conventional 
rehabilitation, without rigorous evaluation, could waste 
limited resources. Our neutral results will be further 
interrogated through a process assessment that will 
examine the social and economic influences on the 
behaviour of carers and patients. ATTEND was developed 
from the evidence base current at the time and focused 
on pragmatic solutions. Future research in this area 
could incorporate more behavioural change theory and 
evidence when developing a new intervention.
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Abstract
Background: Globally, most strokes occur in low- and middle-income countries, such as India, with many affected
people having no or limited access to rehabilitation services. Western models of stroke rehabilitation are often
unaffordable in many populations but evidence from systematic reviews of stroke unit care and early supported
discharge rehabilitation trials suggest that some components might form the basis of affordable interventions in
low-resource settings. We describe the background, history and design of the ATTEND trial, a complex intervention
centred on family-led stroke rehabilitation in India.
Methods/design: The ATTEND trial aims to test the hypothesis that a family-led caregiver-delivered home-based
rehabilitation intervention, designed for the Indian context, will reduce the composite poor outcome of death or
dependency at 6 months after stroke, in a multicentre, individually randomized controlled trial with blinded
outcome assessment, involving 1200 patients across 14 hospital sites in India.
Discussion: The ATTEND trial is testing the effectiveness of a low-cost rehabilitation intervention that could be
widely generalizable to other low- and middle-income countries.
Trial registration: Clinical Trials Registry-India CTRI/2013/04/003557. Australian New Zealand Clinical Trials Registry
ACTRN12613000078752. Universal Trial Number U1111-1138-6707.
Keywords: Caregivers, Costs, Disability, Rehabilitation, Stroke
Background
Stroke causes 6 million deaths each year among 17 mil-
lion affected people, with the greatest burden experi-
enced in populations of low- and middle-income
countries [1]. In these countries, the burden of stroke is
increasing, owing to lifestyle changes and rapid ageing of
populations. Furthermore, stroke tends to affect people
at relatively younger ages where there is poor control of
established risk factors, in particular high blood pressure
[2], with significant social and financial consequences
for families, owing to limited financial protection from
the costs of care and minimal social safety nets [3].
Stroke usually affects at least two people in a family, the
patient and at least one family caregiver, with epidemic
proportions of premature loss of productive lives in
developing countries, such as India [4–6].
Like many developing countries, India is experiencing
an epidemiologic transition, in which the burdens of
infectious disease, maternal and child health problems
are decreasing, while the burden of non-communicable
chronic diseases, such as stroke and injury, is increasing
[7]. In India, based upon an annual incidence of stroke
of 135 to 145 per 100,000, and early case fatality of
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between 27 % and 41 % [7–10], it has been estimated
that 1.5 million people experience stroke each year,
and a further 500,000 people live with stroke-related
disability. The long-term consequences of stroke on
families in India, particularly in rural areas, are likely
to be significant.
The most important treatment for patients with stroke
is well-organized specialist care [11], which allows rapid
and well-coordinated assessment and diagnosis [12, 13],
early recognition and management of complications,
early rehabilitation, education, and appropriate long-
term support and secondary preventative therapy. Stroke
unit care has greater public health impact than treat-
ment with thrombolysis (alteplase) alone, even with the
most optimal thrombolysis rates [11], because thromb-
olysis rates are rarely greater than 20 % (with a 5–10 %
absolute benefit), yet stroke unit care is applicable to
all (with a 5 % absolute benefit). Organized stroke
care should be a public health priority in low- and
middle-income countries, to ameliorate the increasing
burden of stroke.
Although appropriate stroke unit care and rehabilita-
tion may meet important clinical, physical and psycho-
social needs during the early post-stroke phase, the
needs of patients and families in the long term cannot
solely be addressed in hospital [14, 15]. Advocates for
early supported discharge and home-based stroke re-
habilitation, which is based upon a coordinated stroke
unit model of care, argue that it offers several advan-
tages: satisfying patient choice; reducing risks (and costs)
associated with inpatient care through reductions in
length of hospital stay; a better rehabilitation setting, as
the home setting is more focused towards realistic goals,
social inclusion and a supportive environment; and lead-
ing to savings in direct and indirect costs [16, 17]. Early
supported discharge provides a continuous process of
rehabilitation that spans the in-hospital period and the
weeks of resettlement and readjustment at home. A
meta-analysis of 11 trials (mainly conducted in devel-
oped countries, where fully funded community rehabili-
tation teams are available) shows that early supported
discharge services significantly reduced the odds of death
or dependency by 21 % (odds ratio 0.79; 95 % confidence
interval 0.64–0.97), without major adverse effects, either
on patients or caregivers [17].
Although acute stroke units are increasing as re-
sources improve in India, they meet the needs of only a
tiny fraction of the country’s vast population, and the
majority of Indians do not have access to rehabilitation
services, either in hospital or following discharge. The
development of effective low-cost community rehabili-
tation services for emerging major chronic diseases,
such as stroke in India, has the potential for significant
public health impact. Such interventions, if shown to
be effective and affordable, could be widely scaled up or
generalizable. Indeed, the research question of how to
create sustainable and multiprofessional rehabilitation
systems in low- and middle-income countries, includ-
ing the provision of services to the rural population,
was considered the second most important research
priority (after equality of healthcare access) for disabled
people in a recent Lancet expert panel [18]. Currently,
most Indian stroke units are situated in the private
sector [19, 20]. Clear evidence that low-cost interven-
tions are cost-effective in India would facilitate their
expansion within the public hospital system, where
rehabilitation has some important features that differ
from those in high-income countries: therapy is driven
largely by physiotherapists, with limited input from
other health professionals, such as occupational thera-
pists; it is often poorly coordinated; and most people
receive care within a large family unit (‘a joint family’,
often called an extended family) after discharge [21].
A modified version of the Western model of early
supported discharge, together with a development of the
Indian-suggested solution based on rehabilitation deliv-
ered by a trained family caregiver, appears to be the
most promising hybrid model of stroke care that could
be widely implemented, if shown to be successful. Similar
models have been shown to be cost-effective in the UK
[22, 23]. To develop appropriate health policy, though,
effectiveness and cost-effectiveness of any new model of
care including rehabilitation needs rigorous evaluation in
the relevant setting.
Methods
The ATTEND study is a multicentre, prospective, indi-
vidually randomized, blinded outcome assessed, controlled
trial (prospective, randomized, open, blinded, endpoint
design) of early supported discharge with a trained
family-led caregiver.
The intervention is a stroke rehabilitation package of
care that starts in hospital and continues at home,
compared with usual care, in at least 1200 patients with
mild to moderate disability recruited from 14 hospital
sites across India.
The inclusion criteria are:
 Adults (≥18 years);
 Recent (<1 month) acute ischaemic, haemorrhagic
or undifferentiated stroke;
 Residual disability (requiring help from another
person for everyday activities);
 Expected to survive to discharge from hospital,
with a reasonable expectation of 6 month survival
(i.e. not palliative, no evidence of widespread
cancer etc.);
 Able (or by proxy) to provide informed consent.
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Exclusion criteria are:
 Unable to identify a suitable family-nominated care-
giver for training and subsequent delivery of care;
 Unwilling or unable to adhere to follow-up.
Randomization
Eligible patients are identified by the trial stroke coord-
inator (usually a physiotherapist) and medical coordin-
ator. A patient information sheet (Additional file 1) is
shared with the patient and nominated caregiver, and
outlines the study objectives and risks and benefits to
the patient or caregiver. Informed consent from each
participant and his or her caregiver is obtained based on
the International Conference on Harmonisation Good
Clinical Practices guidelines (ICH/GCP) and ethical
guidelines for biomedical research on human partici-
pants published by the Indian Council of Medical
Research, New Delhi (Fig. 1). If the caregiver changes by
the time of the 3- or 6-month follow-up periods, the
new caregiver will be asked to provide consent for the
caregiver aspects of follow-up after reading the patient
information sheet. Stroke patients often do not have the
capacity to consent, owing to the acute effects of stroke.
Capacity for informed consent is assessed by the medic-
ally qualified principal investigator at each site. The
ethics committee have approved ATTEND to obtain
consent from a legally acceptable representative in such
cases. Once consented, patients are randomized by the
trial stroke coordinator to the intervention or control
arm in a 1:1 ratio within 7 days of hospital admission,
using a secure, central, password-protected, web-based
system, stratified by centre and stroke severity.
Intervention arm
Patients allocated to the intervention arm have their
family-nominated caregiver trained by a specially trained
trial stroke coordinator health professional (e.g., nurse,
therapist) using a trial-specific structured assessment
(cognition, language, function and mobility) and recom-
mended rehabilitation package. The rehabilitation package
includes a structured checklist and culturally appropriate
manual (adapted to local Indian contemporaneous stroke
practice) covering key activities relevant to daily living
(e.g., positioning, transfers, mobilization, feeding, dressing,
activity and motor practice, and monitoring of mood).
Detailed instructions for selected training exercises are
used from http://www.physiotherapyexercises.com. Train-
ing begins in hospital immediately after randomization for
those allocated to the intervention, with a goal of
approximately 60 min training per day for about 3 days,
with the intention of accelerating the patient’s hospital
discharge, when it is safe to do so, in addition to usual
hospital care. The trial stroke coordinator visits the
patient and caregiver’s home, if they are allocated to the
intervention arm, on up to six occasions over the next 2
months, to provide guidance and to monitor progress
after discharge, and is available by telephone for further
support and guidance as the patient progresses.
A detailed written intervention guide, adapted from
previous work [24], instructs all trial stroke coordinators
in delivering the structured intervention in a standardized
manner; this is reinforced at training sessions during the
annual collaborators’ meetings.
The intervention components are:
 Information on stroke recovery trajectory, risk,
identification and management of low mood,
importance of repeated practice of specific activities.
 Positioning, transfers and mobility.
 Discharge planning.
 Joint goal setting with patient, nominated family
caregiver and therapist (reviewed with coordinator
as patient progresses and new goals set).
 Task-orientated training (particularly walking, upper
limb and self-care tasks) with personalized copy of
culturally appropriate manual.
The detailed intervention guide and manual are kept
confidential and will only be published after the last
patient follow-up has been completed, to avoid con-
tamination of the control patients during the conduct
of the trial.
Control arm
These patients will receive usual hospital care in terms
of access to rehabilitation, timeliness of discharge and
follow-up, without any explicit provision of accelerated
discharge or caregiver training.
Outcome measurement
The primary outcome measure is the effect of treatment
allocation on death or dependency (a score of 0–2 on
the modified Rankin scale [25]) at 6 months after
randomization [26]. Patients will be seen after 3 and 6
months by an independent blinded assessor who will
collect the primary and secondary outcome data.
Secondary outcome measures are:
 Effect of treatment on shift in disability, as measured
by the modified Rankin scale, and analyzed with
shift (ordinal) analysis;
 Answers to the simple validated recovery (Have you
made a complete recovery from your stroke?) and
dependency (Do you need help from another person
for everyday activities?) questions [27];
 Hospital length of stay;
 Place of residence;
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Fig. 1 Study flow chart. ADL, activities of daily living; EQ-5D-3L, EuroQol 5-Dimensional, 3 Levels; NIHSS, National Institutes of Health Stroke Scale;
WHOQOL-BREF, World Health Organization Quality of Life (Brief)
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 Scores on the Barthel Index [26];
 Score on the Caregiver Burden Scale [28];
 Health-related quality of life (World Health
Organization Quality of Life Assessment and
EuroQol 5-Dimensional scores) [29, 30];
 Patient and caregiver mood (Hospital Anxiety and
Depression Scale) [31];
 Extended activities of daily living (Nottingham
Extended Activities of Daily Living Scale) [32];
 Health care resource use (visits to health professionals,
hospitalization, and medication use) and direct costs
for the patient (e.g. payment to the caregiver to act as
carer for this patient, total direct costs of healthcare
paid by the family since time of stroke);
 Indirect costs (e.g. family member giving up paid
employment to act as caregiver) of the family;
 Direct medical costs (e.g. total expenditure during
hospital admission, including first place where
patient was taken, general or private admission,
length of hospital stay, admission charges,
investigation charges and drug treatment);
 Non-medical direct costs (e.g. travelling costs).
Clinic or telephone follow-up will be offered if home
visits are not possible.
Data are collected on paper forms with an English
translation on one side and the appropriate local Indian
language on the other side. Each patient is identified by
a unique identifier with only local sites holding the
master log of names. The trial database is held and
maintained by The George Institute for Global Health,
with access for analysis determined by the steering
committee. Future access to participant level data and
statistical code will depend on additional funding to
safeguard and prepare the data and is contingent upon
compliance with data management guidelines in India
and Australia.
Adverse events
Given that patients with stroke are expected to experience
frequent adverse events, we defined our ‘expected’ events
a priori. These are listed in a checklist at each follow-up.
Any other adverse event is also recorded. Our expected
serious events are: (1) deaths categorized as vascular
(stroke, myocardial infarction, other vascular), infection,
fracture, other and (2) Hospitalizations (stroke, myocardial
infarction, other vascular, infection, fracture, other).
Risks to internal validity
The main risks to the internal validity of the trial are
‘contamination’ between treatment groups, threats to the
fidelity of the intervention and unblinding. To prevent
‘contamination’ between intervention and control pa-
tients in the ward during the hospital stay, we advise
that the stroke coordinators delivering the intervention
interview patients and carers in a private consulting or
treatment room or use curtains around the patient’s bed.
The time spent by the routine ward physiotherapist with
control and intervention patients is monitored and
recorded, to check that there is no systematic bias in
routine physiotherapy. To help prevent control patients
from viewing the trial manual, the manuals are given to
intervention patients at the time of the first home visit
and a general stroke booklet (placebo) is given to both
groups. The topic of ‘contamination’ forms part of the
regular training at site initiation, site visits and annual
collaborators’ meetings.
Fidelity of the trial intervention is monitored during site
initiation and subsequent site training visits by the clinical
coordination team and a consultant physiotherapist
contracted to help with training. Logs of all intervention
activities are collected and analyzed to summarize the
duration of each intervention and the main activities
within the intervention. In addition, we will document
whether the trial participants were assessed or treated by
the usual routine care physiotherapists, and measure
the total time spent per patient, to ensure that both
intervention and control patients have the same back-
ground rehabilitation care.
Blinding is maintained by employing a dedicated
blinded outcome assessor for each site. It is a require-
ment that the blinded outcome assessor not share the
same office as the stroke coordinator and has separate
computer and scanning equipment. The detailed written
intervention guide has been kept confidential from the site
principal investigators and blinded outcome assessors at
each site. At the annual collaborators’ meetings, there are
separate training sessions for the stroke coordinators and
blinded outcome assessors, to maintain confidentiality of
the intervention details. Patients are asked not to disclose
details of home visits to the blinded outcome assessor, and
intervention patients are asked to hide the trial manual
when the blinded outcome assessors visit. The trial inter-
vention is stopped one month before the first follow-up at
3 months to help reduce unblinding. Any inadvertent
unblinding is recorded by the blinded assessor. Exam-
ples of unblinding are discussed at the plenary sessions
at the collaborators’ meetings to share experiences, and
to implement strategies to prevent future occurrences.
Sample size and statistical consideration
In the meta-analysis of early supported discharge trials,
the proportion of people dead or dependent at the end
of follow-up was 50 % and the likely beneficial effect of
early supported discharge treatment was an odds reduc-
tion of 21 % (95 % confidence interval 3–26 %). There-
fore, the proposed minimum sample size of 1200 (600
per group) provides at least 90 % power (two-tailed α,
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0.05) to detect plausible modest 10.5 % reductions in
death or dependency in the intervention group with
inflation by 20 % to account for patients dropping out of
the trial. Ideally, a higher recruitment will allow a greater
precision for treatment estimates, and could permit
more detailed subgroup analysis; thus, when 1200 patients
have been recruited, and if funding and time permits, the
data and safety monitoring committee will advise on
whether it is safe to continue recruitment. Experience
during 2014 and early 2015 has allowed prediction that
the trial will complete recruitment in early 2016, based on
current strategies.
The intention to treat principle will be applied in all
analysis. The primary endpoint measure is the propor-
tion of those dead or dependent (modified Rankin scale
score 0–2) at 6 months. This will be analyzed using an
unadjusted logistic regression model. Binary secondary
outcomes will be analyzed similarly, using analysis of
variance (t tests) for continuous variables. For the shift
analysis of modified Rankin scale using all seven categor-
ies (including 6 for death), ordinal logistic regression will
be used, after verifying the proportional odds assump-
tion. A statistical analysis plan will be completed prior
to analysis and unblinding of the trial data.
Ethics
Ethical approval has been obtained from Research Integ-
rity, the Human Research Ethics Committee at the
University of Sydney and at each local site (Table 1).
Protocol amendments will be first approved by the
University of Sydney ethics committee and then by local
ethics committees before implementation. The current
approved protocol is version 1.3, dated 9 December 2013.
Data collection and study management
Data will be collected for all patients randomized in
the trial. Baseline data will be collected by the stroke
coordinator and the follow-up data by the blinded out-
come assessor on paper forms with appropriate local
translation and are scanned and directly sent to the
data management team for entry into the electronic
database. The investigators and institution will allow
monitors to verify the data collected on case report
forms with respect to all pertinent medical records,
according to ICH/GCP guidelines [33].
A data and safety monitoring committee, composed of
five experts in the fields of stroke medicine, rehabilitation,
statistics and clinical trials, with appropriate Indian repre-
sentation, is monitoring the study, guided by a written
charter with appropriate stopping rules.
The trial is governed by a steering committee formed
by the applicants of the National Health and Medical
Research Council (NHMRC) grant, and supplemented
as agreed by the committee. The steering committee is
co-chaired by Richard Lindley and GV Murthy. Other
members include Jeyaraj Pandian, Pallab Maulik, Peter
Langhorne, Lisa Harvey, Maree Hackett, Marion Walker,
Anne Forster, BR Shamanna, Craig Anderson and Stephen
Table 1 Trial sites
Collaborator Centre City Name of ethics committee
Dr Jeyaraj D Pandian Christian Medical College and Hospital Ludhiana, Punjab Institutional Ethics Committee
Dr MV Padma All India Institute for Medical
Sciences and Technology
New Delhi Institute Ethics Committee
Dr PN Sylaja Sree Chitra Tirunal Institute for
Medical Sciences and Technology
Trivandrum, Kerala Institutional Ethics Committee
Dr P Vijaya Lalitha Super Specialty Hospital Guntur, Andhra Pradesh Lalitha Super Specialities Hospital
Ethics Committee
Dr Sanjith Aaron Christian Medical College Vellore, Tamil Nadu Office of Research Institutional
Review Board
Dr Jayanta Roy Apollo Gleneagles Kolkata Institutional Ethics Committee
Dr Lydia John Baptist Christian Hospital Tezpur, Assam Research Ethics Committee
Dr Subhash Kaul Nizam Institute for Medical Sciences Hyderabad Nizam’s Institute of Medical Sciences
Institutional Ethics Committee
Dr Dheeraj Khurana Postgraduate Institute for Medical
Sciences and Research
Chandigarh Institute Ethics Committee
Dr NC Borah Guwahati Neurological Research
Centre Hospitals
Assam Institute of Neurological Sciences Trust Ethics Committee
Dr DS Halprashanth Global Hospitals Chennai Institutional Ethics Committee
Dr B Lokesh BGS Global Hospital Bangalore Institutional Ethics Committee
Dr Vivek Nambiar Amrita Institute of Medical Sciences Kochi Institutional Ethics Committee
Dr Sachin Sureshbabu St Stephen’s Hospital New Delhi Ethics Committee of St. Stephen’s Hospital
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Jan. The steering committee is responsible for all major
decisions regarding the running of the trial, the appoint-
ment of trial staff and financial reconciliation for the
NHMRC funding.
The day-to-day management of the trial is undertaken
by a management committee comprised of co-principal
investigators Professors Pandian and Lindley, together
with Mr Mohammed Alim, the trial senior project
manager (based at The George Institute, India), the trial
clinical coordinator (based at the Christian Medical
College Ludhiana), and representatives from the Indian
Institute of Public Health, Hyderabad, together with
appropriate trial administrative staff. These meetings are
conducted weekly by teleconference. Trial monitoring is
performed according to the monitoring plan and as per
ICH/GCP, by the monitors from Indian Institute of
Public Health.
The main results of the trial will be published in the
name of the ‘ATTEND Collaborative Group’ with all
contributions named in the primary trial manuscript.
According to new NHMRC policy, this primary publica-
tion must be free to access. All publications must be
approved by the steering committee with appropriate
authorship determined by the steering committee and
journal regulations. The NHMRC funding will be ac-
knowledged in all publications.
Discussion
The beneficial effects of early supported hospital discharge
and home-based rehabilitation on a patient’s recovery
from stroke are probably due to improved focusing of
therapy around functioning and activities that are most
relevant and familiar within the home environment with
family support. Yet, as most of this research has been
undertaken in urban settings of high-income countries,
the impact in low- and middle-income countries is
unclear. Moreover, uncertainty over the essential staffing
and organizational requirements of such services (i.e. a
complex intervention and organizational transfer) has
hampered their wider implementation and development
in different settings, even in the UK [34].
ATTEND is testing the effectiveness of a low-cost
rehabilitation intervention that could be widely
generalizable to other low- and middle-income coun-
tries. If the trial provides evidence of safety, efficacy
and cost-effectiveness, it is likely that adaptations of
the intervention could then be considered to augment
routine care in high-income countries, with culturally
appropriate adaptations to other low-income, marginalized
or disadvantaged populations.
The ATTEND intervention was developed during
2010–2012 based on emerging new Indian stroke services,
modified by accumulating evidence from the stroke unit
and early supported discharge trials, as advised by an
expert panel of stroke researchers and trial organizers.
The intervention was a pragmatic culturally adapted pack-
age piloted in Ludhiana, Punjab, India [35] and was
further modified based on this experience. After the main
trial was funded, the clinical coordination team developed
the final intervention guide with further advice from the
steering committee, and a trial manual for the intervention
patients was produced.
Careful thought was given to the time and cost im-
plications for the interventions, while keeping in mind
the number and quality of interventions included in
the package; the stroke coordinator is trained to deliver a
tailor-made package for patient-specific functional needs.
The efficacy and safety of health interventions are
best evaluated in randomized controlled trials and our
prospective, randomized, open, blinded, endpoint study
design helps ensure avoidance of bias in the follow-up of
patients, a recurrent problem in previous rehabilitation
trials. Extensive measures were taken to ensure that
assessment was blinded in ATTEND, e.g., keeping the
details of the intervention confidential to the stroke
coordinators, ensuring separate training of the blinded
outcome assessors, and employing dedicated research staff
for the blinded assessment.
India launched its National Programme for Preven-
tion and Control of Diabetes, Cardiovascular Diseases
and Stroke in January 2008. The programme aims to
strengthen infrastructure at all levels of care at the
community level with the help of caregivers, who are
important in the delivery of this programme, and are
thus clearly aligned with a family-led rehabilitation
model [36].
If ATTEND does not show efficacy or results in an
unexpected hazard, data from the trial will inform the
reasons why and what modifications could be made
while balancing the additional costs against the infra-
structure and human resource needs.
Trial status
The first patient was randomized on 13 January
2014 and the recruitment is expected to complete by
February 2016. The study recruitment is continuing
as planned.
Additional file
Additional file 1: Model informed consent form. (PDF 237 kb)
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APPENDIX 4 
 
Appendix Overview 
This appendix comprises of a publication titled “The need for theory-based evaluation of 
care coordination initiatives: Considerations from the 2017 International Conference on 
Realist Research, Evaluation and Synthesis.”  
This is a publication arising from a serendipitous and engaging discussion with 3 other 
researchers, at an international conference in 2017. We had come to present our work 
which was informed by realist evaluation, and found that the conference stimulated debate 
in advancing the methodology of evaluating complex interventions across different fields 
(e.g. environmental health, public health and education). We noted the call for manuscripts 
on the use of realist evaluation by the International Journal of Care Coordination, and 
decided to combine our reflections to inform other researchers interested in applying 
Realist evaluation to their research. This paper provides an overview of our reflections of 
the topical debates about the application of realist methodology to health services research 
and potential implications for care coordination initiatives.   
Authors’ contributions: MV conceived the original idea for the paper. MV and HL developed 
the structure of the manuscript, and synthesised the individual contributions from all 
authors. MV drafted the initial manuscript, and all authors helped revise the manuscript and 
respond to reviewer’s comments.  
Manuscript details: Vugts M, Liu H, Boumans J, Boydell E. The need for Theory-based 
evaluation of care coordination initiatives: Considerations from the 2017 International 
Conference on Realist Research, Evaluation and Synthesis. International Journal of Care 
Coordination. 2018 
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Discussion & Opinion Paper
The need for theory-based evaluation
of care coordination initiatives:
Considerations from the 2017
International Conference on Realist
Research, Evaluation and Synthesis
Miel Vugts1 , Hueiming Liu2, Joge Boumans1 and
Edward Boydell3
Abstract
Research in the field of care coordination faces the challenge of providing transferable explanatory insights regarding
what principles and initiatives work in practice and why. Such insights are crucial in developing effective solutions
for global disease burdens. Realist research approaches have demonstrated potential to deliver stronger theoretical
contributions of evaluation studies across fields of research. These were discussed at the International Conference for
Realist Research, Evaluation and Synthesis in Brisbane (from 24 to 26 October 2017). This paper provides an overview
and reflection on the conference by four participants. It focuses on (1) topical debates and challenges for the application
of realistic methodology in health services research, as presented at the conference and (2) implied opportunities and
challenges for (realist) evaluation of care coordination initiatives. Based on the reflections, future realist evaluation on
evaluating complex care coordination initiatives is recommended.
Keywords
Program evaluation, health services research, evaluation studies, research design, delivery of health care, integrated
Introduction
Uses of care coordination principles aim to help patient
navigation through health care systems and improve
their experiences and outcomes.1 Care coordination
researchers could potentially benefit from progress in
realist evaluation (RE) methodology, as they are
in need of adequate strategies for accumulating explan-
atory knowledge about how initiatives work under
complex conditions. The theme of the International
Conference for Realist Research, Evaluation and
Synthesis in Brisbane (from 24 to 26 October 2017)
was the ability of RE to deliver on its promises.
Authors participated at the conference as PhD students
(MV, HL, and JB) or evaluation consultant (EB)
coming from different research fields and sharing
(hands-on) experiences of benefiting from the opportu-
nities and dealing with challenges in applying realistic
principles in their evaluation work. Topical insights
were accessed into general methodological develop-
ments and ongoing projects across various fields of
research. This facilitated reflection about implied meth-
odological and practical opportunities and challenges
for applying RE worth sharing with fellow evaluators
(researchers, commissioners, and policy makers) from
the field of care coordination.
The need for theory-based methodology in empirical
evaluation of care coordination initiatives
Systematic reviews on the effectiveness of various care
coordination initiatives are able to show a rich variety
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Netherlands
2George Institute for Global Health, Australia
3Independent Researcher, Australia
Corresponding author:
Miel Vugts, Tilburg University, P.O. Box 90153, Tilburg, 5000 LE,
The Netherlands.
Email: m.a.p.vugts@uvt.nl
International Journal of Care
Coordination
0(0) 1–7
! The Author(s) 2018
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/2053434518779751
journals.sagepub.com/home/icp
205
of initiatives with study outcomes that are heteroge-
neous and mostly promising.2–4 However, scant report-
ing of initiatives’ characteristics (e.g. their logics) and
the contexts in which they were implemented generally
hinders synthesis and transfer to similar future circum-
stances.7,8 Improved reporting of primary studies will
help accumulating yields of evaluation projects, but
may not suffice to improve understanding how care
coordination initiatives work under complicated or
complex conditions.9,10 Care coordination initiatives
get complicated when targeting multiple outcomes
(e.g. reductions of both economic costs and effort for
patient transitions as perceived by patients, families, pro-
fessionals, organizations), and/or involve multiple inter-
ventions (e.g. facilities for inter-professional flows of
information as well as for patient self-management).11
Complex individual patient health needs, agency of local
stakeholders, social determinants of health, and differen-
ces in culture and organization of health care systems are
sources of complexity determining the needs for—and
circumstances of—care coordination.12,13 Qualitative eval-
uations provide complementary in-depth insight into com-
plexity but, even when synthesized, acknowledged limited
transferability (e.g. between different geographic regions
or health jurisdictions).14,15 Some studies adjudicated
or integrated existing theoretical frameworks of care coor-
dination.1,5,6 Synthesis between trials, qualitative, and
theoretical work could be improved.
Key concepts of realistic evaluation
Black swans lurk in prey of the “law” based on the
million observations that swans are white. (Ray Pawson)
RE is an increasingly popular approach, not a set of
technical procedures, for building and testing program
theories about why mechanisms (M) are triggered in
certain contexts (CþM) to produce certain outcomes
(O).16 Mechanisms exist in the domain of the real. They
are not directly observable (not in the empirical
domain). The question is what works, in what respect,
over what duration, how, for whom, under what cir-
cumstances, and why.17 The realist view implies that
(social) realities of policies or programs cannot be
reduced to directly observable outcome patterns (e.g.
correlations) or meanings constructed by subjects.16
The “swan analogy” (quoted), used by Pawson, may
illustrate this key point:7 mere observations of the color
of swans in a certain area, regardless how many, leads
to the conclusion that swans are white. However, this is
not as adequate as conceiving “reality” as a set of
simple rules (i.e. of evolution) generating the particu-
larities of the species of swans, including them being
observed as black in some places. This “generative”
view of causation agrees with complex adaptive sys-
tems theory in the sense that minor contextual changes
can cause substantial (non-linear) influences on out-
come patterns.16 Therefore, realists stress that evaluat-
ing outcomes independent of context makes no sense,
criticize “hierarchies of evidence” and prioritization of
particular sets of methods, do not determine the use of
specific ones but hold ideas for how they could be
applied to inform program theories.18
Objectives
The objectives of this paper are to (1) focus on topical
challenges and debates in realist methodology in gen-
eral and illustrations from projects in health services/
policy research discussed at the conference and there-
upon to (2) reflect on their implications, especially for
future realist (inspired) theory-based evaluation of care
coordination initiatives under complexity. In contrib-
uting to the objectives (1 and 2), authors covered four
conference themes based on their backgrounds (see ini-
tials of authors included in the headings of next sec-
tions). Ideally, critical reflection is elicited in evaluators
(scientists, policy makers, and health professionals)
supportive in overcoming challenges for future (realis-
tic) work on transferable explanations of outcome het-
erogeneity in care coordination initiatives.
Conference themes and their implications
General challenges in the application of RE on
research methods (MV and HL)
The conference showcased the continuing impact of
RE upon research methods with relevance to health
services/policy research along with its challenges (see
Box 1). RE seems well accepted for program theory
building and testing on an initiative (e.g. an element
of a larger policy) at early (piloting) stages to under-
stand how and why (mixed) outcome patterns are
produced across contexts before scaling up to different
social, political, cultural, or environmental contexts.19
In the face of increasing profile of realist approaches in
research and evaluation, Tilley and Pawson cautioned
against “mechanistic” use of methods.19,20 Instead,
they highlighted that realist evaluators need to combine
high-quality interaction with research subjects and sub-
ject matter knowledge, with a level of intellectual craft
(i.e. being able to find and compare plausible explan-
ations), and creativity in the analysis and presentation
of realist findings. Pawson also argued that evaluators
need to shift the unit of analysis from the “program”
itself to the “program theory” (the ideas behind it), to
do more RE on policy (i.e. big ideas), and explore
policy histories.20 Immersion in realistic argument
2 International Journal of Care Coordination 0(0)
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elicited attendants to reflect about its older philosoph-
ical roots,21 which may have already been influencing
interpretations of evaluation findings in researchers,
clinicians, and policy makers more implicitly for
longer. Evaluators’ topical outputs, including work
in adapting methods to realistic principles, and
empirical evaluations from the field of health services/
policy research (using qualitative methods and realist
syntheses) are summarized in Box 1. It also describes
tension we recognize of realist approaches with
Medical Research Council (MRC) guidelines for eval-
uating (processes of) complex interventions hinted
at by Gill Westhorp (in a pre-conference workshop),
and on a debate about whether (and when) a random-
ized controlled trial (RCT) is usefully performed within
an RE. This debate was continued in response to pre-
sentations sequel to previously published work12,22,23
by Marchal,18 Hawkins,24 and Porter.25
Implications
Potential implications for choosing methods and fitting
them to purpose in RE seem infinite, which could
simultaneously feed a sense of opportunity and uncer-
tainty. Therefore, it is expected that besides specific
guidance for applying RE (e.g. reporting guidelines
and course materials), a (broad) background and expe-
rience of various social and/or clinical (evaluation)
research methods will be of general help to evaluators.
Given the biomedical evidence paradigm omnipresent
in medicine and public health (enacted by funding
bodies and journals), realist arguments against the
RCT as “golden standard” challenges re-thinking
about what rigorous research methods are. In time,
the realistic position may evolve as an opposing
force to the legitimacy of context and theory
“ignorant” evaluation, favoring the practical value of
Box 1. Additional details on general challenges of RE.
General sessions about the implications for evaluation methods
Several sessions elaborated on details of qualitative RE, including data collection40,41 and analysis methods with details of choosing
and using software packages.42,43 Maxwell’s plea for realist mixed-methods designs, with research questions at its center,
seemed generally well accepted.44 Quantitative analysis methods in the context of RE, that is, for testing hypothetical patterns
indicating elements of program theories (e.g. using propensity scores and latent constructs), are at an exploratory stage.24,45
Realistic economic evaluation methods developing as well.46
Examples of methods used by ongoing realist (inspired) studies from the field of health services/policy research selected from the book of
oral abstracts:47
Qualitative or mixed-methods:
– Patient-centered decision-making in indigenous cancer
– Oral health promotion for schoolchildren in rural Andean communities (Peru)
– Medical patient journeys in Tasmania
– Preventing sexual violence and abuse in (Australian) Indigenous communities
– Technical assistance to support local innovation of sustainable funding for population health initiatives in the United States
– Lean’ health system reform in Saskatchewan and Tasmania
– Coordinators for enhancing access to telehealth for children in rural and remote Australia
Realist reviews:
– Optimal perinatal surgical services for rural women
– Early years interventions to improve child health and well-being
– Comprehensive geriatric assessment in primary care
– Technology-supported intervention for engaging hospitalized patients in their care
Tension between realist principles and MRC guidelines
Despite its reference to realistic work,9 the MRC contains from this perspective: (1) a limited conception of complexity, (2)
acceptance of pragmatic divergence from “ideal” RCT designs (which, however, remain to be prioritized at all stages), and 3)
recommendation for theory-based process evaluation alongside outcomes assessment in trials (but does not recommend
shifting the unit of analysis from programs to program theories).
Debate about the role of RCTs in RE
In previous literature, it was suggested that the “realist RCT” (i.e. using “normal” RCT methods for the aims of RE) may be an
oxymoron because realistic conceptions on generative causation and complexity contradict the assumption that control
groups are necessary in experimentation, that random allocation results in equal group conditions in all relevant aspects, and
that quantitative data can suffice for explanatory purposes.16,18 Discussion seemed tamed when Hawkins argued that the most
useful information an RCT could provide for the aims of RE is a “final” assessment to confirm previous explanatory work:
when there are clear hypotheses on outcome pattern changes as the result of a single mechanism (well-framed and “cut-off”
from any other) “firing” in a context bounded through experimental control.24
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scientific evaluation: a better ability to show that noth-
ing is as practical as a good (program) theory. For real-
istic evaluation of care coordination, with its likely
dependency on factors related to time and multiple
levels of systems, one could think of using (mixed-)
methods,26 involving characteristics of action research
and (comparative) case studies (qualitative), as well as
techniques for structuring large amounts of data, and
multi-level, longitudinal, and path analytic modeling
(quantitative). A “big idea” lending itself for a realistic
approach is the strategic agenda of the World Health
Organization for people-centered integrated health serv-
ices, as it explicitly includes a crucial responsibility for
adaptation to local circumstances for which policy
makers could use complementary understanding.27
Collaboration and co-creation of evidence are
needed in dynamic contexts (JB and HL)
Hawkins gave four main recommendations for evalua-
tors and commissioners for RE in the real world based
on her experience in international development evalu-
ation and public policy:28 (1) Innovative initiatives in
dynamic context require creative evaluative thinking
and; 2) Decisions and changes need to be informed by
insights. Realist evaluators must be aware of a dynamic
context to which a uniquely designed evaluation plan is
needed. Such design requires creative thinking.
Changes in the environment taking place must be
acknowledged during an evaluation. To such changes,
evaluation plans are possibly to be adaptation.
Therefore, rapid feedback loops based on ongoing
data analysis are and integration of learning into deci-
sions are necessary. Furthermore, (3) a practical
approach is needed and it should be context and system
sensitive.Due to the complexity, it is impossible to eval-
uate all parts of the all systems involved. Decisions
are to be made about which part is of most interest.
(4) Collaboration and co-creation are key elements.
In working from a realist approach, evaluators and
commissioners benefit from a flexible attitude and a
collaborative relationship of sharing evaluative
insights. The same points are illustrated by JB’s plan
for a collaborative and co-creative RE on care concepts
for people with dementia living in residential care facil-
ities29 (Box 2). However, how difficult such approaches
can be was saliently illustrated by a representative from
an Indigenous working group observing the suitability
for Indigenous peoples. RE seemed overall acceptable
if Indigenous communities are being actively and
continuously involved for a real-world impact.
Otherwise, it was cautioned, research can seem like a
form of “colonialism,” for which researchers would
only advance in their careers.
Implications
Taken into account the above and our own experien-
ces, evaluating initiatives in care coordination using RE
would be a good fit. First, one of the principals of care
coordination is patient centeredness, that is, focusing
on patients’ needs, engagement, and participation.1 In
RE, collaboration and co-creation of the researcher
with the key stakeholders, patients foremost, are
highly encouraged. Thus, following an RE approach
of patient participation preserves patient centeredness
and focuses evaluation outcomes more on patients’
needs. Second, RE would stimulate iterative develop-
ment of care coordination initiatives involving key
stakeholders from the first until final step to implemen-
tation. In doing so, implementation may be more likely
to succeed and/or be understood.Third, RE using par-
ticipatory action research embodying an iterative co-
creation cycle in the collection and analysis of data,
enabling action, and involving communities in an
ongoing, respective, and accountable manner, may be
accepted by and be suitable for empowering communi-
ties (e.g. Indigenous Australians).30,31 To the knowl-
edge of the authors, REs including community
member participation were not published yet.
Box 2. Example (by JB) of planning a participatory RE approach.
In a PhD research on evaluating care concepts for people with dementia living in residential care facilities,31 JB shows what
realistic evaluation research in a real health care setting implies in concrete. In planning a “pathway” of realist research in time,
the decision was made to facilitate an iterative development process by performing several successive short studies that build
upon the knowledge gained through the previous one(s). Thereby, creating opportunity for creative evaluative thinking pro-
cesses in response to new insights and information. Detailed plans about which parts of the system are investigated are made
before the start of every study. This is one of many kinds of decisions that are taken collaboratively and in co-creation at each
step within a mentoring team of key stakeholders (employees) from the two participating care organizations: coaches,
managers, and members from the board of directors. Meetings are held every couple of months, discussing the results of
previous studies and designs of upcoming studies. In this way, system or context-sensitive knowledge brought in by the
stakeholders and scientific knowledge can be synthesized for arriving at explanations for outcome patterns that stakeholders
need in practice.
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Challenges in informing practice and policy (EB)
A major focus of the conference was the application of
RE to inform better policy and practice.20 Several par-
ticipants presented findings of impact evaluations
commissioned by Government and non-government
agencies across a range of sectors including healthcare.
However, a key challenge explored was how to better
communicate about complexity; in a way that supports
relevance to, and uptake by, intended audiences.19 This
implies avoiding formulaic or particularly wordy
descriptions of findings (as Context-Mechanism-
Outcome configurations).19 A realist lens could also
assist in understanding this issue of uptake and the
mechanisms through which our research and evalua-
tions might be adopted. Presentations examined
visual representations of realist program theories for
better communication and stronger methodological
uptake.32,33 Another avenue for relevance was a call
for closer relationships in co-creation between commis-
sioners, researchers/evaluators, implementers, and
people affected by a particular intervention.34 This
offers both substantive (see previous section on collab-
oration and co-creation of evidence are needed in
dynamic contexts) and communicative advantages.
One presentation dealt specifically about how realist
findings on integrated care initiatives were differently
received at various organizational levels.35
Implications
For the time being, the above-described experienced
challenges within wider domains of (health services)
research offer starting points for high-quality applica-
tions of realistic principles to care coordination
research. “High quality” thus implies that the stand-
ards of RE are met and that stakeholders take over
their findings at all relevant organizational levels.
Recommendable for achieving this is to balance subject
matter knowledge with a solid grounding in realist
methodology within an evaluation team. RAMESES
protocols, which provide guidance and reporting stand-
ards for RE and synthesis,17,36 may serve as practical
artifacts in ongoing dialogue between program imple-
menters, evaluation commissioners, and the evalua-
tion team.
Conclusion
Care coordination efforts often constitute dynamic
contexts suited to realist approaches. A realist research
approach is compatible with several care coordination
“principles,” including patient centeredness and gover-
nance structures representing stakeholder groups.1
There are no restrictions on methods that can be
applied for “signifying” elements of realistic program
theories on care coordination. It is, however, generally
recommendable to collaborate with crucial stakehold-
ers in a process of iterative co-production and creative
evaluation and to strategically convey complexities to
policy makers and practitioners. Program theories
could, for example, come to complement larger strate-
gic policy frameworks and facilitate their adoption
for better health services integration, which is needed
globally in a timely manner.1,27 For better supporting
to the accumulation of explanatory knowledge
about how care coordination works under complexity,
following up on early realist work in the field is recom-
mended (5,37,38,39).
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PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to 
address in a systematic review protocol*  
Section and topic Item 
No 
Checklist item Yes/ No/ Not 
applicable 
ADMINISTRATIVE INFORMATION  
Title:    
 Identification 1a Identify the report as a protocol of a systematic review     Y 
 Update 1b If the protocol is for an update of a previous systematic review, identify as such    NA 
Registration 2 If registered, provide the name of the registry (such as PROSPERO) and registration number    Y 
Authors:    
 Contact 3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of 
corresponding author 
    Y 
 Contributions 3b Describe contributions of protocol authors and identify the guarantor of the review     Y 
Amendments 4 If the protocol represents an amendment of a previously completed or published protocol, identify as such and list 
changes; otherwise, state plan for documenting important protocol amendments 
    NA 
Support:    
 Sources 5a Indicate sources of financial or other support for the review     Y 
 Sponsor 5b Provide name for the review funder and/or sponsor    NA 
 Role of sponsor 
or funder 
5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol    NA 
INTRODUCTION  
Rationale 6 Describe the rationale for the review in the context of what is already known      Y 
Objectives 7 Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, 
comparators, and outcomes (PICO) 
      Y 
METHODS  
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as 
years considered, language, publication status) to be used as criteria for eligibility for the review 
      Y 
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or 
other grey literature sources) with planned dates of coverage 
    Y 
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could 
be repeated 
   Y 
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Study records:    
 Data 
management 
11a Describe the mechanism(s) that will be used to manage records and data throughout the review     Y 
 Selection 
process 
11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the 
review (that is, screening, eligibility and inclusion in meta-analysis) 
     Y  
 Data collection 
process 
11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any 
processes for obtaining and confirming data from investigators 
     Y 
Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data 
assumptions and simplifications 
     Y 
Outcomes and 
prioritization 
13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, 
with rationale 
    Y 
Risk of bias in 
individual studies 
14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the 
outcome or study level, or both; state how this information will be used in data synthesis 
    Y  
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised      Y 
15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and 
methods of combining data from studies, including any planned exploration of consistency (such as I2, Kendall’s τ) 
 NA 
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)      Y 
15d If quantitative synthesis is not appropriate, describe the type of summary planned       Y 
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within 
studies) 
      NA 
Confidence in 
cumulative evidence 
17 Describe how the strength of the body of evidence will be assessed (such as GRADE) NA 
* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important 
clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the 
PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.  
 
From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and 
meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647. 
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Additional Files 3-5 
Additional file 3: Eligibility Criteria Forms 
Inclusion Criteria Study 
Type of study:  
Process evaluation  
Qualitative study within RCT 
 
Design:  
RCT 
Complex intervention   
 
Setting: primary health care  
Exclusion criteria  
Not a journal article, not a specific trial, not a report based on empirical research 
(e.g. protocol, editorial), not reported in English, and not human research. 
 
Other 
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 Additional file 4:  Data extraction tables 
Table 1: Details of the RCTs and its complex intervention  
Article  
 
Summary of trial being evaluated  
 
 
Causal 
assumptions 
clarified 
(hypothesis of 
how the 
intervention 
would work) 
(Y/N) 
Setting 
(Rural, 
Urban, 
Countries 
Disease (eg mental 
health, diabetes) 
Mental health 
Main trial outcomes positive/ 
negative/equivalent 
 
 
Cost analysis (Y/N/NA) 
 
 
 
 
Table 2: Details about the process evaluation  
Article  
 
  
Labelled as 
a process 
evaluation 
(Y/N) 
  
Stated 
purpose 
(Y/N) 
 
 
Pre-
specified 
protocol 
(Y/N)  
Processes examined at which stage 
a) Feasibility and piloting- 
Acceptability, Testing of processes, 
Feasibility  
 
b) Evaluation of effectiveness- are 
the main trial designs and  findings 
reported (Y/N/NA), Fidelity, 
mechanism, contextual influences 
 
c)Post-evaluation implementation- 
integrating of intervention into 
new context, long term 
maintenance    
  
 
Specified 
theory 
(Y/N)  
(Theory 
e.g. Realist) 
 
 
Methods used (eg stakeholder interviews, 
routine monitoring data, documentary 
analysis, observations) 
 
. 
Analysis  
(if applicable -quantitative 
data on fidelity dose, reach 
-detailed modelling across 
sites 
-integration of quantitative 
process data and outcome 
datasets 
-qualitative and quantitative 
analysis building on each 
other 
-analysing process data prior 
to trial outcomes 
-generating hypothesis or 
post hoc explanation) 
 
 
Table 3:  to learn what the strengths and limitations of the PE in these contexts and to discuss what can be used to overcome it eg. Sampling, resources 
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Study Strengths of process evaluation Limitations of the process evaluation 
 For example: Boase 2011 Insights provided by the SAMS researchers of the trial may 
have enhanced data quality. 
Interviews conducted by the researchers and thus known by the practice nurses, and 
different data may have been collected otherwise.  
 
Conducted at the end of the trial, and if interviewed at the start may have provided 
data to address the findings of competing time and demands during the 
implementation of the trial.  
 
 
Table 4:  to provide information so as to learn from previous process evaluations in implementing future trials in these contexts  
Study 
  
Implementation Issues (stated themes) Implementation barriers  Implementation facilitators 
For example: Boase 
2011 
Organisation of research 
 
 
 
 
 
 
 
 
 
 
 
 
Delivering the intervention 
Recruitment into the study and whether it 
included the practice nurse’s opinion at the 
start.  
Time issues- not having it compensated 
adequately to deliver the intervention and to do 
the administrative tasks associated with the 
study.  This at times led to resentment from 
other team members who perceived that 
clinical time was taken up by research time 
resulting in increased work pressure overall.  
 
 
Competing demands- from GP, patients, 
research  
 
 
Standardised script to have it the same across 
the sites meant that at times it was not patient 
centred, and at times made the interactions 
with established patients awkward. 
 
 
Having the buy in of the practice nurse from the start of the 
study 
 
 
The intervention and the allocated time provided an 
opportunity to do things differently, and to allow for patient 
empowerment and patient centred care. Thus for most of 
them, positively changed their practice. 
 
Having time set aside for the practice nurse was perceived 
positively. 
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Additional file 5: Appraisal form for the Risk of Bias 
Criteria Study  
Planning:   
Degree of separation between outcome and process evaluation teams stated and described.  
Design and conduct:  
Process evaluations should clearly state their purpose.  
The intervention should be clearly described and causal assumptions clarified  
Process evaluations should state the choice of methods and justify them in terms of the stated aims of the evaluation, and the selected timing (eg retrospective 
data collection, was it planned initially) 
 
If the process evaluation is done at the evaluation stage:  
Transparently report of the process data are analysed blind to trial outcomes or for post- hoc explanation   
 
If qualitative methods used, the study was appraised with the use of COREQ (Domain 1: research team and reflexivity, Domain 2: study design, Domain 3: 
analysis and reporting)  
 
Reporting:   
Process evaluations should be clearly labeled   
Publish a full report of evaluation components or a protocol paper  
Risk of Bias 
Low, Unclear, High 
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 Author Title Year Setting Disease Condition RCT Outcomes Cost 
Considerations 
(Y/N/NA) 
1. Gask L, Ludman E, 
Scaefer J. 
Qualitative study of an intervention for 
depression among patients with diabetes: how 
can we optimise patient-professional interaction 
2006 Primary health care, 
Manchester UK 
Depression and Diabetes Positive N 
2. Chew-Graham CA, 
Lovell K, Roberts C, 
Baldwin R, Morley M, 
Burns A, et al 
 A randomised controlled trial test the feasibility 
of a collaborative care model for the 
management of depression in older people 
2007 Primary Care trust, 
Manchester 
Depression Positive N 
3. Lovell K, Bower P, 
Richards D, Barkham 
M, Sibbald B, Roberts 
C, et al 
 Developing guided self-help for depression using 
the Medical Research Council complex 
interventions framework: A description of the 
modelling phase and results of an exploratory 
randomised controlled trial 
2008 Primary care Units England. 
United Kingdom 
Depression Negative N 
4. Slade M, Gask L, 
Leese M, McCrone P, 
Montana C, Powell R, 
Stewart M, Graham-
Chew C 
Failure to improve appropriateness of referrals to 
adult community mental health services—lessons 
from a multi-site cluster randomized controlled 
trial  
2008 General Practice, 
Community Services. 
London & Manchester, 
United Kingdom 
Depression (Mental 
Health) 
negative Y 
5. Gask L, Bower P, 
Lovell K, Escott D, 
Archer J, Gilbody S, 
Lankshear A, 
Simpson AE, 
Richards DA. 
What work has to be done to implement 
collaborative care for depression? Process 
evaluation of a trial utilizing the Normalisational 
Process Model 
2010 Primary health care, UK Depression NA N 
6. Chalder M, Wiles NJ, 
Campbell J, 
Hollinghurst SP, 
Searle A, Haase AM, 
et al 
 A pragmatic randomised controlled trial to 
evaluate the cost-effectiveness of a physical 
activity intervention as a treatment for 
depression: The treating depression with physical 
activity (TREAD) trial 
2012 General practices in the 
Bristol and Exeter areas, 
United Kingdom 
Depression Negative Y 
7. Bennett M, Walters K, 
Drennan V, 
Buszewicz M 
 Structured Pro-Active Care for Chronic 
Depression by Practice Nurses in Primary Care: 
A Qualitative Evaluation 
2013 General Practice. United 
Kingdom 
Depression Positive N 
8. Stallard P, Phillips R, 
Montgomery AA, 
Spears M, Anderson 
R, Taylor J, et al 
 A cluster randomised controlled trial to 
determine the clinical effectiveness and cost-
effectiveness of classroom-based cognitive-
behavioural therapy (CBT) in reducing symptoms 
of depression in high-risk adolescents 
2013 Schools. United Kingdom Depression Negative Y 
9. Coupe N, Anderson 
E, Gask L, Sykes P, 
Richards DA, Chew-
Graham C 
 Facilitating professional liaison in collaborative 
care for depression in UK primary care; A 
qualitative study utilising normalisation process 
theory 
2014 Primary care GP. Bristol, 
London, and greater 
Manchester. United 
Kingdom 
Depression Positive N 
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 Synthesis (depression in UK) Types of intervention: collaborative care models, 
introducing CBT in schools, introduction of 
physical activity,  
9 studies in UK 
looking at 
depression 
between 2006-
2014) 
  4 positive RCTs, 4 
negative and 1 NA. 
3/9 studies for 
costs analysis.  
10. Oishi SM, Shoai R, 
Katon W, Callahan C, 
Unutzer J, Arean P, et 
al 
Impacting late life depression: Integrating a 
depression intervention into primary care 
2003 Primary care Practices. 
United States 
Depression NA (not complete) N 
11. Dietrich AJ, Oxman 
TE, Williams JW, 
Kroenke K, Schulberg 
HC, Bruce M, et al 
Going to scale: Re-engineering systems for 
primary care treatment of depression 
2004 5 Medical groups and health 
plans in the USA, with 60 
practices participating 
Depression Positive NA 
12. Gask L, Dixon C, May 
C, Dowrick C 
 Qualitative study of an educational intervention 
for GPs in the assessment and management of 
depression 
2005 Group Health Clinics. 
Western Washington. USA 
Depression Negative N 
13. Lee PW, Dietrich AJ, 
Oxman TE, Williams 
Jr JW, Barry SL 
 Sustainable impact of a primary care depression 
intervention 
2007 Health care organisations. 
USA 
Depression Positive N 
14. Chung B, Jones L, 
Dixon EL, Miranda J, 
Wells K, Community 
Partners in Care 
Steering Council 
Using a Community Partner Participatory 
Research Approach to Implement a Randomised 
Controlled Trial: Planning Community Partners in 
Care 
2010 USA (community multi 
agencies for minority 
groups) 
Depression NA N 
15. Chaney EF, 
Rubenstein LV, Liu 
CF, Yano EM, Bolkan 
C, Lee M, et al 
 Implementing collaborative care for depression 
treatment in primary care: A cluster randomized 
evaluation of a quality improvement practice 
redesign 
2011 Primary care settings, 
Veteran affairs in several 
states USA 
Depression Positive Y 
16. Rapp AM, Chavira 
DA, Sugar CA, 
Asarnow JR 
Integrated Primary Medical-Behavioral Health 
Care for Adoolescent and Young Adult 
Depression: Predictors of Service Use in Youth 
Partners in Care Trial.  
2017 Primary Health Care USA Depression  Positive N 
Synthesis (depression in USA) All 7 studies were a version of collaborative care 
models either between primary and tertiary care, 
or increasing the outreach through settings 
outside of health.  
7 studies in USA 
looking at 
depression.  
  4 positive, 2 NA and 1 
negative 
1Y, 4 N, 1 NA 
17. Thornett AM, Mynors-
Wallis LM 
Credibility of problem-solving therapy and 
medication for the treatment of depression 
among primary care patients 
2002 Primary Care setting, South 
Australia 
Depression Positive NA 
18. Gensichen J, Guethlin 
C, Sarmand N, 
Sivakumaran D, 
Patients' perspectives on depression case 
management in general practice - A qualitative 
study 
2012 General Practices. Germany Depression Positive N 
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 Jager C, Mergenthal 
K, et al 
19. Chatterjee S, 
Chowdhary N, 
Pednekar S, Cohen 
A, Andrew G, Araya 
R, et al 
 Integrating evidence-based treatments for 
common mental disorders in routine primary 
care: Feasibility and acceptability of the MANAS 
intervention in Goa, India 
2008 Primary Health care, Goa, 
India 
Depression Positive N 
20. Richter-Sundberg L, 
Nystrom ME, Krakau 
I, Sandahl C 
 Improving treatment of depression in primary 
health care: A case study of obstacles to perform 
a clinical trial designed to implement practice 
guidelines 
2015 Primary Health care Units. 
Sweden 
Depression NA N 
Synthesis (depression) Interventions mostly around collaborative 
care through increasing expertise of different 
roles (e.g. lay worker, nurse for pro-active 
care, GP for PHC) (15 studies), at times to 
implement practice guidelines (4 studies), 
and trialling specific interventions such as 
physical exercise and CBT (2 studies). 
2003-2015 9 were in UK, 6 in USA, 
and 1 Sweden, 1 Germany, 
1 Australia and 1 in India. 
Overall 19 studies in 
depression. 
10 positive RCTs, 5 
Negative, 4 NA 
4/19 Y, 13 N, 2 
NA 
1. Tai SS, Nazareth I, 
Donegan C, Haines A 
Evaluation of general practice computer 
templates. Lessons from a pilot randomised 
controlled trial 
1999 North London. United 
Kingdom 
Diabetes (and asthma) Positive N 
2. Hetlevik I, Holmen J, 
Kruger O, Kristebsen 
P, Iversen H, 
Furuseth K 
Implementing Clinical guidelines in the treatment 
of Diabetes Mellitus in General Practice 
2000 Norway Diabetes Mellitus  Negative N 
3. Ilag LL, Martin CL, 
Tabaei BP, Isaman 
DJ, Burke R, Greene 
DA, et al 
 Improving diabetes processes of care in 
managed care 
2003 United States, nine 
university- affiliated primary 
care internal medicine 
practices affiliated with a 
managed care organisation.  
Diabetes Negative on main 
outcome measures 
but positive on 
process outcomes 
N 
4. Smith S, Bury G, 
O'Leary M, Shannon 
W, Tynan A, Staines 
A, Thompson C 
The North Dublin randomized controlled trial of 
structured diabetes shared care 
2004 Ireland Diabetes Neutral N  
5. Jackie Sturt, Hafrun 
Taylor, Andrea 
Docherty, Jeremy 
Dale, Taylor Louise 
A psychological approach to providing self-
management education for people with type 2 
diabetes: the Diabetes Manual 
2006 Primary health care UK Diabetes NA NA 
6. Pylypchuk G, Vincent 
L, Wentworth J, Kiss 
A, Perkins N, 
Hartman S, et al 
 Diabetes risk evaluation and microalbuminuria 
(DREAM) studies: Ten years of participatory 
research with a First Nation's home and 
community model for type 2 diabetes care in 
northern Saskatchewan 
2008 First Nations, Northern 
Saskatchewan, Canada 
Diabetes type 2 not significantly 
positive 
N 
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 7. Smith S, Paul G, Kelly 
A, Whitford D, O'Shea 
E, O'Dowd T 
 Peer support for patients with type 2 diabetes: 
Cluster randomised controlled trial 
2011 General Practice. Ireland Type 2 Diabetes mellitus Equivalent Y 
8. Ratanawongsa N, 
Bhandari VK, Handley 
M, Rundall T, 
Hammer H, 
Schillinger D 
Primary care provider perceptions of the 
effectiveness of two self-management support 
programs for vulnerable patients with diabetes 
2012 Community health network. 
San Francisco 
Type 2 Diabetes mellitus Positive N 
9. Lakerveld J, Bot S, 
Chinapaw M, van 
Tulder M, Kingo L, 
Nijpels G 
Process evaluation of a lifestyle intervention to 
prevent diabetes and cardiovascular diseases in 
primary care 
2012 Semi-rural region of West 
Friesland 
Type 2 diabetes mellitus Negative Y(economic 
evaluations done 
separately) 
10. Paul G, Keogh K, 
D'Eath M, Smith SM 
 Implementing a peer-support intervention for 
people with type 2 diabetes: A qualitative study 
2013 General Practices, Ireland Type 2 Diabetes mellitus positive N 
11. Carlisle K, Warren R  A qualitative case study of tele-health for in-
home monitoring to support the management of 
type 2 diabetes 
2013 Queensland. Australia type 2 diabetes Positive N 
12. Grimshaw JM, 
Presseau J, Tetreo 
Jm , Eccles MP, 
Francis JJ, Godin G, 
Graham ID, Hux, JE, 
Johnston M, Legare 
F, Lemyre L, 
Robinson N, 
Zwarenstein M. 
Looking inside the black box: results of a theory-
based process evaluation exploring the results of 
a randomized controlled trial of printed 
educational messages to increase primary care 
physicians' diabetic retinopathy referrals 
2014 Primary care setting, 
Ontario, Canada 
Diabetes (leading to 
retinopathy) 
Negative N 
13. Burridge LH, Foster 
MM, Donald M, 
Zhang J, Russell AW, 
Jackson CL 
 Making sense of change: patients' views of 
diabetes and GP-led integrated diabetes care 
2014 Primary Care, Brisbane. 
Australia 
Type 2 Diabetes NA N 
14. Naik AD, Lawrence B, 
Kiefer L, Ramos K, 
Utech A, Masozera N, 
et al 
 Building a primary care/research partnership: 
lessons learned from a tele-health intervention 
for diabetes and depression 
2015 Primary care teams 
Veterans affair Medical 
centre in Southern USA 
Depression & Uncontrolled 
diabetes 
not stated in paper N 
15. Eborall HC, Dallosso 
HM, McNicol S, 
Speight J, Khunti K, 
Davies MJ, et al 
 Explaining engagement in self-monitoring 
among participants of the DESMOND self-
monitoring trial: A qualitative interview study 
2015 Primary care trust, United 
Kingdom 
type 2 diabetes mellitus Positive N 
16. Ramadas A, Chan C, 
Oldenburg B, Hussien 
Z, Quek K 
 A Web-Based Dietary Intervention for People 
with Type 2 Diabetes: Development, 
Implementation, and Evaluation 
2015 In the community, recruited 
from outpatient medical 
clinics of public hospitals 
Kuala Lumpur. Malaysia 
Type 2 Diabetes Mellitus Positive N 
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 17. Kenealy TW, Parsons 
MJG, Rouse PB, 
Doughty RN, 
Sheridan NF, 
Hindmarsh JKH, 
Masson SC, Rea HH. 
Tele-care for Diabetes, CHF or COPD; Effect on 
Quality of Life, Hospital Use and Costs. A 
Randomised Controlled Trial and Qualitative 
Evaluation 
2015 New Zealand Diabetes, Chronic Heart 
Failure, COPD 
Neutral Y 
Synthesis (diabetes) The interventions included improving 
guidelines referral and treatment (7 studies), 
patient self-management and community 
support (7 studies) and tele-health (3 studies).  
1999-2016 3 Ireland, 1 Norway, 2 
USA, 2 Canada (1 of the 
First Nations), 3 UK, 2 
Australia, 1 New Zealand, 
1 Malaysia 
17 studies on diabetes (2 
included other chronic 
disease) 
6 Positive, 10 
Negative/Neutral, 1 
N/A 
3/16 Y, 13/16 N, 
1/16 NA 
1. Pearl A, Wright 
S, Gamble G, 
Doughty R, 
Sharpe N 
Randomised trials in general practice--a New 
Zealand experience in recruitment 
2003 General Practices .New 
Zealand 
Heart failure Positive NA 
2. Lobo CM, Euser 
L, Kamp J, 
Frijling BD, 
Severens JL, 
Hulscher MEJL, 
et al 
Process evaluation of a multifaceted intervention 
to improve cardiovascular disease prevention in 
general practice 
2003 General Practices, 
Netherlands 
Cardiovascular Disease Positive Y 
3. Weiss MC, 
Montgomery AA, 
Fahey T, Peters 
TJ 
Decision analysis for newly diagnosed 
hypertensive patients: a qualitative investigation 
2004 General Practice. South 
West-England. United 
Kingdom 
Hypertension  Positive N 
4. Murchie P, 
Campbell NC, 
Ritchie LD, 
Thain J 
Running nurse-led secondary prevention clinics 
for coronary heart disease in primary care: 
Qualitative study of health professionals' 
perspectives 
2005 North East Scotland, UK Cardiovascular Disease 
(Coronary Heart Disease) 
Positive N 
5. Byrne M, 
Cupples ME, 
Smith SM, 
Leathem C, 
Corrigan M, 
Byrne MC, et al 
Development of a complex intervention for 
secondary prevention of coronary heart disease 
in primary care using the UK Medical Research 
Council framework 
2006 General Practices Urban & 
Rural Settings The island of 
Ireland, where 2 different 
healthcare systems exist. In 
the north, in line 
with Britain, the National 
Health Service allows 
everyone free access to 
general practice and hospital 
services. In the south, a 
mixed public and 
private healthcare system 
operates, with less 
than 30% of the population 
qualifying for free 
general practice and hospital 
services. 
Cardiovascular disease Positive N 
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 6. Heaven, B, 
Murtagh, M. 
Rapley, T.May, 
C., raham, R. 
Kaner, E., 
Thomson, R. 
Patients or research subjects? A qualitative study 
of participation in a randomised controlled trial of 
a complex intervention 
2006 GP clinics in UK 
CVD (AF patients at risk 
for a stroke) 
NA NA 
7. Clark RA, Yallop 
JJ, Piterman L, 
Croucher J, 
Tonkin A, 
Stewart S, et al 
 Adherence, adaptation and acceptance of 
elderly chronic heart failure patients to receiving 
healthcare via telephone-monitoring 
2007 General Physicians, Rural 
Australia 
Cardiovascular disease Positive N 
8. Fakiri FE, Hows 
MW, Uitewaal 
PJM, Frenken 
RA, Bruijnzeels 
MA. 
Process evaluation of an intensified preventive 
intervention to reduce cardiovascular risk in 
general practices in deprived neighbourhoods 
2008 General practices in 
deprived neighbourhoods, 
United Kingdom 
Cardiovascular disease Negative N 
9. Wentzlaff DM, 
Carter BL, 
Ardery G, 
Franciscus CL, 
Doucette WR, 
Chrischilles EA, 
et al 
Sustained Blood Pressure Control Following 
Discontinuation of a Pharmacist Intervention 
2011 Iowa. United States of 
America 
Hypertension  positive N 
10. Passey ME, 
Laws RA, 
Jayasinghe UW, 
Fanaian M, 
McKenzie S, 
Powell-Davies 
G, et al 
Predictors of primary care referrals to a vascular 
disease prevention lifestyle program among 
participants in a cluster randomised trial 
2012 2 Rural 3 urban Division of 
General practice in New 
South Wales. Australia 
Cardiovascular disease Positive N 
11. Nelson P, Cox 
H, Furze G, 
Lewin RJP, 
Morton V, Norris 
H, et al 
 Participants' experiences of care during a 
randomized controlled trial comparing a lay-
facilitated angina management programme with 
usual care: a qualitative study using focus groups 
2013 District General Hospital, 
North England. United 
Kingdom 
Cardiovascular disease 
(Angina) 
Positive NA 
12. Fairbrother, 
Peter 
McCloughan, 
Lucy Adam, 
Geraldine Brand, 
Richard Brown, 
Cecil 
Watson, Mary 
Cotter, Nicola 
Mackellaig, Juliet 
McKinstry, Brian  
Involving patients in clinical research: The 
Telescot patient panel 
2013 Primary health care 
Scotland, UK 
CVD (Stroke) 
NA N 
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 13. Hanley, J.Ure, 
J.Pagliari, C. 
Sheikh, 
A.McKinstry, B. 
Experiences of patients and professionals 
participating in the HITS home blood pressure 
tele-monitoring trial: A qualitative study 
2013 Primary health care in 
Edinburgh, UK 
CVD with Hypertension as 
the major risk factor 
Positive  N  
14. Laws, R. A, 
Fanaian, M, 
Jayasinghe, U. 
W.McKenzie, S. 
Passey, 
M.Davies, G. 
P.Lyle, D. 
Harris, M. F 
Factors influencing participation in a vascular 
disease prevention lifestyle program among 
participants in a cluster randomized trial 
2013 Urban and rural PHC in 
Australia 
CVD prevention positive (changes in 
self- reported physical 
behaviours, but only 
those referred to life 
style modification 
program achieved 
improvement in diet or 
weight.  
N 
15. Manca DP, 
Greiver M, 
Carroll JC, 
Salvalaggio G, 
Cave A, Rogers 
J, et al 
Finding a BETTER way: A qualitative study 
exploring the prevention practitioner intervention 
to improve chronic disease prevention and 
screening in family practice 
2014 Primary care,  Canada 
(urban setting) 
Chronic disease- diabetes 
and heart disease (among 
others) 
positive N 
16. Liu H, Massi L, 
Laba TL, Peiris 
D, Usherwood T, 
Patel A, Cass A, 
Eades AM, 
Redfern J, 
Hayman N, 
Howard K, Brien 
JA, Jan S. 
Patients' and Providers' Perspectives of a Polypill 
Strategy to Improve Cardiovascular Prevention in 
Australian Primary Health Care: A Qualitative 
Study Set Within a Pragmatic Randomized, 
Controlled Trial.  
2015 Australia PHC CVD Positive Y 
17. Liu H, Laba T, 
Massi L, Jan S, 
Usherwood T, 
Patel A, Hayman 
N, Cass A, 
Eades A, Peiris 
D.  
Facilitators and barriers to implementation of a 
pragmatic clinical trial in Aboriginal health 
services.  
2015 Australia PHC CVD NA NA 
18. Liu H, Massi L, 
Eades AM, 
Howard K,  
Peiris D, Redfern 
J, Usherwood T, 
Cass A, Patel A, 
Jan S, Laba T.  
Implementing a pragmatic randomised controlled 
trial in Australia: lessons learnt from the Kanyini 
Guidelines Adherence with the Polypill study 
(Kanyini GAP)  
2015 Australia PHC CVD NA NA 
19. Huntink E, 
Wensing M, 
Timmers IM, 
Lieshout JV 
Process evaluation of a tailored intervention 
programme of cardiovascular risk management 
in general practices 
2016 Netherlands Cardiovascular risk 
management (high 
cardiovascular risk, and 
depressive symptoms) 
Negative N 
20. Parsons, J. A. 
Yu, C. H. Y. 
Baker, N. A. 
Practice doesn't always make perfect: A 
qualitative study explaining why a trial of an 
educational toolkit did not improve quality of care 
2016 General Practices in 
Ontario, Canada 
CVD prevention  Negative (possible 
harms) 
N 
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 Mamdani, M. M. 
Bhattacharyya, 
O. Zwarenstein, 
M. Shah, B. R. 
21. Presseau J, 
Grimshaw J, 
Tetroe JM, 
Eccles MP, 
Francis JJ, 
Godin G, 
Graham ID, Hux 
JE, Johnston M, 
Legare F, 
Lemyre L, 
Robinson N, 
Zwarenstein M.  
A theory-based process evaluation alongside a 
randomised controlled trial of printed educational 
messages to increase primary care physician's 
prescription of thiazide diuretics for hypertension 
2016 Ontario, Canada Cardiovascular disease 
management(prescription 
of thiazide for 
hypertension) 
Negative N 
22. Yan LD, Chirwa 
C, Chi BH, 
Bosomprah S, 
Sindano N, 
Mwanza M, 
Musatwe D, 
Mulenga M, 
Chilengi R. 
Hypertension management in rural primary care 
facilities in Zambia: a mixed methods study 
2017 Rural Zambian clinics Hypertension NA (ongoing trial) NA 
23. Wells S, Rafter 
N, Kenealy T, 
Herd, Geoff, 
Eggleton K, 
Lightfoot R, 
Arcus K, 
Wadham A, 
Jiang Y, Bullen 
C.  
The impact of a point of care testing device on 
CVD risk assessment completion in New Zealand 
primary-care practice: A cluster randomised 
controlled trial and qualitative investigation 
2017 General practices in 
Northland region, New 
Zealand, 
CVD risk assessment Negative Y 
24. Grant A, 
Dreischulte T, 
Guthrie B 
Process evaluation of the data-driven 
quality improvement in primary care (DQIP) 
trial: active and less active ingredients of a 
multi-component complex intervention to 
reduce high-risk primary care prescribing 
2017 Primary Health care in UK. 
33 practices from one 
Scottish health board 
Cardiovascular and renal 
adverse events 
Positive N 
25. Grant A, 
Dreischulte T, 
Guthrie B 
Process evaluation of the Data-driven 
Quality Improvement in Primary Care 
(DQIP) trial: case study evaluation of 
adoption and maintenance of a complex 
intervention to reduce high-risk primary 
care prescribing 
2017 Primary Health care in UK. 
33 practices from one 
Scottish health board 
Cardiovascular and renal 
adverse events 
Positive N 
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 Synthesis (CVD)  Ten of the studies were about improving the 
screening and management of CVD using 
best-practice guidelines. (e.g. educational 
materials to improve referral, or decision 
analysis).  Ten of the studies were about 
organisational change with models of care 
that incorporated new roles such as a nurse-
led clinic, or the use of a lay worker for 
angina management, and technology (e.g. 
tele-monitoring, point of care testing). 5 of the 
studies explored trial implementation such as 
recruitment of patients and providers, and 
were less about the intervention. 
2013-2017 2 New Zealand, 2 
Netherlands, 9 UK, 1 
Ireland, 6 Australia, 1 USA, 
3 Canada, 1 Zambia 
(interesting that is so 
international, which I 
assume has to do with the 
recognition of CVD) 
25 studies in CVD. (1 for 
chronic diseases, in 
which CVD is 
mentioned) 
15 Positive, 5 
Negative, and 5 N/A 
3 Y, 15 N, 6 NA 
1. Van Den Bemt L, 
Schermer TRJ, 
Smeele IJM, 
Boonman-de 
Winter LJM, Van 
Boxem T, Denis 
J, et al 
 An expert-supported monitoring system for 
patients with chronic obstructive pulmonary 
disease in general practice: Results of a cluster 
randomised controlled trial 
2009 General Practice. 
Netherlands 
COPD Negative N 
2. Casey D, 
Murphy K, 
Cooney A, Mee 
L, Dowling M. 
Developing a structured education programme 
for clients with COPD 
2011 Primary care, Ireland COPD NA N 
3. Julia A. E. 
Walters,E, Helen 
Courtney-Pratt , 
Helen Cameron-
Tucker, Mark 
Nelson, 
Andrew 
Robinson, Jenn 
Scott, Paul 
Turner, E. Haydn 
Walters and 
Richard Wood-
Baker 
Engaging general practice nurses in chronic 
disease self-management support in Australia: 
Insights from a controlled trial in chronic 
obstructive pulmonary disease 
2012 Australia PHC COPD NA N 
4. Fairbrother P, 
Pinnock H, 
Hanley J, 
McCloughan L, 
Sheikh A, 
Pagliari C, et al 
 Exploring tele-monitoring and self-management 
by patients with chronic obstructive pulmonary 
disease: A qualitative study embedded in a 
randomized controlled trial 
2013 Lothian. Scotland, UK Chronic Obstructive 
Pulmonary Disease  
NA N 
5. Van der Weegen 
S, Verwey R et 
al 
The Development of a Mobile Monitoring and 
Feedback Tool to Stimulate Physical Activity of 
People with a Chronic Disease in Primary Care: 
A User-Centred Design 
2013 Netherlands PHC Chronic Obstructive 
Pulmonary Disease or 
Type 2 diabetes 
NA NA 
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 6. Vest BM, York 
TRM, Sand J, 
Fox CH, Kahn 
LS  
 Chronic kidney disease guideline 
implementation in primary care: A qualitative 
report from the TRANSLATE CKD study 
2015 Primary Care Practices, 
New York. United States 
Chronic Kidney Disease Positive N 
7. Verwey R, van 
der Weegen S, 
Spreeuwenberg 
M, Tange H, van 
der Weijden T, 
de Witte L 
Process evaluation of physical activity 
counselling with and without the use of mobile 
technology: A mixed methods study 
2016 Netherlands Chronic Obstructive 
Pulmonary Disease or 
Type 2 diabetes 
Positive NA 
Synthesis (COPD, and CKD) 4 of the studies were about improving self- 
management of patients through educational 
materials, or use of monitoring, with support 
from health providers. 2 of the studies were 
about stimulating physical activity through 
the use of technology. 1 study was about 
implementing management guidelines in CKD 
in PHC. 
2009-2016 3 Netherlands, I Ireland, 1 
UK (Scotland), 1 USA, 1 
Australia 
6 addressing COPD (2 
including other chronic 
disease), and 1 
addressing CKD. 
2 Positive, 1 
Negative, 4 N/A 
0 Y, 5 N, 2 N/A. 
Overall Synthesis of 69 
studies in total 
Overall, the complex primary care 
interventions fit within the general categories 
of facilitating patient self-management (13 
studies), organisational change to include 
collaborative care (16 studies), facilitating 
better case management using clinical 
information systems (e.g. tele-health) (15  
studies), and the use of decision support and 
guideline implementation (e.g. referral 
systems) (22 studies). In addition, 5 studies 
were exploring the conduct of trials in 
primary health care e.g. the recruitment of 
patients.  
1999-2017 22 UK, 9 USA, 1 Sweden, 1 
Germany, 10 Australia, 1 
India, 3 Canada, 5 Ireland, 
1 Norway, 3 New Zealand, 
1 Malaysia, 5 Netherlands, 
1 Zambia  
In addition, 2 studies 
focused on First Nations 
peoples in Australia and in 
Canada. 3 studies (Chung, 
Fakiri, Ratangawonsa) 
were focused on the 
populations living in 
disadvantage. 
20 Depression, 17 
Diabetes, 25 CVD, 6 
COPD and 1 CKD. 
33 Positive, 21 
Negative and 14 Not 
applicable.  
10 Y, 47 N, 11 
Not applicable.  
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Author Title Year 
Labelled as 
Process 
Evaluation 
(Y/N) 
Stated 
Purpose 
(Y/N) 
Protoc
ol 
(Y/N) 
Processes 
examined at 
which stage 
Use of Theory (Y/N) Methods Analysis 
Tai SS, Nazareth 
I, Donegan C, 
Haines A 
Evaluation of general practice computer 
templates. Lessons from a pilot randomised 
controlled trial 
1999 N Y N 
Feasibility 
and Piloting 
N 
qualitative (semi-structured 
interviews designed to assess the 
users' views) and quantitative 
(change in use of the template 
during the study period) 
NA 
Weiss MC, 
Montgomery 
AA, Fahey T, 
Peters TJ 
 Decision analysis for newly diagnosed 
hypertensive patients: a qualitative investigation 
2004 
Qualitative 
study 
Y N 
Feasibility 
and Piloting 
N Semi-structured Interviews Decision Analysis 
Jackie Sturt, 
Hafrun Taylor, 
Andrea 
Docherty, 
Jeremy Dale, 
Taylor Louise 
A psychological approach to providing self-
management education for people with type 2 
diabetes: the Diabetes Manual 
2006 N Y N Feasibility Y 
Using the MRC complex 
intervention framework the 
intervention was developed. 
Theory driven, needs assessment 
through focus group, and the use 
of a feasibility survey  
Use of a survey to 
determine the feasibility 
of the developed 
intervention to be further 
tested in a definitive RCT 
Byrne M, 
Cupples ME, 
Smith SM, 
Leathem C, 
Corrigan M, 
Byrne MC, et al 
 Development of a complex intervention for 
secondary prevention of coronary heart disease 
in primary care using the UK Medical Research 
Council framework 
2006 N Y N 
Feasibility 
and Piloting 
Y Semi structured Interviews NR 
Chew-Graham 
CA, Lovell K, 
Roberts C, 
Baldwin R, 
Morley M, 
Burns A, et al 
 A randomised controlled trial test the feasibility 
of a collaborative care model for the 
management of depression in older people 
2007 N Y N 
Feasibility 
and Piloting 
N 
Semi-structured Interviews and 
questionnaires 
Thematic analysis 
Clark RA, Yallop 
JJ, Piterman L, 
Croucher J, 
Tonkin A, 
Stewart S, et al 
Adherence, adaptation and acceptance of 
elderly chronic heart failure patients to receiving 
healthcare via telephone-monitoring 
2007 N Y Y 
Feasibility 
and piloting 
N 
Triangulation of descriptive 
statistics, feedback surveys and 
qualitative analysis of clinical 
notes.  
Thematic analysis of the 
clinical notes and open 
ended comments from 
survey and triangulated 
with the satisfaction 
survey. 
Lovell K, Bower 
P, Richards D, 
Barkham M, 
Sibbald B, 
Roberts C, et al 
Developing guided self-help for depression using 
the Medical Research Council complex 
interventions framework: A description of the 
modelling phase and results of an exploratory 
randomised controlled trial 
2008 N Y N 
Feasibility 
and piloting  
yes- use of MRC 
Interviews, systematic review 
and modelling.  
Framework analysis 
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Chatterjee S, 
Chowdhary N, 
Pednekar S, 
Cohen A, 
Andrew G, 
Araya R, et al 
 Integrating evidence-based treatments for 
common mental disorders in routine primary 
care: Feasibility and acceptability of the MANAS 
intervention in Goa, India 
2008 N Y N 
Feasibility 
and Piloting & 
post 
evaluation 
N 
Stakeholder semi structured 
interviews 
Thematic analysis 
van Steenkiste 
B, van der 
Weijden TM, 
Stoffers JH, Grol 
RP 
 Patients' responsiveness to a decision support 
tool for primary prevention of cardiovascular 
diseases in primary care 
2008 Y Y N 
Feasibility 
and Piloting 
N 
routine monitoring data, 
observations (e.g. Patients’ 
actually having read the booklet 
and returning for the second 
consultation; comprehension and 
perceived relevance of the 
information; perceived 
reassurance.) 
Descriptive statistics, and 
logistic regression to 
dependent variables and 
independent variables.  
Chung B, Jones 
L, Dixon EL, 
Miranda J, 
Wells K, 
Community 
Partners in Care 
Steering Council 
Using a Community Partner Participatory 
Research Approach to Implement a Randomised 
Controlled Trial: Planning Commnunity Partners 
in Care 
2010 N Y N Feasibility Y 
Baseline survey, community 
dialogue to obtain community 
feedback 
NA 
Gask L, Bower 
P, Lovell K, 
Escott D, Archer 
J, Gilbody S, 
Lankshear A, 
Simpson AE, 
Richards DA. 
What work has to be done to implement 
collaborative care for depression? Process 
evaluation of a trial utilizing the Normalisational 
Process Model 
2010 Y Y N 
Feasibility 
and piloting 
(exploratory 
trial) 
Normalisation 
Process Model 
Pre study data collection of focus 
group and interviews, and post 
study data collection of 
interviews 
Used a template or apriori 
coding manual from 
normalisation process 
model.  
Casey D, 
Murphy K, 
Cooney A, Mee 
L, Dowling M. 
Developing a structured education programme 
for clients with COPD 
2011 
N, 
Developme
nt of 
programme 
Y N 
Feasibility 
and Piloting 
N 
Content analysis and concept 
analysis and 2 qualitative studies 
Constant Comparative 
approach 
Chalder M, 
Wiles NJ, 
Campbell J, 
Hollinghurst SP, 
Searle A, Haase 
AM, et al 
 A pragmatic randomised controlled trial to 
evaluate the cost-effectiveness of a physical 
activity intervention as a treatment for 
depression: The treating depression with 
physical activity (TREAD) trial 
2012 
N, 
Qualitative 
study 
Y Y 
Feasibility 
and Piloting 
Y (Self 
Determination 
Theory) 
Interviews NA 
Bennett M, 
Walters K, 
Drennan V, 
Buszewicz M 
 Structured Pro-Active Care for Chronic 
Depression by Practice Nurses in Primary Care: A 
Qualitative Evaluation 
2013 N Y Y 
Feasibility 
and Piloting 
N In depth interviews Thematic analysis 
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Carlisle K, 
Warren R 
 A qualitative case study of telehealth for in-
home monitoring to support the management of 
type 2 diabetes 
2013 N Y Y 
Feasibility 
and Piloting 
N Semi structured Interviews Not described.  
Van der 
Weegen S, 
Verwey R et al 
The Development of a Mobile Monitoring and 
Feedback Tool to Stimulate Physical Activity of 
People with a Chronic Disease in Primary Care: A 
User-Centered Design 
2013 N Y N Feasibility Y 
Qualitative individual interviews 
and focus group. Literature 
search re behaviour change and 
self-management 
Three staged iterative 
process. Literature review 
to identify end users and 
context, stage 2, the 
literature, experts and 
patient representatives 
consulted to set up a use 
case. Stage 3 where 
individual interviews and 
focus groups based on the 
use case helped to identify 
end user requirements, 
and build a prototype.  
Fairbrother, 
Peter 
McCloughan, 
Lucy 
Adam, 
Geraldine 
Brand, Richard 
Brown, Cecil 
Watson, Mary 
Cotter, Nicola 
Mackellaig, 
Juliet 
McKinstry, 
Brian 
Involving patients in clinical research: The 
Telescot patient panel 
2013 N Y Y Feasibility N Patient' panel and Focus groups Thematic 
Ramadas A, 
Chan C, 
Oldenburg B, 
Hussien Z, Quek 
K 
 A Web-Based Dietary Intervention for People 
with Type 2 Diabetes: Development, 
Implementation, and Evaluation 
2015 Y Y Y 
Feasibility 
and Piloting 
N 
Self-administered questionnaire 
(to determine program 
reception) 
Descriptive statistics of 
the process evaluation 
measures.  
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Naik AD, 
Lawrence B, 
Kiefer L, Ramos 
K, Utech A, 
Masozera N, et 
al 
 Building a primary care/research partnership: 
lessons learned from a telehealth intervention 
for diabetes and depression 
2015 
Formative 
evaluation 
Y N 
Feasibility 
and Piloting, 
and 
Evaluation of 
effectiveness 
Y 
Qualitative data from the 
research/clinical partnership 
meetings that was recorded and 
coded. Triangulated with other 
information such as research 
staff personal communication, 
field notes and minutes of 
meetings.  
Qualitative Framework 
analysis 
Vest BM, York 
TRM, Sand J, 
Fox CH, Kahn LS 
 Chronic kidney disease guideline 
implementation in primary care: A qualitative 
report from the TRANSLATE CKD study 
2015 Y Y Y 
Feasibility 
and Piloting 
Y Semi-structured Interviews Thematic Content Analysis 
Synthesis 
The quality data items do not fit these studies 
as they seem to be more applicable to the 
effectiveness stage. Though the COREQ ones 
still matter for the qualitative study/methods. 
The methods (literature search, consensus 
process, focus group interviews) can inform the 
intervention development and subsequent 
evaluation (e.g. testing of change in 
determinants). Use of classic theory especially 
psychological/behavioural ones seem relevant 
for chronic diseases given the emphasis on self-
management as reflected in Box 1.  
1999
-
2016 
5 labelled 
as process 
evaluations  
20 to 
stated 
purpose.  
8 Y 20 Studies 9  
18 used interviews. 3 used focus 
group discussions, 4 used 
questionnaires or surveys, 2 
studies used routine monitoring 
data, field notes, minutes of 
meetings and observations.  
Thematic analysis, 
constant comparative 
approach most commonly 
used, with some using 
framework analysis.  
Hetlevik I, 
Holmen J, 
Kruger O, 
Kristensen P, 
Iversen H, 
Furuseth K 
 Implementing clinical guidelines in the 
treatment of diabetes mellitus in general 
practice: Evaluation of effort, process, and 
patient outcome related to implementation of a 
computer-based decision support system 
2000 Y  Y N Effectiveness N 
Use of number of patient 
registrations (fraction as the 
process evaluation) and a 
questionnaire to determine user 
friendliness, perceived benefit 
and feedback about 
implementation strategies 
Quantitative analysis 
according to variables and 
across two time points. 
Thornett AM, 
Mynors-Wallis 
LM 
 Credibility of problem-solving therapy and 
medication for the treatment of depression 
among primary care patients 
2002 N Y N 
Evaluation of 
effectiveness 
N 
Credibility scale questionnaires, 
Kruskall-Wallis rank test of 
relationships. 
Statistical analysis 
Ilag LL, Martin 
CL, Tabaei BP, 
Isaman DJ, 
Burke R, 
Greene DA, et 
al 
 Improving diabetes processes of care in 
managed care 
2003 N Y N 
Evaluation of 
effectiveness 
N 
Quantitative measures of 
processes of care (e.g. measuring 
HbA1c), and a Likert scale 
acceptability survey given to the 
health providers 
Quantitative analysis 
between groups, with 
hierarchical liner mixed 
models for continuous 
models for categorical 
variables to control for 
random subject effects 
and random practice-site 
effects.  
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Lobo CM, Euser 
L, Kamp J, 
Frijling BD, 
Severens JL, 
Hulscher MEJL, 
et al 
 Process evaluation of a multifaceted 
intervention to improve cardiovascular disease 
prevention in general practice 
2003 Y Y N 
Evaluation of 
effectiveness 
N 
Implementer reports and 
questionnaires to health 
providers  
 
Descriptive statistical 
analysis.  
Pearl A, Wright 
S, Gamble G, 
Doughty R, 
Sharpe N 
 Randomised trials in general practice--a New 
Zealand experience in recruitment 
2003 N Y N effectiveness N Evaluation questionnaire  Descriptive 
Smith S, Bury G, 
O'Leary M, 
Shannon W, 
Tynan A, 
Staines A, 
Thompson C 
The North Dublin randomized controlled trial of 
structured diabetes shared care 
2004 N Y N 
Evaluation of 
effectiveness 
N 
processes of care and qualitative 
study, (and outcome study 
reported together) 
Triangulation of mixed 
methods 
Gask L, Dixon C, 
May C, Dowrick 
C 
 Qualitative study of an educational intervention 
for GPs in the assessment and management of 
depression 
2005 N Y Y 
Evaluation of 
effectiveness 
(Y) 
N Interviews 
Qualitative Content 
Analysis 
Gask L, Ludman 
E, Scaheffer J.  
Qualitative Study of an intervention for 
depression among patients with diabetes: how 
can we optimise patient-professional 
interaction? 
2006 N Y N 
Evaluation of 
effectiveness 
N 
Qualitative semi structured 
interviews and content analysis 
of recorded case management 
(i.e. the intervention itself) 
Constant Comparative 
approach 
Heaven, B. 
Murtagh, M. 
Rapley, T. 
May, C. 
Graham, R. 
Kaner, E. 
Thomson, R. 
Patients or research subjects? A qualitative 
study of participation in a randomised controlled 
trial of a complex intervention 
2006 N  Y N 
Post hoc 
effectiveness
? 
Y (informed by ideas 
of symbolic 
interactionism, 
phenomenology and 
critical psychology.  
Mixed Methods: Part of an 
observational study alongside a 
RCT (comprising of video of 
consultation) and participant 
interview post clinic and 3 
months post clinic (* this study 
only reports on the 3-5 days post 
clinic interviews.  
Constant Comparative 
approach to the 
qualitative data, and 
informed by ideas from 
symbolic interactionism, 
phenomenology and 
critical psychology.  
Fakiri FE, Hows 
MW, Uitewaal 
PJM, Frenken 
RA, Bruijnzeels 
MA. 
Process evaluation of an intensified preventive 
intervention to reduce cardiovascular risk in 
general practices in deprived neighbourhoods 
2008 Y Y N 
Evaluation of 
effectiveness- 
fidelity and 
reach 
N 
Fidelity data e.g. ranking of the 
intervention as delivered by the 
protocol, and the Reach data 
through the number of 
consultations completed 
Descriptive analysis 
235
Slade M, Gask 
L, Leese M, 
McCrone P, 
Montana C, 
Powell R, 
Stewart M, 
Graham-Chew 
C 
Failure to improve appropriateness of referrals 
to adult community mental health services—
lessons from a multi-site cluster randomized 
controlled trial  
2008 N  Y Y 
Evaluation of 
effectiveness 
N 
Outcomes, process data was 
presented and implementation 
was explored through the nested 
qualitative data.  
Logistics analysis and 
thematic analysis of the 
qualitative data.  
Van Den Bemt 
L, Schermer 
TRJ, Smeele 
IJM, Boonman-
de Winter LJM, 
Van Boxem T, 
Denis J, et al 
 An expert-supported monitoring system for 
patients with chronic obstructive pulmonary 
disease in general practice: Results of a cluster 
randomised controlled trial 
2009 Y Y N 
Evaluation of 
effectiveness 
N 
For the process evaluation, the 
respiratory experts’ database 
was examined to collect data on 
their recommendations. The 
nurse consultant collected data 
on GPs’ implementation of 
recommendations. Patient 
questionnaires comprised 
questions about disease 
management. (i.e. documentary 
analysis and questionnaires)  
Compared the 
implementation across 
control and intervention 
groups. Process evaluation 
and outcome evaluation 
was presented together.  
Smith S, Paul G, 
Kelly A, 
Whitford D, 
O'Shea E, 
O'Dowd T 
 Peer support for patients with type 2 diabetes: 
Cluster randomised controlled trial 
2011 Y Y Y 
Evaluation of 
effectiveness 
N 
Interviews and FGD's. Routine 
monitoring data 
Descriptive parallel 
qualitative analysis based 
on descriptive 
phenomenology 
Passey ME, 
Laws RA, 
Jayasinghe UW, 
Fanaian M, 
McKenzie S, 
Powell-Davies 
G, et al 
 Predictors of primary care referrals to a vascular 
disease prevention lifestyle program among 
participants in a cluster randomised trial 
2012 N Y Y 
Evaluation of 
effectiveness 
N Routine monitoring data Univariate analysis 
Gensichen J, 
Guethlin C, 
Sarmand N, 
Sivakumaran D, 
Jager C, 
Mergenthal K, 
et al 
 Patients' perspectives on depression case 
management in general practice - A qualitative 
study 
2012 N Y Y 
Evaluation of 
effectiveness 
N Interviews Content Analysis 
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Julia A. E. 
Walters,E, 
Helen 
Courtney-Pratt , 
Helen 
Cameron-
Tucker, Mark 
Nelson, 
Andrew 
Robinson, Jenn 
Scott, Paul 
Turner, E. 
Haydn Walters 
and Richard 
Wood-Baker 
Engaging general practice nurses in chronic 
disease 
self-management support in Australia: insights 
from a controlled trial in chronic obstructive 
pulmonary disease 
2012 N Y N Effectiveness N 
Mixed methods (quant survey 
and interviews) 
Iterative thematic analysis 
with triangulation of 
quant data 
Ratanawongsa 
N, Bhandari VK, 
Handley M, 
Rundall T, 
Hammer H, 
Schillinger D 
 Primary care provider perceptions of the 
effectiveness of two self-management support 
programs for vulnerable patients with diabetes 
2012 N Y Y 
Evaluation of 
effectiveness 
N self-administered questionnaire Descriptive analysis  
Lakerveld J, Bot 
S, Chinapaw M, 
van Tulder M, 
Kingo L, Nijpels 
G 
 Process evaluation of a lifestyle intervention to 
prevent diabetes and cardiovascular diseases in 
primary care 
2012 Y Y Y 
Evaluation of 
Effectiveness 
Re-AIM Questionnaires 
Confirmatory factor 
analysis 
Paul G, Keogh 
K, D'Eath M, 
Smith SM 
 Implementing a peer-support intervention for 
people with type 2 diabetes: A qualitative study 
2013 N Y Y 
Evaluation of 
effectiveness 
N Stakeholder interviews and  FGD 
Framework analysis and a 
matrix based method of 
analysing qualitative data. 
Nelson P, Cox 
H, Furze G, 
Lewin RJP, 
Morton V, 
Norris H, et al 
 Participants' experiences of care during a 
randomized controlled trial comparing a lay-
facilitated angina management programme with 
usual care: a qualitative study using focus groups 
2013 N Y Y 
Evaluation of 
Effectiveness 
N Focus group discussions Thematic analysis 
Fairbrother P, 
Pinnock H, 
Hanley J, 
McCloughan L, 
Sheikh A, 
Pagliari C, et al 
 Exploring tele monitoring and self-management 
by patients with chronic obstructive pulmonary 
disease: A qualitative study embedded in a 
randomized controlled trial 
2013 N Y Y 
Evaluation of 
effectiveness- 
views of the 
intervention 
Schermer three 
degress of 
telemetric self 
management 
Semi structured Interviews Framework analysis 
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Stallard P, 
Phillips R, 
Montgomery 
AA, Spears M, 
Anderson R, 
Taylor J, et al 
 A cluster randomised controlled trial to 
determine the clinical effectiveness and cost-
effectiveness of classroom-based cognitive-
behavioural therapy (CBT) in reducing symptoms 
of depression in high-risk adolescents 
2013 Y Y Y 
Evaluation of 
effectiveness 
REAIM 
Questionnaires and Qualitative 
Interviews 
Thematic analysis 
Hanley, J. 
Ure, J. 
Pagliari, C. 
Sheikh, A. 
McKinstry, B. 
Experiences of patients and professionals 
participating in the HITS home blood pressure 
tele-monitoring trial: A qualitative study 
2013 N Y Y 
Effectiveness 
(though 
informed by 
interviews at 
the pilot and 
feasibility 
stage, and 
there was a 
protocol-
evolution 
allowed) 
Y (Normalisation 
process theory) 
Semi-structured qualitative 
interviews and a focus group to 
validate the findings and discuss 
implementation 
Ongoing iterative analysis 
“The trial context 
permitted triangulation 
with quantitative data. 
Owing to the 
protocolpermitted 
evolution in practice, it 
gives an indication 
of some of the issues 
which would need to 
be addressed for BP 
telemonitoring to be used 
in routine practice.” 
Laws, R. A. 
Fanaian, M. 
Jayasinghe, U. 
W. 
McKenzie, S. 
Passey, M. 
Davies, G. P. 
Lyle, D. 
Harris, M. F 
Factors influencing participation in a vascular 
disease prevention lifestyle program among 
participants in a cluster randomized trial 
2013 N y y effectiveness N 
Mixed methods of quantitative 
analysis of survey, clinical audit 
data, practice questionnaire on 
capacity for preventive care, and 
referral and attendance records, 
interviews with implementers of 
the program 
Quantitative data analysis 
(to find the characteristics 
and the factors influencing 
attendance) and 
qualitative thematic 
analysis. 
Manca DP, 
Greiver M, 
Carroll JC, 
Salvalaggio G, 
Cave A, Rogers 
J, et al 
Finding a BETTER way: A qualitative study 
exploring the prevention practitioner 
intervention to improve chronic disease 
prevention and screening in family practice 
2014 N Y N 
Evaluation of 
effectiveness 
Y (Grounded theory) 
semi-structured interviews and 
focus groups 
Constant Comparative 
approach 
Richter-
Sundberg L, 
Nystrom ME, 
Krakau I, 
Sandahl C 
 Improving treatment of depression in primary 
health care: A case study of obstacles to perform 
a clinical trial designed to implement practice 
guidelines 
2015 N Y N 
Evaluation of 
effectiveness 
N Semi-structured Interviews qualitative analysis 
238
Eborall HC, 
Dallosso HM, 
McNicol S, 
Speight J, 
Khunti K, Davies 
MJ, et al 
 Explaining engagement in self-monitoring 
among participants of the DESMOND self-
monitoring trial: A qualitative interview study 
2015 N Y N Evaluation of 
effectiveness 
N Qualitative semi structured 
interviews 
Constant Comparative 
approach 
Grimshaw JM, 
Presseau J, 
Tetreo Jm , 
Eccles MP, 
Francis JJ, 
Godin G, 
Graham ID, 
Hux, JE, 
Johnston M, 
Legare F, emyre 
L, et al.. 
Looking inside the black box: results of a theory-
based process evaluation exploring the results of 
a randomized controlled trial of printed 
educational messages to increase primary care 
physicians' diabteic retinopathy referrals 
2014 Y Y Y 
Evaluation of 
effectiveness 
Y (Theory of 
planned behaviour) 
Surveys at two time points 
Compared groups 
factorially on changes at 
the two time points pre 
and post intervention. 
Thematic analysis of the 
open comment section 
Burridge, L. H. 
Foster, M. M. 
Donald, M. 
Zhang, J. 
Russell, A. W. 
Jackson, C. L. 
Making sense of change: patients' views of 
diabetes and GP-led integrated diabetes care 
2014 N Y N 
Evaluation of 
effectiveness 
Y, Normalisation 
Process Theory 
Qualitative study (as part of a 
mixed methods evaluation) 
Thematic Analysis with a 
modified framework 
based on NPT. 
Coupe N, 
Anderson E, 
Gask L, Sykes P, 
Richards DA, 
Chew-Graham 
C 
 Facilitating professional liaison in collaborative 
care for depression in UK primary care; A 
qualitative study utilising normalisation process 
theory 
2014 N Y Y 
Evaluation of 
effectiveness 
Normalization 
process theory 
(NPT) 
Interviews Thematic analysis 
Kenealy TW, 
Parsons MJG, 
Rouse PB, 
Doughty RN, 
Sheridan NF, 
Hindmarsh JKH, 
Masson SC, Rea 
HH. 
Telecare for Diabetes, CHF or COPD; Effect on 
Quality of Life, Hospital Use and Costs. A 
Randomised ControlledTrial and Qualitative 
Evaluation 
2015 N Y N 
Evaluation of 
effectiveness 
N 
Individual and focus group 
interviews and questionnaire. 
(note that other process 
measures such as the nurse 
keeping a log of their activities 
for calculation of health care use 
was also collected) 
Thematic analysis 
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Liu H, Massi L, 
Laba TL, Peiris 
D, Usherwood 
T, Patel A, Cass 
A, Eades AM, 
Redfern J, 
Hayman N, 
Howard K, Brien 
JA, Jan S. 
Patients' and Providers' Perspectives of a Polypill 
Strategy to Improve Cardiovascular Prevention 
in Australian Primary Health Care: A Qualitative 
Study Set Within a Pragmatic Randomized, 
Controlled Trial.  
2015 Y Y Y Effectiveness Y 
Qualitative interviews and 
triangulation with outcomes, and 
knowledge of trial 
implementation 
Iterative thematic 
analysis, with the use of 
the Realist framework to 
guide the development of 
the themes.  
Liu H, Laba T, 
Massi L, Jan S, 
Usherwood T, 
Patel A, 
Hayman N, Cass 
A, Eades A, 
Peiris D.  
Facilitators and barriers to implementation of a 
pragmatic clinical trial in Aboriginal health 
services.  
2015 Y Y Y Effectiveness N 
Qualitative interviews and 
triangulation with outcomes, and 
knowledge of trial 
implementation 
Iterative thematic analysis  
Liu H, Massi L, 
Eades AM, 
Howard K,  
Peiris D, 
Redfern J, 
Usherwood T, 
Cass A, Patel A, 
Jan S, Laba T.  
Implementing a pragmatic randomised 
controlled trial in Australia: lessons learnt from 
the Kanyini Guidelines Adherence with the 
Polypill study (Kanyini GAP)  
2015 Y Y Y Effectiveness N 
Qualitative interviews and 
triangulation with outcomes, and 
knowledge of trial 
implementation 
Iterative thematic analysis 
Huntink E, 
Wensing M, 
Timmers IM, 
Lieshout JV 
Process evaluation of a tailored intervention 
programme of cardiovascular risk management 
in general practices 
2016 Y Y N 
Evaluation of 
effectiveness 
N 
Mixed methods- quantitative 
measures (survey results and 
scoring of recorded motivational 
interviews) and qualitative data 
of interviews conducted.  
Quantitative analysis of 
the scores, and qualitative 
analysis using the pre-
specified tailored 
intervention for chronic 
diseases   
Presseau J, 
Grimshaw J, 
Tetroe JM, 
Eccles MP, 
Francis JJ, 
Godin G, 
Graham ID, Hux 
JE, Johnston M, 
Legare F, 
Lemyre L, 
Robinson N, 
Zwarenstein M.  
A theory-based process evaluation alongside a 
randomised controlled trial of printed 
educational messages to increase primary care 
physician's prescription of thiazide diuretics for 
hypertension  
2016 Y Y Y 
Evaluation of 
effectiveness 
Y (Theory of 
planned behaviour) 
Pre, post postal questionnaire to 
a random sub-sample of family 
physicians in each trial arm 
Analysis of co-variance to 
test for group differences 
using a 2X3 factorial 
design and content 
analysis of the open 
ended question about 
perceived barriers to 
thiazide prescription. 
Tested whether baseline 
measures of TPB 
constructs predicted self-
reported thiazide 
prescribing 
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Verwey R, van 
der Weegen S, 
Spreeuwenberg 
M, Tange H, van 
der Weijden T, 
de Witte L 
Process evaluation of physical activity 
counselling with and without the use of mobile 
technology: A mixed methods study 
2016 Y Y Y 
Evaluation of 
effectiveness 
N 
Mixed methods (using semi-
structured interviews, 
questionnaires to patients and 
use of IT tool through system 
logging) 
Descriptive analysis and 
triangulation of findings.  
Parsons, J. A. 
Yu, C. H. Y. 
Baker, N. A. 
Mamdani, M. 
M. 
Bhattacharyya, 
O. Zwarenstein, 
M. Shah, B. R. 
Practice doesn't always make perfect: A 
qualitative study explaining why a trial of an 
educational toolkit did not improve quality of 
care 
2016 Y Y N Effectiveness N 
In-depth semi-structured 
telephone interviews with 
physicians who received the tool 
kit.  And written commentary 
from reflective feedback forms 
collected from 10% of practices 
randomised and approached) 
who participated in chart audit as 
part of the clinical data study.  
Qualitative description 
which entails an 
inductively- derived 
thematic analysis, and 
triangulated with the 
written comments from 
the questionnaires   
Yan LD, Chirwa 
C, Chi BH, 
Bosomprah S, 
Sindano N, 
Mwanza M, 
Musatwe D, 
Mulenga M, 
Chilengi R. 
Hypertension management in rural primary care 
facilities in Zambia: a mixed methods study 
2017 N Y Y 
Evaluation of 
effectiveness 
N 
Data on novel retrospectively 
generated process and outcome 
indicators for hypertension 
management, informed by those 
from Western countries, 
but adapted to the Zambian 
primary care clinics. Extracted 
using EMR. Semi-structured in-
depth interviews with health care 
providers and a representative 
from the central medication 
distribution agency 
. 
We used an explanatory 
sequential design by 
conducting a quantitative 
analysis of outcome 
measures , which was 
then explained through a 
qualitative follow up 
component. 
Wells S, Rafter 
N, Kenealy T, 
Herd, Geoff, 
Eggleton K, 
Lightfoot R, 
Arcus K, 
Wadham A, 
Jiang Y, Bullen 
C.   
The impact of a point of care testing device on 
CVD risk assessment completion in New Zealand 
primary-care practice: A cluster randomised 
controlled trial and qualitative investigation 
2017 N Y N 
Evaluation of 
effectiveness 
N 
Qualitative data on practice 
processes for CVD risk 
assessment and feasibility of POC 
testing were collected 
at the end of the study by 
interviews and questionnaire. 
Braun and Clarke's 
approach to thematic 
analysis was used to 
generate 
initial codes, collate codes 
into potential themes and 
refine the identified 
themes and categories 
into a coherent pattern.  
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Grant A, 
Dreischulte T, 
Guthrie B  
 
Process evaluation of the data-driven 
quality improvement in primary care (DQIP) 
trial: active and less active ingredients of a 
multi-component complex intervention to 
reduce high-risk primary care prescribing 
2017 Y Y Y 
Evaluation of 
effectiveness 
Y (NPT)  
Data generation was by in-depth 
interview with key staff exploring 
participant’s perceptions of the 
intervention components. 
Analysis was iterative 
using the framework 
technique and drawing on 
normalisation 
process theory. 
Grant A, 
Dreischulte T, 
Guthrie B  
Process evaluation of the Data-driven 
Quality Improvement in Primary Care 
(DQIP) trial: case study evaluation of 
adoption and maintenance of a complex 
intervention to reduce high-risk primary 
care prescribing 
2017 Y Y Y 
Evaluation of 
effectiveness 
Y (NPT) 
Mixed-methods parallel process 
evaluation of 
a cluster trial, reporting the 
comparative case study of 
purposively selected practices.  
Use of interviews at two 
time points and the use of 
quantitative data to 
explore whether the 
qualitative judgements 
made about 
implementation were 
consistent with observed 
data on reach, delivery, 
maintenance and 
effectiveness. Use of NPT 
alongside the cross and 
within-case comparisons.  
Rapp AM, 
Chavira DA, 
Sugar CA, 
Asarnow JR 
Integrated Primary Medical-Behavioral Health 
Care for Adolescent and Young Adult 
Depression: Predictors of Service Use in Youth 
Partners in Care Trial 
2017 N Y Y 
Evaluation of 
Effectiveness 
Y ( Behavioural 
Model of Health 
Service Use) 
Secondary Analysis of data from 
the trial to investigator the 
predisposing factors 
(demographics), enabling factors 
(e.g. perceived stigma of 
depression) , need factors and 
outcomes (receipt of mental 
health services)  
Statistical analyses, and 
plots of significant 
interactions. Investigating 
possible interactions 
between variables, and 
individual logistic 
regression for the possible 
independent variables, 
with mental health 
treatment as outcome.  
Algorithm to finally 
identify the subset of 
variables that best 
predicted mental health 
service use.  
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Synthesis  
2000
-
2017 
16 labelled 
as process 
evaluations
(13 after 
2008, and 5 
after 2015) 
  
22 Y, 
and 16 
N 
44 studies  
13 studies (7 Classic 
theories, 3 
evaluation 
frameworks, 3 
implementation 
theories)  
2000-2004: 6 studies 
documented specific processes 
of care as part of the process 
evaluation, and were often 
reported as part of the main 
trial. The acceptability of an 
intervention was often 
investigated using 
surveys/questionnaires. 
2005 onwards- 9 studies used 
only interviews to explore 
implementation and 
acceptability, 15 studies used 
interviews triangulated with 
other sources of data (e.g. chart 
audit). 5 studies used 
questionnaires or surveys.  1 
study used secondary analysis of 
trial data.  
Descriptive statistics were 
used for the quantitative 
data. Thematic, constant 
comparison and 
framework analysis for 
the qualitative data.  
The studies that used 
mixed methods, used the 
quantitative data to 
indicate level of 
implementation, reach 
and the dose. This was 
use to triangulate the 
qualitative findings on 
implementation and 
intervention 
acceptability.  
Oishi SM, Shoai 
R, Katon W, 
Callahan C, 
Unutzer J, 
Arean P, et al 
 Impacting late life depression: Integrating a 
depression intervention into primary care 
2003 N Y Y 
Post 
evaluation 
Implementati
on 
N 
Focus group discussions and semi 
structured interviews 
Thematic analysis 
Dietrich AJ, 
Oxman TE, 
Williams JW, 
Kroenke K, 
Schulberg HC, 
Bruce M, et al 
 Going to scale: Re-engineering systems for 
primary care treatment of depression 
2004 N Y Y 
Post-
evaluation 
Yes- Diffusion of 
Innovations theory 
Documentary analysis of care 
manager logs, health care 
organisation’s administrative 
data to access cooperation in 
implementation and changes in 
the processes of care in each 
practice. Clinical surveys 
Descriptive  
 
Lee PW, 
Dietrich AJ, 
Oxman TE, 
Williams Jr JW, 
Barry SL 
 Sustainable impact of a primary care depression 
intervention 
2007 N Y Y 
Post 
evaluation 
Implementati
on 
N Interviews Descriptive evaluation 
Pylypchuk G, 
Vincent L, 
Wentworth J, 
Kiss A, Perkins 
N, Hartman S, 
et al 
 Diabetes risk evaluation and microalbuminuria 
(DREAM) studies: Ten years of participatory 
research with a First Nation's home and 
community model for type 2 diabetes care in 
northern Saskatchewan 
2008 N N N 
Evaluation of 
effectiveness, 
and post 
intervention 
N 
documentary analysis, 
Population survey, pilot and 
randomised trial 
documentary analysis 
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Wentzlaff DM, 
Carter BL, 
Ardery G, 
Franciscus CL, 
Doucette WR, 
Chrischilles EA, 
et al 
 Sustained Blood Pressure Control Following 
Discontinuation of a Pharmacist Intervention 
2011 N Y Y 
Post-
evaluation 
implementati
on 
N routine monitoring data Intention to treat analysis 
Chaney EF, 
Rubenstein LV, 
Liu CF, Yano 
EM, Bolkan C, 
Lee M, et al 
 Implementing collaborative care for depression 
treatment in primary care: A cluster randomized 
evaluation of a quality improvement practice 
redesign 
2011 N Y N 
post 
evaluation 
Implementati
on 
N 
The study intervention is EBQI as 
applied to collaborative care 
implementation. The study uses 
a cluster randomized design as a 
formative evaluation tool to test 
and improve the effectiveness of 
the redesign process.  Data 
sources include survey and 
administrative data sources, and 
the care manager registry-based 
measures (e.g. patients routinely 
referred outside of the trial).  
The context evaluation is 
descriptive and uses 
subgroup analysis. (e.g. 
clinician adoption status) 
Synthesis  
2003
-
2015 
0 as 
process 
evaluations 
5 Y, 1 N 4Y,  
7 studies, 
(note the 
cross over 
with quality 
improvement 
studies) 
NPT for 1 
3 used interviews, 2 used 
documentary analysis, and 1 
used the administrative data 
and registry data 
Descriptive statistics, 
subgroup analysis and 
thematic analysis.  
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Author Year Planning 
(Y/N/ NA) 
Design and Conduct (Y/N/NA) Reporting (Y/N/NA) 
Team 
description 
Purpose 
clearly 
stated  
Interven-
tion and 
causal 
assumptions 
Justify 
choice of 
timing and 
methods.  
Report if 
analysis 
was done 
blind to 
trial 
outcomes
/ or post 
hoc 
COREQ for qual studies. (31 items 
under Domain 1: research team and 
reflexivity, Domain 2: study design, 
Domain 3: analysis and reporting) 
Clearly 
labelled 
Linked to a 
full report of 
evaluation 
components
/ protocol 
paper.  
Tai SS et al. 1999            
 
  
Weiss 2004            
 
  
Jackie Sturt,  2006            
 
  
Byrne 2006            
 
  
Chew-
Graham 
2007            
 
  
Clark 2007            
 
  
Lovell 2008            
 
  
Chatterjee 2008            
 
  
Van 
Steenkiste 
2008         
Chung 2010         
Gask L,  2010            
 
  
Casey  2011            
 
  
Chalder 2012            
 
  
Bennett  
 
2013            
 
  
Carlise 2013            
 
  
Van der 
Weegen 
2013            
 
  
Fairbrother  2013            
 
  
Ramadas A,  
 
2015         
Naik 2015            
 
  
Vest 2015            
 
  
          
Hetlevik  2000         
Thornett 2002         
Ilag 2003         
Lobo  2003         
Oishi  2003            
 
  
Pearl 2003            
 
  
Smith S 2004            
 
  
Gask L,  2005            
 
  
Gask L 2006            
 
  
Heaven, B. 2006            
 
  
Fakiri 2008         
Slade 2008            
 
  
Van Den 
Bemt 
2009         
Smith  2011            
 
  
Passey  2012         
Genichen 2012            
 
  
Walters JAE  2012            
 
  
Ratanawong
sa  
2012         
Lakerveld J 2012         
Paul  2013            
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Nelson 2013            
 
  
Fairbrother 2013            
 
  
Stallard 2013            
 
  
Hanley  2013            
 
  
Laws 2013         
Manca 2014            
 
  
Richter-S.  2015            
 
  
Grimshaw 2014         
Burridge 2016            
 
  
Coupe 2014            
 
  
Eborall 2015            
 
  
Kenealy TW,  
 
2015            
 
  
Liu H  2015            
 
  
Liu H 2015            
 
  
Liu H 2015      
      
 
  
Huntink  2016            
 
  
Presseau   2016         
Parson 2016            
 
  
Verwey 2016            
 
  
Yan 2017            
 
  
Wells  2017            
 
  
Grant  2017            
 
  
Grant  2017            
 
  
Rapp 2017         
          
Murchie   2005            
 
  
Lee 2007         
Pylypchuk  2008         
Wentzlaff  2011            
 
  
Chaney  2011         
Oishi 2013            
 
  
 
Notes on quality assessment: Quality was assessed using a pre-specified tool, based on the MRC PE guidance. 1) Planning: 
a) Degree of separation between outcome and process evaluation teams described. 2) Design and conduct: a) purpose 
clearly stated, b) Intervention clearly described, causal assumptions clarified. c) Justify choice of timing and methods. d) If 
applicable- Transparently whether the report of the process data are analysed blind to trial outcomes/ or post hoc. e) 
COREQ for qual studies. (31 items under Domain 1: research team and reflexivity, Domain 2: study design, Domain 3: 
analysis and reporting). 3) Reporting: a) Clearly labelled as PE. b) Published a full report of evaluation components or a 
protocol paper. These criteria were assessed by HL and MN and classified under yes (green), no (red), uncertain/unclear 
(orange), and not applicable (yellow). Additionally, studies with a qualitative study component was evaluated against the 
consolidated criteria for qualitative research checklist (COREQ) which has 31 individual items separated into 3 domains.(17) 
If more than one item was obviously or specifically mentioned for each of the three domains it was classified as yes 
(green), no (red) when it was obviously not present, and uncertain (orange). 
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Appendix 4- Illustrative examples for the synthesised findings 
Implementation factors - illustrative examples  
Mechanisms: Perceived Fit of the Intervention  
 
In a trial to increase the referral for diabetic retinopathy screening, physicians described that patient’s lack of belief in screening, and access to 
specialists as key barriers to screening. Thus, the intervention of printed educational materials did not alter their referral behaviour. 
(Grimshaw)  
 
Implementation: Roles and Responsibilities  
 
In study to integrate the role of a Depression Clinical Specialist with the primary care provider and the consulting psychiatrist- the process 
evaluation found “DCSs spoke of the importance of a clear role within the health care team. The model envisions the DCS as a care manager 
who works in partnership with the patient and the PCP. DCSs pointed to the importance of not being perceived as taking over the patient’s 
depression care. Instead, the DCS reports to the PCP whether a patient is experiencing side effects, for example, and discusses alternate 
treatment options, but it is the PCP who decides when to change dosage or medication type. DCSs noted the need to be flexible in working with 
different physician and system styles.” (Oishi) 
 
 
Context: Health system structures 
 
From a process evaluation of the 'recruitment' of health care organisations in America to scale up an effective model of depression care- 
authors stated that:  “Additional momentum comes from the US Preventive Services Task Force (USPSTF) through its endorsement of 
depression screening in adults “in clinical practices that have systems in place to assure accurate diagnosis, effective treatment, and careful 
follow up.” They state, “Benefits from screening are unlikely to be realized unless such systems are functioning well.” (Dietrich)  
 
The underlying capacity and knowledge of the implementers are described as conducive to their model of pro-active care for chronic 
depression using practice nurses: “Practice nurses in the UK are employed by GPs to work in their practices as part of the primary healthcare 
team. They are at minimum Registered Nurses (RNs), usually with substantial nursing experience and some may have a specialist qualification 
in practice nursing, although it is not a formal requirement. A minority are also Registered Mental Health Nurses (RMHN), but most will have 
only received some theoretical background and short clinical placements in mental health settings during their RN course.” (Bennett)  
 
Collaborative Approach  
  
“The CBPR model guided development of a research/clinical partnership based on a facilitation team consisting of ‘external facilitators’ 
(research team), ‘internal facilitators’ (primary care leadership) and a ‘clinical advisory committee’ drawn from the primary care community. 
Qualitative themes focused on: how the intervention components (‘evidence’) aligned with local clinical cultures, barriers and facilitators to 
acceptance and adoption of the intervention processes within the context of clinical workflows and identified ‘facilitators’ of intervention 
uptake and sustainability.” (Naik) 
 
“We found that using a Community-Partnered Participatory Research approach in the design phase (Vision) led to many changes in study 
design to improve the fit of the study with community priorities (e.g. Aligning community boundaries with existing county service planning 
areas), as well as enrich the study’s potential scientific contributions (e.g., through expanded outcomes of community and policy relevance).” 
(Chung) 
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Section/topic  # Checklist item  Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4-5 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
5 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
2 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
5,6 
(published 
protocol 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
6 
(published 
protocol) 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
5 (in 
protocol) 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
6 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
6 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  6 
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Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
6 
 
Page 1 of 2  
Section/topic  # Checklist item  Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
6,25 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
6,23-25 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
6 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
Table 1, 
and 
Appendix 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Table 2, 
and 
appendix 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Table 1, 
Appendix 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  7-11 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  6,7 
Table, 
Appendix  
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  N/A 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
6, and 
table 1 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
14 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  12-15 
FUNDING   
249
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
16 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
Page 2 of 2  
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APPENDIX 6 
 
Appendix Overview 
This appendix comprises of the supplementary files of the publications in Chapter 3. 
Supplementary files:  
 Relevant to the three publications include- 
1) CONSORT Flow Diagram 
2) CONSORT checklist of the completed RCT 
3) Coding Framework 
4) Interview Guides 
5) Table of participant characteristics 
6) Illustrative quotes  
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APPENDIX A: CONSORT 2010 Flow Diagram for Kanyini GAP 
Assessed for eligibility (n=731)  
Excluded  (n= 108  ) 
   Not meeting inclusion criteria (n=108)  
Analysed  (n=311) 
 
Lost to follow-up (Patients Dead=1, Refuses 
further participation=3, unable to contact=3)  
(n= 7 ) 
Discontinued intervention (Patients’ choice, 
discontinued by treating doctor, discontinued 
while hospitalised, Side effects) (n=84)  
Allocated to polypill-based strategy (n=311) 
BP measures =308 
Total Cholesterol measures=310 
Lost to follow-up (Patients dead=1, Refuses 
further participation=3, unable to contact=2, 
Missing n=1)   (n=7) 
Discontinued intervention N/A 
Allocated to usual care N=312 
BP measures=309 
Total Cholesterol measures=310 
 
Analysed  (n= 312) 
 
 
Allocation 
Analysis 
Follow-Up- visit at 1 Month +6, 12 18, 24, 
30 and 36 months 
Randomized (n=623) 
Enrollment 
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CONSORT 2010 checklist  Page 1 
CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 1 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 2 
2b Specific objectives or hypotheses 2 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 2 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons No changes 
made 
Participants 4a Eligibility criteria for participants 2 
4b Settings and locations where the data were collected 3 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
2-3 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
3 
6b Any changes to trial outcomes after the trial commenced, with reasons 3 
Sample size 7a How sample size was determined 3 
7b When applicable, explanation of any interim analyses and stopping guidelines N/A 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 2 
8b Type of randomisation; details of any restriction (such as blocking and block size) 2 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
2 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
2 
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CONSORT 2010 checklist  Page 2 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 
assessing outcomes) and how 
N/A 
11b If relevant, description of the similarity of interventions 2 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 3 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 3 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
4 
13b For each group, losses and exclusions after randomisation, together with reasons 4 
Recruitment 14a Dates defining the periods of recruitment and follow-up 3-4 
14b Why the trial ended or was stopped 4 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 5 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
4 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
4-5 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended N/A 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
5 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 5 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 6 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 9 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 7,9 
Other information  
Registration 23 Registration number and name of trial registry 9 
Protocol 24 Where the full trial protocol can be accessed, if available In Ref: 18 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 9 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
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 PEAK Coding Framework 
ADHERENCE 
- strategies for adherence 
- complexity 
- burden of pills 
- drug holiday 
- 
ACCEPTABILITY OF POLYPILL 
- advantages: less tabs, ease, convenience, 
cost 
- disadvantages: fixed combination, side 
effects, tailoring of meds 
BEING WELL 
- self care 
- general health 
- family and community support 
- stress 
GOOD CARE 
- provider-patient relationship 
- access to health services 
- other support services 
HEALTH LITERACY 
- health-seeking behavior 
- missed dose effect 
 
 
TRIAL IMPACT 
- current treatment  
- patient management 
- effects on services, (e.g. bottom line, 
time) 
- effects on patient, (e.g. changes in 
med-taking behavior, increased health 
awareness) 
- tailoring of meds 
RESEARCH MOTIVATION 
- greater good 
- personal good 
 
FINANCIAL CONSIDERATIONS 
Closing the Gap policy, 
Pharmaceutical benefit scheme, 
Safety Net, Cost of medications & 
health care 
 
REAL WORLD 
- Population Health Approach 
- use of absolute risk 
- primary prevention 
- ‘ideal patient’ 
– ‘On the shelf’ 
- policy implications 
- future polypill combinations 
 
 
ABORIGINAL HEALTH CONSIDERATIONS 
- social justice 
- determination 
- cultural safety 
Additional File 3: Coding 
Framework 
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SUPPLEMENTAL MATERIAL 
Supplementary methods 
The Kanyini GAP Study- health professionals interview guide (GP’s) 
Initial Broad 
Descriptive 
Questions 
Probing Questions (These are a guide only. It is not expected that you ask all these questions) 
OVERALL VIEWS ON POLYPILL IN CVD MANAGEMENT  
To establish pre and post trial views of a general polypill strategy for CVD, as well as the specific KGAP polypill  
What is your overall 
view of a polypill 
strategy in CVD 
management? 
– Why did you become involved in this study? i.e. motivation for taking part 
o Experience in general being involved with the Kanyini  
GAP Polypill strategy/study? 
– What experience have you had with prescribing other fixed-dose combination or multidrug component medications 
in cardiovascular disease? What about other therapeutic areas? 
– Could you describe what you think are the negative/positive aspects of using a polypill strategy to manage CVD?  
o How does this compare to other therapeutic areas? 
o Have your views about prescribing a polypill changed since being involved in this study? Can you please 
describe? What did you think of the components that were in this polypill (Aspirin, BP lowering, statin)? 
– What would be your ideal combination pill? 
OVERALL VIEWS ON PATIENT ADHERENCE TO CARDIOVASCULAR MEDICATIONS 
– To understand conceptualisation and significance of medication adherence from prescriber perspective and what role they, other health care 
providers, the health system and policies play  
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What are your views 
on patient 
adherence with 
cardiovascular 
disease 
medications? 
– How important do you think adherence to medications is with respect to cardiovascular disease outcomes? 
o How does this compare to other therapeutic areas? 
– Thinking in terms of a few patients who you know best who are concomitantly prescribed anti-platelets, BP lowering 
and lipid lowering medications , either as fixed combination pills or not, how do you think these patients perceive 
the function of their cardiovascular medications? 
– Do you know if your patients take their medications? 
– In your experience, what do you think are the barriers/facilitators to patients adhering with cardiovascular 
medications? (e.g. medicine-, patient- health system/policy-, disease-related, cultural) 
o What role does a patient’s cultural background have? 
o What role does current policy have? 
– What role do you think GP’s play in supporting patients to take their medications?  
o Is the polypill helpful in doing this? 
o Does it help you be more effective in managing CV risk? 
o What about other staff? 
 
PROVIDER SATISFACTION/ PROBLEMS WITH  THE POLYPILL STRATEGY USED IN KANYINI GAP 
– To illustrate the experience with prescribing the polypill, and to compare and contrast this with experience with other cardiovascular 
medications. Note: There is a particular interest in whether there is a difference in practice for polypill group at drug initiation. 
– To understand if there was any difference in usual care management throughout the trial 
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Could you describe what 
it has been like to look 
after your patients in the 
polypill group? 
 
 
 
 
 
– What were the major advantages of prescribing the polypill used in Kanyini Gap?  
– What were the major disadvantages of prescribing the polypill used in Kanyini Gap?  
– What was your experience with commencing participants on the polypill? 
o Did you change/alter treatment prior to commencing on trial? 
– Did you change or alter treatment prior to commencing patients on trial? 
o  How did this compare with your previous experience with starting cardiovascular medications? 
– How did you find tailoring your patients’ medicines when they were on the polypill?  
– How do you decide if the ingredients in the polypill are or are not enough for your patients? 
– How do you know what needs to be increased, e.g. through targets, etc.? 
–  Were there any times when you were not happy with the polypill and had to change to other medicines? If so, 
please describe. 
– Were there any problems prescribing additional treatments? 
– How did you find assessing response to treatment for patients on the polypill? 
– Were there any terminations of patients due to unawareness of trial or new treatment, etc.? 
– In your opinion, do you think being on the trial has influenced the behaviour of patients? (i.e. re RCTs – people 
may be more compliant, tend to follow protocols, etc.) 
Could you describe what 
it has been like to look 
after your patients in the 
usual care group? 
– What was your experience in providing usual care to the participants not taking the polypill throughout the 
trial? 
– Did you feel that you changed your management in any way for this group during the course of the study? If so, 
how? 
PATIENT SATISFACTION/ PROBLEMS WITH  THE POLYPILL STRATEGY 
To illustrate feedback given to the prescribers from patients about the polypill 
To understand if the usual care patients reported any difference in management throughout the trial 
258
What have been your 
patients’ 
impressions/thoughts 
about being in the polypill 
group? 
 
 
 
 
 
 
 
 
– Did you receive any feedback from your patients about their experience in the trial? If so, please describe. 
– Do you feel that your patients were satisfied with the care they received whilst in the polypill group? 
– What were the major advantages of taking the polypill from the patient perspective?  
– What were the major disadvantages of taking the polypill from the patient perspective?  
– How well tolerated was the polypill in general? 
o Did any of your patients experience any side-effect issues with the polypill? If so how did you manage these 
issues? 
– Did your patients report any problems accessing the medicines? 
o Any problems with filling the script from the pharmacy (cost, confusion etc)? 
o Any problems with the packaging or instructions? 
– Did your patients report any barriers to actually taking the medicines? If so, please describe 
– Is there anything else which could be done to make the treatment/polypill more effective? 
– What have been your 
patients’ 
impressions/thoughts 
about being in the 
usual care group? 
– Do you feel that your patients were satisfied with the care they received whilst in the usual care group? 
 
GENERAL IMPRESSIONS OF THE STUDY 
To understand how the trial integrated into everyday practice 
259
What has it been like 
for you to be 
involved in the GAP 
study?  
– What was the impact on you and your health service in choosing to be a part of this trial? 
o Did you experience any problems with the general administration of this trial? If so please explain. 
o Were there any benefits to you or your practice as a result of participating in this trial? If so please explain. 
– Would you be interested in participating in future clinical trials as a result of your experience with this study? If no, 
why not? 
SUITABILITY OF THE TRIAL DESIGN  
To understand if other trial related variables may have impacted on outcomes 
What are your 
thoughts about the 
design of the GAP 
polypill study? 
 
– What was your experience with the screening process? 
o Were you satisfied with the process of gathering baseline information about study participants? 
o Were the eligibility criteria satisfactory? 
o What did you think of using absolute risk based entry criteria? 
– Were there any difficulties experienced in communicating study information to participants? 
– How did you find the randomisation visit? 
– How did you find the follow-up and monitoring of your patients? 
– Did you experience any problems sharing/ coordinating care with providers who were not involved in the study? 
TRANSLATION INTO CLINICAL PRACTICE AND POLICY 
To understand how the trial results may or may not translate into practice. 
If found to be 
beneficial, what 
would you see as the 
role of the polypill in 
everyday practice? 
– What are your views on the use of the polypill in the study setting compared to in everyday practice? 
– How do you think a cardiovascular polypill will impact on your day-today professional practice? 
– If the polypill is found to be beneficial, what would be your advice to government on implementing its use in the 
general population? 
CONCLUDING QUESTIONS 
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– We will also be conducting some interviews with patients involved in the trial to understand their experiences. In your opinion, what areas 
to you think we should explore? 
– Are there any aspects about medication adherence that you would specifically like explored? 
– Is there anything else you would like to say that we have not talked about in this interview? i.e. about the polypill or the study 
 
The Kanyini GAP Study- health professionals interview guide (pharmacist) 
Initial Broad Descriptive 
Questions 
 
Probing Questions (These are a guide only. It is not expected that you ask all these questions) 
Purpose of process evaluation is to establish overall views on a polypill based approach to CV risk management. 
OVERALL VIEWS ON POLYPILL IN CVD MANAGEMENT 
To establish pre and post trial views of a general polypill strategy for CVD, as well as the specific KGAP polypill 
What is your overall view 
of a polypill strategy in 
CVD management? 
– Could you describe what you think are the negative/positive aspects of using a polypill strategy to manage 
CVD?  
o How does this compare to other therapeutic areas? 
o Have your views about prescribing a polypill changed since being involved in this study? Can you please 
describe? What did you think of the components that were in this polypill (Aspirin, BP lowering, statin)? 
– What would be your ideal combination pill? 
OVERALL VIEWS ON PATIENT ADHERENCE TO CARDIOVASCULAR MEDICATIONS 
To understand conceptualisation and significance of medication adherence from providers perspective and what role they, other health care 
providers, the health system and policies play 
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 What are your views on 
patient adherence with 
cardiovascular disease 
medications? 
– How important do you think adherence to medications is with respect to cardiovascular disease outcomes? 
o How does this compare to other therapeutic areas? 
– Thinking in terms of a few patients who you know best who are prescribed anti-platelets, BP lowering and lipid 
lowering medications in combination, how do you think these patients perceive the function of their 
cardiovascular medications? 
– In your experience, what do you think are the barriers/facilitators to patients adhering with cardiovascular 
medications? (eg medicine-, patient- health system/policy-, disease-related) 
– What role do you think you play in supporting patients to take their medications? 
– How do you think the polypill strategy compares to other patient adherence aids, i.e. Webster pack?  
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PROVIDER SATISFACTION/ PROBLEMS WITH  THE POLYPILL STRATEGY USED IN KANYINI GAP 
– To illustrate the experience with supplying the polypill, and to compare and contrast this with experience with other cardiovascular 
medications. Note: There is a particular interest in whether there is a difference in practice for polypill group at drug initiation. 
– To understand if there was any difference in usual care management throughout the trial 
Could you describe what it 
has been like to look after 
your patients in the 
polypill group? 
(drawing on your 
experiences) 
– What were the major advantages of supplying the polypill used in Kanyini Gap?  
– What were the major disadvantages of supplying the polypill used in Kanyini Gap?  
– What was your experience with participants commencing on the polypill? 
o  Do you have any examples? 
o How did this compare with your previous experience with starting cardiovascular medications? 
o Where there any concerns by patients in starting the polypill, i.e. concern about efficacy, change of 
routine, etc? 
– How did you find counselling  your patients about the polypill? 
– Did you think that you changed your management in any way for the participants who were taking the 
polypill? If so, how? 
– Were there any problems when additional treatments for cardiovascular disease were prescribed? i.e. need to 
tailor medications 
PATIENT SATISFACTION/ PROBLEMS WITH  THE POLYPILL STRATEGY 
To illustrate feedback given to the providers from patients about the polypill 
To understand if the usual care patients reported any difference in management throughout the trial 
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 What have been your 
patients’ 
impressions/thoughts 
about being in the polypill 
group? 
 
 
 
 
 
 
 
 
– Did you receive any feedback from your patients about their experience in the trial? If so, please describe. 
– Do you feel that your patients were satisfied with the care they received whilst in the polypill group? 
– What were the major advantages of taking the polypill from the patient perspective?  
– What were the major disadvantages of taking the polypill from the patient perspective?  
– How well tolerated was the polypill in general? 
o Did any of your patients experience any side-effect issues with the polypill? If so how did you manage 
these issues? 
– Did your patients report any problems accessing the medicines? 
o Any problems with filling the script from the pharmacy (cost, PBS safety net, confusion etc)? 
o Any problems with the packaging or instructions? 
– Did your patients report any barriers to actually taking the medicines? If so, please describe 
  
264
GENERAL IMPRESSIONS OF THE STUDY 
To understand how the trial integrated into everyday practice 
What has it been like for 
you to be involved in the 
GAP study?  
– What was the impact on you and your health service in choosing to be a part of this trial? 
o Did you experience any problems with the general administration of this trial? If so please explain. 
o Were there any benefits to you or your pharmacy as a result of participating in this trial? If so 
please explain. 
– Would you be interested in participating in future clinical trials as a result of your experience with this study? 
SUITABILITY OF THE TRIAL DESIGN 
To understand if other trial related variables may have impacted on outcomes  
What are your thoughts 
about the design of the 
GAP polypill study? 
 
- Were there any difficulties experienced in communicating study information to participants? 
- Did you encounter any difficulties when the polypill patients were new to your pharmacy?  
- Did you experience any problems sharing/ coordinating care with providers who were not involved in the 
study? 
TRANSLATION INTO CLINICAL PRACTICE AND POLICY 
To understand how the trial results may or may not translate into practice. 
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If found to be beneficial, 
do you think the polypill 
could be used in everyday 
practice? 
(Last is the magic wand 
Q...) 
– What are your views on the use of the polypill in the study setting compared to in everyday practice? 
– How do you think a cardiovascular polypill will impact on your day-today professional practice? 
– If the polypill is found to be beneficial, what would be your advice to government on implementing its use in 
the general population? 
CONCLUDING QUESTIONS 
 
– We will also be conducting some interviews with patients involved in the trial to understand their experiences. In your opinion, what 
areas to you think we should explore? 
– Are there any aspects about medication adherence that you would specifically like explored? 
– Is there anything else you would like to say that we have not talked about in this interview? 
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The Kanyini GAP Study- Patient interview guide     
Purpose of the interview:  Capture what it is like for people to manage CVD and how to manage their tablets, and how the burden 
of taking tablets in daily life could be made easier/better/worse. How a polypill might influence this (or not); or how the trial 
might influence this (or not).                                                                                                                                                                              
Area of Interest Initial Broad 
Descriptive 
Questions 
Possible Probing Questions  
(These are a guide only. Depending on what the patient tells you, you do not have to ask all these 
questions or use the words exactly as written.) 
Health care 
experience 
Can you tell me about 
your health care since 
you’ve been on the trial? 
o How is your health in general? 
o What are some of the good/bad things about your health care? 
o Are there differences or similarities with your health care since you’ve been part of this study compared to usual care?   
o And compared to other illnesses? 
o What type of support do you get from family, community or social groups with looking after your health? 
o What kind of roles/responsibilities do you have in your family? 
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Satisfaction/ 
problems with  the 
polypill strategy 
What are your thoughts 
about your current 
treatment for your heart? 
 
 
o Do you know the 4 medications in the polypill and what they’re for? (Aspirin, BP lowering x2, statin (lipid 
lowering/cholesterol, etc.) 
o How do you find the tablets you are taking? 
o What do you think are the major advantages of your current treatment (polypill or usual medications)?  
o What do you think are the major disadvantages of your current treatment (polypill or usual medications)?  
 What things would worry you about changing your usual medications? 
o Would you be happy to continue taking your current treatment (polypill or usual medications)? 
o What might happen that would make you change from taking the polypill or your usual meds? 
o What problems have you experienced with your current treatment (polypill or usual medications)? ( i.e. side effects, 
cost issues) 
o How can your doctor improve your current treatment? 
o What sort of support do you get in managing your blood pressure, cholesterol, etc? 
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Medication taking 
behaviour 
 
Many people find it 
difficult to take their 
medications everyday. 
Has there been a time 
when you haven’t been 
able to take your 
medications every day? 
OR 
What suggestions would 
you give to people, who 
do struggle with taking 
medications, i.e. what 
has worked for you? 
 
 
 
 
- How many pills do you take a day? 
- How easy do you find taking your medications? 
o What are the things that help you to take your medications? (i.e. family, Webster pack, other memory aids, 
time of day, etc.) 
o How would you know if you’ve not taken your medication? 
- When do you find it more difficult to take medications? 
o What are the things that might make you stop taking a medication? 
- What other things might change the way you take your medications? 
- Can you describe any time or situation when you didn’t want to take your medications? 
o What things were influencing your decision? 
- Who would you speak to if you were having trouble with your medications? 
o When have you had to do this? 
- Which of your medications do you think are the most important to you and why? 
- How do you usually get your supply of medications? 
- Have there been times when you share medications with family members? 
- Have there been times when you halve tablets, or just take them on alternate days for example? 
o What has been the main reason/s for this? 
What has your 
experience been with 
taking medications 
throughout this study?  
o How has your experience with taking your medication/s in this study been different / similar to the way you would 
usually take medications? 
o In what ways has this study changed the way you take your medications? 
o What things have made it easier or harder for you to take your medications while being involved in this study? 
o Has the cost of medications been an issue for you? 
o Have other costs, e.g. cost of attending GP, travel to the health service, other specialist services, etc. been an issue? 
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Translation to 
current practice 
What has 
helped/prevented you 
from taking your 
medications throughout 
this study that might be 
different to everyday life? 
(e.g. without being 
monitored as much as 
during the trial) 
• Now that the study is over, what things might change the way you take your medications (polypill or usual 
medications)? 
o Do you think you would be able to take your current treatment in the same way that you have throughout the 
study? 
• What other things would help you take your medications? 
o What type of support from nurses/health workers/AMS might assist you in taking your medications? 
o What can the government/doctors/pharmacists do to help? 
General views 
about the trial 
What are your thoughts 
about the Kanyini Gap 
study in general? 
• How have you found being involved in the study? 
o What things did/didn’t you like about being involved? 
• Tell me how you think the study worked, and what it was hoping to achieve?  
• What were the things that made you want to participate in the study initially? 
o What were the benefits to you of participating? 
• What concerns did you have about participating in this study? 
o Were there any things that may have stopped you from participating initially? 
o What were the risks of participating in the study? 
• Once you were enrolled, what would have changed your mind about being in the study? 
o  Did you feel that you could withdraw at any time? 
• Did you know who to contact if you had any concerns about the trial? 
• What were your thoughts about your privacy throughout this study? 
Concluding 
questions 
 • Are there things which we can do better to improve the study or the running of the trial? 
• Is there something else that you would like to say, that we have not talked about in this interview?  
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Supplementary Tables   
Table 1: Patient characteristics 
Characteristics POLYPILL  USUAL CARE  TOTAL  
Sample size  22  25  47  
Age, years (SD)*  67.1 (8.4)  63.9 (10.3)  65.4 (9.5)  
Gender (Female)  10 (46%)  12 (48%)  22 (47%)  
Aboriginal/ Torres Strait Islander  6 (27%)  13 (52%)  19 (40%)  
Primary prevention  12 (55%)  9 (36%)  21 (45%)  
Secondary prevention  10 (46%)  16 (64%)  26 (55%)  
Drug treatment (at baseline)           
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High-risk primary prevention  
   Yes to all 3 (BP* lowering, aspirin and statin)  7 (18%) 6 (24%) 13 (28%)  
No to all 3  5 (23%) 3 (12%) 8 (17%)  
Secondary prevention  
   Yes to all 3 (BP* lowering, aspirin and statin)  7 (18%) 15 (60%) 22 (47%)  
No to all 3  3 (14%)  1 (4%) 4 (9%)  
Health service           
Indigenous health services (Aboriginal community 
controlled and government-run)  8 (36%)  13 (52%)  21 (45%)  
General Practice  14 (64%)  12 (48%)  26 (55%)  
Accessibility/Remoteness Index of Australia 
(ARIA) †           
ARIA 1  15 (68%)  15 (68%)  30 (64%)  
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ARIA 2-3  7 (32%)  10 (45%)  17 (36%)  
* SD Standards deviation BP Blood pressure 
 
†
 
ARIA 1- metropolitan and inner regional  ARIA 2-3- outer regional and remote
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Table 2: Provider characteristics 
Characteristics GP* Pharmacist AHW/Nurse* 
Sample Size 25 13 9 
Age groups †2 
   20-39 (%providers) 5 (11%) 5 (11%)  6 (13%) 
40-69  18 (38%) 7 (15%)   3 (6%)  
Male Gender (%providers) 15 (32%)  10 (21%)  4 (9%)  
Years practicing (median, range)  25 (2 to 35) 13 (2.5 to 32) 3 (0.5 to 17) 
Years at site (median, range)  11.5 (0 to 30)  6 (0 to 12) 1 (1.2 to 17)  
Formal cross-cultural training (%providers) 18 (38%) 3 (6%)  n/a  
Adherence support services offered  n/a  10  n/a  
Health Service  
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Indigenous Health Service (%providers)  16 (34%) n/a  9 (19%) 
General Practice (%providers) 10 (21%) n/a n/a  
Accessibility/Remoteness Index of Australia (ARIA)  
   ARIA 1 (%providers) 16 (34%) 9 (19%) 6 (13%) 
ARIA 2-3 (%providers) 10 (21%) 4 (9%) 3 (6%) 
* GP General Practitioner AHW Aboriginal health Worker SD standard deviation † Missing data  n=3 
Table 3  
Major Codes and their descriptions  
 
Adherence 
This includes references to, comments from providers and patients on all aspects of patient adherence to medications such as strategies of using a 
routine, having the medications in a dose administration pack. This also includes observation of risks of non-adherence, (i.e. death, effects on 
family/community.) The burden of the number of medications and the complexity of medication regimes contributed to intentional non-adherence 
at times. 
 
Being well 
‘Being well’ is described through comments, attitudes, perceptions of patients' own general health, i.e. physical and emotional well-being, self-
care and lifestyle risk factors, other health issues, and protective/ supportive mechanisms in place such as family and community support. 
 
Good care 
This covers patient satisfaction with health care provision, such as accessibility to health care and other support services, and the provider-patient 
relationship. It also includes the collaboration between providers, pharmacists and IHSs.  
 
Health literacy 
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Health literacy includes patients' knowledge of the importance of adherence to medications, including how, when, why to take medications and 
their efficacy, etc. It also includes analysis of data around health seeking behaviour, i.e. patients’ motivation to find out about their condition and 
to seek treatment, and also the ‘missed dose effect’. 
 
Acceptability of the Polypill 
This code included descriptions of what were the advantages and disadvantages of the polypill strategy.  Many of the patients liked the advantages 
of the ease and convenience because of the reduced number of tablets, single dosing, and cost savings was also listed as positive. Other advantages 
from the providers’ point of view included being more aware of the participants’ absolute risk and starting the patients on the three types of 
medications instead of taking the time to titrate to all medications. However, being unable to titrate and tailor the medications was listed as 
disadvantages. .  Most of the providers suggested having other possible polypill combinations.    
 
‘Real World’ 
This code contained views from both patients and providers in regards to what they hoped to see after the trial.  The responses varied from the 
polypill being just another ‘combination’ medication out there, to potentially being disappointed if it was not on the shelf, and that the polypill 
would be ideal only in certain circumstances, e.g. for primary prevention. Many of the providers and patients from the IHSs expressed the 
understanding and support for the polypill for the Aboriginal population given the higher incidence, possible limited literacy and difficulty in 
taking many medications. 
 
Financial Considerations 
The majority of patients reported knowing they have to spend the money on medications and health care, and would do so to improve their health.   
A number of policies are in place to reduce the cost of medications and health care for all Australians and these were mentioned often by the 
patients and pharmacists. 
 
Aboriginal Health Considerations 
This code contained views from patients and providers which specifically mentioned factors and issues concerning Aboriginal health such as 
burden of disease, access to culturally safe health services, role of the community and family in maintaining adherence.    
 
 
 
Table 4: Further examples of quotes illustrating the results 
Themes/ subthemes and further examples of the quotes 
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Acceptability of the polypill in improving adherence 
Ease and convenience  
(My daughter) is very happy for me because I’ve never been used to taking tablets and I always find them a bit difficult to take.  Because it’s a 
capsule and because it’s only one, she said “I’m very happy for you mum because it will be so much easier”. (Patient 17,urban GP clinic) 
Cost savings 
I think (the trial) was trying to achieve (for) people possibly forgetting medication and it’s all in the one pill so therefore they don’t have to think 
I’ve got five pills to take, six pills to take, it’s all going to be one.  I thought that was the main thing and another thing was cost to people that, like 
myself that are aged pensioners, most people are struggling to live, we’re not you know, because we own the house and things, we own 
everything, but I mean things could change.  But I thought those were the two important things. (Patient 41, urban GP clinic) 
Adherence depends on other factors 
Wanting to be well 
As I said I just used to take my tablets all the time and it was just a routine.  If you want better health you've got to take your medication and 
things like that. (Patient 23, regional GP clinic) 
Importance of family 
(My grandson) comes and reminds me, he says “Nan, have you had your needle yet?” and that’s good for me too because sometimes I don’t 
remember, and my partner will say “have you taken your tablets today?(Patient 1, urban IHS)  
 
Good Care 
I’d like to see in rural and remote areas more indigenous specific mental health issues and programs and that.  More around narrative therapy 
than cognitive therapy.  Because cognitive therapy don’t work for our mob.  Because we’re story tellers.  So we’d rather sit down and talk and tell 
our stories and get to the basis of the issues.  Rather than say okay, you get depressed when this happens, let’s teach you how to handle it.  To me 
that’s a bandaid treatment. 
 So because I know with, with the studies that I’ve done, mental health could also play a lot on the heart issues.  And cholesterol and all that other 
type of stuff too.... A holistic approach to health.  Not just saying okay, we’ve got mental health over here and general health over here.  Get the 
two of them somehow working together (Patient 30, remote IHS) 
 
You will know that I can guarantee that the majority of our people if we're getting signs of heart attack, shortness of breath, we'll ring GP, we'll 
ring an Aboriginal medical centre before we actually go, even call, think about even calling an ambulance because of the fact that how we're 
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going to be treated, how we're going to be spoken to over the phone. (AHW 26, urban IHS) 
 
[I talk to my doctor about my medications because] I suppose I have certain ways of doing things.  If I have a problem I like to be systematic and 
analyse why it went wrong and if I fix it, will it go wrong again. (Patient 16, urban GP clinic) 
 
Importance of health literacy 
When I question them and quiz them and say you know “how’s your cholesterol going, is everything okay?” they just don’t know.  So at the end of 
the day again there’s a lack of communication occurring somewhere along the line, so if they knew that they were taking a Polypill that was going 
to keep their blood pressure, cholesterol, thin their blood, do all that sort of stuff, then potentially they’d be more inquisitive to make sure that it 
was doing what it was supposed to be doing. (Pharmacist 13, pharmacy related to urban GP clinic)  
 
Policies impacting healthcare costs 
Reduce the cost of them.  Especially when you’re on a lot like I am… a lot of people you know, pensioners are saying, it’s just terrible that they do 
go without (their medications) sometimes because they just can’t afford it. (Patient 27, urban GP clinic) 
 
 
Polypill in patient management 
Limitations of a fixed dose combination 
I think patients would need to be advised, or doctors would need to be advised to start the individual components of the polypill individually to 
start with to make sure there’s not side effects, and then start the patient on it in the future because then you can be certain that there’s no 
individual side effects to the different components. (GP 43, remote IHS) 
 
 Adequacy of the Polypill Components  
The fixed dose combination was fine, but then you’re adding on extra medications as well, so, to get someone up to 80 of Simvastatin and so that 
sort of minimises some of the benefits of actually being on polypill because you’re adding in extra medications anyway…There were often, the 
decisions around polypill were actually harder than I was expecting rather than just a great concept and you put them on polypill, there was often 
quite a lot of thought about how you’re switching statins.  I think one guy we even had strangely on a mixture of two statins because of what he 
was on before and what was in the polypill.  (GP 8, urban IHS)  
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Other combinations in the future  
I think having a wider range of dosages.  The concept’s brilliant and the patients actually really enjoyed being on it.  They really like having just 
one tablet.  The feedback was consistently good from the patients, that they liked the concept of everything rolled into one.  So having flexible 
dosages, a wider range of different choices would be a way round that. (GP 37, regional GP clinic) 
Who could it be suitable for? 
High-risk primary prevention patients 
I think the one difficulty when faced with a patient who really doesn’t have much health literacy and much knowledge about their own 
cardiovascular risk one of the difficulties is convincing them that they need to be – will end up needing to be on four or five medications when 
they’ve been on none and I think a polypill is generally a very useful tool for doing that. (GP 27,  IHS) 
  
A strategy to address CVD burden of disease in Indigenous patients 
I mean when you see the people that are dying around you … the same age as you and even younger, it’s all to do with health that they died not 
taking medication. Maybe if they were given the one pill instead of taking half a dozen they might be still here today. (Patient 4, urban IHS) 
 
Well I think it could have significant impacts on Aboriginal health if it were to be introduced as a generally available medication.  And I think we 
can’t underestimate how much it may make some change because we do know that cardiac disease is the major cause of Aboriginal mortality.  
And I think if it’s made easier to manage then you know, the impacts could be significant so and I think generally for the general population as 
well.  But I think if there were a public policy imperative as to try to positively affect Aboriginal mortality then this is one approach that will aid 
that. (GP  23, urban IHS) 
 
I still think it's not going to benefit the people that probably need the most benefit.  So I think in some ways it's not necessarily addressing the 
equity gap because those that are most disadvantaged and most at risk are not going to be the ones that would benefit from this treatment, from 
this particular polypill.  But from other polypills I don't know, maybe they would.   (GP 40, remote IHS) 
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APPENDIX 7 
 
Appendix Overview 
This appendix comprises of the supplementary files of the publications Chapter 4. 
Supplementary files:  
 “Protocol of a process evaluation of a family led rehabilitation post stroke in India”-  
1) Template for the observations and documentary analysis 
2) Interview Guides for the health provider 
3) Interview guide for the carer 
4) Interview guide for the patient 
5) Consent form to participate in interviews 
 
 “Family- led rehabilitation post stroke in India- findings of a process evaluation alongside a 
randomised controlled trial”-  
1) Participant characteristics and Illustrative quotes.  
2) Coding Tree 
3) CONSORT statement (main trial paper) 
4) COREQ checklist 
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Additional File 1: Template for observations and documentary analysis  
 Name of researcher:  
Date and length of time of observations:  
Location/s at which the observations were carried out:  
Hospital: Description Comments 
Trial Set up (may be in site 
feasibility documentation and 
can be asked of the SC)  
  
Recruitment of the site   
Demographics, patient load 
that the hospital serves (may 
be in the site feasibility 
documentation) 
  
Average cost of inpatient care 
per day- funding, such as out 
of pocket etc., costs of a 
physiotherapists visit in usual 
care. 
  
Size of hospital   
Description of the stroke unit 
and organisation of care, work 
load 
  
Use of any policies, guidelines, 
tools (e.g. patient information 
sheets) for stroke 
management 
  
Usual routine activities e.g. 
frequency of MDT meetings, 
number of physiotherapists 
meetings with the patients and 
families, working environment 
  
Role of the SC in the unit, 
participation in the daily 
activities, role in recruitment 
of patients, informed consent 
process.  
  
Trial implementation   
* Observations of patients 
(usual care) stay in the unit 
-if patient is enrolled into trial, 
provide the ID. 
- number of ward rounds, 
presence of family, care 
provided by the stroke team 
e.g. education, or wound 
management etc., discharge 
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planning, communication with 
carers/ family members 
* Observation of patients’ 
(intervention)stay in the unit 
-if patient is enrolled into the 
trial, provide ID. 
-number of days in hospital, 
number of ward rounds, 
presence of family, care 
provided by the stroke team, 
communication with carers/ 
family members 
-Interactions with the SC. What 
is done? What components of 
the intervention are delivered 
and what do you observe are 
the reactions of the 
patients/carers? 
 
  
*Is there any chance of 
contamination?  
  
Documentary analysis (by the 
monitors)  
For a sample of patients in 
usual care/ intervention arm:  
 
days admitted, PTs visits, 
communication with family,  
discharge plan: what it covers 
 
  
Trial Impact   
Effectiveness- analysis of the 
unblinding forms.   
  
Open field notes   
Memo 
*Researchers’ overall 
reflections and impression of 
the site; and recommended 
plan of action if needed?  
 
E.g. if there is un-blinding, of if 
there is contamination.  
 .  
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Additional File 2: The ATTEND Study- health professionals (Stroke Unit) interview guide  
Initial Broad 
Descriptive Questions 
Probing Questions (These are a guide only. It is not expected that you ask all these questions) 
OVERALL VIEWS ON BURDEN OF STROKE IN INDIA 
– To understand conceptualisation and significance of burden of stroke from provider perspective and what role they, other 
health care providers, the health system and policies play  
What are your views on 
the burden of stroke in 
India on an individual, 
community and 
systems level? 
– Do you know what supports your patients have post stroke? What do you think are the barriers and 
facilitators in enabling their full recovery? 
o What role does a patient’s cultural background have? 
o What role do the hospital and primary health care have in enabling patient recovery? 
o What role does current policy have? 
 
– What role do you think the stroke unit has in enabling a full recovery?   
o Is it more as an outpatient clinic? What resources are there? 
Overall views on stroke rehabilitation management   
To establish pre and post trial views of the usual stroke management and the intervention of a family led rehabilitation after stroke 
What is your overall 
view of a family led 
rehabilitation after 
stroke? 
o Why did you become involved in this study? i.e. motivation for taking part 
o Experience in general of being part of trial, What experience have you had RCTs? In 
what areas were they in eg drug trials? 
o Could you describe what you think are the negative/positive aspects of a family led 
rehabilitation, and early discharge? 
o How does this compare with the usual care provided? 
o Have your views about early discharge and training of family/caregiver at home changed since 
being in the trial? How so and why? 
o  What are your thoughts about the 5 components of the intervention?  
1. Information on stroke recovery trajectory, risk, identification and management of low mood, 
importance of repeated practice of specific activities 
2. Joint goal setting with patient, nominated family caregiver and therapist (reviewed with 
coordinator as patient progresses and new goals set) 
3. Positioning, transfers and mobility 
4. Task orientated training (particularly walking, upper-limb and self-care tasks) with personalised 
copy of culturally appropriate manual 
5. Discharge planning 
o What would be your ideal model of care for rehabilitation management post stroke? Is there 
anything more than what is being offered in the intervention that you would like to see? 
 
PROVIDER SATISFACTION/ PROBLEMS WITH  ATTEND 
– To illustrate the experience with ATTEND patients and contrast this with patients in usual care Note: There is a particular 
interest in whether there is a difference in practice for intervention group if randomised to SC visits. 
– To understand if there was any difference in usual care management throughout the trial 
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Could you describe what it has 
been like to look after your 
patients in the intervention 
group? 
 
 
 
– Did you change or alter treatment prior to commencing patients on trial? 
– (for usual care PT) Were there any patients who did not need your care  due to being 
involved in the trial?  
– In your opinion, do you think being on the trial has influenced the behaviour of patients? 
(i.e. re RCTs – people may be more compliant) 
Could you describe what it has 
been like to look after your 
patients in the usual care group? 
– What was your experience in providing usual care to the participants not being part of the 
intervention arm?  
– Did you feel that you changed your management in any way for this group during the 
course of the study? If so, how? 
PATIENT SATISFACTION/ PROBLEMS WITH  ATTEND 
To illustrate feedback given to the providers from patients in ATTEND 
To understand if the usual care patients reported any difference in management throughout the trial 
What have been your patients’ 
impressions/thoughts about 
being in the intervention group? 
 
 
– Did you receive any feedback from your patients about their experience in the trial? If so, 
please describe. 
– Do you feel that your patients were satisfied with the care they received from SC? 
– What were the major advantages and disadvantages of the family led rehabilitation from 
the patients’ perspectives? Eg early discharge, costs? 
What have been your patients’ 
impressions/thoughts about 
being in the usual care group? 
– Do you feel that your patients were satisfied with the care they received whilst in the 
usual care group? 
 
GENERAL IMPRESSIONS OF THE STUDY 
To understand how the trial integrated into everyday practice 
What has it been like 
for you to be involved 
in the ATTEND study? 
(either as a PI, as part 
of the stroke team , as 
the SC) 
– What was the impact on you the stroke unit in choosing to be a part of this trial? 
o Did you experience any problems with the general administration of this trial? If so please 
explain. 
o Were there any benefits to you or the stroke unit as a result of participating in this trial? If so 
please explain. 
– Would you be interested in participating in future trials as a result of your experience with this 
study? If no, why not? 
SUITABILITY OF THE TRIAL DESIGN  
To understand if other trial related variables may have impacted on outcomes 
What are your thoughts 
about the design of 
ATTEND study? (mainly for 
the SC and PIs) 
 
– (If PI- how was the recruitment process, what are your thoughts about the trial eligibility 
criteria?) 
– (If SC, or PI) Were there any difficulties experienced in communicating study information to 
participants? 
– How did you find the follow-up visits of your patients? 
– Did you experience any problems sharing/ coordinating care with providers who were not 
involved in the study? 
– Any thoughts about the primary outcomes 
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TRANSLATION INTO CLINICAL PRACTICE AND POLICY 
To understand how the trial results may or may not translate into practice. 
If found to be beneficial, 
what would you see as the 
role of ATTEND in 
everyday practice? 
– What are your views on early supported discharge and family led rehabilitation if translated into 
into everyday practice? 
– How do you think incorporating ATTEND outside of the trial will impact on your day-today 
professional practice? Eg costs 
– If ATTEND is found to be beneficial, what would be your advice to government on implementing 
its use in the general population? 
CONCLUDING QUESTIONS 
We will also be conducting some interviews with patients and carers involved in the trial to understand their experiences.  
In your opinion, what areas to you think we should explore? 
 
Are there any aspects about stroke management and rehabilitation post stoke that you would specifically like explored? 
Is there anything else you would like to say that we have not talked about in this interview? 
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Additional File 3: The ATTEND Study- Carer interview guide     
Purpose of the interview:  Capture what it is like for carers to manage patients post stroke. How the burden could be made easier/better/worse. How the intervention 
package might influence this (or not); or how the trial might influence this (or not).           
                                                                                                                                                                    
Area of Interest Initial Broad Descriptive 
Questions 
Possible Probing Questions  
(These are a guide only. Depending on what the carer tells you, you do not have to ask all these questions or use the 
words exactly as written.) 
Health care 
experience 
Can you tell me about 
experience in caring for 
your family member? 
How did you find the 
care in the hospital? 
 
 
- What type of support do you get from family, community or social groups with looking after your family member’s 
health? 
- What other roles/responsibilities do you have in your family? How do you balance this with caring for your family 
member post stroke? 
Satisfaction/ 
problems with  the 
intervention 
package 
What are your thoughts 
about the treatment for 
helping your family 
member post stroke? 
What has been the most 
helpful? 
 
 
- What did you think of the hospital visit, the home visits?  (if in the intervention arm) 
 
- What was helpful? ( eg. stroke recovery trajectory, how to identify low mood, importance of specific activities) 
 
- What was not helpful? 
 
- Would you be happy to recommend this type of care to someone else, if applicable. 
 
- How can the doctor or the stroke unit improve their care? 
 
- What has been most important in helping your family member get better? 
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Asking about 
specific 
components if not 
already covered 
 
Information about 
stroke trajectory, risk, 
identification of low 
mood 
 
Goal setting 
 
Positioning, transfers 
and mobility 
 
 
Task oriented training, 
the use of the cultural 
manual 
 
Discharge planning 
 
 
- How do you know what you know about stroke? Is it from family, SC, doctor.  
 
- How was it trying to help your family member achieve goals that were set? 
o What are the things that helped? And what things didn’t?  
 
- How was it to do the training and to maintain mobility etc? 
o What are the things that might make your stop helping your family member? (pain?, tiredness, low mood, 
others helping?) 
 
- Can you describe any time or situation when he or she didn’t want to do your training exercises?  
o What were some reasons for stopping? 
 
- Who would you speak to if you were having trouble with following the rehab training and tasks for your family 
member? 
o When have you had to do this? 
 
- Did the discharge planning in the hospital help? In what way? 
 
Relationships How would you describe your relationship with your health providers (stroke coordinators, doctors, nurses, 
physiotherapists?  
With your family member post stroke as compared to before the stroke? (could be sensitive) 
Translation to 
current practice 
Would you recommend 
this intervention to 
others? 
 
- Has the cost of care been an issue for your family? If the intervention package required a fee, would you pay for it? 
Have other costs, e.g. cost of attending GP, travel to the health service, other specialist services, etc. been an issue? 
- Now that the study is over, would you think the intervention helped in your family members’ recovery or would your 
family have managed anyway? (intervention arm) 
- What other things would have helped you in your recovery and what more supports would you like in an ideal 
situation? 
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General views 
about the trial 
What are your thoughts 
about ATTEND trial in 
general? 
 How have you found being involved in the study? 
o What things did/didn’t you like about being involved? 
 Tell me how you think the study worked, and what it was hoping to achieve?  
 What were the things that made you want to participate in the study initially? 
o What were the benefits to you of participating? 
 What concerns did you have about participating in this study? 
o Were there any things that may have stopped you from participating initially? 
o What were the risks of participating in the study? 
 Once you and your family member were enrolled, what would have changed your mind about being in the study? 
o  Did you feel that you could withdraw at any time? 
 Did you know who to contact if you had any concerns about the trial? 
 What were your thoughts about your privacy throughout this study? 
Concluding 
questions 
  Are there things which we can do better to improve the study or the running of the trial? 
 Is there something else that you would like to say, that we have not talked about in this interview?  
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Additional File 4: The ATTEND Study- Patient interview guide     
Purpose of the interview:  Capture what it is like for people to manage post stroke. How to manage their disability, how the burden could be made easier/better/worse. How 
the intervention package might influence this (or not); or how the trial might influence this (or not).           
                                                                                                                                                                    
Area of Interest Initial Broad Descriptive 
Questions 
Possible Probing Questions  
(These are a guide only. Depending on what the patient tells you, you do not have to ask all these questions or use the 
words exactly as written.) 
Health care 
experience 
Can you tell me about 
your stroke? 
How was the care in the 
hospital? 
 
- What are some of the good/bad things about your health care? 
  
- What type of support do you get from family, community or social groups with looking after your health? 
o What kind of roles/responsibilities do you have in your family? 
Satisfaction/ 
problems with  the 
intervention 
package 
What are your thoughts 
about your current 
treatment for your 
stroke? 
 
 
- What did you think of the in hospital visit, the home visits?   
 
- What was helpful? ( eg. stroke recovery trajectory, how to identify low mood, importance of specific activities) 
 
- What was not helpful? 
 
- Would you be happy to recommend this type of care to someone else, if applicable. 
 
- How can your doctor or the stroke unit improve your current treatment? 
 
- What has been most important in helping you get better? 
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Asking about 
specific 
components if not 
already covered 
 
Information about 
stroke trajectory, risk, 
identification of low 
mood 
 
Goal setting 
 
Positioning, transfers 
and mobility 
 
 
Task oriented training, 
the use of the cultural 
manual 
 
Discharge planning 
 
 
- How do you know what you know about stroke? Is it from family, SC, doctor.  
 
- How was it trying to achieve goals that were set? 
o What are the things that helped? And what things didn’t?  
 
- When do you find it more difficult to do training and to maintain mobility etc? 
o What are the things that might make you stop? (pain?, tiredness, low mood, others helping?) 
 
- Can you describe any time or situation when you didn’t want to do your training exercises?  
o What things were influencing your decision? 
 
- Who would you speak to if you were having trouble with following the rehab training and tasks? 
o When have you had to do this? 
 
- Did the discharge planning in the hospital help? In what way? 
 
Relationships How would you describe your relationship with the SC?  
With your nominated carer? (could be sensitive) 
Translation to 
current practice 
Would you recommend 
this intervention to 
others? 
 
- Has the cost of care been an issue for you? If the intervention package required a fee, would you pay for it? Have 
other costs, e.g. cost of attending GP, travel to the health service, other specialist services, etc. been an issue? 
- Now that the study is over, would you think the intervention helped in your recovery or would you have managed 
anyway? 
- What other things would have helped you in your recovery and what more supports would you like in an ideal 
situation? 
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General views 
about the trial 
What are your thoughts 
about ATTEND trial in 
general? 
 How have you found being involved in the study? 
o What things did/didn’t you like about being involved? 
 Tell me how you think the study worked, and what it was hoping to achieve?  
 What were the things that made you want to participate in the study initially? 
o What were the benefits to you of participating? 
 What concerns did you have about participating in this study? 
o Were there any things that may have stopped you from participating initially? 
o What were the risks of participating in the study? 
 Once you were enrolled, what would have changed your mind about being in the study? 
o  Did you feel that you could withdraw at any time? 
 Did you know who to contact if you had any concerns about the trial? 
 What were your thoughts about your privacy throughout this study? 
Concluding 
questions 
  Are there things which we can do better to improve the study or the running of the trial? 
 Is there something else that you would like to say, that we have not talked about in this interview?  
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ATTEND Study Interview evaluation  
 
   INFORMATION FOR PARTICIPANTS 
Introduction 
 
You are invited to take part in the interview evaluation of the ATTEND study, which is part of the 
process evaluation of the study. As a patient or carer involved in this study you would be aware 
that this is a research study which looks to compare an Early Supported Discharge with a trained 
family-led caregiver-delivered, home-based rehabilitation program with usual care. You are invited 
to take part in the study to share your views about your health care experience and also about the 
study. 
We know that patients’ rehabilitation is likely to be affected by things such as cultural issues, costs 
of medications and additional support, relationships with your health providers. This might be very 
important in whether family led rehabilitation is effective. We are therefore seeking to explore 
your views on the advantages and disadvantages of family led rehabilitation post stroke in India.  
Your views on these issues will help us understand what role family led rehabilitation has in 
providing best practice care for post stroke patients.  The findings will help us understand the 
research and how it could work in India.   
 
Who can participate in the interview? 
Participants and their carers from both usual care and intervention arm in the ATTEND trial will be 
invited to participate in this interview evaluation from a sample of participating sites. 
 
What is required in the interview? 
If you participate in this study you will be interviewed by a study team member. We would like to 
talk to you for around 30-60 minutes. The interview process is informal and flexible as our main 
aim is to hear your experiences and views. We will fit within your schedule and if necessary speak 
with you over more than one visit if that is more convenient.  Please let us know what works well 
for you.   
 
What will happen once we have collected your information? 
We would like to record your interview(s).   
All information will remain confidential. Study information will be stored in a securely locked file 
and password assessed electronic folder at the George Institute for Global Health and will be 
accessed only by study team members. Nothing written in reports will link you personally to the 
study. 
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Ethics Approval 
 
This study has been approved by the Human Research Ethics Committee (University of Sydney, 
Australia) and your local Ethics Committee.  
 
Contact Details 
If you have any problems, concerns, questions or complaints about this study, you should preferably contact 
<Investigator Name> 
<Designation> 
<Site Name> 
<Site Address>  
<Contact Number>                                 
 
OR 
Name of the ethics committee member :  ______________________ 
Designation     :  ______________________ 
Contact No     :  ______________________ 
 
OR 
The Manager 
Human Ethics Administration 
University of Sydney 
NSW 2006, Australia 
Telephone +61 2 8627 8176; Facsimile +61 2 8627 8177  
Email:  ro.humanethics@sydney.edu.au 
 
 
  
This information sheet is for you to keep. 
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ATTEND Study Interview evaluation 
PARTICIPANT CONSENT FORM 
 
Participant: 
 
Name: …………………………………………………………………………………………………………. 
 
Address: …………………………………………………………………………………………………….. 
 
 I have read the participant information sheet 
 I feel free to accept or refuse to participate in the interview 
 I have had a chance to ask questions and all of my questions have been answered to my 
satisfaction 
 I have been given and I understand the information on the interview concerning its nature, 
purpose, and duration, including any known or expected inconvenience. 
 I agree that some of my words (not my name) will be used in the study reports 
 I agree that the interview will be taped 
 I do not have any objections to the interview record being kept at the end of the study 
 By signing this form, I give my free and informed consent to take part in this study as 
outlined in the information sheet and this consent form. I understand that I am free to 
withdraw from the study at any given time. I have been given a copy of this consent form. 
By signing this form I have not given up my legal rights. 
 
 
Name of participant:…………………………………………………………………………………………………… 
 
Signature of participant: ……………………………………………………………...Date:…..…………………… 
 
Name of interviewer: …….………………………………………………………………………………….………… 
 
Signature of interviewer: ……………………………………………………………...Date: …………………… 
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Table 1: Characteristics of the patients and site characteristics of the health providers interviewed   
Characteristics of patients interviewed Intervention patients (N=11) Usual care patients (N=11) 
Age ranges 
25-39 
40-55 
55-75 
 
3 
4 
4 
 
2 
6 
3 
Gender 
Male 
Female 
 
8 
3 
 
6 
5 
Education 
No schooling 
Primary school completed 
High school completed 
College/ University completed 
 
2 
2 
2 
5 
 
1 
3 
2 
5 
Carer Type 
Spouse 
Daughter/daughter in law 
Son/Son-in law 
Mother/ Father 
Brother/ Sister 
 
3 
2 
4 
1 
1 
 
5 
4 
1 
1 
0 
Site 
Government Academic hospital 
Christian Missionary hospital  
Private Corporate hospital 
 
3 
7 
1 
 
5 
4 
2 
Sampled Hospital 
characteristics 
Site 1  Site 2  Site 3  Site 4  Site 5  Site 6  
Geographical Location Central, urban North, urban South, urban North, rural South, urban South, urban 
Type of hospital Government 
Academic hospital 
Government 
Academic hospital 
Christian 
Missionary 
hospital 
Christian 
Missionary 
hospital 
Private Corporate 
hospital 
Private Corporate 
hospital 
Size of hospital 1766 beds 
 
1500 beds  1750 beds  120 beds  270 beds 250 beds  
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Use of stroke management 
guidelines 
Present Present Present Not specifically, 
general 
assessment and 
management 
Present Present 
Presence of allied health team 
for outpatient follow up 
Occupational, 
Speech and 
physiotherapists 
Occupational, 
Speech and 
physiotherapists, 
Specialised stroke 
unit nurses 
Physiotherapists Physiotherapists Occupational, 
Speech and 
physiotherapists 
Physiotherapists 
Health providers interviewed 
(N=28) 
7 Doctors 
4 Hospital Physiotherapists 
1 Clinical Nurse 
8 *Stroke Coordinators 
8 * Blinded Assessors 
*(additional 2 stroke 
coordinators and blinded 
assessors from a Christian 
hospital and corporate hospital) 
 
 
1 Doctor 
 
1 Hospital 
Physiotherapist 
 
1 Clinical Nurse 
 
1 Stroke 
Coordinator 
 
1 Blinded Assessor 
 
 
 
1 Doctor 
 
1 Hospital 
Physiotherapist 
 
0 Clinical Nurse 
 
1 Stroke 
Coordinator 
 
1 Blinded 
Assessor 
 
 
 
2 Doctors 
 
1 Hospital 
Physiotherapist 
 
0 Clinical Nurse 
 
1 Stroke 
Coordinator 
 
1 Blinded 
Assessor 
 
 
 
1 Doctor 
 
1 Hospital 
Physiotherapist 
 
0 Clinical Nurse 
 
1 Stroke 
Coordinator 
 
1 Blinded 
Assessor 
 
 
 
1 Doctor 
 
0 Hospital 
Physiotherapist 
 
0 Clinical Nurse 
 
1 Stroke 
Coordinator 
 
1 Blinded 
Assessor 
 
 
 
1 Doctor 
 
0 Hospital 
Physiotherapist 
 
0 Clinical Nurse 
 
1 Stroke 
Coordinator 
 
1 Blinded 
Assessor 
 
 
 
Box 1: Illustrative quotes across the themes 
Early supported discharge welcomed in concept 
“Discharging them early is helping them to reduce the burden of cost of hospital. The core hospital cost was 
cut down for them because most of the patients who are in and around our place are very much low 
socioeconomic rate. Early discharge helped them to get back to home quickly, and also the cost was reduced 
so that really helped them.” (Stroke coordinator) 
 
“Every day we are turning back at least three, on an average three patients with stroke who needs admission, 
we are turning back for lack of beds.  So, if this trial can prove that early assisted discharge is fruitful, then 
the bed turnover time can be faster.” (Neurologist)  
 
Stroke Education is needed 
“I studied B.Com in College. Now I am sitting like this, not useful to anyone and worrying about giving trouble 
to others around me…Just conduct a meeting and say avoid eating oil, alcohol. Now a days even kids are 
getting this disease.” (Intervention Patient) 
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 “A patient came to me with a stroke. It was a five-day old stroke. The patient has complete hemiplegia. When 
I told the patient you have come after five days. If you could have come within six hours or four and a half 
hours, there was a drug which could have been given to you which could have made him better. Then the 
patient relative asked, "I never knew we should come within three hours. You never told me.  You are a doctor, 
we are laymen. We don't know that we should come within that hour…” (Neurologist) 
 
ATTEND is an acceptable model of care 
“She says when (the stroke coordinator) went to their house and gave the treatment they could make out the 
mood of her father and it was always like he was very excited and happy when (the stroke coordinator) 
came…they have told us to continue with the exercises. And my father keeps on doing those all the time. Now 
he does not require much support from us. So he does it every morning and evening...We were told that within 
six months improvement will be there. Now that has happened even before six months. After that also we are 
continuing...I could not have done so much with my limited knowledge.” (Intervention  Carer) 
 
“I see from the patient’s perspective. That their goal is ultimately being independent. They want to return to 
(their) profession. So for that case ATTEND has covered everything about being functional. That’s all, from 
the therapists view we have to make that person quite functional rather than teaching him only one exercise to 
the caregiver.” (Stroke Coordinator) 
Sustaining patient and carer motivation was a key challenge 
“We used to give the caregiver a goal setting scale and a training pattern in mobility training. These three are 
more important. Sometimes the patient is not very much cooperative like the patient is really depressed, then 
we have to counsel the caregiver and the patient. You have to do it, otherwise the complications will be more 
aggressive or exaggerate.” ( Stroke Coordinator) 
 
“It’s very difficult. He has got stroke and because of taking care of him I was not able to take care of kids. 
Whatever I am earning is spending on him. No improvement at all…His parents are old and with their earnings 
only I was able to manage and take care. My two kids are very small. He said he has completed MBA. Now he 
is not able to speak...We couldn’t buy clothes. We couldn’t eat properly…” (Intervention carer) 
 
ATTEND is a sustainable model of care especially for those with limited access to rehabilitation 
 
“There is one who stays ahead of our lane. But she was aged, around sixty-five, she was an old woman. She 
was a victim of stroke. Her whole body had become numb. So I was the one who had gone to her house and 
helped her perform exercises. I had told her family members about what to do. I am doing this because the 
same thing has happened to my father.” (Intervention carer) 
 
“To be honest, I didn’t think there was any other way that a person with stroke could actually manage, because 
most of our patients are from the villages…there are no physiotherapists out there who will go to the homes or 
whom patients can go to and get help. Even before this study started out, we were giving the relatives itself the 
education that they needed and trying to teach them to help their patients…Most patients cannot afford for to 
go to a physiotherapist. ” (Neurologist) 
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CONSORT 2010 checklist  Page 1 
CONSORT 2010 checklist of information to include when reporting a randomised trial* 
Please note this checklist is based on the published trial outcomes paper which is referred to in our manuscript (ref 11): The ATTEND 
Collaborative Group, Family-led rehabilitation after stroke in India (ATTEND): a randomized controlled trial. Lancet. 2017. 
http://dx.doi.org/10.1016/S0140-6736(17)31447-2 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 1 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 1 
2b Specific objectives or hypotheses 1 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 1 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons Not applicable 
Participants 4a Eligibility criteria for participants 1-2 
4b Settings and locations where the data were collected 2 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
3 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
3-4 
6b Any changes to trial outcomes after the trial commenced, with reasons Not applicable 
Sample size 7a How sample size was determined 4 
7b When applicable, explanation of any interim analyses and stopping guidelines Not applicable 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 2 
8b Type of randomisation; details of any restriction (such as blocking and block size) 2 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
 
2 
2 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to  
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interventions 2 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 
assessing outcomes) and how 
2 
11b If relevant, description of the similarity of interventions Not applicable 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 4-5 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 4-5 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
3 
13b For each group, losses and exclusions after randomisation, together with reasons 3 
Recruitment 14a Dates defining the periods of recruitment and follow-up 5  
14b Why the trial ended or was stopped 5 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 3-4 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
3-4 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
5 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended Not applicable 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
5-6, 10 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 6 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 11 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 11 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 10-11 
Other information  
Registration 23 Registration number and name of trial registry 1 
Protocol 24 Where the full trial protocol can be accessed, if available 1 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 5 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
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Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist 
Developed from: 
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item 
checklist for interviews and focus groups. International Journal for Quality in Health Care. 2007. Volume 
19, Number 6: pp. 349 – 357. (as recommended by the EQUATOR network) 
 
No.  Item  
 
Questions/description Reported on Page  
Domain 1: Research team and 
reﬂexivity  
  
Personal Characteristics    
1. Interviewer/facilitator Which author/s conducted the inter view or focus 
group?  
7 
2. Credentials What were the researcher’s credentials? E.g. PhD, 
MD  
7 
3. Occupation What was their occupation at the time of the 
study?  
N/A 
4. Gender Was the researcher male or female?  7 
5. Experience and training What experience or training did the researcher 
have?  
In pre-specified 
protocol (11) 
Relationship with participants    
6. Relationship established Was a relationship established prior to study 
commencement?  
7 
7. Participant knowledge of the 
interviewer  
What did the participants know about the 
researcher? e.g. personal goals, reasons for doing 
the research  
7 
8. Interviewer characteristics What characteristics were reported about the inter 
viewer/facilitator? e.g. Bias, assumptions, reasons 
and interests in the research topic  
7, 17 
Domain 2: study design    
Theoretical framework    
9. Methodological orientation 
and Theory  
What methodological orientation was stated to 
underpin the study? e.g. grounded theory, 
discourse analysis, ethnography, phenomenology, 
content analysis  
6, 7 
Participant selection    
10. Sampling How were participants selected? e.g. purposive, 
convenience, consecutive, snowball  
7  
11. Method of approach How were participants approached? e.g. face-to-
face, telephone, mail, email  
7 (and elaborated in 
published protocol) 
(11) 
12. Sample size How many participants were in the study?  10 
13. Non-participation How many people refused to participate or 
dropped out? Reasons?  
N/A 
Setting   
14. Setting of data collection Where was the data collected? e.g. home, clinic, 
workplace  
7 
15. Presence of non-participants Was anyone else present besides the participants 
and researchers?  
N/A 
16. Description of sample What are the important characteristics of the 
sample? e.g. demographic data, date  
7 & Supplementary 
file 1 
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Data collection    
17. Interview guide Were questions, prompts, guides provided by the 
authors? Was it pilot tested?  
7 (and elaborated in 
the published 
protocol) (11) 
18. Repeat interviews Were repeat interviews carried out? If yes, how 
many?  
N/A 
19. Audio/visual recording Did the research use audio or visual recording to 
collect the data?  
7 
20. Field notes Were ﬁeld notes made during and/or after the 
interview or focus group? 
7 
21. Duration What was the duration of the interviews or focus 
group?  
7 
22. Data saturation Was data saturation discussed?  N/A 
23. Transcripts returned Were transcripts returned to participants for 
comment and/or correction?  
N/A 
Domain 3: analysis and ﬁndings    
Data analysis    
24. Number of data coders How many data coders coded the data?  7 
25. Description of the coding tree Did authors provide a description of the coding 
tree?  
7 and supplementary 
file 2 
26. Derivation of themes Were themes identiﬁed in advance or derived from 
the data?  
7 
27. Software What software, if applicable, was used to manage 
the data?  
7 
28. Participant checking Did participants provide feedback on the ﬁndings?  N/A 
Reporting    
29. Quotations presented Were participant quotations presented to illustrate 
the themes/ﬁndings? Was each quotation 
identiﬁed? e.g. participant number  
10-13, and additional 
illustrative quotes in 
the supplementary file 
30. Data and ﬁndings consistent Was there consistency between the data presented 
and the ﬁndings?  
10-13, Figure 2 and 
supplementary file 1  
31. Clarity of major themes Were major themes clearly presented in the 
ﬁndings?  
10-13 
32. Clarity of minor themes Is there a description of diverse cases or discussion 
of minor themes?       
10-13 (incorporated 
into major headings) 
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APPENDIX 8 
 
Appendix Overview 
This appendix comprises of the supplementary files of the publication in Chapter 5. 
Supplementary files: 
“Exploring use of economic evidence for investment in prevention” - 
1) Interview guide 
2) Coding Tree 
3) Documentary Analysis 
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General Framework for Economic Evaluation of Prevention  
Version 3, 8 May 2015 
 
 
 
General Framework for Economic Evaluation of Prevention 
Overview of consultation themes 
 
Context (role of evidence (in general) in decisions around investment in disease prevention 
programs) 
 Could you tell me a bit about your role and the role of your organisation/ department in making 
investment decisions in disease prevention programs? 
 In your experience, what role does evidence (generally) play in these decisions to initially 
invest/not invest in disease prevention programs?  
o If some role:  What evidence is relevant? How is it gathered? 
o If no or minimal role: What factors would influence a decision? Do you think that 
decision making could be improved with a more evidence-based approach?  If so, what 
sort of evidence do you have in mind? What can be done to promote greater use of 
evidence? 
 
Role of economic evidence  
 What do you see specifically as the role of economic evidence in your 
organisation/department? 
 In your mind, what sort of evidence does this constitute? In other words, what sort of data 
are we looking at here? How does that data then inform your decision making? 
 
Design and implementation 
 How do you (or your organisation) come up with ideas for new programs in the area of disease 
prevention? 
 What type of evidence do you use? Where do you get it? 
 What role does economic evidence have in this phase of design and development of new 
programs? 
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Economic evaluation 
 Once you’ve decided on program to fund, is there a process in your organisation for building in 
evaluation? Is it routinely followed? What sort of evaluation does this involve? What are you 
looking for in these evaluations? What sort of data are you looking to collect? 
 What role, if any, is there for economic evaluation?  
o If no role or minimal: should there be a greater role? Is this something you are working 
towards? How? 
o If there is a role: How has this role developed in your organisation? What capacity do 
you have for carrying out these evaluations?  Are they commissioned to external 
organisations?  
 Do you use specific guidelines in either conducting or commissioning economic  evaluations?  
o If so, how would you rate the usefulness of such guidelines?  
o If not, is this something that would be of use? Have you had any previous experience 
with such guides? 
 What sort of support would be of use to you and your organisation/department?  
 
The content of economic evaluation   
The central idea of this study is that there is a perception amongst many practitioners that economic 
evaluation evidence – as it is conventionally presented - is not well suited to the evaluation of 
prevention programs. In particular, the conventional focus on individual level health outcomes (such 
as life years gained, cases of illness prevented) doesn’t fully capture what it is that many disease 
prevention programs try to achieve (many of which are outside health) and are based on too short a 
timeframe. As such, it is argued that they unfairly penalise disease prevention vis-a vis other type of 
health sector programs when decisions are made over the allocation of funding. 
 How would you respond to such a point? Do you agree with this criticism?  
 What sort of evidence would be important to you in making decisions regarding investment? For 
instance if we did an evaluation on a health promotion program and were unable to detect 
changes in ‘hard’ health outcomes, but saw changes in process and behavioural indicators, how 
would such evidence figure in your decision to fund such a program?  
 What role is there for outcomes in other sectors (e.g. education and employment)? 
 What role is there for outcomes that occur decades into the future? 
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 What other type of outcomes/indicators might be important? 
 Do you have any suggestions about making such evidence available to decision makers?   
 
Use of economic evaluation 
 What do you see as advantages associated with greater use of economic evaluation evidence in 
investment in disease prevention programs? 
 What do you see as possible downsides? 
 What are the factors that might hinder the use of current economic evidence in decision 
making? Have you experienced a situation where economic evidence was not available but could 
have been useful? Is there anything that can be done to better promote its use? 
 What are some current gaps in the economic evidence base in prevention? 
 What have you observed about how colleagues in other departments and agencies (within and 
outside health) have used economic evidence? What are your thoughts about the positives and 
negatives about their approach? 
 Are there any other issues around the use of economic evidence in your 
organisation/department that we haven’t covered?   
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Supplementary file 2: Coding Tree 
Hierarchical Name    
Nodes\\Build research capability    
Nodes\\Content of economic evaluation    
Nodes\\Content of economic evaluation\Participant definition or approach to evaluation    
Nodes\\Content of economic evaluation\Participant definition or approach to 
evaluation\Conflicting stakeholder views 
   
Nodes\\Content of economic evaluation\Participant definition or approach to 
evaluation\Definition or approach to evaluation 
   
Nodes\\Content of economic evaluation\Participant definition or approach to 
evaluation\Financial drivers 
   
Nodes\\Content of economic evaluation\Recommendations    
Nodes\\Context    
Nodes\\Context\Academic    
Nodes\\Context\Health    
Nodes\\Context\organisation purpose    
Nodes\\Context\Treasury    
Nodes\\Decision making    
Nodes\\Decision making\Applicability of evidence to policy makers    
Nodes\\Decision making\Available resources (people, $)    
Nodes\\Decision making\Available time frame (ROI)    
Nodes\\Decision making\Business case    
Nodes\\Decision making\Capacity to be implemented    
Nodes\\Decision making\Champions    
Nodes\\Decision making\Collaboration    
Nodes\\Decision making\Duty of care    
Nodes\\Decision making\Financial implications of investment    
Nodes\\Decision making\Financial implications of investment\Direct cost to government    
Nodes\\Decision making\Financial implications of investment\Savings to budget or avoided 
costs 
   
Nodes\\Decision making\Flexibility and autonomy    
Nodes\\Decision making\Health equity    
Nodes\\Decision making\Holistic or intersectoral    
Nodes\\Decision making\Institutional considerations    
Nodes\\Decision making\Organisational structure    
Nodes\\Decision making\Politics    
 
Nodes\\Decision making\Risk and balancing interests    
Nodes\\Definition of evidence    
Nodes\\Definition of evidence\Activity Based Funding    
Nodes\\Definition of evidence\Anecdotal    
Nodes\\Definition of evidence\Economic evidence    
Nodes\\Definition of evidence\Performance metrics    
Nodes\\Definition of evidence\Process data    
Nodes\\Definition of evidence\Research    
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Nodes\\Design and implementation of program    
Nodes\\Design and implementation of program\Baseline    
Nodes\\Design and implementation of program\Funding needs    
Nodes\\Design and implementation of program\Infrastructure    
Nodes\\Design and implementation of program\Leverage    
Nodes\\Design and implementation of program\Long term investment    
Nodes\\Design and implementation of program\Measurability of project    
Nodes\\Design and implementation of program\Mismatched evidence    
Nodes\\Design and implementation of program\Responsibility    
Nodes\\Design and implementation of program\Scalability    
Nodes\\Design and implementation of program\Workforce    
Nodes\\Evaluation    
Nodes\\Examples of programs    
Nodes\\Focus on prevention    
Nodes\\Focus on prevention\Cost-sharing    
Nodes\\Focus on prevention\Cultural shift    
Nodes\\Focus on prevention\Difficult to evaluate    
Nodes\\Focus on prevention\Duty of care and accountability    
Nodes\\Focus on prevention\Marketability of product    
Nodes\\Focus on prevention\Measurability    
Nodes\\Focus on prevention\Need economic evidence for funding    
Nodes\\Focus on prevention\Political climate    
Nodes\\Focus on prevention\Popularity    
Nodes\\Focus on prevention\Types of intervention    
Nodes\\Role of economic evaluation    
Nodes\\Role of economic evaluation\Cost benefit analysis    
Nodes\\Role of economic evaluation\Costing    
Nodes\\Role of economic evaluation\Extent    
Nodes\\Role of economic evaluation\In house versus external    
Nodes\\Role of economic evaluation\Return of investment    
Nodes\\Strategies    
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Supplementary Table: Documentary analysis 
In their guidelines or evaluation frameworks for economic analysis, what types of analysis do they suggest? 
NSW Population Health research 
strategy 
NSW Health will undertake, support and commission research that: 
 where appropriate, focuses on: 
o economic evaluations (p7) 
NSW Government Evaluation 
Framework August 2013 
Evaluation is a key tool to support evidence based policy and decision making in government (p.2) 
Evaluation can provide the necessary evidence to improve services and guide better resource allocation 
decisions (p.2) 
Evaluation is about asking questions of our programs such as (p.5): 
 Do they provide value for money  
 Is there a better way to achieve the same result? Can resources be allocated more efficiently 
Table 1 p. 3 Types of evaluation: 
Summative – CE and CBA – answers the questions of efficiency by standardising outcomes in terms of their 
dollar value to answer questions of value for money. These analyses can also be used in formative stages to 
compare different options. 
Questions it answers: What are the net effects; is the program the best use of the resources it costs? 
The following should be considered when choosing programs for evaluation p.8: 
 Size of investment – resource intensive programs should be evaluated to ensure they deliver intended 
outcomes and provide the best value for money 
Appendix A: Glossary of terms p.19: 
 CBA/Cost efficiency analysis: Evaluation of the relationship between program costs and outcomes. Can 
be used to compare different programs with the same outcomes to determine the most efficient 
intervention. 
NSW Government Advertising 
Handbook 
Section 7 (1) of the Act sets out the requirements for cost benefit analysis and peer review of government 
advertising campaigns (p.6) 
 Requires CBA if the cost of that campaign I likely to exceed $1M 
 Peer review if cost of the campaign is likely to exceed $50K 
The Cabinet Standing Committee on Communications and Government advertising needs to approve all 
advertising programs likely to exceed $1M 
Agencies proposing advertising campaign should prepare the CBA – and should contact NSW Treasury for 
advice and guidance (refers to document: NSW Treasury Circular 10/11 Economic Appraisal Guidelines - 
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Economic appraisal  
guidance for government advertising) 
The purpose of the peer review is to provide informed and objective feedback on the need and cost 
effectiveness of the proposed advertising, as well as to monitor compliance of all campaigns with the relevant 
legislation and policies (p.10). 
As part of developing an advertising strategy, agencies should determine and document how they intend to 
measure the effectiveness of their advertising activities (p.11). 
NSW Government Guidelines for 
Economic Appraisal 2007 
Cost-benefit analysis and Cost-effectiveness analysis. 
 Both techniques require as many of the benefits and costs as is possible to be quantified in monetary 
terms 
 CEA is used when major benefits can’t be valued in dollar terms (or when it will be unduly expensive to 
undertake the valuation) 
 CEA is most often used in areas such as education, health, law and order and the environment – where 
CBA can prove more difficult 
 Unquantified benefits and costs should be taken into account 
Principles and Guidelines for Economic 
Appraisal of Transport Investment and 
Initiatives. Transport Economic 
Appraisal Guidelines 2013 
CBA is the preferred approach.  Economic impact analysis is used to measure quantified but non monetised 
effects. However when the benefits are similar or a particular objective is required, CEA may be applicable to 
transport projects. 
Sydney’s Walking Future 2013 One of the priorities in this strategy is to deliver cost effective solutions (p.9), however the criteria used is not 
reported. 
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In the reports of prevention strategies, if done, how are the economic outcomes described? 
NSW Get Healthy Information 
and Coaching Service: The first 
five years 2009-13. 
Outcomes reported: 
 Uptake and usage (p.6,7) 
 Relationship between promotional efforts and uptake 
 Starting risk factor profile 
 Change in behaviour and health outcomes(weight, waist circumference, BMI, physical activity, healthy eating 
behaviours 
 Maintenance of behaviour and health outcomes at 12 months  
Costing study was undertaken (ref 26) 
 Marginal cost of 26 week program smaller than the increase in achievements 
 Mean coaching costs ranged from $640 to $1030 
 Marketing costs were $350 per person 
 Reports plans for further economic evaluation and cost-benefit analysis 
NSW Government Guidelines 
for Economic Appraisal 2007 
NA 
Healthy Spaces and Places 
2009 
NA 
Walking Strategy and Action 
Plan 2015-2030 
No economic outcomes described 
Sydney’s Walking Future 2013 NA 
Closing the gap: 10 years of 
Housing for Health in NSW. An 
evaluation of a healthy 
housing intervention 
Costs per house of different maintenance activities were reported (p. 35) 
 
  
312
4 
 
Cross sectoral work- in what ways are the economic analysis done and how are health outcomes incorporated? (eg transport) 
NSW Population Health 
research strategy 
NSW Health will undertake, support and commission research that (p7) 
 include large scale, collaborative, cross-area or state-wide research projects. 
 uses cross-jurisdictional or whole of government collaborations where appropriate  
NSW Government Evaluation 
Framework August 2013 
The following should be considered when choosing programs for evaluation p.8: 
 Cross-sectoral involvement – programs which are partly or wholly funded by other jurisdictions  
NSW Government Guidelines 
for Economic Appraisal 2007 
Example p. 51: 
Department of Community Services has developed a database of material on certain social welfare costs and benefits, 
including aspects of health, education, child care and so on to assist analysis in such areas.   
Principles and Guidelines for 
Economic Appraisal of 
Transport Investment and 
Initiatives. Transport 
Economic Appraisal Guidelines 
2013 
 The cost of a crash to society is the value of the trauma and property damage caused by the crash. The 
estimated cost of crashes (crash cost values) can be found in Appendix 4. The costs are expressed using human 
capital or willingness to pay values. NSW Treasury recommends that analysis be undertaken using both 
methods for a period to gauge the degree of significance of the change in appraisal results due to two 
approaches. The value of statistical life (VSL) is the parameter used in evaluation of safety benefits in economic 
appraisals of infrastructure or related projects. A literature review (Appendix 4 Table 46) indicates that VSL 
ranges from $1.9m to $9.8m covering various countries. A study conducted for the then Roads and Traffic 
Authority (now Roads and Maritime Services) estimated the value that the NSW community is willing to pay or 
forego in exchange for a reduction in the probability of crash related injuries and death using a stated choice 
(SC) methodology. This value was estimated to be $6.41million in Dec 11 prices, which had been officially 
endorsed by the then Roads and Traffic Authority and acknowledged by TfNSW and NSW Treasury. 
 There are several tools and approaches suggested for use when there are wider socio-economic and 
environmental impacts of transport interventions 
o Multi-criteria assessment - main strength of MCA is that benefits which are unable to be readily 
quantified in monetary terms and are of major importance are included in the evaluation. Also, MCA 
has increased transparency as the criteria and objectives are stated and considered explicitly. On the 
other hand, the limitations of MCA are that there is a lack of theoretical framework, the weighting 
framework maybe subjective and it is harder to take into account impacts occurring at different times. 
o Goal Achievement Matrix - can be used in the analysis of impacts that are not readily able to be 
quantified in monetary terms (such as social objectives), which are prevalent in transport and land 
planning projects. The advantages of GAM are that it explicitly considers a wide range of goals, allowing 
social, environmental and economic outcomes to appropriately influence decision making. It is a simple 
tool that can be used by stakeholders as a means to promote community wide consultation, allowing 
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differing impacts to be considered. It is also able to include equity effects and impacts that are not 
easily monetised in traditional cost benefit analysis. disadvantage of the tool is that there is no common 
framework or system of measurement that can be applied to estimate the level of achievement of all 
goals. The success of the tool is determined by the weights applied to the goals, which tend to be more 
subjective rather than objectively determined. Furthermore, any interaction and interdependence of 
objectives are not taken into account. 
o Strategic merit testing - a technique used to check if the proposed project aligns with the economic, 
environmental and social objectives, policies and strategies of the government.  
o Appraisal Summary Technique has been broadly used in the assessment of the economic, 
environmental and social impacts of a project 
 Accident costs can be estimated based on two main approaches: Willingness to Pay (WTP) and Human Capital 
Cost 
o Human capital cost has several limitations and therefore WTP methods are being used more widely. As 
the accident costs derived from the WTP approach are usually higher than those from the Human 
Capital Approach, a higher priority to safety is given if the WTP accident cost values are used in the 
economic appraisals. 
o Cost per person based on severity of injury and cost per crash is estimated and recommended for use in 
NSW transport economic appraisals (Table 47, p. 269) 
o Value of a statistical life - $6,698,897 
o Value of a statistical life year - $325,434 
Healthy Urban Development 
Checklist 2009 
 The purpose of the checklist is to assist health professionals to provide advice on urban development policies, 
plans and proposals. 
 No economic analysis 
Healthy Spaces and Places 
2009 
Provides a guide for planning, designing and creating sustainable communities that encourage healthy living 
No economic analysis 
Walking Strategy and Action 
Plan 2015-2030 
No economic analysis undertaken 
 Walking strategy reports on the health benefits of walking.  Also reports the productivity benefits of walking 
 Reports (from a previous government study) that walking infrastructure has been shown to deliver a net health 
benefit of 144 cents for each Km walked. 
Sydney’s Walking Future 2013 Reports the inter-sectoral benefits of walking – health, wellbeing, the environment and communities 
Closing the gap: 10 years of 
Housing for Health in NSW. An 
evaluation of a healthy 
Program is designed to improve health outcomes (infectious diseases and chronic disease), however it also reports 
additional program benefits such as education and community capacity building. 
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housing intervention 
NSW Healthy Eating and 
Active Living Strategy: 
Preventing overweight and 
obesity in New South Wales 
2013-2018 
Working in partnership is a guiding principle of the strategy – it recognises that many factors influence overweight and 
obesity which requires a multi-sectoral approach and the development of strategic partnerships across government, 
industry, business, the non-government sector and research groups 
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A few of the participants have mentioned ‘reducing health inequalities’ as an objective – how is this detailed in these documents and how is this 
measured? 
NSW Population Health 
research strategy 
NSW is committed to the use of research evidence in informing decisions to improve population health and reduce health 
inequalities (p2) 
NSW Health will undertake, support and commission research that (p7): 
 where appropriate, focuses on: 
o  disadvantaged communities and population groups (to reduce health inequities) 
o The broad determinants of health 
Aim of the framework: High quality, relevant research is generated and used to improve policy and program  
effectiveness which will lead to better population health and reduced health inequities in NSW (p8) 
Key strategy (S2) (p8). Maximise the use of research to improve population health and reduce health inequities 
S2.1: Facilitate synthesis of and access to research evidence 
 2.1.3 Ensure that the use of existing NSW Health population health datasets promotes equity 
o exploring gaps in data collection systems with the aim of providing enhanced demographic information for 
the purpose of measuring equity (p19) 
o exploring other methods of monitoring health of marginalised groups through health data linkage, and 
using data from social welfare agencies 
S2.2: Develop policy and practice environments that value and use research evidence 
S2.3: Foster research environments that promote the use of research evidence in policy and practice 
Research priorities (p12): 
 Relevance to addressing health inequities within the NSW population 
NSW Get Healthy Information 
and Coaching Service: The first 
five years 2009-13. 
Priority groups for the GHS: 
 Aboriginal people 
 Culturally and linguistically diverse communities 
 People from low socio-economic areas 
 Those living in remote, rural and regional areas if NSW 
 People at risk of diabetes 
GHS Aboriginal program: aboriginal specific resources and three extra coaching calls 
Pro-active marketing to target adults from lower socioeconomic areas 
Demographics of participants reported includes education, Aboriginal status, SEIFA and remoteness (ARIA index). 
GHS is attracting participants in the lowest quintiles of advantage with a higher proportion of participants from the 3rd, 4th 
and 5th quintiles (most disadvantaged) than would be expected from the proportion of NSW adults in those quintiles. 
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Greater proportion of participants from regional locations compared to major cities (p.14) 
NSW Government Advertising 
Handbook 
7.5% of advertising campaign press expenditure should be placed in ethnic newspapers (p.9) 
3% of total government advertising campaign electronic media expenditure is to be placed in ethnic electronic media 
10% of press expenditure to be placed in community language (ethnic and indigenous) newspapers 
5% of total electronic media expenditure in community language (ethnic and indigenous) electronic media 
All advertising and public information videos are required to have captioning (for hearing impaired community) 
NSW Government Guidelines 
for Economic Appraisal 2007 
Types of benefit (p. 22) 
 Benefits to consumers not reflected in revenue flows: 
o Equity considerations of pricing policies may result in the service not being charged, however these benefits 
should be quantified as much as possible or described in detail if quantification is not possible 
Economic Assessment Of Environmental Impacts 
 Inter-generational equity principle - the present generation should ensure that the health, diversity and 
productivity of the environment is maintained or enhanced for the benefit of future generations 
Principles and Guidelines for 
Economic Appraisal of 
Transport Investment and 
Initiatives. Transport 
Economic Appraisal Guidelines 
2013 
 Not related to health inequalities – however in terms of equity, low-income mobility benefits are incorporated into 
the analysis. 
 Infrastructure Australia – a strategic priority is ‘Improving social equity and quality of life in our cities and regions’. 
 Greater equity of access is reported as an unquantifiable benefit of transport interventions (Table 2.1 p. 50) 
 Social inclusion is a consideration in transport evaluation and  
Healthy Urban Development 
Checklist 2009 
 Recognises that population growth, if not carefully planned for and managed may not contribute positively to the 
health of the community and may perpetuate the health inequalities that currently exist in NSW 
 Equity is a guiding principle in the development of the checklist.  Equity is understood here to mean that access to 
all aspects of a community (including health, safety, open space, transport and economic development) is fair to all 
residents regardless of socioeconomic status, cultural background, gender, age or ability 
Walking Strategy and Action 
Plan 2015-2030 
Reports walking is the most equitable form of transport for short trips available to people of all ages, incomes and locations. 
NSW Healthy Eating and 
Active Living Strategy: 
Preventing overweight and 
obesity in New South Wales 
2013-2018 
Reducing inequity is one of the guiding principles of the strategy. 
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